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Thesis Abstract
Breathlessness is a common and problematic symptom in heart failure. Opioids have 
traditionally been considered as analgesics, but a potential role for their use in 
breathlessness is beginning to emerge. This thesis commences with a review of the 
existing literature in support of a possible role for opioids in the management of 
breathless in heart failure. A systematic review of existing human symptom control 
studies in this thesis suggests that opioid administration may have a small but significant 
benefit in chronic heart failure. However, only six studies were included in the review 
and most were either small or of poor methodological quality. This presents a relative 
gap in the knowledge on this topic.
A randomised controlled trial was therefore performed to assess the effect of opioids on 
breathlessness in chronic heart failure. This crossover trial involved the comparison of 
two oral opioids with placebo. Thirty-five participants completed the trial, making it the 
largest trial of its type in this area. Opioid administration was shown to be safe in this 
patient cohort. No statistically significant differences were demonstrated for 
breathlessness severity between treatments.
Participants were subsequently invited to participate in a three month open label 
extension. Thirty three participants in total were followed up with thirteen remaining on 
active therapy. This is the first trial of its type in breathlessness in heart failure and 
represents the longest participant follow-up in this area. Whilst not as robust as the initial 
trial, this extension period revealed that opioid continuers rated a statistically significant 
improvement in breathlessness severity from baseline compared to non-continuers.
Finally, a semi-structured interview study in ten participants with heart failure revealed 
for the first time that opioids are acceptable in this population and they describe 
troublesome symptoms that might respond to opioid treatment.
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Chapter 1:
Opioids for breathlessness in heart failure;
How might drugs traditionally regarded as analgesics improve other 
symptoms?
“Among the remedies which it has pleased Almighty God to give to man to relieve his 
sufferings, none is so universal and so efficacious as opium.”
Thomas Sydenham
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Section 1) Introduction
Thomas Sydenham (1624-1689), the great English physician and apothecary, was one of 
the pioneers of opioid therapy in Western medicine, creating a solution of opium, sherry 
and spices to manage a variety of ills in his patients (Hamilton and Baskett, 2000). 
Opioids or “morphine-like medicines” have an historical association with healing, 
suffering (through addiction and misuse) and even war. Today, opioids are used widely 
in the management of pain in many patients worldwide. Increasingly there is evidence 
that opioids may help to relieve another troublesome symptom, namely breathlessness.
Traditionally, opioids have been left “in reserve” for patients as they approach death and 
so are most familiar to physicians in palliative medicine. With growing recognition of 
alternative uses of opioids however, they are increasingly incorporated in a patients’ 
overall management as their symptoms worsen. Those chronic diagnoses that are most 
associated with breathlessness include cancer, chronic obstructive airways disease and 
heart (or cardiac) failure. Physicians are more comfortable with the administration of 
opioids in cancer patients and there is a small but growing evidence base for the use of 
opioids in Chronic Obstructive Pulmonary Disease (COPD) to manage breathlessness 
(Jennings et al., 2001, Abemethy et al., 2003). However, similar research into the relief 
of breathlessness with opioids in CHF has been slow to materialise. This is despite the 
number of patients living with chronic heart failure (CHF) increasing at this time 
(Department of Health, 2000, Thomas and Rich, 2007) and therefore more patients are 
likely to require symptom relief. Opioids are already recommended for breathlessness in 
chronic heart failure in clinical guidelines (SIGN, 2007) once other therapies have been 
administered. This use however is recommended without a defined evidence base and 
uptake of this guideline has been slow due to this and perceived problems with opioid 
therapy in general.
This chapter aims to provide some of the background information as to the importance of 
research in this area. The research topic incorporates a number of subjects including heart 
failure, breathlessness as a symptom and knowledge of opioids. A brief overview of heart 
failure in Section 3 will detail the background in relation to the research topic with 
consideration for the need for research in this area, but is not designed as a 
comprehensive review of heart failure. It simply describes some of the background to 
CHF and discusses some of the investigations and interventions referred to in the RCT
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(Chapter 4). The sensation of breathlessness in particular is difficult to quantify and the 
mechanisms as to why CHF patients may be breathless will be discussed in Section 4. 
Existing therapies for the management of breathlessness in general will also be 
discussed.
Opioids are proteins produced naturally by the body and exert their effects by activating 
opioid receptors. These naturally occurring “endogenous” opioids and the receptors that 
they activate will be discussed in Section 2. In addition, the site of action of exogenous 
opioids (i.e. external / pharmaceutical) will be detailed.
This will be followed by a review in Chapter 2 of the potential role of opioids in the 
mechanisms involved in the pathophysiology of heart failure including studies in animal 
models and the potential problems in interpretation that the use of such models may 
have. This chapter of the thesis will conclude with a summary of the key findings and 
with an assessment of the need for research in this area.
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Section 2) Opioids; Morpheus awakes in the mammalian world
2.1 Historical Perspective
Opioids have been manipulated by physicians for centuries, although knowledge of 
endogenous opioids (those naturally occurring in the body) has only become apparent 
within recent years. In circa 3400 BC the Sumarians first documented the cultivation of 
the opium poppy (papaver somniferum) in lower Mesopotamia (Hamilton and Baskett, 
2000). Hippocrates detailed the use of the extract of the poppy in medicine in the fourth 
century BC. Later Galen, a Greek physician in the second century AD, administered 
opium extracted from the opium poppy to patients to relieve pain and, of relevance to this 
thesis, to improve the clinical status of patients with symptoms suggestive of heart failure 
amongst other diagnoses (Waldhoer et al., 2004). In essence therefore, one could say that 
this thesis builds on evidence collected about two millennia ago! Since that time, the 
active compounds from the opium poppy have been isolated and subsequent synthetic 
analogues have been produced. Morphine (named after Morpheus, the God of sleep and 
dreams) was first isolated over 200 years ago by Friedrich Sertumer, a German chemist 
(Huxtable and Schwarz, 2001, Hamilton and Baskett, 2000). Many synthetic and non­
synthetic preparations have since been developed. “Opioid” is the all-encompassing term 
for all substances with a pharmacological action similar to morphine and all other 
“morphine-like” medicines. “Opiate” is a narrower term used for only the alkaloid 
derivatives of the opium poppy, rather than all products with morphine-like properties. 
Hence “opioid” is the correct term to use in our context and will be referred to 
throughout this thesis.
2.2 Endogenous opioids
The human body produces its own natural (endogenous) opioid proteins and these have 
been implicated in a number of processes. Opioid receptors are stimulated by the binding 
of these endogenous opioid proteins that are released as a natural response to injury, 
infection, trauma, stress and surgery amongst other causes (Molina, 2006). It is 
considered that these naturally occurring opioids may mediate the metabolic and 
haemodynamic responses required to restore homeostasis (Molina, 2006).
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Three main types of endogenous opioid peptides exist; enkephalins, dynorphins and 
endorphins. Interestingly, all of these three main types of endogenous opioid share the 
same amino-terminal amino acid sequence (Tyr-Gly-Gly-Phe-Met or Tyr-Gly-Gly-Phe- 
Leu) suggesting a similar method of activation at the receptor level (Roques et al., 1999). 
These proteins are derived from larger protein precursors that are encoded by three 
different genes; pro-enkephalin, pro-dynorphin and pro-opiomelanocortin (Simon and 
Gioannini, 1993) {please refer to Cesselin 1995 for a review on this topic}. In general 
terms, the genetic information stored in the DNA code is transcribed in the nucleus of the 
cell forming a copy of the DNA in the form of messenger ribonucleic acid (mRNA). This 
mRNA is translated into a sequence of amino acids by ribosomes in the cytoplasm. These 
collections of linked amino acids become proteins when they are complete and able to 
adopt their natural shape (Thibodean and Patton, 1997). Hence measurement of mRNA 
can be a surrogate for measurement of the particular production of certain proteins (such 
as endogenous opioids or opioid receptors).
Table 1.2.1 below demonstrates some of the endogenous peptide products from these 
precursors, noting the similarity of amino acid structure of the different endogenous 
opioid peptides. These genes and their genetic protein products are expressed in different 
locations in the human body. The locations with reference to the cardiovascular and 
respiratory systems will be discussed later. Differential splicing of the precursor proteins 
may result in other opioid or non opioid products. This is particularly apparent for pro­
opiomelanocortin.
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Table 1.2.1: Endogenous opioid products of the three opioid precursors (Adapted from 
Roques et al. (1999)
Precursor Peptide Amino acid sequence Other non­
opioid
products from 
precursor
Pro-enkephalin Met-enkephalin Tyr-Gly-Gly-Phe-Met
Leu-enkephalin T yr-Gly-Gly-Phe-Leu
Met-enkephalin-8 T yr-Gly-Gly-Phe-Met-Arg- 
Gly-Leu
Met-enkephalin- 
Arg-Phe (MEAP)
T yr-Gly-Gly-Phe-Met-Arg- 
Phe
Pro-dynorphin Dynorphin A Tyr-Gly-Gly-Phe-Leu-Arg-
Arg-Ile-Arg-Pro-Lys-Leu-
Trp-Asp-Asn-Gln
(Also neo­
endorphins)
Dynorphin B T yr-Gly-Gly-Phe-Leu-Arg- 
Arg-Gln-Phe-Lys-Val-Val- 
Thr
Pro­
opiomelanocortin
(POMC)
B-endorphin Tyr-Gly-Gly-Phe-Met-Thr-
Ser-Glu-Lys-Ser-Gln-Thr-
Pro-Leu-Val-Thr-Leu-Phe-
Lys-Asn-Ala-Ala-Ile-Val-
Lys-Asn-Ala-His-Lys-Lys-
Gly-Gln
Melanotropic 
(Melanocyte 
Stimulating 
hormone -  
MSH);
Corti cotropic 
peptides (e.g. 
ACTH)
Given that common amino-acid sequences are shared between endogenous opioids, all 
opioid receptors can be activated by each opioid protein if sufficient concentrations of 
peptide are reached (Simon and Gioannini, 1993). However, given the differences in size 
and sequence between these compounds, the three main types of endogenous opioids
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have preferences for the three types of opioid receptor. These receptor : peptide 
associations are detailed in the next section.
The production of endogenous compounds should not be seen in isolation as in general a 
variety of feedback mechanisms can adjust the production of many other compounds and 
this is also true for opioids. For example, Pro-opiomelanocortin (POMC) undergoes 
enzymatic cleavage in the pituitary into Adreno-Cortical Thyrotropic Hormone (ACTH) 
and Beta-Lipotrophin, which is the immediate precursor of beta-endorphin. In normal 
human subjects, beta-endorphin levels rise in the circulation in conjunction with ACTH 
following stimulation of corticotrophin releasing factors from the hypothalamus 
(McLoughlin et al., 1993). Beta-endorphin may be shortened by enzymatic cleavage 
outside the pituitary (its main site of production) into alpha-, gamma- or delta- endorphin 
dependent upon the site of cleavage (McLoughlin et al., 1993). No clear physiological 
role for beta-endorphin has yet been identified (Guillemin et al., 1977).
Similarly, the potential roles for other circulating endogenous opioids is unclear. Met- 
enkephalin has been isolated in human plasma (Boarder et al., 1982, Clement-Jones et 
al., 1980), with no obvious defined role. The presence or absence of dynorphins in 
plasma is difficult to assess by current techniques (McLoughlin et al., 1993) and hence 
their role in circulation is similarly difficult to elucidate.
Understanding of the endogenous opioid agonists has suffered from unclear 
nomenclature based on initial discoveries. Examples of this include the nociceptin or 
orphanin protein, similar in structure to dynorphin, which does not have the amino-acid 
sequence necessary to activate the three recognised opioid receptors. This protein has 
been termed “opioid” without the necessary ability to activate traditional opioid receptors 
(Reinscheid et al., 1995) and therefore caution should be used when interpreting data 
from papers involving nociceptin as an agonist. ‘Endomorphins’ are another similar 
example (Venkatesan et al., 2003). Hence the nomenclature of peptides similar in 
structure to the traditional opioid proteins has further complicated the research in this 
area. Studies involving such peptides have been excluded from this thesis given the 
unknown and probably unrelated site and action of these proteins.
Caution is also advised when interpreting some of the data involving enkephalins in
particular. Some studies have detected enkephalin-like proteins (such as MEAP {Met5
Enkephalin-Arg6-Phe7} or met-enk-arg-gly-leu) which can occur due to differential
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splicing of the precursor protein and may or may not be involved in endogenous opioid 
activity in a similar way to met- or leu-enkephalin peptides. Measurement or 
administration of such proteins might be relevant in such studies as they are formed from 
the same common preproenkephalin precursor as met- or leu-enkephalin (Pepe et al., 
2004), but at best these are surrogates for the enkephalins of interest. For example, 
MEAP has been located in basic science studies involving rat and guinea pig in both 
lung (in high concentrations) and heart (Tang et al., 1982), but at different selective 
ratios to met-enkephalin in those tissues. Studying MEAP may not be relevant, as it 
appears to undergo differential splicing from pre-pro-enkephalin than met-enkephalin 
(van den Brink et al., 2003). Barron (2000) describes MEAP as the “promiscuous 
peptide” due to its stimulation at low doses of both delta and kappa receptors, with mu 
receptor stimulation also occurring at higher concentrations of ligand, indicating 
uncertainty of its method of activity. It is difficult to know whether these surrogates for 
enkephalin compounds are truly involved in opioid activity. To the best of my 
knowledge, the potential differences in detection of these different enkephalin-like 
proteins are not discussed in detail in the wider literature and this further adds to the 
complexity and confusion surrounding endogenous opioids.
2.3 Opioid receptors
Since the elucidation of opioid receptors in the body, efforts have been made to target 
specific opioid receptors with new opioid drugs. These opioid receptors are coupled to 
inhibitory G proteins and exist in different locations and concentrations in a variety of 
tissues (Davis and Pasternak, 2005), which adds further evidence to suggest a role in 
maintaining homeostasis. Three main types of opioid receptor have been described: mu, 
kappa and delta (Kosterlitz, 1985). These three types have been recently cloned using 
DNA technology (Gaveriaux-Ruff and Kieffer, 1999, Satoh and Minami, 1995). Other 
receptors have previously been described, but remain poorly characterised (Waldhoer et 
a l, 2004). Further subtypes of these three known receptor classes are believed to exist 
(Davis and Pasternak, 2005). Depending on their type and location, activation of these 
receptors have differing effects which has lead to the possibility of more targeted drug 
therapy using synthetic opioid drugs that have different receptor profiles.
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Research into receptor:opioid interactions is difficult due to both the relative affinities of 
opioids for each receptor and the comparative distributions of opioids and receptors in 
the body. Distribution of opioid receptor subtype and endogenous opioids can be varied 
both in different species and within the same species. Many investigators have noted very 
similar distribution of opioid receptors between mammalian species, but that the relative 
concentration of receptors and type of receptor differs widely at these sites between 
species (Khatchaturian et ah, 1993).
Definitions of opioid receptors are also not assisted by reclassification (to OP receptors 
for the 3 main receptor types) and discovery of receptors termed to be opioid-like which 
subsequently prove not to be opioid receptors at all (e.g the Sigma receptor) (Dhawan et 
al., 1996). For the terms of this thesis, the three main types of opioid receptor only are 
discussed and their common nomenclature (mu, kappa, delta) are used rather than their 
more recent classifications (namely OP3, OP2 and OP1 respectively) (Groneberg and 
Fischer, 2001) to allow greater clarity. In addition, Opioid Receptor-Like (ORL) 
receptors have been discovered (Connor and Christie, 1999, Trescot et ah, 2008), but 
again they are considered to lack the traditional activation of G proteins and are not 
stimulated by traditional opioid agonists as the other three recognised receptors are. This 
again adds to the confusion surrounding opioid receptors and their properties.
Opioid receptors are transmembrane and share approximately 60% of a common 
structure (Satoh and Minami, 1995). The three recognised classical opioid receptors have 
been cloned using DNA recombination technology (Evans et ah, 1992, Reisine and Bell, 
1993, Satoh and Minami, 1995, Connor and Christie, 1999). Opioid receptors can also 
undergo heterodimerisation with each other in situ which may lead to a further 
enhancement of their action in other areas throughout the body (Martin and Prather, 
2001). As previously described, opioid receptors are G-protein coupled (Reisine and 
Bell, 1993, Zimlichman et ah, 1996) and have an inhibitory action on the manufacture of 
cAMP (Pepe et ah, 2004). Cyclic AMP is responsible for maintaining intracellular 
calcium concentrations and subsequent myocardial contractility (Figure 1.2.1). This is in 
contrast to a hormone involved in the perpetuation of heart failure, namely 
norepinephrine (norepinephrine) which has a stimulatory action on adenylate cyclase, 
thus increasing intracellular calcium concentrations and contractility (Mann et ah, 1992). 
The location of opioid receptors in relation to the cardiorespiratory system and the 
interaction of opioids with neurohormones like norepinephrine and its importance is 
discussed in Chapter 2.
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Figure 1.2.1: Diagram to show the relationship between transmembrane opioid receptors, 
G proteins and the manufacture of cyclic AMP through adenylate cyclase. Opioid 
receptor stimulation through endogenous opioids causes a stimulation of the inhibitory G 
protein system (Gi). This in turn reduces the production of cAMP by adenylate cyclase. 
cAMP has multiple downstream effects, which are therefore inhibited by opioid receptor 
stimulation. Conversely, norepinephrine stimulates Gs (stimulatory G proteins), causing 
an increase in cAMP production and enhancement of its downstream effects. Adapted 
from Trescot et al. (2008).
regulation of cell processes and transcription
▼
cAMP increases intracellular calcium concentrations
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2.4 Exogenous opioids and opioid antagonists
All pharmaceutical (exogenous) opioids essentially have a similar class effect with 
respect to analgesia and side effect profile, despite efforts to target certain classes of 
receptors. However, they do differ by route of administration, bioavailability, duration of 
action, route of excretion and potency (Oxberry and Simpson, 2005). The side effect 
profile can vary between individual patients and opioid used, with different opioids 
having a greater frequency of certain opioid-related side effects and lower frequency of 
others. Hence, a growing number of pharmaceutical opioids have been developed and 
they are widely used throughout healthcare. Clinically, opioids are prescribed on an 
empirical basis until an agent is found that is effective without intolerable side effects 
(Davis and Pasternak, 2005). Common side effects may include nausea, vomiting, 
drowsiness, itch, constipation and dry mouth (Oxberry and Simpson, 2005). More serious 
potential effects such as tolerance, dependence, significant respiratory depression and 
addiction are considered rare when opioids are prescribed by appropriately trained 
healthcare professionals (Hanks et al., 2004). Despite this, widely held beliefs 
concerning “morphine” and associated strong analgesics are held by lay, patient and 
healthcare populations (Lambert et a l, 2007). This “opiophobia” may prevent use of 
opioids despite a clinical indication and this phenomenon is described further in the 
qualitative chapter of the thesis (Chapter 6).
Despite these effects, opioids have a number of advantages that have been utilised in 
anaesthesia. In particular, there is minimal direct depression of cardiac function, 
preservation of autoregulation of blood flow to vital organs including the heart, and 
absence of interactions with cardiac drugs. In addition, the control of mechanical 
ventilation and toleration of endotracheal tubes is also improved with opioid drugs (Hug, 
1999). These cardio-respiratory factors have allowed intra-operative use of exogenous 
opioids and demonstrates that use of opioids is compatible with cardiac medications. 
Unfortunately the safety of opioid use in some patient groups is still questioned (Auret 
and Schug, 2005, Cattermole and Graham, 2009, Hoffman and Reynolds, 1987) despite 
palliative care and anaesthetic experience. The RCT and three month follow-up chapters 
will seek to address the fears of some that even low doses of opioids cause significant 
clinical cardiorespiratory interference and adverse events.
Many opioid antagonists have been developed to counteract the effect of opioids at the
cellular level. Some antagonists are designed to target a single receptor class, others (like
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naloxone) have multiple opioid receptor affinities at sufficient concentrations (Davis and 
Pasternak, 2005). Opioid antagonists have been used by researchers to explain the 
pharmacological mechanisms of action of opioids, or clinically by observing the effects 
of the antagonist then extrapolating the findings to propose a hypothesis of the actions of 
opioids (Davis and Pasternak, 2005). This is a complex area, however, as sufficient doses 
of antagonist are required to block the effect of opioids, antagonists tend to have a shorter 
duration of action and many opioids can stimulate more than one class of receptor.
2.5 Endogenous and exogenous opioid:receptor affinities and interactions
It remains unclear whether endogenous opioids can exert an effect by systemic release 
into the circulation, or whether their release must be localised within the same tissue as 
the location of opioid receptors (i.e. an autocrine or paracrine effect) (Khatchaturian et 
al., 1993). Most experimentation with exogenous opioids in mammalian species models 
has involved systemic administration, which is typically the means by which morphine­
like medicines are administered in humans. As with other compounds, various disease 
states may cause up- or down-regulation of receptors, as potentially will the chronic 
administration of agonists or antagonists. These potential limitations and complexities 
must be taken into account when evaluating the literature.
Table 1.2.2 reveals the common endogenous and exogenous opioid agonists and 
antagonists. It should be noted that these compounds predominantly exert their effects 
through the receptors stated, though there is variable activation of other opioid receptors 
dependent on dose and location. For example, met- and leu- enkephalins have high 
affinity for delta receptors, low affinity for mu receptors and negligible affinity for kappa 
receptors (Corbett et al., 1993b). Dynorphins A and B have highest affinity for kappa, 
but also affinity for mu receptors with less (though still present) affinity for delta 
(Corbett et al., 1993b). Lastly, Beta endorphin has almost comparable affinity for both 
mu and delta receptors, with low affinity for kappa sites (Corbett et al., 1993b). Hence 
opioids can activate all receptors at sufficient concentrations, but have varying specificity 
for receptor types. The non-selective nature of these endogenous opioid peptides has 
limited their use in clinical experimentation.
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Table 1.2.2: Endogenous and exogenous opioids and their receptor stimulation:
Endogenous agonists Receptor preference
Dynorphins Kappa
Endorphins Mu
Enkephalins Delta
Common Exogenous agonists
Morphine Mu
Diamorphine Mu
Oxycodone Mu / Kappa
Fentanyl Mu
Codeine Mu
Exogenous antagonists
Naloxone Mu*
Naloxicine Mu
Naltrexone Mu*
Norbinaltorphimine Kappa
* Antagonises all opioid receptors at comparatively low concentrations (for naloxone 
mu>kappa>delta)
Most of the exogenous opioid agonists are selective primarily for mu receptors, with 
variable amounts of selectivity for kappa and delta receptors. In addition, the relative 
potencies of administered opioids are different dependent upon the actual compound and 
route of administration. For example, oral morphine is considered to be approximately 
ten times more potent than oral codeine, with doses adjusted accordingly (Twycross et 
a l, 2002). This adds to the complexity of research in this area. For a comprehensive 
review see Herz (1993).
For reference for the RCT study detailed later in the thesis, the relative affinities of the 
synthetic opioids used and endogenous opioids classes are displayed in Table 1.2.3.
These affinities are relative to each group (exogenous and endogenous) and should not be 
considered as directly comparable. Relative affinities have been used as there remains 
conjecture over the actual potencies of these compounds at receptor sites in different 
species. Neither of the two synthetic compounds mentioned bear direct relation to any of
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the endogenous opioid proteins, but morphine could be considered as similar to the 
endorphins as the mu receptor is predominantly stimulated, whereas oxycodone could 
represent both endorphins and dynorphins as the mu and kappa receptors are 
predominantly activated.
The oxycodone affinities in particular have been difficult to elucidate, since different 
studies involving oxycodone have varying affinities expressed at the kappa receptor. 
Oxycodone is broken down into oxymorphone (and subsequently to oxymorphols and 
nor-oxymorphone) and noroxycodone (subsequently reduced to noxycodols and nor- 
oxymorphone). All these metabolites have differing affinities for the opioid receptors and 
it remains unclear as to the metabolites that cause the analgesic effects observed with 
oxycodone. For example, in an in vitro study, Lalovic et al. (2006) demonstrated a low 
affinity for oxycodone at the kappa receptor, but also a low affinity for the mu receptor 
compared to morphine, despite their similar analgesic properties in vivo. In contrast, 
Ross'& Smith (1997) and Nielsen et al. (2007) demonstrate that kappa-receptor binding 
antagonists prevent the analgesic response of oxycodone but not morphine in rat studies, 
implying that the method of action of oxycodone is via a kappa receptor mediated 
mechanism. In essence, this area is complex and conclusive results from these receptor­
binding studies do not appear to be present as a consensus in the literature to date. Hence, 
overall effects of oxycodone are a combination of effects on both kappa and mu receptors 
predominantly.
Table 1.2.3: Relative affinities of endogenous and exogenous opioids on opioid receptors 
from in vitro studies {adapted from: (Fowler and Fraser, 1994, Pugsley, 2002, van den 
Brink et al., 2003, Corbett et al., 1993a)}
Opioid Mu Kappa Delta
Endorphin +++ (>50%) - ++ (>40%)
Enkephalin + (<10%) - ++++ (>90%)
Dynorphin + (20%) +++ (>60%) + (<10%)
Morphine ++++ (>95%) - (<1%) + (<5%)
Oxycodone +++ ++ +
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As with all medication, some individuals respond differently to the administration of 
opioids than others. Variation in response occurs for both a class effect of opioids 
themselves and for individual opioids in a given patient. This is important to consider 
prior to any interventional trial involving medications as individual responses will alter 
patient-related outcomes. Individual variation exists for the pharmacokinetics and 
pharmacodynamics of these drugs (Rollason et al., 2008). Pharmacokinetic factors such 
as the transport and metabolism of exogenous opioids, and pharmacodynamic factors 
such as the type and frequency of opioid receptors and the signalling pathways associated 
with the effects of opioids can all have the potential for individual variation (Smith, 
2008). Hence there are a number of points in the process from absorption to excretion 
that can vary between different patients. Genetic factors may be important in response, 
but studies in this area are difficult to perform and as yet genetic markers are unable to be 
used to predict either the efficacy of opioid treatment or the development of adverse 
effects with treatment (Skorpen et al., 2008).
2.6 Conclusion
The isolation of opioid receptors and endogenous opioid ligands has given a greater 
scientific interest for the manipulation of opioids as a potential means of regulating 
certain diseases or body processes. Traditionally opioids were viewed as analgesics, but 
recent research at the cellular level has implicated a potential role for opioids in a variety 
of homeostatic processes. The clinical evidence for a role for opioids in heart failure in 
described in the literature review.
The endogenous opioid system and proposed role in homeostasis is difficult to interpret 
in relation to both human physiology and cardiorespiratory disorders as a specific entity 
in isolation. As Khachaturian et al. (1993) correctly discuss, the agonists and antagonists 
used can activate numerous receptor types given sufficient concentrations. Opioid 
precursors may be differentially processed in different locations (see table 1.2.1 for 
potential products of POMC for example). In addition, care must be taken when 
extrapolating animal or basic science work into the proposed effect in humans in vivo. 
These uncertainties further complicate the pharmacological research of endogenous 
opioid function (Khatchaturian et al., 1993).
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2.7 Key points
• Opioids are proteins produced naturally by the body and appear to have a role in 
homeostasis as they are widely distributed in many tissues
• Opioid receptors can be manipulated using external (or exogenous) opioids in 
pharmaceutical form
• Some exogenous opioids have different receptor profiles to others, but tend to 
share class effects. Commonly used opioid antagonists are generally non-specific 
for opioid receptors at high doses
• Pharmaceutical opioids are considered to have their intended method of action 
through the mu opioid receptor, but relative affinities for other receptor types 
vary between compounds (compare morphine and oxycodone)
• Pharmaceutical opioids have traditionally been involved in pain management and 
anaesthesia, the latter owing to their lack of interference with common cardiac 
drugs compared with other anaesthetic agents
• The area of research into opioids is complex due to the lack of specificity of 
opioids for the three main types of opioid receptors and the measurement of 
precursor proteins that act as surrogates for the opioid compound of interest
• Discoveries of proteins with similar characteristics to endogenous opioids or 
opioid receptors, that lack their traditional opioid-like effect, has further 
complicated interpretation
• Individual human variation in the pharmacokinetics and pharmacodynamics of 
opioids also complicates the area of clinical research in humans
• Symptom based opioid research is under-researched possibly reflecting the 
reluctance of the prescription of opioids
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Section 3) Chronic Heart Failure: mechanisms, markers and management
3.1 Historical perspective
The syndrome of heart failure was probably first described in texts from the fourth 
century BC following observations from Hippocrates of excess fluid in bodily tissues 
coupled with increasing shortness of breath (Katz, 2004). For a number of centuries 
thereafter it was considered that this was a result of the development of a “cold humour” 
until Harvey described the concept of a circulation of fluid around the body in 1628. 
Following this, the signs and symptoms of heart failure could be related to 
haemodynamic causes. From the 18th century onwards, further advances in understanding 
were made following observations of the structural changes that occur in the heart in 
cardiac failure, namely hypertrophy of the cardiac muscle or dilatation of the atrial and 
ventricular cavities, both of which result in cardiac enlargement (Katz, 2004)..
Since the development of Starling’s law and subsequent identification of structural 
changes and neurohumoral factors, our understanding of heart failure has changed 
further. Starling’s law states that, up to a point, progressive dilatation of the heart can be 
advantageous in that further dilatation increases the ability of the heart to perform work, 
and therefore maintain the circulation (Opie, 2001). It would therefore appear that the 
body institutes structural changes to the circulation (i.e. cardiac hypertrophy or 
dilatation) and produces chemical factors into the circulation (neurohumoral factors) that 
seek to maintain the output of the heart in cardiac failure. Ultimately, if the cause of the 
cardiac failure is not removed, many of these factors are over-produced or have 
increasing effects that are deleterious to the cardiovascular system in an attempt to 
maintain circulation (Packer, 1988). This is part of the difficulty in the management of 
heart failure, progressive clinical deterioration in cardiovascular function in the long term 
caused in part by mechanisms instituted to maintain circulation in the short term. As 
knowledge of these proposed mechanisms advances, it is clear that the syndrome of heart 
failure is extremely complex involving multiple interactions of anatomical, functional 
and biological alterations (Mann, 2004a).
Only in the past century have drug therapies been available that target the proposed 
haemodynamic and neurohumoral changes that occur in heart failure. These will be 
discussed in more detail later in this chapter.
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3.2 Definition of heart failure
Heart failure is a clinical syndrome that can be divided by time to onset (into acute and 
chronic) or by causative mechanism depending on the timing of the greatest limitation of 
function in the cardiac cycle (into systolic or diastolic). It can be further subdivided 
according to aetiology; the most common aetiologies in the Western world comprising of 
ischaemic heart disease, hypertension and cardiomyopathy (Weatherall et al., 1996). The 
acute management of heart failure can differ from chronic management, hence the 
distinction between acute and chronic types. Acute heart failure can present as either 
pulmonary oedema or as fluid overload and is initially treated with diuretic therapy to 
diminish volume overload. Chronic heart failure (CHF) can decompensate to produce 
symptoms of pulmonary oedema or fluid overload, typically requiring higher doses of 
diuretics in the short term, but is otherwise managed with drugs that prevent further 
deterioration in cardiac function.
In addition, systolic heart failure (with impairment of cardiac function occurring during 
ventricular contraction) differs from diastolic heart failure (which occurs due to impaired 
filling of the heart) (Chatterjee and Massie, 2007). The latter condition is less recognised 
and although can demonstrate similar clinical findings on examination has been 
neglected in the research literature. Therapies to treat systolic heart failure are well 
researched, but the optimum management of diastolic heart failure is much less well 
known (Chatterjee and Massie, 2007). Most research trials for heart failure in general 
incorporate measures of severity for systolic failure, resulting in exclusion of diastolic 
patients. For the purposes of accuracy in this thesis therefore, and given these 
differences, the term “heart failure” will relate to chronic heart failure (CHF) occurring 
due to systolic dysfunction.
3.3 Incidence and prevalence of heart failure
The incidence and prevalence of heart failure is increasing with the average age of the 
population and greater survival after acute coronary events (Department of Health, 2000, 
Kannel, 2000, Thomas and Rich, 2007). It represents a significant cause of morbidity and 
mortality. In 2002, it was considered that up to 900,000 people had a diagnosis of HF in 
the UK (Petersen et al., 2002). It is the most common cause of death in hospitalised
patients and was found to be the most common cause of all hospital re-admissions in a
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small Scottish study (McMurray et al., 1993). Given this significant burden, in recent 
years there has been great interest in the management of heart failure. The emergence of 
specific drug treatments such as ACE inhibitors and Angiotensin receptor antagonists 
and the re-emergence of Beta-blocker therapy in the management of this condition have 
lead to an improvement in the underlying disease process by slowing the rate of 
development of more severe symptoms (Satwani et al., 2004, Davies, 2006). However, 
this will inevitably result in higher numbers of patients living through heart failure, often 
with significant symptoms causing detriment to their quality of life. Indeed, the predicted 
burden of heart failure demonstrates notable suggested increases in the prevalence of 
heart failure, in hospital admissions and GP consultations from extrapolation from 
previous epidemiological data (Stewart et al., 2003). These patients will still experience 
troublesome symptoms due to their disease, but it is feasible that they will have a longer 
period with these symptoms than prior to the introduction of the standard therapy we use 
today. Hence it is likely that there is an increasing prevalence of patients with CHF and 
in turn an increased number of symptomatic patients living through their disease. This 
makes the focus on symptom control for these patients more important.
3.4 Pathophysiology
The pathophysiology of heart failure is well researched elsewhere in the literature (See 
Section 2, Heart failure: a companion to Braunwald’s heart disease, Ed. Mann D.L. 2004 
for a review). Various systemic changes occur in heart failure following an initial cardiac 
insult, resulting in cardiac dysfunction. Cardiac dysfunction leads to a reduced cardiac 
output, with further cardiac insults resulting in greater cardiac dysfunction. Reductions in 
cardiac output result in the activation of compensatory mechanisms that exist to preserve 
oxygen delivery to vital organs through haemodynamic changes (Roig, 2006). These 
changes in CHF include the chronic activation of the neuroendocrine system, producing a 
number of circulating factors that include opioids (Fontana et al., 1993, Francis et al., 
1985, Francis, 1990) and results in activation of the sympathetic nervous system, 
peripheral vasoconstriction and salt and water retention (Roig, 2006, Francis et al.,
1985). This neurohumoral or neurohormonal activation is one important theory and 
mechanism to explain the events that occur in CHF (Katz, 2004, Watson et al., 2006, 
Roig, 2006, Packer, 1988). Some of these neurohormones and their effect in CHF are 
much better researched than others. The effect of these naturally occurring (endogenous)
opioids in CHF is under-researched compared to some of these other circulating factors.
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It is important to note that most of the neurohormones accepted to play a role in the 
progression of heart failure are required for the normal homeostasis of the human body. 
For example, norepinephine (noradrenaline) is required to increase adrenergic drive in 
response to exercise, traumatic injury or a variety of other stresses that require an 
increase in cardiac output (Port et al., 2004). However, this release is relatively transient 
in normal circumstances but becomes detrimental if its activation is prolonged.
In normal circumstances, baroreceptors in the heart and great vessels regulate blood flow 
to the vital organs by inhibiting both the sympathetic nervous system and Anti-diuretic 
hormone (ADH) via impulses sent to the cardiovascular centres in the brain. Whenever 
blood flow is compromised however, as following a cardiac insult, these baroreceptors 
monitor the subsequent fall in cardiac output and reduce the number of inhibitory signals 
sent to the brainstem. This results in activation of the sympathetic nervous system 
leading to increased blood flow and retention of fluid via stimulation of RAAS and ADH 
to maintain blood volume (Packer, 1988).
Patients with CHF have markedly reduced baroreceptor activity (Hirsch et al., 1987), 
resulting in a reduced number of inhibitory signals and ultimately an overactivity of these 
vasoconstrictor systems (Clark and Cleland, 2000, Watson et al., 2006, Ferguson et al., 
1984). Various chemical factors - “neurohormones” - are implicated in the correct 
functioning of these vasoconstrictor systems, with norepinephrine and adrenaline 
involved in the functioning of the sympathetic nervous system and ADH, Angiotensin, 
Aldosterone and Renin involved in the Renin-Angiotensin-Aldosterone (RAAS) 
vasoconstrictor system. In general, these factors are released to maintain the systemic 
circulation in response to cardiac dysfunction. This is considered beneficial in the short 
term, but is increasingly seen as detrimental in the longer term (Benedict et al., 1993, 
Mann et al., 1992, Roig, 2006, Clark and Cleland, 2000). In CHF the chronic activation 
of the sympathetic nervous system increases vascular resistance and has a positively 
inotropic effect, ultimately increasing workload and afterload for the struggling heart in 
chronic heart failure. This in turn reduces cardiac output, leading to further sympathetic 
activation and so on (van den Brink et al., 2003) as demonstrated in Figure 1.3.1 below.
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Figure 1.3.1: Cycle of involved mechanisms following a cardiac insult that reduces 
cardiac output. Reduced cardiac output leads to a subsequent fall in blood pressure, 
resulting in a lowering of the basal output from arterial baroreceptors. This in turn results 
in an attenuation of the inhibition of the sympathetic nervous system, causing amongst 
other effects an activation of RAAS, an increase in peripheral resistance and subsequent 
increase in blood pressure. This therefore seeks to increase the afterload to the heart. 
Ongoing cardiac insults, as in CHF, results in a continuation of this cycle, which is 
ultimately results in the ongoing activation of the sympathetic NS and further cardiac 
insults. (Adapted from Cleland and Clark 2000 and Francis et al 1985).
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In addition to arterial baroreceptors, mechanical receptors (ergoreceptors in skeletal 
muscle) and chemoreceptors are all considered responsible for maintaining sympathetic 
activity in heart failure (Watson et al., 2006). Chemoreceptors monitor levels of blood 
gases in the circulation and are thought to influence respiratory function by altering 
respiration according to serum levels of oxygen and carbon dioxide (Duffin and 
McAvoy, 1988). Hypoxia leads to an activation of these receptors and subsequent relay 
of this information to the NTS in the brain, which in turn can activate the sympathetic 
nervous system (Madden and Morrison, 2005). Baroreflex stimulation normally reduces 
the effect of chemoreceptor (chemoreflex) activation and vice versa (Somers et al.,
1991), so in human CHF where baroreflex activity is reduced, chemoreceptor activity is 
enhanced (Heistad et al., 1974). In addition, peripheral chemoreceptors in the lung 
adjacent to alveolar capillaries have an input into the central autonomic centres in the 
brain (Holaday, 1983). These reflexes and receptors are potentially important as they are 
also implicated in mechanisms for breathlessness, which is described in more detail later. 
Figure 1.3.2 illustrates the relative inputs to the autonomic centre in the brainstem and 
outputs to the opposing sympathetic and parasympathetic systems in both health and in 
CHF.
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Figure 1.3.2: The relative balance of inputs to the vasomotor centre in the brainstem and 
subsequent outputs through the sympathetic and parasympathetic systems to regulate 
cardiovascular function. In health, there is a relative balance of baroreceptor and 
cardiopulmonary receptor input greater than chemoreceptors and ergoreceptors to the 
vasomotor centre, leading to a relative output from the centre favouring the 
parasympathetic system over the sympathetic. In CHF, the opposite is true, with a greater 
emphasis on the inputs from chemo- and ergo-receptors leading to enhanced sympathetic 
activity (i.e. a relative change in balance to favour sympathetic activation over 
parasympathetic) -  adapted from Clark & Cleland 2000
Sympathetic
(Adrenergic)
activity
The Renin-Angiotensin-Aldosterone-System (RAAS) has also been implicated as one of 
the major systems contributing to CHF and has been the target of much pharmaceutical 
intervention. This system again is important for nonrial homeostatic regulation of blood 
pressure and salt and water retention, but becomes detrimental if its activation is 
prolonged following the development of decreased cardiac output after an initial cardiac 
insult as in CHF (Camm, 1998). Angiotensin II is a potent vasocontrictor and its presence 
activates further cascades of downstream effects including remodelling of the heart 
musculature and production of other peptides important in CHF such as Aldosterone.
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Figure 1.3.3 demonstrates the importance of the RAAS system and also the site of action 
of some drugs used in CHF described in section 2.7.
Figure 1.3.3: To illustrate the major neurohormones involved in the progression of CHF. 
Renin in the kidney converts angiotensinogen to angiotensin I; ACE converts 
Angiotensin I to ATII and de-activates bradykinin in the lung. ACEI act at the level of 
ACE, ARBs act on the ATI receptor, Spironolactone inhibits Aldosterone effects, 
betablockers (BB) antagonise the actions of norepinephrine. Key neurohormones and 
their relationship to each other are shown in colours. Aldosterone production has a 
negative feedback effect on renin activity.
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As previously stated, sustained over-activation of the sympathetic nervous system and 
RAAS is detrimental. For example the SOLVD and CONSENSUS multicentre RCT 
studies in CHF revealed that patients with more severe CHF exhibited higher levels of 
norepinephrine and angiotensin II. Subsequently patients with CHF were more likely to 
die during follow-up if they had higher circulating levels of norepinephrine, angiotensin 
II and aldosterone, adding weight to the argument that neurohormonal control in CHF 
was important for prognosis (Francis et al., 1990, Eriksson et al., 1994). In addition, data 
from the Val-HeFT trial also demonstrated that CHF patients with lower norepinephrine 
concentrations and lower levels of RAAS activation had a lower mortality (Latini et al., 
2004). It is suggested that both the sympathetic nervous system and RAAS are 
chronically activated in CHF and that RAAS can increase sympathetic activity and vice 
versa, leading to a cascade (Watson et al., 2006). The RAAS system has direct effects on 
sympathetic activity; both aldosterone and angiotensin II potentiate the effects of 
norepinephrine and ACEI reduce both circulating levels of norepinephrine and increases 
parasympathetic tone (Clark and Cleland, 2000). Aldosterone also has ai direct effect on 
depressing baroreceptor function (Clark and Cleland, 2000). Hence these two 
vasoconstrictor systems are interlinked through the effects of the neurohormones 
involved in their activity. This is demonstrated in Figure 1.3.4 which attempts to show 
the cyclical interlinking of these important factors in CHF. Chronic activation of these 
vasoconstrictor systems through neurohormonal de-activation therefore needs to be 
attenuated to improve mortality rates and severity. Table 1.3.1 describes the, 
neurohormones traditionally considered as being important and their role in the 
development of CHF.
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Figure 1.3.4: Diagram of the chronic activation of the sympathetic nervous system 
through potentiation of norepinephrine from the key events and systems involved in 
CHF. The red line demonstrates the interlinking of RAAS and the sympathetic nervous 
systems. Otherwise the colour scheme is designed to link to the other figures in section 3.
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Table 1.3.1: Summary of Neurohormones traditionally considered in heart failure 
{Adapted from (Swanton, 2003, Watson et al., 2006, Benedict et al., 1993, Mann, 
2004b)}
Neurohormone Level in CHF Role / Potential effect
Norepinephrine Elevated in relation 
to severity of CHF
Implicated in enhanced sympathetic 
overdrive to maintain cardiac output but 
cardiotoxic if exposure prolonged (mediated 
via cAMP increases in intracellular calcium) 
leading to further cardiac muscle dysfunction. 
Vasoconstriction, activation of RAAS, 
sodium reabsorption increased
Natriuretic 
factors (ANP, 
BNP)
Elevated in relation 
to severity of CHF
Natriuretic and diuretic (reducing salt and 
water retention), reduces rate of cardiac 
remodelling, inhibits Renin Angiotensin 
Aldosterone system, Aldosterone and 
Vasopressin (ADH) release
Endothelin Increased in plasma 
in relation to 
severity of CHF
Upregulated receptors may have role in 
cardiac fibrosis and circulating endothelin 
causes vasoconstriction
Angiotensin II Released in 
response to failing 
cardiac output
Involved in remodelling of myocardium 
through fibrosis and hypertrophy; salt and 
water retention; peripheral vasoconstriction; 
activation of norepinephrine and aldosterone 
release
Aldosterone Cardiac release 
increased
Promotes sodium retention, leading to fluid 
retention. Also implicated in remodelling of 
cardiac muscle, scar formation & enhancing 
norepinephrine
Not all neurohormones released in heart failure are considered detrimental and it is 
considered that some are released (e.g. natriuretic peptides, bradykinin) in order to 
balance or counter over-stimulation of the more detrimental types (e.g. norepinephrine) 
(Roig, 2006, Packer, 1988). Natriuretic peptides released in CHF, for example,
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antagonise the actions of RAAS as shown in Table 1.3.1. Hence certain neurohormones 
may actually be cardioprotective rather than detrimental to the failing myocardium, and 
circulating levels of these hormones are not necessarily indicative of causing myocardial 
damage per se themselves. Alternatively, some of these neurohormones may simply 
reflect the process of CHF and the level of neurohormonal activation; higher levels of 
natriuretic peptides for example having a worse prognosis than those without (Latini et 
al., 2004, Balion et al., 2006). Unfortunately in CHF, the balance of these 
neurohormones tends to favour those ultimately resulting in a maladaptive process and 
further progression of CHF. It is therefore not so simple to suggest that all 
neurohormones have a detrimental effect in CHF and it is possible or feasible that 
opioids released in CHF may have a potentially cardioprotective effect. This possibility 
is explored further in Chapter 2.
Other changes can also occur in heart failure, such as cardiac muscle remodelling, 
arrhythmias, metabolic disturbances and impaired end-organ function (Cleland, 2004) 
but discussion of these complex events is beyond the scope of this thesis. Suffice to say 
that neurohormonal activation is one unifying theory that results in many of these 
changes in heart failure and is therefore considered extremely important to regulate. 
Current treatments for CHF are generally targeted towards reversing the processes that 
are seen to occur in CHF, particularly neurohormonal changes. Further limitation of any 
detrimental neurohormonal activation is considered to be beneficial, particularly as many 
current drug interventions indirectly attempt to further reduce sympathetic overdrive 
(Davila et al., 2005) or vasoconstrictor activation and remain the target for future heart 
failure therapies (Massie and Shah, 1995). Although opioids have been identified as part 
of this overall neurohormonal activation, therapy has been limited to acute heart failure 
and end-stage chronic heart failure without a good clinical evidence base.
3.5 Clinical syndrome of heart failure
Heart failure can be classified using the New York Heart Association (NYHA) grading 
system which assesses the functional status of the patient. This is a measure of how 
limited the patient is by typically the most predominant symptom, namely breathlessness. 
Other symptoms of heart failure can include oedema, fatigue, cough, anorexia, cachexia 
and other systemic symptoms (Johnson and Gibbs, 2006). This observation of a systemic
disease impacting on the overall physiology of the patient has led researchers to further
40
investigate the variety of neurohumoral substances that are produced during heart failure, 
as described above. For a review of the clinical signs and symptoms, please refer to 
Mann (2004b).
Recently the Heart Failure Association of the European Society of Cardiology produced 
a position statement for the involvement of palliative care in heart failure (Jaarsma et al., 
2009). They detail key areas for improvement or integration, including delivery of care, 
education, health policy and notably the need for research. A relative gap exists in the 
evidence base for the clinical use of interventions that control disease progression and 
those that actually target the symptoms produced rather than the pathological processes. 
The management of breathlessness in particular and the current hypotheses as to the 
mechanisms involving in the development of breathlessness are detailed in Chapter 3.
3.6 Diagnosis and prognosis
The diagnosis of CHF is based on a history of the spectrum of symptoms described 
above, clinical signs and investigations to confirm the diagnosis. The investigations 
included in the standard diagnosis for CHF are described below. Again, this is not a 
comprehensive review but designed to provide a brief background for reference later for 
the RCT (Chapter 4). Ongoing review of signs and symptoms are required to determine 
disease progression and to review any potentially reversible factors. The New York Heart 
Association classification (Table 1.3.2) is a commonly used measure involving categories 
of functional status. These categories are important as they not only describe the patient’s 
status but are also a useful prognostic tool. The major problem with the classification is 
that it is subjective, but when used correctly as part as a generalised assessment it can be 
useful to monitor general improvement or deterioration (Francis and Tang, 2004a).
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Table 1.3.2: The NYHA classification of CHF
Functional
Class
Functional capacity
I Patients with cardiac disease but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea or angina pain.
II Patients with cardiac disease resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity results 
in fatigue, palpitation, dyspnea or angina pain.
III Patients with cardiac disease resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary physical 
activity causes fatigue, palpitation, dyspnea or angina pain.
IV Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort. Symptoms of heart failure maybe 
present at rest. If any physical activity is undertaken, discomfort is 
increased.
In accordance with Department of Health Guidelines (DoH 2000), required 
investigations for CHF include:
• 12 Lead ECG
• Echocardiogram
• Other investigations to add weight to the clinical symptoms and signs or to 
exclude other causes of breathlessness (for example; Chest x-ray, B-type 
natriuretic peptide (BNP), Haemoglobin concentration, renal function, weight)
The ECG is a useful tool to assess the underlying rate and rhythm of the heart. 
Arrhythmias may be indicative of the cause of heart failure, or may represent one of the 
consequences of heart failure. The presence of arrhythmias can represent another marker 
of disease severity and may be a potential source of additional treatment that may benefit 
the patient other than standard anti-heart failure therapy alone. Heart rate variability and 
analysis of the ventricular complexes may provide further clues towards the aetiology of 
heart failure or can act as prognostic markers (Stevenson, 2004). A more detailed review 
of the potential changes in heart failure can be found in Mann (2004b).
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Echocardiography is used to confirm the diagnosis of heart failure from the clinical 
findings elicited from the history and examination of the patient. It allows the structure 
and function of the heart to be assessed. It is useful to determine the nature of heart 
failure (e.g. systolic or diastolic) and aetiology of the disease (e.g valvular abnormalities, 
cardiomyopathy or ischaemic heart disease). Part of the examination includes an 
assessment of the left ventricular ejection fraction (EF). This is an estimate of the ratio of 
stroke volume to end-diastolic volume, which can vary from day to day in the same 
patient and has a degree of inter-operator variability (Francis and Tang, 2004a). Absolute 
numerical values of the ejection fraction are therefore not wholly reliable due to this 
variation in assessment. However, it does provide as estimate of the degree of systolic 
dysfunction (LVSD) which has an inverse relationship with ejection fraction (i.e. the 
lower the ejection fraction the greater the degree of systolic dysfunction) (Francis and 
Tang, 2004a). Magnetic resonance imaging is considered to provide a more reliable 
estimate of ejection fraction, though echocardiography will remain in routine practice 
due to its ease of use and ease of availability.
In addition, diagnostic tests to allow more rapid identification of heart failure in patients 
attending with breathlessness have been devised. Given the aetiology of heart failure, 
many patients will have co-existing diagnoses contributing to breathlessness. For 
example, a heavy smoker may have heart failure, ischaemic heart disease, chronic 
obstructive pulmonary disease or even lung cancer that may result in breathlessness. One 
such diagnostic test involves measurement of plasma b-type natriuretic peptide (BNP) 
levels. BNP is a protein released by the cardiac ventricles as a result of myocardial stress 
(Ambrosino and Serradori, 2006). It is stored as a larger peptide (pro-BNP) and is 
released following enzymatic cleavage to N-terminal pro-BNP (NT-proBNP), which is 
inactive, and BNP (the active product) (Francis and Tang, 2004b). Measurement of BNP 
typically involves the evaluation of NT-proBNP as a surrogate measure for BNP (Clerico 
et al., 2007) and in this respect the terms NT-proBNP and BNP are used interchangeably. 
BNP measurement is useful in two ways. Firstly, it has a negative predictive value 
whereby normal levels are predictive of the absence of heart disease (Maisel et al., 2008). 
A level above 50pg/ml is considered indicative of CHF (Swanton, 2003) which can aid 
diagnosis. Secondly, patients with more severe heart failure tend to have higher 
concentrations of circulating BNP (Ambrosino and Serradori, 2006). BNP and NT- 
proBNP are also independent predictors of mortality in CHF (Balion et al., 2006). 
Monitoring of BNP levels is not yet routine in the UK, but this may change in
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forthcoming years and it is recommended in Royal College of Physicians Guidelines for 
CHF (NICE guideline number 5 2003).
3.7 Current pharmacological management of CHF
The Department of Health (2000) developed guidelines for the management of CHF as 
part of their National Service Framework for care. These guidelines were produced in the 
light of large multicentre randomised controlled trials, often in thousands of patients. As 
documented previously, targets for drug therapy have been those detrimental 
neurohormones chronically released following a cardiac insult. Recommendations for the 
treatment of CHF included use of Angiotensin Converting Enzyme Inhibitors (ACEIs) as 
the first line treatment. Clinical trials and experience demonstrate that these drugs 
prolong life, delay progression of CHF and can improve symptoms. These drugs are 
often titrated in dose in combination with Beta blockers, which have been shown to 
reduce mortality in combination with ACEIs. Previously beta blockers had been 
considered potentially detrimental (Cleland et al., 1998) and are still normally prescribed 
in patients with stable heart failure symptoms only. With co-prescription of diuretics, this 
combination of three drug classes forms the mainstay of therapy for most CHF patients. 
As their condition becomes more advanced, aldosterone antagonists have been shown to 
reduce mortality in patients on existing standard therapy (RALES study investigators, 
1996, Pitt et a l, 2003) and digoxin withdrawal in CHF is recognised to increase hospital 
admissions and worsen symptoms, suggesting a symptom benefit with digoxin in CHF 
(Packer et al., 1993). These drugs are therefore added in to the pharmaceutical regimen in 
selected patients. Other drugs involved in the prolongation of natriuretic peptide activity 
(Packer et al., 2002) and reduction of other potentially detrimental neurohormones such 
as endothelin are undergoing clinical trials (Packer et al., 2005).
Since the Department of Health guidelines in 2000, Angiotensin receptor blockers 
(ARBs) have emerged as an alternative to ACEI in intolerant patients and Aldosterone 
antagonists have been evaluated for symptomatic CHF in European and American 
guidelines for CHF management (Swedberg et al., 2005, McMurray and Swedberg, 
2006). Table 1.3.3 summarises the common drugs used in CHF. The site of action of 
these drugs can be seen in Figure 1.3.3 shown earlier.
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It can be seen that effective drug management has targeted the relative reduction in effect 
of the neurohormones secreted in CHF. As opioids are part of the neurohormonal picture, 
enhancing the effect of these substances may be seen to contradict the conventional 
wisdom of reducing the effect of the neurohormones secreted (for example ACEI reduce 
the formation of ATII, Beta-blockers reduce the effect of norepinephrine etc.). However, 
manipulation to enhance the effect of opioids does not set a precedent in terms of 
neurohormones. For example, prolongation of the effect of natriuretic factors is 
considered beneficial (Packer et al., 2002) and therefore it is feasible to suggest that 
some neurohormones are best inhibited, and some (possibly opioids) are best stimulated.
45
Table 1.3.3: Pharmaceutical intervention strategies in CHF
Drug Action Benefit in CHF RCT examples
ACEI Inhibit Angiotensin 
Converting Enzyme 
(thus preventing 
formation of the potent 
vasoconstrictor ATI1)
Mortality reduction 
Delay progression 
Symptom improvement
SOLVD 1991
CONSENSUS
1987
Beta
blockers
Inhibit Sympathetic 
Overdrive associated 
with CHF
Mortality reduction in 
combination with ACEI
COPERNICUS
2001
C IB ISI1994 
CIBIS I I 1999 
MERIT-HF 
1999
ARB Inhibit effect of 
Angiotensin II by 
blocking the ATI 
receptor
Comparable mortality and 
hospital admissions to 
ACEI
ELITE II 2000
Aldosterone
antagonists
Prevents development 
of myocardial fibrosis, 
intravascular depletion 
and catecholamine and 
endothelin release 
(Mann chap 9) through 
aldosterone inhibition
Mortality reduction in 
combination with ACEI
RALES 1999 
Pitt et al 
(2003)
Diuretics Reduction of oedema & 
excess fluid
Improvement of acute 
symptoms with mortality 
reduction
Latta et al 
(1990),
Allman and 
Norris (1990)- 
comparative 
studies only
Digoxin Increases availability of 
calcium in cardiac 
muscle resulting in 
inotropic effect
Reduced hospital 
admissions with digoxin
DIG mortality 
trial 1997 
RADIANCE 
1993
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Hence management of chronic heart failure is directed mainly towards prevention of 
further myocardial injury rather than treatment of specific symptoms. This is important 
for research as therapies targeted at slowing the rate of progression of CHF have 
dominated the literature in this area for the past few decades. Multi-centre randomised 
controlled trials involving thousands of patients advocate the use of the current standard 
treatment regimens. However, primary endpoints for these trials have concentrated on 
either rates of death or rates of hospitalisation. Quality of life and the patient experience 
whilst living through chronic heart failure has generally not been considered as part of 
these studies, except as secondary endpoints. The focus of these large trials was to 
demonstrate treatment efficacy and rates of hospitalisation and death due to chronic heart 
failure have fallen since the introduction of these therapies (Department of Health, 2000). 
More importantly, as a result of these trials, patients with CHF are living longer with 
their disease, leading to an expanding cohort of patients who are kept alive by their 
standard therapy (Thomas and Rich, 2007, Kannel, 2000, Stewart et a t, 2003).
Symptom control research therefore has been relatively neglected but given that many 
patients are living through the disease with symptoms that adversely affect their daily 
lives, research into improving symptoms provides a potential avenue for improving the 
quality of life of a great number of patients. Instead of looking from the perspective of 
the disease by trying to modify or slow progression of symptoms, relatively little is 
known about the management of problems like breathlessness once a patient has CHF 
sufficient to cause symptoms despite the use of preventative approaches. Hence a relative 
gap in our knowledge exists in the area of symptom palliation in CHF.
Non-pharmacological interventions for advancing heart failure are also available but are 
beyond the scope of this review. Please see McMurray and Swedberg (2006) for a review 
of the evidence for the above treatments. Various other drugs are being evaluated for 
symptomatic heart failure, including cardiac inotropes, but again discussion of this is 
beyond the scope of this thesis (see Oxberry & Johnson (2008) for review).
Although ACEIs may not only slow the progression of disease but also improve 
symptoms, relatively few of the drugs listed above are considered to directly improve 
symptoms in CHF. Most have been designed to prolong life or maintain the functional 
class of the patient, as mortality, NYHA class and rate of hospital admissions are most
frequently the primary outcomes of the large multicentre cardiology RCTs in this area.
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As noted previously, symptom management and quality of life are either secondary 
outcomes or not considered at all in the analysis (especially in the earlier RCTs). 
Evaluating treatments from the patient perspective of quality of life and symptom control 
has thus far often been a secondary priority. Hence, a potential knowledge gap exists for 
therapies that have the primary goal of symptom control. The general management of 
breathlessness in CHF from a symptom based perspective is discussed in the next 
section.
3.8 Key points
• Heart failure is a complex systemic disease process that can be subdivided into 
many types according to aetiology, timing or type of physical dysfunction
• Stable symptomatic CHF should be considered as a different disease to acute 
heart failure or acute-on-chronic heart failure due to different reasons for the 
development of symptoms including breathlessness
• The incidence and prevalence of chronic heart failure is increasing due to the 
ageing population, better survival after acute cardiac events and improved drug 
therapies
• Various systemic changes including the release of neurohormones occur in heart 
failure, most of which are considered detrimental and that may be potentially 
manipulated by drug therapy
• Neurohormonal activation has been targeted by effective drug therapies, most of 
which focus on reducing the impact of the neurohormone (such as for 
norepinephrine, angiotensin, aldosterone), but not exclusively (consider 
natriuretic hormones)
• Much of the current recent pharmaceutical research has focussed on the reduction 
of the speed of progression of the disease rather than symptom control
• Diagnosis and disease progression typically involves the measurement of ejection 
fraction on echocardiography alongside a suitable clinical history with BNP 
emerging as an adjunct to this process
• There is growing recognition that heart failure patients should have better 
palliation of their symptoms
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• More patients are living through chronic heart failure with symptoms that at 
present are poorly palliated due in part to a lack of available evidence of the 
efficacy of symptomatic measures
• It could be said that the initial reluctance by medical practitioners to use opioid 
medications without information from an evidence base mirrors the initial 
counter-intuitive thoughts surrounding the use of beta-blockers in chronic heart 
failure. Despite previous misgivings, beta blocker therapy has now become 
accepted practice in chronic stable heart failure
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Section 4) Breathlessness -  a problematic symptom
4.1 Introduction
Breathlessness is a common symptom in many disease states and can become more 
problematic as the condition becomes more advanced. Daily episodes of breathlessness 
are reported in over half of chronic heart failure (CHF) patients taken from a 
representative community sample in the UK and this understandably impacts on their 
quality of life (Barnes et a i, 2006). Hence breathlessness represents a troublesome 
symptom for many patients with CHF, with the prevalence of this symptom likely to rise 
given the rising prevalence of this chronic disease.
The terms “dyspnoea” or “dyspnea” and breathlessness have been used interchangeably 
in the literature to date. The American Thoracic Society (ATS) has defined 
breathlessness as “a subjective experience of breathing discomfort that consists of 
qualitatively distinct sensations that vary in intensity. The experience derives from 
interactions among multiple physiological, psychological, social, and environmental 
factors, and may induce secondary physiological and behavioural responses” (American 
Thoracic Society, 1999). For the purpose of this thesis, breathlessness, shortness of 
breath and dyspnoea will be used interchangeably.
4.2 Measurement of breathlessness
Many physical indicators are utilised in clinical practice as surrogates for dyspnoea, but 
none are necessarily specific for the actual sensation of feeling short of breath.
Measuring oxygen saturation, for example, simply informs the clinician of the level of 
oxygenation in the blood, and respiratory rate per minute can be influenced by a number 
of factors (hyperventilation due to anxiety, for example). Hence various subjective 
measurement tools have been developed in order to measure and monitor the sensation of 
breathlessness from the perspective of the patient.
These tools include Numerical Rating Scales (NRS), Visual Analogue Scales (VAS), 
Verbal Rating Scales (VRS) and the modified Borg scale for breathlessness. Recently the 
value of these scales has been evaluated from a clinical perspective. It is considered that
a change of 10% in a VAS scale, or 1 point on the modified Borg score as being
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clinically significant (Booth, 2006). It is also recommended, given the complexity and 
multi-factorial nature of breathlessness, that these scales should be used in combination 
with each other and with physical physiological measurements (Booth, 2006).
Descriptors for breathlessness have also been formulated which reveal that patients with 
different diagnoses resulting in breathlessness describe different qualitative experiences 
for the feeling of dyspnoea. Wilcock et al. (2002) is one study that compares responses 
of the feeling or sensation of breathlessness between patients with differing primary 
diagnoses and suggests that patients with different aetiologies for their symptoms 
describe a different experience. For example, patients with a lung cancer mass describe 
the inability to get enough air, feeling out of breath and breathing that requires more 
effort as the most common responses. In contrast, CHF patients most commonly describe 
feeling out of breath, chest tightness and inability to get enough air. This suggests that 
the description of breathlessness differs from one disease to another, further complicating 
the method of evaluating the patient experience.
Given these observations, the development of dyspnoea is likely to be multi-factorial 
potentially involving the peripheral and central respiratory systems, cardiovascular 
system and other inputs from the periphery and higher cortical centres. In heart failure, a 
number of potential mechanisms have been proposed. Of course, given the more elderly 
nature of the heart failure population, patients often have co-existing respiratory disease, 
notably chronic obstructive airways disease, which can further complicate the nature and 
mode of breathlessness.
4.3 Respiratory homeostasis — control of breathing
In order to understand the potential mechanisms of breathlessness and possible 
management strategies to employ, one must first consider the mechanisms involved in 
normal function. Respiratory activity is co-ordinated by the respiratory centre in the 
brain. This centre receives inputs from both the periphery and centrally and modulates 
the control of breathing based on these inputs. It also exhibits an intrinsic rhythm to 
breathing, generated from within the brainstem, and exerts the necessary effects via 
neurons that innervate the respiratory muscles including the diaphragm (Florez and 
Hurle, 1993).
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Regulation of respiratory function is derived primarily by the autonomic nervous system 
involving sympathetic and parasympathetic components (Mazzone and Canning, 2002). 
Peripheral and central chemoreceptors located in blood vessel walls deliver information 
regarding changes in circulating arterial gas concentrations and pH. Information is 
transmitted by the carotid (IX nerve) and aortic (X -  vagus -  nerv e) nerves whose nerve 
afferents terminate in the nucleus tractus solitarius (NTS). This is the same autonomic 
centre responsible for cardiovascular homeostatic maintenance (Holaday, 1983) as 
discussed previously.
Autonomic effects are regulated by opposing pathways, the sympathetic and 
parasympathetic {the parasympathetic being the predominant regulator of function 
(Mazzone & Canning 2002)}. The major parasympathetic components in the brainstem 
linked to the NTS are the NA (nucleus ambiguous) and DVN (dorsal vagus nucleus). 
Sympathetic outflow is regulated through the NTS to the hypothalamus (Holaday, 1983). 
Information is also obtained by the respiratory centre from' stretch receptors in thè 
respiratory muscles and pulmonary mechanoreceptors located within the airways 
themselves. These mechanoreceptors include a subtype termed juxta-capillary (“j ” 
receptors) which monitor chemical irritation in the airway mucosa. Again, information is 
carried from these sites by the vagus nerve to the NTS (Florez and Hurle, 1993). Figure
1.4.1 illustrates these points. Interestingly, many of these structures are important sites 
for location of opioid receptors as discussed in Chapter 2. In addition, an analogy of 
breathlessness with pain has been suggested, given that the areas involved in the sensory 
cortex are similar for pain and breathlessness in imaging studies in humans and that the 
neurophysiology for pain and breathlessness may therefore be similar (Lansing et al., 
2009). Opioids are powerful analgesics and it is interesting to hypothesise that they may 
also be involved in breathlessness management. A review of respiratory homeostasis can 
be found in Mazzone & Canning (2002) but it is interesting to speculate the potential role 
both centrally and peripherally of opioids in the regulation of breathing function. What is 
not known is whether opioid expression at these sites alters in breathless patients 
compared to normal controls.
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Figure 1.4.1.: Respiratory function mediated by the autonomic nervous system {adapted 
from Manning & Schwarzstein (1995)}: Afferent information from peripheral structures 
(chest wall, j receptors, chemoreceptors and ergoreceptors) input into the respiratory 
centre in the brainstem using the sensory vagus nerve. Inputs from the sensory cortex 
also occur at this point. The respiratory centre instructs a respiratory response to this 
information via the motor cortex to the respiratory muscles. Arrows indicate the direction 
of flow of information. Areas shaded in green are located in the CNS, blue areas are 
located in the peripheral respiratory system.
Motor
cortex
< * • Sensory cortex
Respiratory
muscles
Chest wall, j 
receptors and 
ergoreceptors
4.4 Mechanisms of breathlessness in CHF
Many potential mechanisms of dyspnoea or the sensation of breathlessness at rest or on 
movement have been proposed. In general, due to the small scale nature of the studies 
performed thus far, conclusions as to the potential mechanisms of breathlessness have 
been extrapolated across basic science and animal models of dyspnoea as well
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breathlessness induced in healthy human models. Studies involving breathlessness in 
chronic heart failure patients are rare.
A number of potential mechanisms for the formation of dyspnoea in general have been 
proposed but the pathophysiology of intractable breathlessness in disease remains poorly 
understood. These suggested mechanisms include the effect of hypoxia and hypercapnea 
via central and peripheral chemoreceptors; alterations in localised feedback from 
receptors in the lung to irritation, stretch and interstitial congestion in pulmonary 
capillaries; changes in vagal inputs supplying afferent information to the central nervous 
system; altered feedback from muscular chest wall and juxta-capillary mechanoreceptors 
(Manning and Schwartzstein, 1995, Chua and Coats, 1995, Thomas and von Gunten, 
2002). Yokoyama et al (1994) hypothesise that dyspnoea seen in chronic heart failure 
patients may be due to either stimulation of peripheral or central chemoreceptors by 
excessive carbon dioxide production, or mechanoreceptor stimulation in the lung due to 
pulmonary congestion and respiratory muscle fatigue. It is considered that the hypothesis 
of “afferent mismatch”, whereby subjects feel breathless if the sensory experience does 
not meet the expectations of the sensorimotor cortex, may represent the final common 
pathway of the sensation of breathlessness in conjunction with some or all of the other 
mechanical and chemical inputs (American Thoracic Society, 1999).
Research involving the mechanisms of dyspnoea specifically in CHF is scarce. On 
exercise, increased ventilation in CHF may occur from abnormal respiratory patterns, 
early lactic acidosis, increased pulmonary capillary pressures and increased physiological 
pulmonary areas of “dead space” (Sullivan et al., 1988). In addition to those mechanisms 
described above, abnormal breathing patterns are observed in some patients with CHF. 
These abnormal patterns include Cheyne-Stokes respiration (cyclical rises and falls in 
ventilation associated with episodes of apnoea and concomitant hypoxaemia) and 
periodic breathing (rises and falls in ventilation without true periods of apnoea). 
Sometimes these patterns are present at rest or during sleep; some patients require 
exercise to demonstrate the phenomenon (Ribeiro, 2006). These abnormal breathing 
patterns are associated with poorer prognosis in CHF and increased sympathetic activity 
(Leung et al., 2006, Leung et al., 2003, Corrà et al., 2006). Ponikowski and colleagues 
(Ponikowski et a l, 1999) studied 74 chronic stable heart failure patients to identify such 
patterns. They discovered over half of the patients had either Cheyne-Stokes or Periodic 
breathing episodes. These patients had more advanced symptoms, reduced baroreceptor
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activity and increased chemosensitivity when compared to heart failure patients with 
normal breathing patterns, in keeping with sympathetic overactivation.
Sleep disordered breathing or sleep apnoea is also prevalent in patients with heart failure, 
through chronic enhanced activation of the sympathetic nervous system and is similarly 
associated with a worse prognosis (Ferreira et al., 2006). Hence, sympathetic overdrive is 
considered to be a mechanism in the sensation of breathlessness in CHF in a number of 
different breathing patterns. The proposed mechanisms of breathlessness specific for 
CHF are detailed in Table 1.4.1.
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Table 1.4.1: Potential mechanisms for breathlessness in CHF {from Chua and Coats 
(1995), Manning & Schwarzstein (1995), Ferreira et al (2006)}
Mechanism Proposed theory in CHF
Ventilation Restrictive lung pattern secondary to loss of lung volume due to
abnormalities cardiomegaly and stiffening of lung parenchyma due to fluid 
retention. Reduced effective diffusion due to ventilation: 
perfusion mismatch.
Pulmonary
function
Reduced transfer factor in CHF resulting in reduced lung 
compliance, alveolar oedema resulting in reduced gas exchange
abnormalities and bronchial hyper-responsiveness due to interstitial oedema 
leading to airway narrowing.
Pulmonary
haemodynamics
Elevation of pulmonary vessel pressures leading to fluid 
accumulation and eventual fibrosis of small vessels, resulting in 
reduced microvascular permeability.
Chemoreceptors Increased sensitivity of arterial peripheral and central 
chemoreceptors to hypoxia and CO2 in CHF.
Mechanoreceptors Heightened response of j-receptors in the lung to stretch and 
irritants secondary to pulmonary oedema resulting in an 
increased stimulus for ventilation in CHF. Upper airway and 
facial mechanoreceptors may be responsible for the improvement 
seen with moving air across the face.
Ergoreceptors in 
skeletal muscle
Enhanced sensitivity of these mechano/metabo-receptors 
allowing increased ventilation at lower levels of muscular 
exercise, perceived as dyspnoea.
Muscle function Decreased diaphragmatic and accessory muscle function due to 
histochemical and metabolic changes as a result of CHF with 
subsequent muscular weakness and reduced endurance.
Periodic / Sleep 
disordered
Heightened respiratory drive during exercise probably related to 
the sympathetic overdrive seen in CHF and resulting in the
breathing patterns sensation of feeling out of breath.
Cortex-afferent Neuromechanical dissociation between mechanical effort and the
“mismatch” mechanical response of the respiratory system, leading to 
sensations of unsatisfied respiratory effort. Considered to be the 
final common pathway of breathlessness.
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Given the nature of these proposed mechanisms, it is clear that the sensation of , 
breathlessness is a complex and multi-factorial symptom. Interventions should not 
therefore be attempted in isolation and should form part of a multi-faceted approach. It is 
unlikely therefore that significant breathlessness will be totally abolished by one therapy 
alone.
4.5 Management of breathlessness
In the absence of any potentially reversible cause, acute episodes of breathlessness in 
heart failure are treated with a combination of both pharmacological and non- 
pharmacological treatments (Johnson, 2007, Millane et al., 2000). The majority of these 
interventions are provided without any substantial evidence base to recommend their use 
(Oxberry and Lawrie, 2009). In addition, there are few other drugs that are used or in the 
process of development to help alleviate this distressing symptom. Hence, palliative care 
guidelines for management of intractable breathlessness tend to generalise for all disease 
aetiologies, as so little evidence exists for symptom management in specific disease 
categories. The experiences of treatments for breathlessness in one disease tend therefore 
to be extrapolated to all diseases involving breathlessness. In general, these guidelines 
are also employed for breathlessness secondary to other diseases such as COPD or lung 
cancer.
The relief of intractable breathlessness requires a multi-modal approach, given that the 
mechanisms for breathlessness are multi-factorial. Correct positioning of the patient, 
explanation of the proposed management strategy to reduce anxiety, breathing retraining 
techniques and the use of a hand-held fan to deliver air across the face have been 
suggested for all patients (please see Bausewein et al (2008) for review). Pharmaceutical 
strategies are employed in addition to these simple measures, dependent on the nature of 
the breathlessness, aims of treatment and stage of advancement of the disease.
The first pharmaceutical management strategy to mention is the use of oxygen. A trial of 
oxygen therapy is suggested if the patient is hypoxic or if it is considered by the clinician 
to be beneficial (particularly if the patient is anxious) (Abemethy et al., 2005).
Correction of hypoxia alone however may not result in relief of dyspnoea, and non- 
hypoxic patients may still find a symptom benefit from oxygen therapy (Thomas and von
Gunten, 2003). Only very small, poor quality trials of oxygen therapy for dyspnoea exis
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in CHF (Booth et al., 2004) and there is a suggestion that use of oxygen is no different to 
the use of air via a face mask (Davis, 1999). It is now considered that the continuous 
movement of cool air over the sensory distribution of the 2nd and 3rd branches of the 
trigeminal nerve of the face is beneficial due to the stimulation of mechanoreceptors 
(Booth et al., 2008) and that some of the improvement seen due to oxygen therapy is 
secondary to this mechanism. Hence, simple therapy with a hand-held fan may provide 
relief in some patients. In addition, most patients with CHF are not hypoxic yet remain 
breathless (Munger e ta l, 1994).
Opioids are used for breathless patients with advanced disease and the evidence for this 
use in CHF is detailed in Chapter 3. Traditionally, opioids have been thought to reduce 
respiratory drive to hypercapnea and hypoxia and hence are considered to be useful in the 
management of dyspnoea through the reduction of respiratory effort (Poole et al., 1998). 
They provide the mainstay of pharmaceutical therapy for breathlessness in terminal 
illness (Oxberry and Lawrie, 2009). A Cochrane review by Jennings et al (2001) 
demonstrated a small but statistically significant symptom improvement with opioids 
given by either the oral or parenteral route in a total of nine trials in patients with 
dyspnoea from various aetiologies. No differences were noted between oral and 
parenteral routes in the meta-analysis and the studies were too small to recommend one 
opioid over another. Since that review, Abemethy et al (2003) performed an adequately 
powered placebo controlled RCT of sustained release oral morphine (MST) in patients 
with intractable breathlessness. The majority of the 48 patients involved had a diagnosis 
of COPD. Thirty eight patients completed the study, again with a small but statistically 
significant improvement of breathlessness with MST 20mg daily. This dose is equivalent 
to 5mg Oramorph liquid taken 4 times a day (Twycross et al., 2002). Further analysis of 
this data suggested that the four patients with a diagnosis of coronary disease, including 
CHF, had a better response than those without coronary disease (Currow et al., 2007). 
This secondary paper is discussed in further detail in Chapter 3. Opioids have also been 
shown to increase exercise capacity in patients with COPD in a small pilot study (Light 
et al., 1989). In addition to a potential role in breathlessness, patients with a chronic 
cough have also shown a symptom benefit with morphine in a small pilot study (Morice 
et al., 2007). The Scottish SIGN guidelines already recommend opioids for the treatment 
of breathlessness in CHF without an evidence base in support of this (SIGN, 2007).
Benzodiazepines are the other major pharmacological group used for intractable
breathlessness. Again, only a small evidence base exists for their use and results are
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extrapolated across all breathless aetiologies due to the paucity of research. It appears 
that they should be used as an adjunct to other therapies for breathlessness in patients 
where anxiety may be a component (Thomas and von Gunten, 2003). There are no 
studies for the relief of breathlessness specifically in CHF involving benzodiazepines. 
Other interventions include heliox (Ahmedzai et al., 2004) and nebulised furosemide 
(Stone et al., 1994, Shimoyama and Shimoyama, 2002, Kohara et al., 2003) but these 
therapies are significantly under-researched and are used on the basis of clinical 
recommendation rather than from a substantial evidence base.
4.6 Key points
• Breathlessness is a common symptom in heart failure patients
• Surrogate markers are often used to describe breathlessness which is a sensation 
that is difficult to measure with standard physical methods
• The description of breathlessness in heart failure is under-reported
• The generation of breathlessness is likely to be multifactorial, with an alteration 
in the sensation of the expected level of respiration required compared to the 
actual feedback from respiration (cortex-afferent mismatch) possibly representing 
the final common pathway
• The autonomic centre in the brainstem is responsible for receiving inputs from the 
respiratory system and modulating the respiratory response. The autonomic centre 
is also involved in cardiovascular regulation as described earlier
• Few treatments currently exist for managing intractable breathlessness and results 
from small efficacy trials tend to be extrapolated across all disease groups
• Opioids are already utilised in end-stage and intractable breathlessness. The few 
small RCTs that exist have been performed mainly in COPD or lung cancer
• Current treatments for breathlessness in heart failure are under-researched and are 
provided from a historical clinical perspective
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Section 5) Chapter summary
This first chapter incorporates three topics that at first glance only appear to be partially 
related. However, closer inspection reveals a relative gap in our knowledge. The 
relationship between these three topics is illustrated in Figure 1.5.1 below. It is clear that 
CHF patients become breathless as a part of worsening disease. Some of the mechanisms 
considered to be important in the formation of breathlessness in general also apply to 
breathlessness in CHF, though there are some mechanisms of breathlessness that are 
specific for CHF. Opioids form a key part in the pharmaceutical management of 
intractable breathlessness in advanced disease, albeit without a large evidence base to 
support its use. Several authors have noted both the lack of symptom control palliative 
care research in heart failure and the potential clinical benefits of opioids used in the 
endstage management of breathlessness (Fischer, 1998, Cushen. 1994. Higginson. 1993). 
To date, there is little research evidence in this area, despite the ongoing clinical use ot 
opioids. What is as yet unclear is what role opioids might play in CHF and more 
specifically what effect they might have for breathlessness in CHF.
Figure 1.5.1: Relationship between opioids, breathlessness and CHF. Whilst there is 
relatively clarity regarding the link with CHF and breathlessness, and breathlessness and 
opioid treatment, there is less of a well known link between opioids and CHF
CHF
opioids W  m  breathlessness
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A central theory for the formation of CHF following an initial cardiac insult involves the 
activation of the neurohormonal system. These neurohormones are involved in the 
normal regulation of homeostasis, but are upregulated following an initial cardiac insult 
which is considered beneficial in the short term. However, prolonged activation of some 
neurohormones are considered detrimental. For example, activation of the sympathetic 
nervous system, resulting in elevated norepinephrine and epinephrine, is detrimental and 
is targeted by drug therapy with beta-blockers. Opioids are also considered to be one of 
these classes of neurohormones, but it is unclear in the general cardiology literature as to 
their considered role. Evidence for their proposed action is discussed in Chapter 2. 
However, it is interesting to note that beta-blockers were once considered detrimental for 
CHF, yet now form a main part of standard therapy due to an improvement in the 
research evidence to support their use. Perhaps further research into opioid manipulation 
may alter the perceived view of opioids in a similar manner.
A number of general mechanisms have been hypothesised for the formation of 
breathlessness for all disease states. Specific mechanisms are also proposed for specific 
disease states, including CHF, which can be incorporated into the scheme for generalised 
breathlessness. Opioids are considered to be beneficial for generalised intractable 
breathlessness in advanced disease from all aetiologies, but evidence for this is often 
extrapolated from lung cancer or COPD disease states. Clinical evidence for the use of 
opioids for breathlessness in CHF is detailed further in Chapter 3. However, given that 
specific mechanisms that are considered to contribute to breathlessness in CHF are part 
of the general neurohormonal activation (particularly sympathetic activation), it is 
interesting to hypothesise that manipulation of another neurohormone group, opioids, 
may have a greater role in breathlessness management in CHF compared to generalised 
breathlessness in other groups where this does not occur. In addition, sites of autonomic 
(sympathetic) processing in the brain are also considered to be implicated in the 
formation of generalised breathlessness. These are also the sites for high concentrations 
of opioid receptors as discussed in the next chapter. Can we expand on the clinical 
knowledge of opioids for breathlessness in heart failure first demonstrated over two 
thousand years ago?
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Chapter 2:
Evidence for opioid activity in the cardiorespiratory system
75
Section 1: Basic science and animals (non-heart failure models)
This chapter will provide some of the background to the proposed mechanism for opioids 
in human heart failure. The chapter will be divided into four sections. The first of these 
will document the evidence for opioid involvement in the cardiorespiratory system from 
basic science experimentation and localisation in animals. The second part will detail 
those experiments in whole animals with models of heart failure. The third section will 
demonstrate the measurement and proposed actions of endogenous and exogenous 
opioids in normal human subjects. The last section will discuss the presence of 
circulating endogenous opioids in humans with heart failure and will act as a link to the 
third chapter involving studies using exogenous opioids in human heart failure.
1.1 Opioid receptor distribution in the mammalian cardiorespiratory system
As mentioned in Chapter 1 Section 2, opioid peptides differentially activate three types 
of opioid receptor in the human body (mu, kappa and delta). Of the endogenous opioids, 
endorphins preferentially activate mu receptors, enkephalins preferentially activate delta 
receptors and dynorphins have a preference for kappa receptors.
Opioid receptors have been discovered in various locations using tissue hybridization 
studies and Polymerase Chain Reaction (PCR) methods in animals (Pugsley, 2002). Most 
studies have focussed on localisation of receptors within the rat. Opioid receptors have 
been located at various sites in the brain that are implicated in either the perceived 
cardiorespiratory centres, responsible for controlling and regulating cardiac and 
respiratory function, or in sites implicated in the autonomic control of cardiorespiratory 
activity. Mu, kappa and delta receptor populations have been isolated in rat brain samples 
in the nucleus tractus solitarius (NTS) and nucleus ambiguous (NA), in addition to the 
vagus nerve and cerebral cortex (Goodman et al., 1980, Mansour et al., 1988, Nomura et 
al., 1996). Opioid receptors have also been located in various other central elements of 
the autonomic nervous system in the rat brain (area postrema in medulla, locus coeruleus 
and caudate nucleus) (Atweh and Kuhar, 1977a, Atweh et al., 1978). Opioid receptors 
are present in particularly high concentrations at the NTS in rat brain, the site of the 
primary baroreceptor synapses (Atweh and Kuhar, 1977b, Atweh et al., 1978, Mansour 
et al., 1988) and chemoreceptor inputs (Mazzone and Canning, 2002). As discussed in
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the previous chapter, these autonomic, baroreceptor and chemoreceptor inputs have a 
proposed role both in cardiovascular regulation and the development of breathlessness.
In summary, opioid receptors are found in high numbers in the brainstem close to the site 
of the perceived cardiovascular and respiratory centres with possible influence on the 
autonomic nervous system. To further emphasise this point, the area around the area 
postrema (AP) in the brain near the blood brain barrier has high concentrations of opioid 
receptors. This is important as all afferent baroreceptor fibres pass through this area and 
it is a potentially important for intemeuronal influence (Holaday, 1983). As previously 
described in Chapter 1, the autonomic nervous system has an important regulatory role in 
both cardiovascular and respiratory homeostasis and it appears feasible that opioids may 
be involved in regulatory mechanisms in both cardiovascular and respiratory activity.
In addition to sites in the brain and neuronal tissue, opioid receptors are also peripherally 
in organs and tissues. However, not all opioid receptors áre distributed in the body in 
equal proportions or in different times of development. For example, mu opioid receptors 
are located peripherally in the lungs, adrenals and kidneys but are not expressed in adult 
cardiac myocytes in the rat (Wittert et al., 1996). This is in contrast to kappa receptor 
mRNA which is expressed in the mouse heart and CNS (Pugsley, 2002) and delta 
receptor mRNA which has been isolated in lung, adrenal, kidney and with abundance in 
cardiac tissue in the rat (Wittert et al., 1996). Interestingly, in contrast to adults, neonatal 
rat hearts contain kappa and mu opioid receptors, but very low levels of delta receptors, 
suggesting that opioid receptor expression changes at different stages of development 
(Ela et al., 1997, Zimlichman et al., 1996). There is some evidence that opioid receptor 
expression and level of opioid peptides increase with age in rat models (Boluyt et al., 
1993, Caffrey et al., 1994). Hypertensive rats express a greater density of kappa receptors 
in the heart than normotensive rats (Zimlichman et al., 1996). It is unclear whether 
opioid expression is a cause or an effect of these pathological or ageing processes.
Animal experimentation with opioid agonists and antagonists have provided evidence to 
suggest that mu receptors predominantly and delta receptors (to a lesser degree) are 
involved in the regulation of respiratory activity (Florez and Hurle, 1993). Kappa 
receptors are not expressed in the same numbers in the respiratory nuclei in the brainstem 
in animals (May et al., 1989) and it is interesting that kappa agonists do not cause 
respiratory depression, unlike mu or delta agonists (Florez and Hurle, 1993). In the
respiratory system, all three opioid receptors are present in the nerve fibres innervating
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rat and guinea pig airways (Groneberg and Fischer, 2001, Bhargava et al., 1997). In 
addition, mu and particularly delta receptors are distributed in lung parenchyma 
(Bhargava et al., 1997) and they have also been demonstrated in lung homogenates and 
vagal fibres in the lungs (Ayesta and Florez, 1989). Florez and Hurle (1993) postulate 
that j receptors may be involved in some of the clinical effects seen following rapid 
injection of mu opioids, suggesting that opioid receptors are highly concentrated at the 
site of these pulmonary juxtacapillary mechanoreceptors (j receptors). These receptors 
relay information via the vagus nerve to the autonomic centre in the brain, again 
suggesting involvement of opioids in respiratory regulation. Systemic injection of 
enkephalin analogues cause a triad of signs attributable to the action of j receptors in the 
lung, mediated through the vagus nerve (Sapru et al., 1981). These factors suggest that 
opioids may be involved in the relay of peripheral information from the lungs to the 
autonomic centres in the brain, and hence may be influential in the perception of 
breathlessness.
It is considered that stimulation of mu receptors in particular is involved in the inhibition 
of airway smooth muscle constriction through inhibiting neurogenic cholinergic 
stimulation (Groneberg and Fischer, 2001). Therefore it would appear that opioids are 
involved in the regulation of bronchoconstriction through their effect in the autonomic 
nervous system on inhibition of acetylcholine release in the lung, rather than through 
direct effects on lung tissue (borne out by the lack of efficacy of nebulised opioids in 
human clinical studies -  see Chapter 1 Section 4). Figure 2.1.1 describes the location of 
opioid receptor sites in relation to important mechanisms for cardiorespiratory control 
and builds on the information shown in Figure 1.4.1.
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Figure 2.1.1.: Opioid receptor location at sites important to the regulation of the 
cardiorespiratory system (* denotes potential sites of action from knowledge of receptor 
locations from basic science and animal studies). Areas shaded in green are located in the 
CNS, blue areas are located in the peripheral respiratory system.
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More recently, PET (Positron Emission Tomography) scanning in five healthy human 
subjects using highly selective inert agonists for delta and mu receptors revealed the 
presence of both mu and delta receptor populations in the myocardium of the human 
heart (Villemagne et al„ 2002). An inert agonist selective for kappa receptors was not 
used and therefore the presence or absence of this subtype could not be elucidated. To the 
best of my knowledge this is the first and only study to demonstrate the presence of these 
2 receptor types in humans in vivo. These findings give further argument to the wide 
species variation observed in the type and location of opioid receptors which makes 
translation of in vitro animal data into in vivo human models difficult.
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1.2 Endogenous Opioid distribution in the mammalian cardiorespiratory system
In addition to the variability of opioid receptor distribution in the heart and lungs, opioid 
peptide precursors are also distributed in a variety of ways. Various opioid peptides can 
be synthesised, stored and released by myocytes (Barron, 1999). Millington et al. (1999) 
have demonstrated that cardiac myocytes in the rat heart are able to differentially 
synthesise endogenous opioids from their precursors. Precursors of the endogenous 
opioids are distributed in the sympathetic nerves that innervate the heart in a variety of 
animals (Barron et al., 1995). Given the differential nature of precursors and peptide 
concentrations and the species variation, Barron (1999) suggests that the atria maybe 
more responsible for storage of precursors that are ultimately released as endogenous 
opioid peptides for utilisation in or by ventricular tissues. Van den Brink (2003) also 
suggests that the heart may have a significant reserve of precursor proteins (notably pre- 
pro-enkephalin) that when released are readily broken down by enzymatic cleavage to 
the active endogenous opioids (eg enkephalin) which are much shorter lasting prior to 
their degradation. The inference from these observations is that the heart may utilise 
opioids in an autocrine, paracrine and possibly endocrine manner. This suggests that 
there is the potential for opioids to be released from the heart in response to stimuli that 
either act locally or are released into the wider circulation. The three main types of 
endogenous opioids and their precursors are detailed in separate sections below.
1.2.1 Enkephalins
Enkephalins are the most widely quoted endogenous ligands in the literature due to the 
discovery of significant levels of enkephalin, and notably its precursors, in cardiac 
samples. Enkephalins have been discovered in isolated dog heart tissue (Barron et al., 
1992) and mRNA Proenkephalin, the precursor of Met- and Leu-enkephalin is highly 
expressed in the adult rat heart, particularly the left ventricle myocytes (Weil et al., 
1998). Enkephalin concentrations are much lower than pro-enkephalin levels, suggesting 
that these proteins are stored as precursors and released as required in small amounts 
(Barron et al., 1995, Pepe et al., 2004). Interestingly pro-enkephalin expression in the 
adult rat heart is 4 times greater in the left ventricle than the right, suggesting greater 
enkephalin release into the systemic and coronary circulations (Weil et al., 1998).
In isolated sections of guinea pig heart, Steele et al. (1996) discovered small amounts of 
Leu-enkephalin in both sympathetic and sensory axons innervating the heart whereas
Met-enkephalin was not expressed. Enkephalins are also widely distributed in
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sympathetic neurones and the adrenal medulla in bovine tissue (Livett et al., 1982) and 
the lung in rats and guinea pigs (Tang et al., 1982). Enkephalins have been located at the 
sites of the cardiovascular control centres in the rat brain including the NTS (Mansour et 
al., 1988, Rutherford and Gundlach, 1993). These results suggest that enkephalins may 
have a role in cardiovascular regulation at the peripheral level in heart tissue, in release 
into the systemic circulation, at the neuronal level in the transmission of information in 
the autonomic nervous system and at a central level with involvement at the 
cardiorespiratory centre in the brain.
Are enkephalin concentrations altered during pathological processes related to 
cardiorespiratory insufficiency other than heart failure? There is a possible correlation of 
increased cardiac enkephalin levels in rat models of hypertension versus normotensive 
rats, without an increase in enkephalin levels at other sites (e.g. lung) in these animals 
(Dumont and Lemaire, 1988) and in hypertrophic cardiomyopathy in some animal 
studies (Ouellette and Brakier, 1988, Ouellette et al., 1991). Hamsters with hypertrophic 
cardiomyopathy had 3-4 times the concentration of ventricular preproenkephalin than 
those hamsters without cardiomyopathy, suggesting involvement of opioid synthesis in 
the development of cardiomyopathy and notably heart failure (this is routinely used as an 
animal model of heart failure) (Ouellette and Brakier, 1988). It is unclear whether 
increased synthesis is a result of, or response to, cardiomyopathy and whether this effect 
is deleterious or advantageous. Similarly, ventricular expression of pre-pro-enkephalin 
and enkephalin concentration is raised 3-4 fold in rat models of myocardial infarction 
compared with normal controls (Paradis et al., 1992). Elevated levels of cardiac 
enkephalins or enkephalin activity are also seen in rat models of ageing (Caffrey et al., 
1994). Isolated cardiac ventricular myocytes in the rat have been shown to store 
enkephalin precursors and produce enkephalins following stimulation (Springhom and 
Claycomb, 1992). As discussed previously, the measurements for enkephalin activity and 
stimulation vary, with leu- or met-enkephalin measured in some samples and MEAP and 
other larger potential precursors measured in others. To illustrate the problem,
Springhom and Claycomb (1992) comment that MEAP is isolated from neonatal rat 
hearts, but met-enkephalin and not MEAP is isolated from adult rat myocardial tissue, 
suggesting differential splicing at different stages of development. Accurate 
interpretation of these studies taken together is therefore not without difficulty.
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1.2.2. Dvnorphins
Spampinato et al. (1991) describe the presence of dynorphins in cardiac tissue from a 
variety of species including human samples. Dynorphins are located within sympathetic 
nerve fibres that innervate coronary blood vessels and cardiac myocytes in the guinea pig 
heart (Wegener and Kummer, 1994). Steele et al. (1996) determined the presence of high 
concentrations of dynorphin in sympathetic axons innervating the heart, and to a lesser 
extent sensory axons in this model. This study suggests that endogenous opioid peptides 
(notably dynorphins) are present in both sensory and autonomic pathways in the heart in 
this animal model (Steele et al., 1996). There is some evidence to suggest that precursors 
of dynorphin are synthesised by myocardial tissue (Ventura et al., 1998), although 
overall there is much less evidence to suggest a role in heart tissue when compared to 
enkephalins.
Dynorphins and other highly selective agonists for kappa receptors do not cause 
significant respiratory depression in analgesic doses in many species, though this picture 
has been complicated by the previous lack of selective agonists (most have some mu 
receptor activation causing small amounts of respiratory depression medicated by mu 
activation in the brainstem)(Florez and Hurle, 1993). This is evidence supporting the low 
numbers of kappa receptors in the respiratory centre in the brainstem.
It is difficult to know if dynorphins have circulatory or respiratory activities in animal or 
human subjects. However, a potential role may be apparent owing to the location of ACE 
in lung tissue. Interestingly, ACE not only degrades ATI to ATII, it also cleaves 
dynorphin-13 into its much less potent compound dynorphin-12 (with a 50-230 times 
weaker binding affinity for the kappa receptor) in in vitro studies (Vickers et al., 2002). 
This suggests that the enzyme responsible for the production of a potent vasoconstrictor 
may also be responsible for the degradation of another neurohormone. Clearly further 
work is required to elucidate the nature of this effect in vivo, but it would not be 
surprising that ACE degrades a potentially protective neurohormone in addition to 
stimulating a deleterious one.
1.2.3 Endorphins
Endogenous endorphins have the least evidence for a potential role in cardio-respiratory 
function. Of note, beta-endorphin and endorphin precursors (POMC) were located in 
adult rat atrial tissue in similar distribution to ANP, but were virtually absent in
ventricular myocytes using immunohistochemical and mRNA techniques. Steele’s study
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in the guinea pig heart failed to isolate the presence of endorphins (Steele et al., 1996). 
However, in addition to enkephalins, endorphins also cause respiratory depression when 
administered systemically (Florez and Hurle, 1993), suggesting that they can act at sites 
involved in respiratory regulation but studies have yet to identify them at relevant 
locations.
1.3 Summary for the location of endogenous opioids and opioid receptors in the 
cardiorespiratory system
Given the different locations of opioid receptors and opioid synthesis in the heart it is 
considered that opioids may exert localised autocrine or paracrine effects (van den Brink 
et al., 2003, Pepe et al., 2004, Wittert et al., 1996) in addition to possible endocrine 
effects via the circulation (Molina, 2006). The relatively high expression of delta 
receptors, and to a lesser extent kappa receptors, suggests that the secretion of 
enkephalins and dynorphins by myocardial tissue are involved in a paracrine role. Table
2.1.1 demonstrates the locations of opioid receptors in relation to the identification of 
endogenous opioid agonists. Note that most of the studies have involved rat tissue and 
may not be directly comparable to human subjects. Some endogenous ligands are present 
in the absence of their corresponding receptor and vice-versa, which make assessment of 
their function at those sites problematic. In addition, a multitude of techniques have been 
used to isolate receptors and their endogenous opioid ligands, some of which may be 
more accurate than others. Although endogenous opioid peptides have been located in 
the cardio-respiratory system it is unclear how they are implicated in normal 
cardiorespiratory activity and how they might influence or be influenced by pathological 
processes such as heart failure. In terms of local function in the myocardium, one can 
observe that enkephalins may play a localised role in regulation as the main receptors 
that they activate are also present. Dynorphins on the other hand are only expressed as 
precursors but their preferred receptors are present in myocardium. Mu receptors are not 
present in myocardium in animal studies, despite the presence of endorphins, though 
these receptors have been isolated in humans in myocardial tissue. This illustrates the 
potential for inter-species variation, which makes interpretation of these findings 
difficult.
Research involving opioid receptor and endogenous opioid locations in the respiratory
system is less prominent than that in the cardiovascular system. Mu and delta receptor
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populations are found in lung tissue. Activation of mu receptors inhibit smooth muscle 
bronchoconstriction through autonomic regulation of respiratory smooth muscle. Opioids 
may have a role in transmission of information from j receptors into the autonomic 
nervous system, suggesting a role in respiratory control, though the evidence for this is 
weak.
Care must also be taken in the review of these effects and location of receptors and 
ligands in isolation. As Mulder & Schoffelmeer (1993) correctly draw attention to, given 
that opioid receptors exist in pre- and post-synaptic locations both centrally and 
peripherally, in addition to location within non-neuronal tissue (e.g. heart, lungs), the 
direct effect of systemic application of opioids may be inhibitory in some locations and 
potentially excitatory in others. The result of which depends on the net magnitude of 
effect. This is one of the problems with the interpretation of basic science studies in 
isolation.
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Table 2.1.1: Location of receptors in the cardiorespiratory system in relation to the sites 
of known endogenous opioid concentrations (Symp NS = sympathetic nervous system, 
Parasymp = parasympathetic nervous system, resp nuclei = respiratory control centre in 
the brain). Squares with Y indicates evidence for the presence of that receptor or ligand, 
N indicates not detected and a blank square represents no good evidence confirming 
presence or disproving absence.
Receptors 
or ligands
Myocardium Myocardial
neurones
Lung Symp
NS
Parasymp
NS
Autonomie
brain
Resp
nuclei
Mu * Y Y Y
Endorphin Y Y N
Kappa Y Y Y
Dynorphin Y Y (symp & 
sensory)
Y Y
Delta Y Y Y
Enkephalin Y Y (symp & 
sensory)
Y Y Y Y Y
♦Presence located using PET in in vivo human studies -  not demonstrated in adult animal 
studies (seen in neonatal only)
1.4 Responses to the application of endogenous opioids in basic science and animal 
studies
1.4.1 Effect on vascular tone
No direct effect on vascular tone was observed in in vitro studies of morphine sulphate 
administered to canine vascular smooth muscle (Flaim et al., 1977). In normal rats, 
systemically administered beta-endorphin resulted in hypotension and that this effect was 
reduced by 5HT (serotonin) antagonists (Lemaire et al,, 1978). Interestingly, no
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consistent effect has been demonstrated in altering blood flow specifically through 
pulmonary vessels with direct application of opioids in in vitro studies (Groneberg and 
Fischer, 200.1) suggesting there is no local effect of opioids in the lung vasculature. A 
more extensive and representative action of opioids on vascular tone is detailed in human 
subjects in Chapter 2 Section 3.
1.4.2 Effect on sympathetic and parasympathetic stimulation 
Given the location of opioid receptors and endogenous opioids within the autonomic 
nervous system, a number of studies have detailed the effects of administration of opioids 
in basic science and animal models on these sympathetic and parasympathetic nervous 
systems. Kappa and delta receptor agonists reduce cardiac output, heart rate and stroke 
volume in isolated heart preparations, in contrast to mu receptor agonists which have 
little effect on isolated heart preparations (Vargish and Beamer, 1989). These actions 
may be mediated in part by inhibition of the sympathetic nervous system. This 
corroborates the findings of higher concentrations of kappa and delta receptors, but not 
mu receptors, in myocardial tissue in animals.
As detailed previously, norepinephrine is a principle transmitter for the actions of the 
sympathetic nervous system. Interestingly, Klein et al. (1981) noted an inhibition of 
norepinephrine release from sympathetic nerve endings in bovine tissue with increasing 
concentrations of Beta endorphin i.e. an inhibitory feedback mechanism. Similar findings 
are demonstrated with met-enkephalin in feline models (Gaddis and Dixon, 1982). 
Stimulation of presynaptic Mu receptors in the rat brain inhibits release of presynaptic 
norepinephrine in in vitro studies (Mulder and Schoffelmeer, 1993, Carr, 1997). Feldberg 
and Wei (1986) demonstrated a reduction in sympathetic tone to the heart and blood 
vessels in anaesthetised normal cats when morphine was administered subcutaneously or 
in the cistema magna in the brain (a site considered to have autonomic influence), though 
isolated experiments such as this may not relate well to normal physiological processes. 
In a separate study, intravenous morphine has been shown to depress sympathetic 
reflexes at the spinal level in rats (Uchida et al., 1999). Chemical sympathectomy leads 
to an increase in enkephalins and enkephalin precursors in isolated rat hearts (Younes et 
al., 2000), suggesting that sympathetic stimulation and opioid production are interlinked. 
However, not all authors have been able to establish this link (Caflfey et al., 1994).
Interestingly, in the heart beta-adrenergic receptors and opioid receptors are co-expressed
and are coupled to functionally opposite G protein families (beta-adrenergic receptors to
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stimulatory G proteins and opioid receptors to inhibitory ones as discussed earlier in 
Chapter 1 section 2) (Pepe et a l, 2004). It is not inconceivable therefore that stimulation 
of opioid receptors has the opposite effect to stimulation of beta-adrenergic receptors. 
Indeed, enkephalin administration markedly reduces the effect of beta-adrenergic 
stimulation by norepinephrine in the isolated rat heart (Pepe et al., 1997) and also 
attenuates the norepinephrine induced rise in intracellular calcium and hence contractility 
in isolated rat ventricular myocytes (Xiao et al., 1997). This is important particularly in 
CHF as sympathetic overstimulation results in a worsening of the disease process and is 
implicated in some of the proposed mechanisms of breathlessness such as periodic 
breathing or cheyne-stokes respiration. Anything that opposes this overstimulation may 
therefore have beneficial effects in CHF.
In support of the hypothesis that opioids may have an inhibitory action on the effects of 
norepinephrine activity, stimulation of cardiac kappa opioid receptors reduces the activity 
of beta-adrenoreceptors, particularly in myocardial ischaemia (Wong and Shan, 2001). It 
is considered that stimulation of Gs protein activation of cAMP by B-adrenergic 
stimulation may be attenuated by stimulation of Gi (inhibitory) proteins by opioid 
receptors that reduce cAMP production (Wong and Shan, 2001, Pepe et a l, 2004). 
Enkephalin administration inhibits pre-synaptic transmission in the sympathetic nervous 
system in guinea pigs and this action is reversed by naloxone (Konishi et al., 1981). 
Endogenous dynorphin administration reduces the response of guinea pig atrial tissue to 
adrenergic stimulation (Ledda et al., 1984), though there was considerable variation seen 
in the responses between different atrial preparations which calls the results of this study 
into question. Similar experiments by the same team in isolated guinea pig atria revealed 
that dynorphin produced a dose-dependent reduction in the cardiac response to 
adrenergic stimulation (through exogenous norepinephrine application) and this effect 
was inhibited by naloxone (Ledda et al., 1985). They hypothesise that kappa receptor 
stimulation was involved, though this assumption was based on previous data and not 
formally tested. Administration of dynorphin as an intravenous infusion into the 
coronary circulation of anaesthetised dogs revealed a significant reduction in 
norepinephrine activity following stimulation in the left cardiac nerve which in turn 
resulted in a reduction in both ventricular pressure and myocardial oxygen consumption 
(Gu et al., 1992). Administration of naloxone prevented these effects. The authors 
hypothesise that endogenous opioids may regulate cardiac function by regulating 
overactivity of norepinephrine. Taken together, these studies give weight to the
hypothesis that endogenous opioids inhibit sympathetic overdrive in heart failure.
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Interestingly, withdrawal of morphine following chronic high dose administration in rats 
results in enhanced cardiac norepinephrine activity, associated with both enhanced 
cAMP production and an influx of calcium in the heart (Martinez et al., 2003). Opposing 
this sympathetic overdrive may help with both reducing the rate of disease progression 
and help with coexistent breathlessness in symptomatic patients.
It is interesting to hypothesise that opioids naturally may exert a cardioprotective effect 
in response to overstimulation of the sympathetic nervous system in acute and chronic 
heart failure. Since the 1970s it has been suggested that morphine inhibits the release of 
norepinephrine at various sites in the rat brain (Mulder and Schoffelmeer, 1993). Similar 
findings have been noted in other animal species, though the pre-synaptic opioid 
receptors activated to elicit this response appear to be different dependent on the species 
involved (Mulder and Schoffelmeer, 1993). It is conceivable that norepinephrine release 
could be antagonised by opioids at other sites. However, whilst it is an attractive unifying 
hypothesis that the inhibition of detrimental persistent sympathetic over-stimulation in 
heart failure is achieved in part by activation of endogenous opioid systems, it should be 
remembered from these studies that not all opioid receptor types or endogenous opioids 
have been located in vivo in humans at sites that may influence this process.
Less is known about the role of endogenous opioids and the parasympathetic nervous 
system. Experiments with isolated segments of inferior mesenteric ganglia of guinea pigs 
revealed that enkephalin containing pre-synaptic neurons may be involved in the release 
of acetylcholine from post-synaptic neurons. Addition of a synthetic enkephalin analogue 
resulted in inhibition of acetylcholine release and this effect was reversed with naloxone 
(Konishi et al., 1981). Mu-selective opioids are considered to have an action at the 
cardiac vagal neurons located in the nucleus ambiguous in the rat. Administration of mu 
selective opioid at this level reduces the action of glycinergic inputs, which in turn 
increases the parasympathetic activity to the rat heart (Venkatesan et al., 2003). These 
mammalian experiments add further interest to the potential role of opioids in autonomic 
control.
Cholinergic neurotransmission in the lung is considered to mediate constriction of the 
airways (compare the effect in blood vessels where the sympathetic nervous system is 
involved in constriction). An in vitro study involving normal human airway tissue 
revealed a reduction in airway acetylcholine neurotransmission in the autonomic nervous
system by administration of mu receptor agonists, which potentially would reduce airway
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constriction (Belvisi et a l, 1992). This suggests that opioids may be involved in the 
regulation of airway control, although human clinical studies in asthma in particular 
(where constriction of the airways leads to breathlessness and wheeze) have not 
determined a therapeutic use for inhaled mu opioids (Groneberg and Fischer, 2001). Not 
all opioids are implicated in the peripheral regulation of respiratory function. In 
particular, stimulation of kappa receptors produces no direct effects on the airways 
(Groneberg and Fischer, 2001).
Table 2.1.2 below details the various cardiovascular effects of opioid agonists when 
delivered either centrally or peripherally in the rat. Some of these effects are likely to be 
mediated via the autonomic nervous system. In particular, norepinephrine release is 
inhibited by kappa or delta receptor stimulation when agonists are administered 
peripherally. Application directly at the NTS, a key site of autonomic control of 
cardiorespiratory activity, yields different effects for different opioids. However, it 
should be noted that the artificial insertion of opioid agents to targeted central structures 
in animals may yield very different results to the systemic administration of opioid 
compounds in humans, particularly when one considers that central injection of opioid 
may yield much higher concentrations within central structures than could ever be 
achieved by systemic administration. Therefore, although the central administration is of 
interest, the activity of opioids administered systemically is of more relevance to the 
clinical situation in humans.
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Table 2.1.2: Cardiovascular effects of opioid receptor stimulation following central or 
systemic administration of opioid agonists in the normal adult rat (adapted from (Ventura 
et a l, 1992, van den Brink et a l, 2003):
Opioid
receptor
Agonist action when 
administered centrally
Agonist action w hen 
administered systemically
Mu
(Endorphin)
Hypotension
Bradycardia
Peripheral vasodilation 
Bradycardia
Delta
(Enkephalin)
Medulla / brainstem
application: Hypotension &
Bradycardia
NTS or intracistemal
application: Hypertension and
tachycardia
Inhibition of norepinephrine release 
& sympathetic vascular constriction 
Hypotension 
Bradycardia
Kappa
(Dynorphin)
NTS: Biphasic effect on 
blood pressure (increase 
initially then progressive 
reduction)
Inhibition of norepinephrine release 
& sympathetic vascular constriction 
Hypotension 
Bradycardia
Inhibition of catecholamine release 
from adrenal medulla
1,4.3 Effect on cardiac muscle contractility
Separate to the effects on the autonomic nervous system by opioids as described above, 
opioid agonists have been shown to directly inhibit cardiac muscle contractility 
(interestingly delta and kappa agonists inhibit atrial contraction and mu agonists inhibit 
ventricular contraction in guinea pig tissue) (Mantelli et a l, 1987, Barron, 1999). In 
isolated rat and guinea myocardial tissue, opioids reduce muscular excitability by both 
reducing action potential amplitude and increasing the threshold for myocardial 
stimulation (Rashid and Waterfall, 1979). Exogenous opioids may affect sodium, 
calcium and potassium channel currents in neurons and cardiac tissue (Pugsley, 2002). 
Activation of delta and kappa receptors suppresses cardiac contractility by reducing 
calcium influx into the myocardium in in vitro experiments involving adult rat left 
ventricular myocytes (Ventura et a l, 1992). Delta receptor activation in particular by 
enkephalins results in a negatively inotropic action on cardiac contractility. Mu agonists
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had no effect in this study. Cafffey et al. (1986) demonstrated that blocking opioid 
receptors with the opioid antagonist naloxone administered via the coronary arteries 
increased contractility of the dog heart and that propranolol (a beta blocker) negated that 
response. They hypothesise that inhibition of cardiac opioid receptors facilitates 
adrenergic activity. In a similar study, Kindman et al. (1991) concluded that opioid 
inhibitors may enhance the contractility of rabbit myocardium to beta-adrenergic 
agonists, but on review of the results both opioid agonists and antagonists had the same 
effect on the myocardium and hence the action of opioids with beta agonists is unclear if 
one took this study in isolation. However, these studies demonstrating reduced cardiac 
contractility with opioids are contradicted by other studies showing the opposite effect 
(Laurent et al., 1986, Tai et al., 1992).
1A A. Effect in cardiac ischaemia
It has already been demonstrated that opioids have a cardioprotective effect in the 
phenomenon of ischaemic preconditioning (Pepe et al., 2004, Schultz and Gross, 2001). 
This preconditioning of the heart using brief episodes of hypoxic ischaemia protects the 
myocardium during a prolonged ischaemic event later, i.e. the damage caused by 
prolonged ischaemia is less than if no preconditioning had occurred previously. Opioids 
are considered to have a role in this mechanism. Ventricular cardiac myocytes taken from 
chick embryos were subjected to ischaemic conditions resulted in significant myocyte 
injury over a prolonged period. A brief episode of ischaemia (5 minutes) followed by a 
more prolonged period, resulted in myocyte protection against ischaemia due to hypoxic 
conditions (Liang and Gross, 1999). A similar response was observed when myocytes 
were pre-treated with morphine sulphate, suggesting that this preconditioning response 
involved in cardioprotection may be mediated by opioid mechanisms. Low 
concentrations of naloxone added to the medium negated this response, suggesting a role 
for opioid receptors in the protective mechanism (Liang and Gross, 1999). Isolated 
human atrial tissue, taken from patients undergoing coronary bypass grafting has been 
shown to express delta-receptor mRNA and that stimulation of these receptors prior to 
ischaemia results in a similar process as ischaemic pre-conditioning, inferring that 
stimulation of delta receptors may be involved in this protective process (Bell et al., 
2000).
Similarly, Lishmanov & Maslov (2004) describe that stimulation of mu and kappa 
receptors inhibit the arrhythmogenic action of norepinephrine in ischaemic conditions,
again conferring protection to the isolated myocardium. Additionally, hypoxic states
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reduce the threshold of morphine activity considerably in vitro (Johnson et al., 1985). 
Hence the activity of circulating opioids may be increased during ischaemia. This 
phenomenon may represent a role for opioids as a protective mechanism against the 
potentially damaging effects of hypoxia. Similarly, the endogenous opioid system may 
be involved in circulatory shock {for review refer to Molina (2006)}.
1.4.5 Effect on Angiotensin II
Very few studies detail the effect of opioids on circulating neurohormones that are 
considered to be involved in chronic heart failure. The effect on norepinephrine activity 
is detailed above. Perhaps this lack of information reflects a need for basic opioid 
research to gain pace with the research enjoyed by the study of other neurohormones in 
heart failure. The effect of opioids on the renin-angiotensin system is really the only 
other neurohormonal mechanism detailed in the literature to date.
Angiotensin II is considered to exert its vasoconstrictive response in part at the level of 
the area postrema (Xue et al., 2003), the site of high opioid receptor concentrations 
(Atweh & Kuhar 1977a). Szilagyi and Ferrario (1981) demonstrate that opioid 
antagonists reduce the vasoconstrictive response of angiotensin II at the area postrema in 
normal dogs, antagonising the action of the RAAS. On further review of this paper 
however, the dogs used in this study were all anaesthetised using morphine in this study 
which is an obvious confounder and therefore the results of this study should be treated 
with caution. Administration of enkephalins, B-endorphin or morphine centrally inhibit 
angiotensin II mediated vasopressin (ADH) release in rat models (Summy-Long et al., 
1981b, Summy-Long et al., 1981a) also suggesting that opioids antagonise the central 
actions of angiotensin.
1.4.6 Effect on chemorecentor activity
As previously discussed, chemoreceptors, the monitors of blood gas concentrations, have 
an increased sensitivity in CHF and are implicated in the proposed mechanisms of 
dyspnoea. Interestingly, administration of opioids in normal humans and animals may 
alter their activity. The chemoreceptor response to hypoxia is diminished by systemic 
opioid administration, with a subsequent reduction in hypoxic drive (in addition to 
hypercapnoeic drive) at the respiratory centre (Florez and Hurle, 1993, Chua et al.,
1997). Administration of met-enkephalin to carotid arteries in anaesthetised normal cats 
resulted in a rapid inhibition of spontaneous chemoreceptor discharge at the carotid sinus
(McQueen and Ribeiro, 1980). Morphine was a less potent inhibitor of chemoreceptor
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activity. Pre-treatment with naloxone negated the effect of morphine and substantially 
reduced the effectiveness of enkephalin (McQueen and Ribeiro, 1980). A human study of 
this effect in CHF (Chua et al, 1997) can be found in Chapter 3. This may be an 
important mechanism as to the known action of opioids on respiration, and provides a 
link between proposed mechanisms of breathlessness, CHF and the effect of opioids.
1.5 Conclusion
It is clear from these basic science and animal studies that both opioid receptors and 
endogenous opioids are distributed at sites where they could influence cardio-respiratory 
mechanisms. However, extrapolation of these results to human subjects has to be made 
with caution. It is unclear whether, for example, these receptors are up- or down- 
regulated in human heart failure. There is simply not the evidence currently to know 
definitively if opioid receptors are involved in cardiorespiratory mechanisms in humans. 
However, there is increasing recognition that given the distribution of opioid receptors in 
these studies, it is possible that they do play a potential role in humans and hence the 
importance of opioids in the possible regulation of various body processes. It is clear that 
opioids and opioid receptors are distributed widely throughout the body. However, it is 
still not known specifically how opioids regulate their effects on cardiovascular and 
respiratory function. The presence of opioid receptors in the regions of the brain that are 
concerned with control of respiratory and cardiac function may be responsible for some 
of these actions. Location within sympathetic and parasympathetic neurons that innervate 
the heart and cardiovascular system may have also play a role, particularly for the 
cardiovascular effects seen following opioid administration. Local activity following 
release into cardiac myocytes and vasculature could explain some of the local effects 
seen, particularly vasodilation.
Results from a number of animal studies suggest opioid receptor antagonists at 
reasonable doses appear to have few cardiovascular effects in normal non-anaesthetised 
animals not under stress, which might suggest that the endogenous opioid system is only 
activated under stressful or pathophysiological conditions (Faden and Holaday, 1979, ' 
Faden, 1993).
Stimulation of the endogenous opioid system appears to attenuate the actions of two
potent mechanisms responsible for the formation and perpetuation of CHF, namely
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norepinephrine and angiotensin, in in vitro animal studies. Given the research and 
clinical application of medications (beta blockers and ACEI) that also reduce the 
overstimulation of these detrimental vasoconstrictor systems in humans, it is interesting 
to hypothesise that stimulation of the opioid system may have an additional effect in 
reducing the effects of these detrimental systems in human heart failure.
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Section 2) Animal models of heart failure and effects of opioids
In the section above, the importance of location of endogenous opioids and opioid 
receptors in non-CHF animals or basic science examples was discussed. This section will 
review the research involving animal models with induced CHF. Dog models of cardiac 
failure are the most prevalent in the literature generated so far in support of the basic 
science research detailed previously. Given the historical wariness of opioid compounds 
in the medical community, “opiophobia”, the majority of studies have involved the use of 
opioid antagonists in the hope that these agents will have a beneficial effect, if the 
assumption that opioid agonists are detrimental is correct. As can be seen in this thesis, 
my primary argument is that the current evidence suggests that opioids may be beneficial 
in CHF and not detrimental. This should be considered on review of the studies below 
that involve opioid antagonism.
The first of such studies to be discussed here involves dogs with right-sided congestive 
cardiac failure (Sakamoto and Liang, 1989). The authors hypothesised that patients with 
heart failure have diminished baroreceptor reflexes secondary to the centrally-mediated 
action of endogenous opioids. Restoration of these reflexes could theoretically be 
performed through opioid inhibition. Right heart failure was induced in 16 dogs by 
tricuspid valve avulsion and pulmonary artery constriction. Four weeks after the initial 
procedure the dogs were included in the trial if they exhibited signs of right heart failure. 
These right heart failure dogs demonstrated significantly reduced baroreceptor sensitivity 
and elevated plasma B-endorphin concentrations compared to the sham controls. 
Significant results included increased baroreflex sensitivity by the opioid antagonists 
naloxone and naloxozine (a relatively selective mu receptor antagonist) in the right heart 
failure dogs compared to the sham operated controls. Similar results did not occur with 
selective delta receptor antagonists or antagonists that did not cross the blood brain 
barrier, leading to the theory that opioid inhibition in these dogs was mediated through 
central mu opioid receptors. In contrast to the authors’ analysis of some of their results, 
there was little overall change in haemodynamics in the heart failure dogs following 
opioid reversal.
Interestingly, the right heart failure dogs demonstrated circulating B-endorphin levels 
significantly higher than the sham-operated dogs. It is considered that B-endorphin levels 
may be raised in human heart failure (Kawashima et al., 1991), as will be discussed in
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Section 4. However, the animal preparation differed from clinical left ventricular failure 
as left atrial pressures were unchanged, unlike in human heart failure with left ventricular 
dysfunction. It has therefore been called into question whether this dog model is an 
accurate reflection of the role of opioids in human chronic cardiac failure.
Another study involving the induction of symptoms of left heart failure in dogs by 
initiation of ventricular pacing concluded that the secretion of B-endorphin does not 
exacerbate circulatory dysfunction in chronic left ventricular heart failure (Mellow et al., 
1992). Plasma B-endorphin levels in these animals were the same as control subjects. 
Unfortunately the dogs were anaesthetised using morphine during pacemaker insertion, 
which is an obvious potential confounding factor. In addition to this, as the authors 
discuss, the assay used to measure B-endorphin levels was not necessarily specific for B- 
endorphin alone and may have also detected a similar compound, B-lipotrophin.
In response to this, Himura et al. (1994) performed a similar trial involving dogs who 
were cardiac paced and developed pacing-induced congestive heart failure. In this study, 
basal plasma B-endorphin levels were elevated in the heart failure dog models. However, 
on this occasion administration of naloxone had no effect on the depressed baroreflex 
activity in the paced animals, unlike the study in right heart failure models. However, 
naloxone administration did increase heart rate, blood pressure and cardiac output in 
these dogs with increases in plasma B-endorphin and norepinephrine in response. Use of 
a longer acting opioid antagonist, naltrexone, prevented the reduction of baroreceptor 
activity seen in dogs with surgically induced right heart failure (Yatani et al., 1997).
Another study employed the right heart failure model to attempt to determine the 
cardiovascular mode of action of naloxone in cardiac failure (Imai et al., 1994). Despite 
reproduction of the findings in the study by Sakamoto and Liang (1989) in that 
administration of an opioid receptor antagonist increased mean cardiac output and aortic 
pressure, it was a selective delta receptor antagonist that produced these findings. A 
selective mu antagonist did not reproduce these effects. Hence the authors postulated that 
naloxone exerts its effects via delta receptor antagonism, in contrast to the conclusions of 
Sakamoto and Liang (1989).
It is difficult to know how to interpret some of these conflicting results and right heart 
failure models for the management of cardiac failure involving chronic left ventricular
dysfunction in humans. These dog models of heart failure tended to have diminished
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baroreceptor activity when compared to sham-operated dogs and plasma B-endorphin 
and norepinephrine levels tended to be higher in the affected animals. These elevated 
hormonal levels are consistent with human heart failure. It is clear that influencing 
baroreflex activity and haemodynamic changes with opioid antagonists have been 
inconsistent with these different animal models of heart failure. Certainly, the method of 
induction of heart failure in these models is more likely to reflect acute processes, rather 
than the chronic neurohumoral activation seen in human chronic heart failure.
Extrapolation of results from animal experiments does not necessarily reflect the 
experience observed in human subjects. This does not mean that all animal studies are 
irrelevant, but results must be taken in the context of the experiment and principles of 
good research practice. Frequently the aim of research in animals is different to that in 
humans, often requiring analysis of potential methods of action rather than clinical 
effectiveness of treatment and hence protocols and experimental designs may differ 
(Musch, 2007). The animals used are often young, without co-morbidities and without 
polypharmacy, unlike the usual human clinical situation (Hackman, 2007). However it 
could be argued that many human clinical studies of safety or efficacy are conducted in 
young subjects (typically males) not in receipt of other competing medications.
Of more concern is that animal trials are often of poor quality with methodological 
problems and there is a lack of systematic review of the available literature (Hackman, 
2007, Sandercock and Roberts, 2002). The aptly named “RATS” group (Reviewing 
Animal Trials Systematically) have suggested the more widespread use of systematic 
reviews of animal studies and detail only six available reviews in total that assess how 
the animal research had informed the allied clinical research in human studies (Pound et 
al., 2004). On a similar note, Perel et al. (2006) conducted systematic reviews for six 
interventions performed in both animals and humans. They determined that three 
interventions had similar outcomes in both animals and humans, but three did not, 
indicating a relatively low level of concordance between animal and human studies. Both 
Pound et al. (2004) and Perel et al. (2006) rightly call into question how animal studies 
directly relate to human trials and comment on the need for greater methodological 
quality and consistency and need for systematic reviews to help inform human trials with 
greater accuracy. Hence, although animal experiments can help to inform a pathological 
process or help to predict the safety or efficacy of a drug, results from such studies 
should not be viewed in isolation.
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Surprisingly little is documented regarding the action and effect of administered opioids 
in normal human subjects since the isolation of morphine by Sertumer in the 19th 
century. Some of the clinical effects (both intended and adverse effects) have been 
documented earlier in Chapter 1. The following effects are taken from the perspective of 
the cardiorespiratory system in isolation.
Demonstration of the action of opioids on vascular tone in animal and human studies is 
mixed and the mechanism of any response seen is unclear. In a very early study, the 
administration of 10-30mg morphine intramuscularly did not result in a significant 
change in blood pressure whilst supine, but caused both bradycardia and hypotension, 
occasionally manifested as syncope, in normal human individuals when subjected to a 
sudden head-up tilt thirty minutes post administration (Drew et al., 1946). This finding of 
postural hypotension was corroborated in a subsequent study in normal man by Weil et 
al, (1975). Rubin and colleagues (Rubin et al., 1983) attempted to demonstrate an effect 
in normal volunteers with an enkephalin analogue, but the variability of their baseline 
and subsequent measurements detract from their results. In 47 normal human subjects, 
intravenous morphine was shown to produce a significant dilation of venous and 
arteriolar vessels (Zelis et al., 1974). These authors hypothesised that this response was 
due to a reduction in the effect of sympathetic discharge as arteriolar dilation with 
morphine was blocked by co-administration of phentolamine. Certainly this would fit 
with the hypotheses for the role of the sympathetic nervous system in the propogation of 
CHF demonstrated in Chapter 1 Section 3 (Figure 1.3.1). If opioids do reduce cardiac 
preload and afterload their production would oppose the haemodynamic activities of 
norepinephrine and the sympathetic nervous system as a whole.
Similarly, administration of intravenous morphine to the forearms of 37 normal medical 
students revealed a notable reduction in hand (and not forearm) vascular resistance. The 
authors suggest that this reduction in cutaneous vascular resistance probably occurs 
through a central mechanism (not local effects) and in turn this could reduce cardiac 
afterload and hence reduce overall cardiac work (Cohen and Coffinan, 1981). An early 
double blind parallel group RCT in a total of 17 patients with coronary artery disease 
identified a small reduction in cardiac work following administration of 8mg morphine 
sulphate administered intravenously (Alderman et al., 1972). A reduction in left
Section 3) Effect of opioids in normal human subjects
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ventricular work and end-diastolic pressure may not be advantageous in the acute setting 
(Peacock et a l, 2008) but in the chronic stable setting of CHF, reduction in ventricular 
work may be advantageous (as demonstrated by the beneficial effect of beta-blockers). In 
conclusion, the effect of exogenous opioids in normal subjects has potentially 
advantageous effects in terms of heart failure management and the mechanism of action 
may be delivered through antagonism of the sympathetic nervous system.
It has been considered for a number of years that opioid administration results in 
peripheral histamine release in blood vessels which may contribute to the vasodilation 
seen with opioids in humans (Feldberg and Paton, 1950). Local concentrations of 
histamine following opioid administration may be sufficient to account for local 
vasodilation, but are thought unlikely to cause a systemic reduction in blood pressure 
alone (Feldberg and Paton, 1950, Johnson e ta l, 1985). Interestingly there appears to be 
an inconsistent species dependent response to pre-treatment with anti-histamines with the 
response to opioids (Fennessy and Rattray, 1971, Evans et a l, 1952). Mansour and 
colleagues observed the effect of morphine (IV 15mg) in reducing forearm vascular 
resistance and increased forearm blood flow in humans but could not demonstrate any 
effect of anti-histaminic compounds on this arteriolar dilation (Mansour et a l, 1970).
This is in contrast the findings of Grossmann et a l (1996) in 15 healthy volunteers who 
noted that intravenous morphine administration resulted in significant venodilation in 
dorsal hand veins which was abolished by co-infusion of anti-histamines. Of course, it is 
feasible that the constituents of the injection (other than the morphine) result in venous 
irritation and subsequent histamine release (interestingly injections of fentanyl, another 
mu opioid agonist, caused no vasodilation). Certainly, histamine release alone would not 
correlate with the improvement in breathlessness seen with opioids when administered in 
acute heart failure. Indeed, histamine itself can produce bronchoconstriction and wheeze 
(Weatherall et a l, 1996), thus resulting in deterioration of respiratory symptoms, in 
contrast to the effects seen from opioid administration clinically. However, it is not clear 
as to the level of contribution on vasodilation that this mechanism has, rather than the 
autonomic response to opioids resulting in the effects observed.
Aside from the haemodynamic consequences of morphine administration, in human 
subjects increasing doses of systemic opioid firstly cause a dose-dependent reduction in 
minute volume and ventilation, leading in turn to a rise in arterial carbon dioxide (C02) 
concentration (Keats, 1985). In addition to reducing the frequency of ventilation, opioids
also reduce the chemoreceptor responsiveness to this rise in arterial C 02, thus leading to
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an overall reduction in ventilation for a given arterial C02 concentration (Florez and 
Hurle, 1993). With increasing doses, the frequency of respiration reduces more than 
further reduction in tidal volume (Keats, 1985), due mostly to an increase in the time 
used for expiration. Weil and colleagues (1975) measured the ventilatory responses of six 
normal men to 7.5mg subcutaneous morphine sulphate. The researchers noted both a 
very mild reduction in resting frequency of ventilation and a significant reduction in 
hypoxic ventilatory drive following morphine administration. They also postulate that 
this decreased responsiveness to chemical stimuli is enacted through peripheral 
chemoreceptors (Weil et al., 1975). This is important, as exaggerated chemoreceptor 
activity occurs in CHF, and it is possible that this is attenuated by morphine 
administration. The effect of opioids in normal humans appears to positively influence 
some of the detrimental systems considered to be responsible for breathlessness in CHF, 
notably reduction in chemoreceptor response and influence centrally at the respiratory 
centre in the brainstem.
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4.1 Presence of endogenous opioids in human heart failure
To identify whether systemic opioids are involved in CHF it is important to assess 
whether opioid concentrations in circulation are higher or lower than normal subjects.
For example, circulating levels of Beta endorphin appear to be raised in stable chronic 
heart failure. Oldroyd et al. (1995) could not consistently demonstrate a chronically 
elevated plasma level above the normal range of their assay in 34 chronic stable heart 
failure patients who had stopped taking their usual cardiac medications. This result 
conflicts with the data presented by other authors. Plasma B-endorphin levels were raised 
in 37 patients with congestive cardiac failure compared to age and sex-matched controls 
in a study by Kawashima et al. (1991). These authors also revealed that patients with 
more severe disease tended to have higher concentrations of circulating plasma B- 
endorphin with a negative correlation with cardiac output. Similar results were shown by 
radio-immunoassay of B-endorphin in a Chinese study of 131 participants with a 
negative correlation of B-endorphin with left ventricular ejection fraction (Zheng et al., 
1991). Pema et al. (1997) demonstrated a consistently raised B-endorphin level in more 
severely affected patients with chronic heart failure compared to normal subjects. This 
was mirrored by resting norepinephrine levels which were also higher in more severely 
affected heart failure patients. With exercise, B-endorphin levels rose in all subjects to a 
similar peak value (i.e. greater proportional rise in normal subjects with exercise) in this 
small study of 37 participants. They postulate that the activation of the endogenous 
opioid system may balance the effect of increased adrenergic drive with exercise.
Fontana and colleagues also demonstrated significantly higher levels of endogenous 
opioids in acute heart failure patients compared to similar healthy controls in 
conjunction with elevated levels of norepinephrine and natriuretic factors (Fontana et al., 
1993). Plasma Beta endorphin levels did not correlate with severity of disease, whereas 
enkephalin and dynorphin concentrations were higher in more severely affected patients. 
Of course, this is not necessarily applicable to CHF. Hence, it is unclear whether Beta 
endorphin levels in particular remain consistently elevated in chronic heart failure, or 
whether it is the presence of acute stressors or decompensations in this population that 
result in transient rises of beta endorphin secretion (Fontana et al., 1993).
Section 4) Endogenous opioid release in human heart failure
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In addition to the effects of local release of opioids in peripheral autonomic neurones, the 
central nervous system and locally in cardiovascular structures, Holaday (1983) 
hypothesises a role for circulating levels of opioids. He suggests that circulating levels of 
opioids are unlikely to be able to cross the blood brain barrier due to their size and 
polarity, but may be able to influence the autonomic nervous system centre at the area 
postrema in the brain (as discussed previously, an area with high opioid receptor 
concentration). Certainly, this theory is plausible, given that this particular area is known 
from the literature relating to the mechanisms of vomiting to be accessible by circulating 
levels of hormones despite them being unable to penetrate the blood brain barrier in rat 
models (Koga et al., 2003, Carpenter et al., 1984). In summary, although the amount of 
evidence is small, it would appear that circulating opioids of all three endogenous types 
are elevated in HF. Whether this is part of a beneficial or detrimental neurohormonal 
process, or whether it simply reflects the actions of stressors on the body, is unknown.
4.2 Effect of opioids on venous tone in human heart failure
In heart failure patients, Vismara et al. (1976) demonstrated in a small study (n=13 heart 
failure patients) that the effect of morphine on venous tone was small compared to the 
overall beneficial clinical effects seen following administration in pulmonary oedema. 
Morphine does appear to cause venodilation, but it does so both in normal individuals 
and in heart failure and therefore cannot be used to fully explain its effect on dyspnoea. 
In acute heart failure, central mechanisms of ventilatory control are perhaps as important 
as circulatory changes, by allowing the patient to breathe more regularly and with more 
control, resulting in reduced anxiety and further improvement in subjective 
breathlessness. In a small study of 10 patients with acute heart failure complicating 
myocardial infarction, Morphine (0.2mg/kg body weight) reduced blood pressure and 
heart rate (Timmis et a l, 1980). Similar results were found in an earlier study comparing 
these patients with normal controls (Thomas et al., 1965). Again the effects of opioids in 
acute heart failure are similar to those discussed previously in normal individuals, but 
this does not mean that the effect would be the same necessarily for CHF. No such 
evidence on venous tone or peripheral resistance with opioids in CHF yet exists.
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4.3 Effect of opioids on neurohumoral changes in human heart failure
4.3.1 Norepinephrine and the sympathetic nervous system
Sympathetic overdrive from increased chronic norepinephrine activity is considered 
detrimental in CHF (Clark and Cleland, 2000, Roig, 2006). Norepinephrine levels are 
increased in CHF (Eriksson et al., 1994) and therefore reducing or blocking this chronic 
activation should therefore be encouraged. In acute severe congestive heart failure high 
circulatory levels of beta-endorphin, enkephalins and dynorphins correlate with elevated 
plasma norepinephrine concentrations (Fontana et al., 1993, Fontana et al., 1998). It is 
unclear as to whether increased levels of some of these endogenous opioids are 
maintained into stable chronic disease rather than during acute exacerbations. For 
example, the same authors later determined elevated levels of Atrial Natriuretic Peptide 
and Endothelin in association with elevated Beta endorphin and Norepinephrine in acute 
congestive heart failure without elevated enkephalin or dynorphin concentrations at 
baseline (Fontana et al., 1998). Interestingly, further acute mental stress in these patients 
increased the levels of all of the above hormones and the infusion of naloxone in these 
patients during mental stress significantly increased blood pressure, heart rate and 
norepinephrine concentrations versus placebo. In a small randomised double blind 
crossover study of ten CHF patients, infusion of beta-endorphin resulted in a significant 
reduction in norepinephrine concentrations (Cozzolino et al., 2004), similarly suggesting 
an antagonistic effect of opioids on sympathetic activity. What is not known is whether 
endogenous opioids are released because of, or in response to, norepinephrine 
stimulation? This is important as opioids may be released as a balance to the effects of 
norephinephrine, which potentially could be beneficial in the long-term. What is also 
unknown is whether administration of exogenous opioid in addition to beta-blocker 
therapy has an additional therapeutic benefit on the effects of norepinephrine. It is 
interesting to speculate that opioids could be utilised as either an adjunct to therapy in 
addition to beta-blockers, or as an alternative to beta blockers in those heart failure 
patients who were unable to tolerate them due to relative contraindications to their use or 
excessive side effects.
4.3.2 Angiotensin II
It is interesting to consider that opioids may antagonise some of the actions of 
angiotensin II. This is obviously a beneficial effect as use of angiotensin II inhibitors 
have been shown to confer survival advantage and a reduction in heart failure related
hospital admissions in the multicentre SOLVD and CONSENSUS trials (CONSENSUS
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Trial Study Group, 1987, The SOLVD Investigators, 1991). Norepinephrine levels were 
significantly reduced following treatment with an ACE inhibitor (Eriksson et al., 1994) 
and as discussed in Chapter 1 Section 3, the RAAS and sympathetic systems are 
interlinked. However, there is no evidence for an association or interaction of 
Angiotensin II / RAAS and opioids in human CHF.
4.3.3 Opioids and Endothelin
The role of Endothelin in the manifestation of heart failure is gaining interest, given its 
potent vasoconstrictor role (Teerlink, 2005). Elevated levels of Beta endorphin are 
correlated with high concentrations of endothelin in human cardiac failure (Fontana et 
al., 1998) suffering from acute exacerbations, although strictly speaking this is 
considered to be a different population to stable CHF. Interestingly, Wang & Hung 
(2003) have shown a reduction in endothelin concentrations in symptomatic congestive 
heart failure following administration of IV morphine (3mg) in a small study comparing 
heart failure and breathless non-heart failure patients. In addition, a significant reduction 
in plasma concentrations of endothelin following infusion of B-endorphin in a double 
blind placebo controlled crossover study involving ten patients with CHF has been 
demonstrated (Cozzolino et al., 2004). Opioids may therefore also have a role in 
reducing the potentially deleterious effects of endothelin, possibly via the activation of 
mu or delta receptors.
4.3.4 Opioids and Natriuretic Peptide
Natriuretic peptides are considered to be beneficial in human CHF (Brandt et al., 1993). 
ANP for example inhibits angiotensin II and promotes diuresis, which is important for 
those patients with CHF in fluid overload. In an observational study of the effects of 
morphine in normal humans, Ogutman et al. (1990) noted the increase in plasma ANP 
following administration of IV morphine at either 0.15mg/kg or 0.3mg/kg. Unfortunately 
there was no control group so direct comparisons could not be made against placebo and 
no other effects (respiratory rate, urine output, blood pressure etc) were documented, 
limiting the study findings. Interestingly, activation of kappa-opioid receptors also 
induces a diuretic response (Leander et al., 1982, Rimoy et al., 1991) which may 
potentially be of benefit in patients with pulmonary oedema in the chronic and acute 
heart failure setting.
Endogenous opioids are degraded by a variety of proteases or enzymes. One such
protease, Neutral endopeptidase (also known as enkephalinase or NEP) is an enzyme that
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degrades certain opioid peptides more readily than others. As the name suggests, met- 
and leu- enkephalins are preferentially broken down by this enzyme, whereas the 
endorphins and dynorphins are much less susceptible to degradation by this particular 
enzyme (Hersh, 1984). NEP is widely distributed in the body, particularly in the lung and 
CNS (Erdos and Skidgel, 1989). Of note is that NEP is also responsible for the 
degradation and inactivation of ANP in vivo (Erdos and Skidgel, 1989, Roques and 
Beaumont, 1990). NEP inhibitors have been commercially devised by the pharmaceutical 
industry, primarily to reduce NEP degradation of ANP and BNP, and are considered to 
be beneficial in heart failure as the effects of these natriuretic peptides are preserved 
(Maki et al., 2001). As discussed in Chapter 1 Section 3, this involves a reduction in 
vasoconstriction & sodium retention and slowing the rate of cardiac remodelling. The 
OVERTURE trial in CHF noted similar effects of the NEP inhibitor (Omapatrilat) versus 
Enalapril (ACEI) in 5770 patients with CHF. Outcomes such as risk of death or 
hospitalisation were not significantly different between the two different treatment 
groups (Packer et al., 2002). Unfortunately there was no assessment of symptom 
response between treatment groups in these patients. The drug used (Omapatrilat) is 
considered to have efficacy versus ACE and hence the lack of noticeable superiority over 
common ACE inhibitors has meant that further research into its use has been inhibited, 
mostly on the basis of cost. Is the beneficial effect of inhibiting NEP purely mediated 
though the prolongation of activity of ANP alone, or can we also surmise that the 
prolongation of opioid activity (particularly enkephalin activity) also has a beneficial 
effect by inhibiting NEP? This evidence adds further weight to our hypothesis than 
opioids may be beneficial for CHF patients.
4.4 Non-symptom control studies in human CHF
As quoted previously, Cozzolino et al. (2004) detailed the effect of Beta endorphin 
infusion in a small RCT involving CHF patients (NYHA 2-3). In addition to the 
statistically significant reduction in norepinephrine and endothelin concentrations with 
beta-endorphin compared to placebo, there was no change in circulating BNP or renin 
concentrations one hour following infusion, though this time period may not have been 
sufficient enough to observe any “downstream” effects in these peptides. However, it is 
unclear as to the clinical value of this infusion, which increased beta-endorphin by 100 
times the basal circulating level. Certainly one could not extrapolate a potential role for
beta-endorphin from this study alone given the magnitude of the increase, which is
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unlikely to be discovered naturally in CHF. However, if infusion of pharmaceutical 
opioids that activate the mu receptor such as morphine demonstrate a similar response 
this may be useful in determining a potential cardioprotective role. The authors conclude 
that high doses of beta-endorphin could preserve cardiovascular function, but they 
hypothesise that this is through increasing the inotropic function of the heart, which 
would appear contradictory to a cardioprotective role versus overstimulation through 
norepinephrine.
Section 5) Chapter summary
As can be seen in the sections above, there is some evidence to support a possible role for 
opioids in CHF. Unfortunately there has been no consistent approach to research in this 
area. Studies in animals and humans have attempted to link severity of heart failure with 
elevated levels of endogenous opioids as part of an overall neurohormonal response, 
which was viewed as detrimental in CHF. This has subsequently led to early trials 
involving the use of opioid antagonists in the management of heart failure symptoms, 
without notable success. It has now emerged that some neurohormones, like natriuretic 
peptides, might be beneficial in CHF and hence the prolongation of their response should 
be encouraged. Tantalisingly, natriuretic peptides are degraded by the enzyme neutral 
endopeptidase (enkephalinase), which also degrades opioid peptides (notably 
enkephalins). Should we now take a second look at opioids?
Information concerning the possible role of opioids in cardiorespiratory regulation comes 
mostly from basic science or animal studies, both of which need to be looked at with 
caution when interpreted in terms of human CHF. Again, a previous lack of distinction 
for stable chronic heart failure and acute types of heart failure does not allow easy 
interpretation of studies that are apparently relevant. In particular, dog models of right 
sided heart failure may not represent the patient experience in CHF. Of interest is that mu 
and delta opioid receptors have been located at sites in the brain implicated in autonomic 
cardiorespiratory control and in the proposed formation of intractable breathlessness in 
humans. Opioid receptors are also located peripherally in the heart and lungs, notably 
kappa receptors in the heart (plus recently mu in human studies) and mu receptors in the 
respiratory system. This may be important in the light of the respiratory effects of opioids 
for intractable breathlessness as most pharmaceutical opioids have a preferential affinity
for mu receptors, with oxycodone also having a notable affinity for kappa receptors in
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addition to mu. Stimulation of kappa receptors results in a diuretic response in humans, 
potentially useful for acute heart failure where fluid overload causes symptoms such as 
breathlessness, but perhaps not so important for stable chronic heart failure where other 
mechanisms causing breathlessness may be more prominent. In this case, different types 
of opioid may have differing effects in both cardiovascular and respiratory parameters, 
particularly important for breathlessness control in CHF.
It remains unclear from the literature as to whether endogenous opioids rise in response 
to, or because of, worsening heart failure. This distinction is important, as opioids may 
actually have a beneficial role in cardiovascular regulation. Endogenous opioids and 
receptor expression increase in various cardiovascular models of cardiovascular disease, 
including hypertension and the ageing process. Opioid release has been noted as 
deferring a degree of cardioprotection in the phenomenon of ischaemic preconditioning. 
Probably the most important point in this chapter is that opioids may antagonise the 
release and effects of norepinephrine, the n'eurohormone thought most responsible for the 
development and prolongation of CHF and also has a role in specific mechanisms of 
breathlessness in CHF. Administration of opioid in normal humans results in a reduction 
in blood pressure and heart rate on tilting and reduces the response to carbon dioxide 
through blunting the chemoreceptor response. In CHF, chemoreceptor activity is 
enhanced, hence this activation may be antagonised by opioids. It is unclear whether 
these effects are manifested through antagonism of the sympathetic nervous system, but 
at the cellular level norepinephrine causes an increase in cAMP through activation of 
stimulatory G proteins, whereas opioids tend to reduce cAMP through activation of 
inhibitory G proteins.
There is therefore enough evidence to suggest a role for opioids in the cardiorespiratory 
system, that detrimental sympathetic activation in CHF may be attenuated by endogenous 
opioids and that opioid concentrations rise in CHF. This circulating rise mirrors both 
detrimental neurohormones such as norepinephrine and beneficial neurohormones such 
as natriuretic factors. The effect of this rise in endogenous opioids is therefore a subject 
for conjecture. The effect of opioid administration in normal humans is actually poorly 
researched given its long history of use and abuse, but exogenous opioids do reduce tidal 
volume at small doses and cause respiratory depression in much larger doses. One might 
extrapolate that the mechanisms involved in this phenomenon might also be those same 
mechanisms implicated in the relief of dyspnoea with opioids. The clinical use of opioids
for breathlessness control in CHF will be discussed in the following Chapter.
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Chapter 3:
Systematic Literature review:
Human symptom control studies in CHF
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Section 1) Introduction: What clinical evidence exists to suggest opioids may help
breathlessness?
Opioids have been used for many years in the management of acute heart failure and in 
the patient who is actively dying on the basis of clinical experience and consensus rather 
than a robust evidence base. However their use in the patient with chronic heart failure 
(CHF) has been discouraged. This is partly due to historical and often unsubstantiated 
concerns about cardio-respiratory depression (Johnson and Gibbs, 2006).
Opioids are accepted in the management of breathlessness in patients with malignant 
lung disease who remain breathless despite optimum management, and who are not 
necessarily imminently dying. A Cochrane review regarding the use of opioids in 
patients in the management of breathlessness in incurable disease (cancer and non- 
malignant disease) concluded that there, was clinical evidence to suggest a small but 
significant symptom improvement with oral or parenteral opioids in this patient 
population (Jennings et a l, 2001). However, the review only included one trial that 
specifically involved CHF patients as a distinct group.
Although there is limited evidence for the use of opioids in the management of 
breathlessness in many life-limiting diseases (Jennings et a l, 2001) there has been little 
research in heart failure patients specifically. This is somewhat surprising as morphine 
has been used for many years in the management of acute cardiac failure (Millane et al., 
2000). For example, Beltrame et al, (1998) remains the only RCT of morphine use in 
acute HF and this was a study of treatment comparisons involving other widely used 
therapies in the management of acute symptoms rather than evaluating the effect of 
morphine alone. Intravenous nitrates (Nitroglycerin 2.5 microgram/min / N- 
Acetylcysteine 6.6 microgram/min over 24 hours infusion) were compared with an 
intravenous diuretic (Frusemide 40mg stat dose / Morphine l-2mg IV over 5 minutes) 
combination in a prospective open label randomised study of 69 consecutive patients 
presenting with clinical and radiological findings of acute pulmonary oedema. 
Treatments were repeated at 60 minutes and throughout the next 24 hours if there was 
inadequate clinical response. Additional medication could also be introduced if there was 
an inadequate response to treatment. Clinical outcomes were the primary and secondary 
outcomes and similar improvements were observed between both groups using intention- 
to-treat analyses.
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Unfortunately the method of randomisation and level of blinding in this study is unclear, 
particularly as the treatment regimens vary so widely. It is feasible that a patient may 
improve simply by having a continuous infusion with the knowledge that treatment is 
ongoing. Additionally, given the acute nature of clinical symptoms observed and the 
necessary provision for alternative treatments, the effect of individual therapies on 
outcome may be blurred. If there is no standardised procedure for initiation of additional 
therapies and decisions are based on clinical parameters alone, the study may be left 
susceptible to bias by the treating team. Variable doses of treatment medications (such as 
morphine l-2mg) also make outcomes less clear per treatment dose. There were only 
physician-rated assessments of dyspnoea, with no assessment by the patient, which could 
again lead to bias. Of note also is that morphine did not cause respiratory depression 
which is often quoted as a reason not to use opioids in cardiorespiratory disease.
More recently, the ADHERE study (Peacock et ah, 2008) provided a retrospective 
analysis of 147362 episodes of hospitalisation in patients with acute decompensated heart 
failure. The analysis focuses on those patients who received morphine with those who 
did not and commented that use of morphine was an independent predictor of mortality 
in acute heart failure. Patients in receipt of morphine required more admissions to 
intensive care, had a longer hospital stay on average and were more likely to be in receipt 
of additional interventions. In summary, it would appear that the use of morphine in 
acute heart failure was disadvantageous. However, retrospective studies are only as good 
as the information that has been documented and there is no clear indication whether use 
of morphine was part of the cause of the decline of these patients, or part of the effect of 
the decline. For example, patients with more severe heart failure, or end-stage heart 
failure, may have received morphine for symptomatic relief of breathlessness, but of 
course these patients are more likely to die than those with less severe symptoms. In 
addition, as Schuler et ah (2008) correctly discuss in their letter following the publication 
of the trial, the timing or reason for morphine use is not known as it may have been used 
as part of anaesthesia on or prior to intensive care. Whilst this study highlights that the 
issue of use of morphine should be investigated, this can only adequately be achieved by 
the use of properly constructed RCTs.
The above trials involve opioids in patients with acute heart failure symptoms. The 
following systematic literature review will involve the breathlessness symptom control
trials in chronic heart failure with opioids that currently exists.
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Section 2) Literature review process
2.1 Selection criteria
The purpose of this literature review is to clarify the current evidence base relating to the 
management of breathlessness with opioids in human chronic heart failure (CHF).
A scoping search prior to the systematic search suggested that there was little published 
evidence regarding the use of opioids in the symptom management of human adults with 
CHF.
The primary research question was:
Do opioids improve the sensation of breathlessness (dyspnoea, dyspnea) in heart 
(cardiac) failure in a human adult population?
2.1.1 Study designs
All randomised controlled trials (crossover and parallel design) investigating the use of 
exogenous opioids in the management of breathlessness in heart failure in adults were 
included. Observational studies involving exogenous opioids were also included. Well 
conducted randomised controlled trials can be viewed as the gold standard of research, 
whereas observational or epidemiological studies are prone to a number of potential 
selection biases (Gordis, 2004). However, given the paucity of research in this area, non- 
randomised trials of poorer quality had to be included to provide background to the topic.
2.1.2 Participants
Studies involving children were excluded as childhood cardiac diseases are often very 
different in aetiology to adult cardiac diseases. This was to allow comparison between 
similar subjects and similar aetiologies. Adults were defined in this review as participants 
aged 18 years and older. Trials involving acute and not chronic heart failure were 
excluded; as previously discussed the mechanisms for breathlessness in acute heart 
failure are different to those causing dyspnoea in chronic heart failure. Non-human 
studies were not included in this specific search, but have been discussed in chapter 2.
2.1.3 Intervention
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Any type, preparation and route of administration of opioid medication were included 
(Step 2 analgesics: codeine, tramadol; and Step 3: morphine, fentanyl, oxycodone, 
hydromorphone or methadone). To generate the maximum number of studies to be 
included there was no restriction on the duration of treatment.
2.1.4 Outcome measures
The primary outcome measure for trials in human subjects with heart failure was patient 
reported breathlessness using validated scales (Borg breathlessness scale, Numerical 
rating scale, Verbal rating scale, Visual Analogue scale). These are recognised scales for 
the measurement of breathlessness as described in Chapter 1 Section 4. Secondary 
outcome measures in these trials included quality of life, sleep, patient satisfaction, 
activities of daily living, mood, secondary care admissions and adverse events (major and 
minor). These outcome measures will be particularly valuable from a patient perspective 
and for clinicians who manage heart failure as they describe the physical and emotional 
impact of any changes in breathlessness severity.
124
Section 3) Search strategy
The Cochrane library, Medline (1950 - 01/03/2009), Embase (1980 - 01/03/2009) and 
Cinahl (1982 -  01/03/2009) databases were searched using the National Electronic 
Library for Health (NELH) advanced search engine. At the time of writing, this has now 
become the NHS Evidence Health Information Resources Portal. An example of the 
search strategy used on Medline is outlined below. There was no limitation with regards 
to dates or language in order to minimise bias. It is unlikely that a search of other key 
databases (e.g.AMED, PsychINFO) would produce results of relevance given this 
clinical topic.
Search strategy (Medline 1950-nresenf) using NELH advanced search platform:
1. SEARCH
2. SEARCH
3. SEARCH
4. SEARCH
5. SEARCH
6. SEARCH
7. SEARCH
8. SEARCH
9. SEARCH
10. SEARCH
11. SEARCH
12. SEARCH
13. SEARCH
14. SEARCH
15. SEARCH
16. SEARCH
17. SEARCH
18. SEARCH
19. SEARCH
20. SEARCH
21. SEARCH
22. SEARCH
23. SEARCH
24. SEARCH
25. SEARCH
26. SEARCH
27. SEARCH
28. SEARCH
29. SEARCH
OPIOID
ANALGESICS-OPIOID#.DE. OR RECEPTORS-OPIOID#.DE.
OPIATE
ENDORPHIN
ENDORPHINS#.W..DE. OR BETA-ENDORPHIN#.DE.
ENKEPHALIN
ENKEPHALINS#.W..DE.
DYNORPHIN
DYNORPHINS#.W..DE.
1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9
MORPHINE
MORPHINE#. W.. DE.
DIAMORPHINE 
TRAMADOL 
TRAMADOL#.W..DE.
CODEINE 
CODEINE#.W..DE.
METHADONE
METHADONE#.W..DE.
OXYCODONE 
OXYCODONE#. W.. DE.
HYDROMORPHONE
HYDROMORPHONE#.W..DE.
FENTANYL 
FENTANYL#. W.. DE.
ALFENTANIL
ALFENTANIL#.W..DE.
BUPRENORPHINE 
BUPRENORPHINE#. W..DE.
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30. SEARCH:
31. SEARCH:
32. SEARCH:
33. SEARCH:
34. SEARCH:
35. SEARCH:
36. SEARCH:
37. SEARCH:
38. SEARCH:
39. SEARCH:
40. SEARCH:
41. SEARCH:
42. SEARCH:
43. SEARCH:
44. SEARCH:
45. SEARCH:
46. SEARCH:
47. SEARCH:
48. SEARCH:
49. SEARCH:
50. SEARCH:
11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 
OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 
28 OR 29
BREATHLESSNESS 
BREATHLESS$
DYSPNEA 
DYSPNEA#. W..DE.
DYSPNOEA
31 OR 32 OR 33 OR 34 OR 35 
CARDIAC ADJ FAILURE
HEART-FAILURE-CONGESTIVE#.DE. OR CARDIAC-OUTPUT- 
LOW#.DE.
LEFT ADJ VENTRICULAR ADJ SYSTOLIC ADJ DYSFUNCTION 
VENTRICULAR-DYSFUNCTION-LEFT#.DE.
HEART ADJ FAILURE
37 OR 38 OR 39 OR 40 OR 41
1 OR 2 OR 3 OR 30
36 AND 43
44 AND 42
42 AND 43
(10 OR 30) AND 36
(10 OR 30) AND 42
47 AND 48
49 AND (CLINICAL-TRIALS# OR PT=CUNICAL-TRIAL#)
Reference lists from eligible studies were reviewed to identify further studies of 
relevance. The National Research Register and MRC Research Register were searched to 
identify any funded research in progress. Searching the grey literature was not possible as 
part of this student project.
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Section 4) Literature review search results (01/03/2009):
The results for three database searches (Medline, Cinahl and Embase) are shown in the 
figures below. Search results are given for the three main search categories, with 
subsequent results of all three categories combined in an amalgamated category. A 
description of those articles that appear potentially relevant based on title and abstract of 
the article are also given. In addition to this, the search of the Cochrane library 
(01/03/2009) revealed 22 results from Cochrane central register of controlled clinical 
trials involving the search terms: opioid (all text) and heart or cardiac failure (all text). 
One article was found of relevance (Johnson et al, 2002).
Figure 3.4.1: Results from the Medline database search (1950 - 01/03/2009):
29276 articles 
found involving 
breathlessness 
and related terms
128712 articles 
found involving 
opioids and 
related terms
151630 articles 
found involving 
CHF and related 
terms
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Figure 3.4.2: Results from the Embase database search (1980 - 01/03/2009):
41638 articles 
found involving 
breathlessness 
and related terms
186197 articles 
found involving 
opioids and 
related terms
181941 articles 
found involving 
heart failure and 
related terms
Figure 3.4.3: Results from the Cinahl database search (1982 -  01/03/2009). This database 
does not have a limit for human selection, so peer reviewed articles are included as an
extra step:
9971 articles 
found involving 
breathlessness 
and related terms
19644 articles 
found involving 
opioids and 
related terms
45684 articles 
found involving 
heart failure and 
related terms
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In total, eight articles of relevance were discovered using the above measures once 
duplicates from the databases were removed. Three articles were discarded from this list. 
The rejected articles are documented in Table 3.4.1. The article by Westphal & Campbell 
(2002) involving nebulised morphine for dyspnoea in patients with a terminal illness, 
including CHF, did not contain any primary data and was thus discarded. The article by 
Gauna et al. (2008), involving the use of opioids in four terminally ill patients with 
breathlessness did not recruit any patients with CHF. The authors had CHF in their 
selection criteria and so the article was selected by the search engine, but the four 
patients involved in the trial had diagnoses of COPD, lung cancer or pulmonary fibrosis 
and hence the trial was rejected on the basis that it did not involve CHF.
As described in Chapter 1 Section 4, abnormal breathing patterns are associated with 
poorer prognosis in CHF (Leung et al., 2006, Leung et al., 2003, Corrà et al., 2006). 
Ponikowski and colleagues (Ponikowski et al., 1999) noted an association of abnormal 
breathing patterns with more advanced symptoms, reduced baroreceptor activity and 
increased chemosensitivity when compared to heart failure patients with normal 
breathing patterns. The role of chemoreceptors is of potential interest given that they are 
also implicated in sympathetic overstimulation in CHF. A recent review by Buchanan et 
al. (2009) details the role of chemoreceptors in breathing control and breathlessness in 
respiratory disease, but their conclusions may be extrapolated to breathlessness in CHF. 
They consider that the NTS is the key location for the relaying of chemoreceptor 
information to the forebrain to mediate the sensation of dyspnoea. As previously noted, 
the NTS is also a site of high opioid activity. Opioids therefore may have an important 
role at this site in the relay of chemoreceptor information processing in higher centres in 
dyspnoea in CHF. As detailed in the previous chapters, opioids may play a role in 
attenuating the sympathetic overdrive, reduced baroreceptor activity and increased 
chemosensitivity associated with advancing CHF. Hence those patients with abnormal 
breathing patterns may benefit the most from administration of exogenous opioids for 
breathlessness.
Administration of dihydrocodeine, a weak opioid, to eight of these patients in a 
randomised double blind placebo controlled manner led to an improvement in breathing 
pattern and associated significant reduction in chemosensitivity (Ponikowski et a l,
1999). Four of these patients with periodic breathing had a return to entirely normal
breathing patterns following addition of dihydrocodeine. These results add to their earlier
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findings discussed later in this review (see Chua et al. (1997)). This study is not included 
in the formal literature review as there was no subjective measurement of dyspnoea in the 
participants.
Table 3.4.1 : Table of excluded studies following literature search
Author Trial description Reason for rejection
Westphal & 
Campbell 2002
Observations of use 
of nebulised 
morphine of 
terminal dyspnoea 
in general
No primary data; review only of use of 
nebulised morphine and reviewers 
experience without documented data
Gauna et al 2008 Observational study 
of use of morphine 
in 4 patients with 
dyspnoea
No patients with CHF selected, though this 
was part of the inclusion criteria for the 
study as a potential cause for breathlessness 
allowing inclusion
Ponikowski
1999
RCT of 
dihydrocodeine 
versus placebo in 8 
CHF patients
Documented change in breathing pattern 
but no subjective patient rating of change in 
breathlessness
130
Section 5) Human symptom control studies in CHF: Included studies
Five articles that matched the selection criteria were therefore included. All of these 
studies were limited by small sample size. Methodological quality, assessed using scales 
such as the Jadad score (Jadad et al., 1996) was not attempted as so few identified trials 
were blinded RCTs. Level of evidence grading using a NICE guideline approach (Gysels 
and Higginson, 2004) was performed and is detailed in Table 3.5.1.
The first of these studies to describe involves the use of the weak opioid, dihydrocodeine. 
It has already been noted that codeine administration allows greater toleration of 
hypercapnea in normal subjects (Stark et a l, 1983), potentially via chemoreceptor 
manipulation. Chemoreceptors monitor levels of blood gases in the circulation and are 
thought to influence respiratory function by altering respiration according to serum levels 
of oxygen and carbon dioxide (Duffin & McAvoy 1988). It is considered that these 
chemoreceptors become upregulated in chronic heart failure, resulting in an exaggerated 
sensitivity to reduction in circulating oxygen or increased carbon dioxide, leading in turn 
to an augmented ventilatory response and hence the sensation of breathlessness (Chua et 
a l, 1996). As described in previous chapters, opioids may be involved in reducing the 
sympathetic activation that is involved in the upregulation of these chemoreceptors. As 
can be seen in Figure 1.3.4, reduction in chemoreceptor activation may alter the 
activation of the major detrimental neurohormonal systems in CHF (namely the 
sympathetic system and RAAS). Chua et a l describe the effect of dihydrocodeine on 
breathlessness and exercise tolerance in 12 male heart failure patients in a randomised 
double blind placebo controlled trial (Chua et a l, 1997). Participants received placebo or 
dihydrocodeine (lmg/kg body weight) on separate days, one hour prior to exercise and 
chemosensitivity assessment. Taking an average male to weigh 70kg, this represents a 
conventional treatment dose of dihydrocodeine (British National Formulary, 2006). 
Participant blinding was attempted by dissolving interventions in identical lemon drinks 
prepared by pharmacy. Details as to the randomisation of the sequence of study 
medication are not given. This is important as if  the majority of participants received the 
active intervention second they may be more used to the subjective testing procedures, 
leading to bias in the results, particularly in a small study. However, the sequence should 
not alter the characteristics of the physical (non-subjective) chemosensitivity tests. Also, 
for chronic disease states, the effect of repeated dosing rather than single dosing is likely 
to have greater clinical impact.
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Given this, the authors noted a significant fall in hypoxic chemosensitivity in these 
patients with dihydrocodeine compared to placebo (mean reduction of 40% from placebo 
value; p value = 0.005). Similar but less impressive results were discovered for 
hypercapnic chemosensitivity (a mean difference of 16% from placebo values p=0.01). 
These reductions in chemosensitivity were coupled with a corresponding increase in 
exercise tolerance (mean exercise duration 455 seconds {SE +/- 27 seconds} versus 512 
seconds {SE +/- 27 seconds} on dihydrocodeine; p = 0.001) and peak oxygen 
consumption (mean 18.0 ml/kg/min +/- 0.6 ml/kg/min versus 19.7 ml/kg/min +/- 0.6 
ml/kg/min; p = 0.002) on the active treatment. The Borg score, a subjective measure of 
breathlessness, was also lower in the active treatment group, indicating a symptomatic 
improvement. However, it was only significantly lower after 6 minutes of exercise and 
was not significantly different at peak exercise. Even at 6 minutes, the mean difference in 
the 11 point Borg score between placebo and dihydrocodeine was only 0.69. It is 
questionable as to whether this truly relates to a notable symptomatic improvement, as a 
difference of greater than one point on the Borg scale is considered to be clinically 
significant (Booth, 2006). In addition, these last three measures may be influenced by 
treatment sequence. The article concludes that manipulation of chemosensitivity with 
opioids may benefit patients with chronic heart failure by reducing the elevated 
sensitivity of chemoreceptors, reducing the sensation of breathlessness and thus 
improving exercise tolerance.
In a similar study, sixteen consecutive stable chronic heart failure patients were recruited 
to a prospective randomised placebo controlled trial involving low dose diamorphine 
(Williams et al., 2003). Patients completed a modified Bruce treadmill exercise protocol 
immediately following either placebo or diamorphine l-2mg IV. The study is defined as 
randomised double blind but there are no details to the blinding or randomisation 
process. It is unclear as to why different doses of diamorphine were used for different 
participants.
Again, the authors noted a significant improvement in aerobic exercise capacity with 
diamorphine through a significant reduction in ventilatory response. Interestingly, the 
greatest improvement occurred at sub-optimal exercise levels, which might suggest that 
opioids would assist those most with breathlessness on moderate exertion. Mean oxygen 
consumption at 6 minutes was 15.7 ml/kg/min (SEM: 1.0 ml/kg'min) for diamorphine 
versus 14.7 ml/kg/min (SEM: 0.9 ml/kg/min) for placebo (p = 0.01). At maximal
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exercise mean oxygen consumption was 21.1 ml/kg/min (SEM 1.6 ml/kg/min) and 20.2 
ml/kg/min (SEM: 1.5 ml/kg/min) respectively in favour of diamorphine. However, these 
results might be counter-intuitive, as for a given workload a lower oxygen consumption 
would be preferable. There was also no significant difference with treatment on exercise 
duration. Unfortunately there was no patient related assessment of an improvement in 
breathlessness performed to correlate with the physical aerobic improvement. It is 
unclear therefore how this study relates to breathlessness in CHF. As for the study by 
Chua et al. (1997) there were no participant withdrawals and low opioid doses were 
considered to have a good safety and side effect profile.
A randomised double blind placebo controlled crossover pilot study evaluated the effect 
of oral morphine on breathlessness in 10 NYHA grade III/IV heart failure patients 
(Johnson et al., 2002). Patients were randomised to oramorph 5mg four times a day or 
placebo for four days followed by a two day washout. The crossover design allowed 
patients to act as their own controls. Randomisation was performed by an external source 
and participants and investigators remained blind to intervention. Breathlessness scores 
on a 100mm visual analogue scale improved significantly from baseline to day one on 
active treatment (median improvement of 23mm: p = 0.022). It could be argued that 
mean values could have been used to describe values for visual analogue scores. 
Interquartile ranges were given alongside median values as a measure of variability. The 
improvement was maintained throughout the active treatment course. A placebo response 
was also observed which returned to baseline values at day four of treatment. Six of the 
ten participants correctly identified the active treatment arm, but the majority of these 
participants received morphine as the first intervention in the crossover. It should be 
noted that this is the only repeat dose study of opioids solely in CHF patients. The 
authors conclude that oral morphine has a role in relieving breathlessness in heart failure 
patients.
The use of nebulised morphine has been discussed in a two patient case reports based on 
the manipulation of peripheral opioid receptors in the lung (Famcombe and Chater, 
1993). Nebulised therapy was added to an optimal heart failure treatment regimen, with 
an initial subjective benefit. However, therapy had little effect on blood gases or vital 
signs in the two patients and ultimately one patient had to be converted to subcutaneous 
morphine as she did not tolerate the nebulised treatment. Most of the study observations 
came from physician or nurse rated improvements rather than patient rated changes and
no formal methods of subjective assessment of breathlessness were used. Co-morbidities
133
such as pre-existing lung disease and multiple concurrent therapies administered during 
the intervention may be confounding factors. In general, the use of nebulised morphine 
has fallen out of favour in the clinical management of breathlessness for all diseases due 
to its lack of consistent objective benefit (Jennings et al., 2001) and the presence of 
alternative routes that are easier to administer to patients.
Currow et al. (2007) produced a further analysis of the study by Abemethy et al. (2003) 
involving patients with intractable dyspnoea from various aetiologies. Originally, 
participants were given 20mg of sustained release oral morphine or placebo per day for 
four days in a randomised controlled crossover fashion. In the original study, 38 patients 
were recruited, of which four were described as having a cardiovascular co-morbidity. 
Compared to those patients who did not have any documented cardiovascular disease, 
those with an abnormality responded better to morphine versus placebo (mean response 
39% change in breathlessness score with morphine versus placebo on a 100mm VAS 
compared to 10% mean change if no cardiovascular disease was present). This outcome 
is potentially of interest, given that patients with cardiovascular disease (including CHF) 
may benefit more from opioids for breathlessness than those without. However, this 
secondary analysis has a number of potential flaws. Firstly, the sample number (four 
affected patients out of 38) is too low to derive meaningful outcomes. Secondly, other 
factors such as a better performance status and lack of availability of home oxygen are 
also associated with a better response to morphine. Of course, we do not know whether 
the patients with cardiovascular disease have better performance status in this trial, or 
availability to home oxygen, and it is possible that these patients respond better due to 
the presence or absence of these factors and not due to their underlying disease. 
Presumably the authors cannot factor these potential differences into the statistical 
analysis due to the small sample size. Thirdly, the original crossover study had no 
washout period between interventions which may have allowed a carryover of treatment 
effect from first to second interventions, although comparison of end of treatment, rather 
than change from baseline was performed. In essence, the single assessment at day 4 of 
treatment meant that a four day washout period occurred between interventions. It is 
open to question whether this four day period was sufficient to be confident that an 
adequate period was observed between assessments. The Summary of medicinal Product 
Characteristics (Napp Pharmaceuticals) for sustained release morphine preparations 
quotes a systemic morphine half life of four hours, but the sustained nature of release 
advocates a constant release of drug for 12-24 hours dependent on preparation. Hence in
effect only three days of washout occurred, which arguably still should have been
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sufficient. Lastly, the original study regards all patients to have breathlessness primarily 
due to respiratory pathologies (mostly COPD) and not due to cardiovascular disease, 
which have been documented as a co-morbidity only (or non-dominant aetiology for 
dyspnoea). These “cardiovascular” co-morbidities are not discussed further, and may not 
actually involve true CHF. However, it should be appreciated that the authors do not state 
that patients with cardiovascular disease have better outcomes with morphine, only that 
further research in the area is warranted given their secondary analysis. The RCT 
described in Chapter 4 will provide evidence to support or disprove this notion 
specifically for CHF.
One further article was discovered following general reading of the research literature 
that did not appear in the literature searches. This illustrates the limitations of such 
literature reviews, however as the study was an observational pilot trial the literature 
search did not appear to neglect trials of great relevance. The study, by Davies et al. 
(1990) determined the response of administration of dihydrocodeine lmg/kg in ten 
subjects with NYHA grade III CHF. Addition of dihydrocodeine was shown to reduce 
dyspnoea during exercise at a “standard” workload. Dyspnoea assessment was made 
using a visual analogue scale. Administration of naloxone increased dyspnoea at a 
standard workload in these patients. The study has only been reported as an abstract in 
the Cardiac Society Newsletter in 1990 and hence the outcome data and quoted statistical 
significance cannot be scrutinised in a proper manner. Hence, no further comment can be 
made regarding their quoted figures. The participants and researchers appear not to have 
been blinded to treatment and the interventions appear not to have been given in a 
random fashion. Lack of clarity concerning the methodology limits the usefulness of the 
study, but it has been quoted for completeness.
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In addition to these symptom control studies, Kindman and Fowler (1989) investigated 
the action of naloxone on 6 patients with stable congestive heart failure (NYHAII and 
III). They hypothesised that, despite clinical improvements seen in acute heart failure 
with opioids, that release of opioids during cardiovascular shock was a deleterious effect. 
Hence use of opioid antagonists may be justified. Various bolus concentrations of 
naloxone were administered, but there were no significant effects on cardiovascular 
parameters (including left ventricular pressures, cardiac output and peripheral resistance) 
although of course this interventional study is limited by very small participant numbers 
in a stable population without evidence of cardiovascular shock. No evidence of effect is 
not the same as no effect, but if nothing else this study demonstrates the previously 
perceived detrimental effects of opioid use in CHF literature.
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The criteria for inclusion of studies in CHF was broad to maximise the number of 
included studies in this area that has been under-researched. For example, all 
pharmaceutical opioids were included as therapeutic measures. Had there been sufficient 
trials, subgroup analyses could have been attempted for immediate and controlled release 
preparations, method of administration (oral, subcutaneous, IV, nebulised) and class of 
opioid (step 2 analgesics versus step 3). Given the heterogeneous nature of the studies 
selected; the type of participant; nature of intervention; difference in measurements, at 
rest or on exercise; no meaningful meta-analysis of the data could be performed. Only 
with greater clarity and standardisation of outcome measurements, greater use of 
randomised controlled trials and studies involving greater numbers of participants will 
this lack of good quality evidence be addressed.
A number of potential biases may occur from the selection of English articles only. For 
example, Grégoire et al. (1995) demonstrated a change in the outcome of one meta­
analysis had non-English language articles been incorporated into the analysis. All 
settings, any duration of follow-up and all ethnic groups in trials were included in order 
to maximise the likelihood of finding eligible research. This approach conversely may 
reduce study validity. Level of evidence grading was performed solely by the author, but 
for publication in peer reviewed journals the process should be repeated by a second 
reviewer independent of the first, with consensus reached for selection and grading of 
included studies.
Only small symptom control studies in both heart failure and non-heart failure patients 
exist but they suggest that opioids could be beneficial in the management of 
breathlessness. However, the current research evidence eludes to a greater potential for 
the use of morphine to regulate the cardiovascular changes seen in heart failure in 
addition to the management of clinical symptoms such as breathlessness. Despite the vast 
number of studies that involve the three individual components of interest, only six 
studies from the systematic literature search have been identified that involve an 
assessment of breathlessness severity with opioid agonists in CHF. These are a 
heterogeneous collection of studies involving small numbers of participants (54 in total) 
and multiple types and doses of opioid. Clearly there is the potential for publication bias 
for these studies. Only three involved the collection of primary data with RCT
Section 6) Chapter summary including review limitations
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methodology, the gold standard of quantitative research (Tilling et al., 2005), in CHF. 
Therefore, there is a distinct lack of good quality, adequately powered RCTs in this area 
of symptom control of breathlessness in CHF.
On a wider point, greater distinction must be made between those patients with stable 
CHF, acute heart failure and those CHF patients who have acute exacerbations as these 
represent three different patient groups with different likely aetiologies for 
breathlessness. The early literature in particular does not make this distinction clear, 
allowing subsequent comparison difficult. One further point is the relation of the current 
breathlessness trials with the actual clinical situation of living through CHF. Only one 
trial involving primary data collection (Johnson et al., 2002) monitored the effects of 
multiple dosing with opioids, rather than a single dose as for the other studies quoted. 
Assessment of multiple dosing should take preference to single dosing if the overall 
clinical effect on CHF is to be determined, particularly if secondary components 
involved with breathlessness such as change in quality of life or physical function are to 
be measured in addition to alteration in breathlessness severity.
Taken together, these studies show that there is a small but expanding evidence base 
recommending the use of opioids in chronic heart failure patients for the management of 
breathlessness. So far it is unclear which cohort of patients will derive most symptom 
control benefit; those patients with low grade symptoms who are able to achieve greater 
exercise potential or those more advanced (NYHAIII-IV) who have a greater 
symptomatic burden.
Finally, several gaps in the knowledge therefore exist in the management of 
breathlessness in CHF with opioids. These include the requirements for:
• A larger sample study of CHF patients with breathlessness to corroborate the 
findings of the ten patient pilot study by Johnson et al. 2002.
• An assessment of different opioids in breathlessness management in CHF, given 
that all the opioids quoted in the literature have a high affinity for mu receptors 
only, rather than the use of oxycodone that has reasonable affinity for the kappa 
receptor as well as the mu receptor, which may have a different response in CHF 
as detailed in Chapter 2.
• An expansion in data from repeated dose studies and randomised controlled trials 
to improve the quality of the existing literature, including safety of opioids in 
CHF.
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• An assessment of the factors that may predispose a patient to responding to 
opioid therapy for breathlessness.
• A longer term follow-up of participants in receipt of opioids greater than the four 
days of repeat dosing by Johnson et al. 2002, the longest follow-up of all 
subjective breathlessness studies in CHF.
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Chapter 4;
Randomised controlled trial of opioids for breathlessness in heart 
failure
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Section 1) introduction
1.1 Why is symptom control with opioids for breathlessness in CHF important?
Breathlessness is a defining symptom of heart failure and forms the basis of the New 
York Heart Association (NYHA) grading. It is a cause of patient distress and has a 
significant impact on quality of life, which is thought to be poorer than some patients 
with incurable cancer (Murray et al, 2002). The prevalence of chronic heart failure 
(CHF) is increasing with the increasing age of the population and with better survival 
following acute coronary events (Thomas and Rich, 2007), suggesting that symptom 
control will become a greater issue in a growing number of patients.
Patients with advanced heart failure can still be limited by breathlessness, despite the 
development of therapies currently used in standard clinical practice. These treatments 
have typically involved the prevention of disease progression through manipulation of 
neurohormones released in CHF and have been evaluated using endpoints such as rates 
of hospitalisation and mortality. As discussed in Chapter 3, very few studies have been 
performed that evaluate response to symptom control therapies, particularly in 
breathlessness in CHF. From this evidence there is clearly a need to further explore the 
role of opioids for breathlessness in CHF.
Breathlessness is a complex symptom with multifactorial aetiologies as described in 
Chapter 1 Section 4. Measurement of breathlessness severity is only one component of 
the evaluation of a breathless patient. Other modalities such as assessment of quality of 
life, physical function and distress caused by breathlessness are also important (Lehman, 
2006a). For breathlessness in CHF in particular, sympathetic overactivation through 
production of norepinephrine is considered to contribute to dyspnoea through changes in 
respiratory patterns (Corrà et a l, 2006, Leung et a l, 2006).
1.2 Opioid therapy for breathlessness
Opioid therapy forms the mainstay of treatment for intractable breathlessness in disease 
states including CHF without an extensive evidence base or clarity regarding its method 
of action in dyspnoea (Oxberry and Lawrie, 2009). Endogenous opioids are released in
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CHF as part of a global neurohormonal response. As described in Chapter 2, there is a 
suggestion from basic science and animal studies that endogenous opioids may 
counteract some of the effects o f norepinephrine, one of the principle detrimental 
neurohormones in CHF. Small studies have shown a potential for breathlessness relief in 
general with opioids (Jennings et al., 2001), given that opioids may counteract the effects 
of norepinephrine it may have an additional impact in breathlessness due to CHF.
Opioids such as morphine and oxycodone bind to the three types of opioid receptor 
distributed throughout the body, but it is considered that morphine preferentially binds to 
mu-opioid receptors, whereas oxycodone has an affinity for kappa as well as mu 
receptors (Davis and Pasternak, 2005). Oxycodone has a higher oral bioavailability than 
oral morphine and is considered to have a lower level of inter-individual variation in 
plasma concentrations (Kalso, 2005). Both morphine and oxycodone produce opioid- 
related side effects, but their relative frequencies can be different. For example, 
oxycodone is considered to have a lower incidence of opioid-induced itching (Kalso, 
2005). Kappa receptor agonists also induce a diuretic response in humans (Rimoy et a/., 
1991). Given that they have slightly different receptor activation profiles, have different 
relative frequencies of side effects and may have different effects on diuretic response, it 
is important to assess their relative roles in breathlessness management in CHF.
The mechanism of action of opioids in breathlessness is currently unclear. Symptom 
improvement may be a class effect for all opioids, but individual types of opioid may 
have a different magnitude of effect. The evidence for the distribution of mu and kappa 
receptor populations and their endogenous agonists, described in Chapter 2, suggests that 
exogenous agonists of these receptors may have different effects on cardiorespiratory 
function. The evidence for opioids in breathlessness in general involves mu agonists 
selectively. The additional effect of a partial kappa agonist on diuresis would make 
oxycodone an attractive opioid in CHF. Hence morphine, a preferential mu agonist, 
should be involved in breathlessness studies to allow comparison with previous studies 
predominantly involving mu agonists. Oxycodone is potentially an attractive alternative 
with its dual mu and kappa agonism. The two treatments are therefore compared with 
each other and with placebo to assess response.
U n lik e  breathlessness in  cancer where there have been a num ber o f  studies evaluating the
effects of opioids (see Jennings et al for Cochrane review), there has only been one small
pilot study of repeat dosing in heart failure patients by Johnson et al. (2002). The paucity
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of research into opioids and heart failure has been noted (Cushen, 1994, Fischer, 1998). 
Current clinical practice either involves the prescription of morphine for breathlessness 
or a reluctance to use morphine without efficacy studies. This double blinded cross-over 
study compared the effects of two opioids against placebo for the relief of breathlessness 
in advanced CHF.
Primary research question:
Do morphine and oxycodone relieve breathlessness in patients with NYHA grade III/IV 
heart failure receiving optimal medical therapy?
1.3 Aims and objectives
Primary objective:
• To assess the relative benefits of oral morphine and oral oxycodone in the 
management of breathlessness in advanced heart failure.
Secondary objectives:
• To monitor any subsequent changes in distress caused by breathlessness, physical 
function, coping with breathlessness and satisfaction with treatment.
• To assess the impact of morphine or oxycodone on quality of life in heart failure.
• To confirm tolerability of therapy in this patient population and to assess relative 
merits of morphine versus oxycodone.
• To explore the characteristics of breathlessness in heart failure patients.
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Section 2) Trial Method
2.1 Participant profile
This study was a three-arm prospective, double-blind, randomised, placebo controlled, 
cross-over single centre study involving patients with NYHA Grade III/IV heart failure 
receiving optimal medical therapy. This patient group was selected because the impact of 
breathlessness is high and therefore may have the most to gain from improved 
breathlessness management. A cross-over design was chosen to reduce the number of 
study participants required as it is recognised that it is difficult to recruit to palliative care 
studies. Optimal medical therapy was defined as use of Angiotensin II antagonists or 
Angiotensin receptor blockers (ARBs) and diuretics at stable doses for at least one 
month. Presence of heart failure was defined by systolic impairment on 
echocardiography with an ejection fraction of less than 45%. A BNP blood test was also 
performed prior to study entry to document the severity of CHF. Patients were excluded 
if  they had co-existing malignant disease or respiratory disease sufficient to potentially 
confound the results given that a clinical benefit with opioids has already been 
demonstrated in these patient groups. This exclusion was based on clinical history, 
hospital records and Peak Expiratory Flow Rate (PEFR) parameters (PEFR < 150ml/min 
excluded).
Patients were also excluded if they had true allergies to opioids, or if they were in receipt 
o f any medications that have a potential interaction with opioids, which may confound 
the results. In addition, patients who had used any opioid medication (including weak or 
step 2 opioids such as codeine and tramadol) in the past month were excluded for the 
same reasons. Patients with a Glomerular Filtration Rate o f <=30 ml/min (as calculated 
by the Cockcroft and Gault formula) were also excluded given that both active 
interventions are renally excreted.
2.2 Interventions
The two intervention arms consisted of oral morphine sulphate (5mg) and oral 
oxycodone (2.5mg) administered four times a day for a total of four days. All three 
interventions were administered in liquid form and all three were clear, colourless
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liquids. The oral liquid placebo was manufactured in accordance with MHRA guidelines 
by Calderdale and Huddersfield NHS Trust pharmacy manufacturing unit. The placebo 
was designed to have very similar characteristics to the active medications (a clear, 
colourless liquid with the same viscosity and similar taste). Oxycodone liquid 
(concentration 5mg in 5ml) and Morphine liquid (concentration lOmg in 5ml) allowed 
equivalent opioid doses for the same volume of liquid (2.5ml for all three interventions) 
in order to maintain blinding.
The oral liquid placebo had to be manufactured to a pre-determined formula and method, 
according to guidelines set out by the MHRA. The formula of the placebo mixture was 
designed by Huddersfield pharmacy as was manufactured as shown in Table 4.2.1:
Table 4.2.1: Ingredients involved in the manufacture of the placebo and method of 
production
Ingredients Method of production
Syrup BP 15%v/v 
Methyl Hydroxybenzoate 0.1 % w/v 
Propyl Hydroxybenzoate 0.01% w/v 
Citric Acid 5% soln q.s 
Distilled water to 100% v/v
1. Make up the citric acid 5% solution
2. Dissolve the Methyl and Propyl 
hydroxybenzoate in 200ml of boiling distilled 
water
3. When dissolved add to the syrup in a 1 litre 
measure
4. Make up to volume with distilled water.
5. Mix well and check the pH (needs to be 
between 4-5).
6. Reduce the pH using the Citric Acid solution 
above.
7. Pack, cap and label in a 500ml amber glass 
bottle with Click-Lock tamper evident cap.
Trial participants were also given a supply of anti-emetic medications (Domperidone 
10mg-20mg PRN TDS) and laxatives (Senna IIPRN ON) for use in the event of the most 
common side effects related to opioid use, namely nausea, vomiting and constipation. 
These were referred to as concomitant medications in the trial.
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2.3 Randomisation
Once eligible patients had been identified, approached and agreed to give informed 
consent, participants were randomly allocated to one of six possible permutations for the 
order of the three interventions (oral morphine, oral oxycodone or placebo). A schematic 
representation is detailed below in Table 4.2.2. The codes for randomisation were 
generated using a computer program and were kept by pharmacy who were independent 
of the study process. The pharmacy subsequently dispensed all three medications for use 
in the required sequence with identical labels except for the treatment order. Hence the 
investigators and participants remained blinded to the treatment sequence to prevent any 
methodological bias. Click-locked bottle adapters and tamper evident seals were 
employed to prevent incorrect utilisation of the study medications.
Table 4.2.2: The six possible combinations of the order of interventions (each participant 
assigned to one combination):
Combination Week 1 treatment Week 2 treatment Week 3 treatment
One Placebo Morphine Oxycodone
Two Placebo Oxycodone Morphine
Three Morphine Placebo Oxycodone
Four Morphine Oxycodone Placebo
Five Oxycodone Placebo Morphine
Six Oxycodone Morphine Placebo
2.4 Participant Assessments
Participants were monitored on all four days whilst on treatment. Assessment of 
breathlessness severity, distress due to breathlessness, satisfaction with treatment, 
presence of side effects and use of concomitant medications occurred on all four days A 
face-to-face baseline and one hour post dose assessment was conducted on day 1 and a 
similar assessment occurred on day 4 for each of the three treatments. In addition on 
these days participants undertook physical assessments and were asked to rate their 
quality of life, physical function, impression of change in breathlessness and description 
of the nature of the breathlessness. On days 2 and 3 o f the four day treatment participants
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were contacted by telephone. Assessments were taken at rest with the same equipment to 
allow standardisation. A summary of these assessments is detailed below in Table 4.2.3. 
Appendix 5 documents an example of the assessment booklet created for the day 1 
treatment 1 assessment.
4.2.3 Schedule of assessments for each participant (repeated for each intervention)
Day 1 
Baseline
Day 1 
1 hour
Day 2 Day 3 Day 4
Data collection Visit Visit Phone Phone Visit
Pulse
Blood pressure 
Respiratory rate 
Oxygen saturation
X X X
NRS* breathlessness, 
distress, satisfaction, 
drowsiness, nausea
X X X X X
Constipation X X X X
Borg score** X X X X X
SF-12*** X X
Breathlessness descriptors**** X X
Karnofsky performance statusf X X
Global rating of change in
breathlessnesstt
X
Concomitant medication X X X X
Adverse events X X X X X
Key:
* 11-point Numerical rating scale (NRS) of average breathlessness over the past 24 hours 
(anchored with “not breathless” and “worst breathlessness imaginable”):
0 1 2 3 4 5 6 7 8 9  10
Not breathless Worst
Breathlessness
Imaginable
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NRS breathlessness scores correlate very closely with VAS breathlessness scores 
(Powers & Bennett 1999) whereby mean breathlessness scores are considered equivalent 
(eg mean 5 on NRS equates to 50 mm on VAS). Hence, the clinically important change 
in VAS quoted as 10% by Booth et al (2006) would equate to one point on an eleven 
point NRS.
** The Borg score, a self-assessment instrument validated for use in breathlessness 
(Borg, 1982) was completed. The modified Borg score was used, but will be referred to 
simply as the Borg score in the thesis.
*** The SF-12 validated Quality of Life (QoL) score acute version 2 (Ware et al., 1996) 
was assessed at baseline (pre-treatment) and day 4 for each of the three study arms.
»♦♦♦Breathlessness descriptors (Wilcock et al., 2002) used to describe the quality of a 
participants’ breathlessness from a fifteen item questionnaire. These 15 items were 
presented in a random order to prevent any preference due to the order or sequence of the 
items.
f  The validated Kamofsky performance status scale (Mor et al., 1984). This scale 
incorporates the components of physical activity, work and self care of patients.
t f  The Global rating of change score is a measurement of response to treatment (Guyatt 
et al., 1993). Participants were asked if their breathlessness has changed and if so by how 
much on a verbal rating scale.
2.5 Study Endpoints
Prim ary: Severity o f  breathlessness as measured b y  the validated Borg score and
Numerical Rating Scale (NRS) for breathlessness (average and worse over 
past 24 hours and current level).
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Secondary: 1) Distress from breathlessness as measured by the NRS score for distress.
2) Satisfaction with treatment of breathlessness and coping with 
breathlessness as measured by the NRS scores for satisfaction and coping 
with breathlessness.
3) Assessment of the overall change in breathlessness severity as 
measured by the Global rating of change in breathlessness score.
4) Assessment of the characteristics of breathlessness in heart failure 
patients by using the descriptors for breathlessness.
5) Adverse effects as measured by NRS scores for nausea and drowsiness, 
constipation assessment, use of concomitant medications and 
identification through self report of other events that may or may not be 
attributable to study drug.
6) Toleration of therapy through compliance monitoring and safety profile 
of each intervention through measurement of physical observational 
parameters.
7) Quality of life scores as measured by the validated SF-12 Quality of 
Life Questionnaire.
8) Change in validated Kamofsky performance scale of physical activity.
2.6 Statistical considerations
Initial assessment by a statistician of sample size using modelling techniques from the 
morphine pilot study by Johnson et al (2002) suggested that a sample size of 33 
evaluable patients would be required to determine a one point change in breathlessness 
score (a = 0.05; /3 = 0.8). Further discussions with Professor Martin Bland, Professor of 
Statistics in Healthcare at York University led to a feasible aim for recruitment of 48 
participants in order to achieve enough data for analysis allowing for a generous 
withdrawal rate of over 30%. This is important to allow for in studies with patients with 
advanced disease where withdrawal rates may be quite significant.
Study data were entered and analysed using the SPSS statistical package version 14. All 
data were analysed according to intent-to-treat criteria. Statistical comparisons compared 
the measurements of primary and secondary outcomes between individuals for each 
treatment. As the results from a crossover trial are not independent, this involved the use
of paired methods of comparison of outcomes between treatments, for example the
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Wilcoxon Signed Rank test for continuous non-parametric data. Paired t-tests were used 
if the data was normally distributed. McNemars test was used for any paired 
dichotomous data. These statistical tests do not allow for period effects, so the likelihood 
of such effects were also measured. Senn (2002) recommends the calculation of a change 
in a parameter between individual active treatments and placebo, allowing the difference 
between individual treatments to be observed and this approach was adopted in the 
analysis.
Missing data is a well recognised problem in longitudinal studies, particularly with 
patients with advanced disease. Missing data was managed by using extreme values. By 
making the assumption that the missing value is the worst it could be for the intervention 
and the best it could be for the placebo, if there remains a statistically significant 
difference between active treatment and placebo then one can be sure that the results are 
robust. Other techniques that were considered involved building a regression equation to 
predict the value of the missing data from the baseline characteristics from patients with 
no missing values or the use of other imputation techniques.
At the end of the study, the participants were asked which of the three arms they prefer 
most and were given the opportunity to continue that treatment on an open-label basis if 
an active drug was identified. As a continuation to the study, participants were invited to 
return three months after cessation of the study for a repeat BNP blood sample and 
repeated assessment measures to assess the effect of therapy over a longer time period. 
The results from this open-label follow-up are discussed in Chapter 6.
2.7 Regulatory approvals
This clinical trial for investigational medicinal products was conducted in accordance
with the UK regulations for clinical trials 2004. The study was given authorisation by the
Leeds East Ethics Committee, Hull and East Yorkshire Research and Development
Department and Medicines and Healthcare Regulatory Authority (MHRA). Yearly
updates were required for Ethics and the MHRA to highlight study progress and presence
of adverse events. The local NHS Research and Development department audited the
study every three to six months to ensure adherence to Good Clinical Practice guidelines.
These guidelines were strictly adhered to, particularly in respect of adverse event, serious
adverse event and serious unexpected adverse event reporting in accordance with
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standard operating procedures for clinical trials. Details of trial reference numbers are 
given in Appendix 3.
2.8 Ethical considerations
Given the nature of the patient population, an attempt was made from the outset to 
incorporate the minimum number of assessments and measurements necessary so not to 
inconvenience the participant unduly but to monitor the effects of treatment closely. The 
length of the trial overall (three weeks), the nature of assessments (face to face on days 1 
and 4 and via telephone on days 2 and 3) and the flexibility of the researcher in the place 
of assessment (clinic, hospital ward or home) reflected the consideration for trial 
participants. The study adhered to the Good Clinical Practice guidelines for the reporting 
of adverse events as set out by the Hull and East Yorkshire NHS Trust R&D department 
standard operating procedures.
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Section 3) Results; Screening information, demographic data and period-sequence 
interaction assessment
The Academic Cardiology heart failure database was utilised to screen potential trial 
participants. Patients attending heart failure clinics were screened in a period from 15th 
November 2007 to 30th April 2009 (18.5 months in total). The screening results are 
described in Figure 4.3.1. From the 2135 patients identified on the database as 
complaining of dyspnoea, only 239 of these were identified as being potentially eligible 
for study inclusion. These patients were all reviewed in clinic to assess eligibility. Of 
these patients, only 84 patients fulfilled the inclusion criteria of the study. Reasons for 
non-inclusion of the remainder are described in Table 4.3.1.
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Figure 4.3.1: Consort diagram for patient screening and inclusion to RCT:
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Table 4.3.1: Reasons of ineligibility for patients identified through the heart failure 
database (n=237 of which 84 eligible)
Reason Patient number
NYHA II at clinic 47
No breathlessness described at clinic 9
COPD / Asthma / Lung pathologies coexistent 18
Renal failure (GFR <30) 5
Not in receipt of ACEI, ARB or Diuretic 4
Drug change at clinic visit 9
Receiving opioids already 9
In other medical trials involving trial medications 9
Improved EF at clinic visit (EF too high) 11
Ineligible according to investigator -  including too poorly for entry, 
multiple co-morbidities, previous compliance issues, main carer to ill 
spouse, due CRT or PPM in near future, drugs with known opioid 
interaction, opioid allergy
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3.1 Participant sample data
Table 4.3.2 below describes the baseline demographic data for all randomised 
participants. Thirty-five participants completed all three treatment periods in the RCT 
and are included in the overall analysis. Two participants withdrew due to adverse events 
and their details are described below. The sample is predominantly an elderly male one, 
with ischaemic heart disease as the predominant aetiology. Most patients were receiving 
both beta-blocker and ACEI/ARB therapy in accordance to the current clinical guidance. 
It should be noted that all participants were in receipt of either and ACEI or an ARB in 
concordance with the inclusion criteria, with some participants on both treatments. There 
were no obvious differences in baseline characteristics between completed patients and 
those that withdrew from the study.
Table 4.3.2: Demographic data for included patients (n=35)
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Age (Mean +/- SD) 
Range
70.2 years (+/-11.1 years) 
4 1 -8 9  years
Gender Male 30 ; Female 5
Documented Aetiology DCM 3
IHD alone 25
IHD / Hypertension 7
NYHA Grade Grade 3:31 
Grade 4: 4
Ejection fraction: Mean +/- SD 33.5% +/- 6.5%; range 15% to 44%
GFR Calculated: (Mean +/- SD) 70.4 ml/min +/- 36.2 ml/min
eGFR: (Mean +/- SD) 55.6 ml/min +/- 19.4 ml/min
Beta blocker present 30
ACEI present 28
ARB present 26
Aldosterone antagonist present 21
Digoxin present 4
BNP : mean and median Mean 210.3 pmol/1; Median 91.1 pmol/1
PEFR: mean and median Mean 262.1 l/min; Median 246 l/min
The two participants that withdrew were males aged 65 and 74 years, both NYHA 3 with 
aetiology of DCM and IHD respectively. Ejection fraction for these two patients lay just 
above the mean for completed patients (36% and 40%) with calculated GFR either side 
of the mean value for completers at 72 and 48 ml/min respectively. Both of these patients 
were in receipt of ACEI and Aldosterone antagonists with one patient also receiving 
beta-blocker and digoxin therapies. BNP levels were 103 and 91.4 pmol/1 for both 
patients, a little below the mean value for the 35 included patients but still within the 
overall range of BNP values and close to the median value for the sample. Peak flow 
results were 190 and 232 l/min, just lower than the median value for the sample, but not 
at the extremes of measurements. In this regard, these patients had no obvious 
demographical baseline differences to the patients who completed the study. Thirty-five 
participants were included in the subsequent data analysis.
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Baseline values for NRS and Borg scores for breathlessness and Karnofsky status are 
detailed in Table 4.3.3. This table demonstrates this population has average levels of 
breathlessness of over 5 on an 11-point NRS, with episodes of breathlessness at their 
worst measuring an average of over 7/10 on an 11-point NRS. Overall this indicates a 
moderate to high level of breathlessness in this sample population. A Mean Karnofsky 
score of 70 represents a level at which the participant cares for self, but is unable to carry 
on normal activity or to do active work.
Table 4.3.3: Mean, median and sample variability as measured by the standard deviation 
for breathlessness severity (average and worst) and performance status at baseline for the 
35 included participants.
NRS Average 
breathlessness
NRS Worst 
breathlessness
Borg Worst 
breathlessness
Borg Average 
breathlessness
Karnofsky
score
Mean 5.1 7.2 4.3 2.9 70
Median 5 7 4 3 70
Standard
deviation
1.80 1.53 2.03 1.40 5.90
3.2 Sequence and Period Analysis
A period effect occurs when the response to treatment changes over time (from one 
period to another), for example due to a change in the underlying disease. A sequence or 
treatment-period effect occurs when there is a difference in response from one treatment 
period to the next, most often in crossover trials due to the “carrying over” of a treatment 
effect due to an inadequate drug washout phase. Both of these two potential effects are 
important as the results due to a treatment may not be valid if either of these two 
properties exist. There are a number o f different ways in which possible period and 
sequence effects can be determined. This section will review and test some of these 
approaches.
The results from the NRS of average response to breathlessness were taken for 
comparison, as this scale was defined as the primary outcome measure for the study. 
First, the Day 4 responses in NRS Average breathlessness were subtracted from the Day 
1 (baseline) responses for each of the three treatment interventions. These were then
161
divided into two groups of two interventions: the first with oramorph followed by 
placebo, and vice versa; secondly those participants who received oxynorm before 
placebo and vice versa. The data was treated as for two separate crossover trials 
involving oramorph and placebo, and oxynorm and placebo. The treatment / period 
response between oramorph and oxynorm (both active interventions) was not considered 
relevant.
In accordance with the management plan set out by Altman (1991), tables were produced 
as shown below for oramorph and placebo, then oxynorm and placebo:
D1-D4 Placebo D1-D4 Oramorph (D-(2) (l)+(2)/2
response on NRS response on NRS (2) difference average
(1)
In total four tables were produced, reflecting the four different sequences (oramorph 
before placebo; placebo before oramorph: oxynorm before placebo; placebo before 
oxynorm).
To test for a period effect, given that the data was not normally distributed, Mann- 
Whitney U tests were employed to assess the potential impact of time on the outcome 
between active and placebo treatments. Non-significant results indicate no evidence of a 
period effect.
These results are as follows:
Placebo before Oramorph versus Placebo after Oramorph: p = 0.208 
Placebo before Oxynorm versus Placebo after Oxynorm: p = 0.243
In the absence of a sequence effect, the patients average response to interventions should 
be the same regardless of the order in which the interventions are administered. Firstly, 
one can compare the baseline results for each week of therapy, to ensure that the three 
day washout was adequate. If it was not, one could expect to see lower mean NRS 
Average breathlessness scores following active treatment the preceding week. Tale 4.3.4 
illustrates the NRS breathlessness scores for each intervention for each of the six possible 
treatment sequences.
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Table 4.3.4: Mean baseline average NRS and average Borg breathlessness scores prior to 
each of the three interventions by treatment sequence
Sequence Oramorph Oxynorm Placebo
Mean
NRS
Mean Borg Mean
NRS
Mean
Borg
Mean
NRS
Mean
Borg
Oramorph-
Oxynorm-
Placebo
(n=4)
4.50 2.75 4.00 2.25 3.25 1.75
Oramorph-
Placebo-
Oxynorm
(n=5)
4.00 2.60 4.40 1.80 5.40 3.20
Oxynorm-
Oramorph-
Placebo
(n=6)
2.67 1.67 5.33 2.75 4.67 2.75
Oxynorm-
Placebo-
Oramorph
(n=6)
4.83 2.83 5.50 2.83 5.67 2.33
Placebo-
Oramorph-
Oxynorm
(n=6)
4.50 2.50 3.83 2.17 5.17 2.50
Placebo-
Oxynorm-
Oramorph
(n=8)
4.25 3.13 5.13 3.48 5.50 3.56
Note that the numbers for each sequence are not identical (not the same numbers in each 
group) due to the sampling procedure -  sequences were determined at random, rather 
than using block design which would attempt to equalise the numbers in each sequence 
group.
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If the active drugs were not having adequate washout, one would expect the placebo 
baseline values to be low compared to when placebo was administered first, before the 
active interventions. Also, if the second active intervention also had a low value 
following the first active intervention, this could be interpreted as being a negative 
washout period or residual drug still being present. If placebo values were low after both 
active interventions this may imply a synergistic response if washout has not been 
effective. In the case of the table above, it can be seen that when placebo is given first, 
the NRS average values are little different to when placebo is second following either 
oramorph or oxynorm, suggesting that there is no effect from week 1 active drug and the 
following weeks’ placebo.
A more formal analysis of sequence effect is determined by using the Mann Whitney U 
test for non-normal data, as shown below for comparison of the mean average NRS 
scores for the two periods for oramorph/placebo and oxynorm/placebo:
Average of the 2 periods (Placebo before Oramorph and Oramorph before placebo): 
Mann Whitney U test -  p = 0.512
Average of the 2 periods (Placebo before Oxynorm and Oxynorm before placebo): Mann 
Whitney test -p  = 0.853
Both of these values are non-significant indicating no evidence of any treatment-period 
interaction.
Finally, two scatterplots of the difference between the periods against the average of the 
periods were performed for oramorph versus placebo and oxynorm versus placebo. 
Vertical separation of the groups is indicative of a difference between the treatments. If 
there is no treatment-period interaction there should be no horizontal difference between 
the groups, and the data should lie symmetrically either side of the line y=0. These have 
been performed but are not shown.
An alternative method to assess for period and sequence effect is to use analysis of 
variance {ANOVA} (Bland and Altman, 2007). One way analysis of variance for 
treatment-period and period demonstrate no statistically significant results, indicating no 
evidence of a treatment-period or period effect with day 4 outcomes (F value 1.96 and p= 
0.15 when period is a factor and F= 0.12 and p= 0.89 when treatment is a factor). In 
summary, the above calculations reveal that there were no notable treatment-period or 
period interactions, allowing further analysis of the data to occur.
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Section 4) Results: Analysis of primary outcome measure: hreath less n e s s  severity
4.1 Treatment differences in primary outcome: breathlessness severity
Table 4.3.5 below demonstrates the differences between baseline (day 1) and completion 
of the intervention (day 4) for each of the three interventions. Positive values represent a 
reduction in rating score and hence symptom improvement. Negative values represent 
symptom deterioration. Differences were calculated as described in the RCT protocol.
Table 4.4.1: Shortness of breath outcomes for all three interventions (mean difference 
with standard deviation: n=35)
Oramorph Oxynorm Placebo
NRS Average 
breathlessness:
Mean difference (SD) and 
median difference
Mean 0.41 
SD 2.51 Median 1
Mean 1.29 
SD 2.19 Median 
1
Mean 1.37 
SD 1.86 Median 
1
NRS Worst breathlessness: 
Mean difference (SD) and 
median difference
Mean 0.80 
SD 2.55 Median 
1
Mean 1.43 
SD 2.70 Median 
1
Mean 1.91 
SD 2.50 Median 
2
Borg Worst breathlessness: 
Mean difference (SD) and 
median difference
Mean 0.16 
SD 2.06 Median 
0.5
Mean 0.87 
SD 2.31 Median 
1
Mean 0.80 
SD 1.93 Median 
1
Borg Average 
breathlessness:
Mean difference (SD) and 
median difference
Mean -0.01 
SD 1.96 Median 0
Mean 0.33 
SD 1.67 Median 
0
Mean 0.27 
SD 1.66 Median 
0
As can be seen from these results, there is a notable placebo response in all 
measurements of breathlessness, whether rated on average in the day or at its worst in the 
day. Of the two active interventions, oxynorm had the higher mean difference in scoring 
compared with oramorph, which had the only increase in score (a very slight worsening 
o f breathlessness from day 1 to day 4 o f treatment). Overall the changes in NRS scoring 
are small, but are consistent with a one point improvement regarded as a clinically
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important difference. Mean differences for Borg are lower than those for NRS and this 
factor will be explored later.
The data was generally normally distributed, sometimes it had a positive skew (Q-Q plots 
for normality performed but not shown). In order to allow comparison between ratings 
for NRS and Borg for average and worst breathlessness severity, paired non-parametric 
tests were the most suitable. Wilcoxon signed ranks tests were used to test for 
associations between interventions (day 1 to day 4 differences compared) for both NRS 
and Borg scoring systems. The results from these tests are shown in Table 4.4.2:
Table 4.4.2: Wilcoxon signed ranks test results for breathlessness severity change (day 1 
minus day 4 scores) between the three interventions
Rating scale Wilcoxon comparison between interventions
NRS Average 
breathlessness
Placebo change in score versus Oramorph change: Z = -1.52; p= 0.129 
Placebo change in score versus Oxynorm change: Z=-0.13; p=0.893 
Oxynorm change in score versus Oramorph change: Z=-1.70; p=0.089
NRS Worst 
breathlessness
Placebo change in score versus Oramorph change: Z = -1.69; p= 0.092 
Placebo change in score versus Oxynorm change: Z= 0.68; p= 0.50 
Oxynorm change in score versus Oramorph change: Z=-0.81; p=0.42
Borg Worst 
breathlessness
Placebo change in score versus Oramorph change: Z=-l .41; p= 0.16 
Placebo change in score versus Oxynorm change: Z=-0.087; p=0.93 
Oxynorm change in score versus Oramorph change: Z=-1.05; p=0.29
Borg Average 
breathlessness
Placebo change in score versus Oramorph change: Z = -0.30; p= 0.76 
Placebo change in score versus Oxynorm change: Z=-0.34; p= 0.73 
Oxynorm change in score versus Oramorph change: Z=-0.65; p=0.52
There are no significant differences between treatments for any breathlessness rating 
scale. This is unsurprising given the placebo response seen in Table 4.4.1. One might 
argue that there is a trend favouring oxynorm over oramorph in change of breathlessness, 
particularly on the Average NRS breathlessness measure (p = 0.09), but this is not 
supported by the other measurement tool outcomes.
How do the responses compare for each individual case? Table 4.4.3 below documents 
the mean change in breathlessness score from day 1 to day 4 (with standard deviation)
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for participants between oramorph and placebo and oxynorm and placebo. Negative 
values represent a greater mean improvement for placebo than active treatment. The 
overall differences in mean responses to active treatment versus placebo are small.
Table 4.4.3: Mean change in breathlessness score (day 1 to day 4) comparison between 
active interventions and placebo for breathlessness severity scales.
Scale Oramorph versus placebo Oxynorm versus placebo
NRS Average 
breathlessness
-0.97 (3.49) -0.09 (2.25)
NRS Worst breathlessness -1.11 (3.91) -0.49 (3.31)
Borg Worst breathlessness -0.64 (2.78) 0.07 (2.52)
Borg Average 
breathlessness
-0.29 (2.60) 0.06 (2.25)
4.2 Comparison of active treatment and placebo on breathlessness severity
Pooled outcomes for overall treatment effect versus placebo have been calculated. 
Responses to oramorph and oxynorm were included together in an “active treatment” 
group and compared to placebo. A boxplot demonstrating median and interquartile 
ranges for active treatment versus placebo (Figure 4.4.1) is shown below for day 4 worst 
breathlessness and is representative for all other boxplots for NRS or Borg ratings. There 
is a difficulty in further analysis of this due to the nature of the pairing of placebo values 
to active values. There does not appear to be any difference between response to placebo 
and response to pooled active treatment for breathlessness over the four day intervention 
period.
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Figure 4.4.1: Boxplot to show the median and interquartile range for NRS worst 
breathlessness scoring at day 4 for pooled opioid treatments (oramorph and oxynorm) 
and placebo for the 35 completed datasets. Higher values represent more severe 
breathlessness.
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4.3 Change of NRS or Borg breathlessness scores over time on treatment
Differences between scores at the start and end of treatment may not fully reflect the 
complete participant experience. Measurements of breathlessness were taken at baseline 
(day 1), day 2, day 3 and day 4 for NRS and Borg measures of breathlessness. Below are 
two examples of line graphs for NRS Average and Worst scores (also representative for 
Borg Average and Worst score graphs (not shown)):
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Figure 4.4.2: Line graph to demonstrate change of mean NRS average breathlessness 
scores over time for each intervention. Higher values represent worse breathlessness.
Drug
---- oramorph
---- oxynorm
placebo
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Figure 4.4.3 Line graph to demonstrate the change in mean worst NRS breathlessness 
score over time for each intervention. Higher scores represent worse breathlessness 
severity.
Drug
---- oramorph
---- oxynorm
placebo
These two graphs illustrate that an initial reduction in breathlessness scores occurs after 
the first day and is maintained throughout the remainder of the treatment course. The 
mean placebo score for breathlessness on day 1 (baseline) is higher than for the active 
treatments, with the overall day 4 mean scores at the end of treatment being 
approximately the same for all three interventions.
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4.4 Percentage data for NRS/Borg responders for the three interventions
A clinically significant cut-off has been identified for improvement in NRS or Borg-rated 
breathlessness severity, as discussed previously. This analysis sought to determine 
whether the lack of statistically significant improvement in breathlessness for active 
treatments versus placebo was due to the varying response rates. It is feasible that some 
participants will rate the active treatment highly if they have responded, but others may 
rate it poorly if there has been a mild response but they have encountered adverse effects 
with the active drug. Table 4.4.4 describes the analysis of responders of change in day 1 
to day 4 scores for breathlessness severity using NRS and Borg for the three different 
treatments in the 35 completed participants.
Table 4.4.4: The number of participants that responded to each intervention with an 
improvement of one point on an NRS or Borg scale of breathlessness severity. 
Frequencies ând percentages are given for the 35 included participants.
Score Oramoiph
frequency
>=1
Oramoiph
%>1
Oxynorm
frequency
>=1
Oxynorm
%>1
Placebo
frequency
>=1
Placebo
%>1
NRS
Average
19 54.3% 22 62.9% 22 62.9%
NRS
Worst
23 65.7% 21 60.0% 24 68.6%
Borg
Worst
17 48.6% 17 48.6% 14 40.0%
Borg
Average
16 45.7% 11 31.4% 10 28.6%
There appears to be little difference between the three treatments using the NRS scale for 
breathlessness, demonstrating the large placebo response in the trial, with almost two- 
thirds of participants on NRS Average breathlessness rating an improvement of one or 
above. However, the average score for the Borg scale for breathlessness does 
demonstrate a favouring for oramorph over the other two treatments. This may simply 
represent an anomaly in the data, particularly as the median score for breathlessness on 
this scale is not significantly different to the other two interventions.
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The crossover study of 38 patients with refractory dyspnoea (mostly COPD) by 
Abemethy et al (2003) described their output in terms of absolute values on the last day 
of treatment for both oral morphine and placebo, rather than measuring the difference 
between baseline and last day of treatment for each intervention. Table 4.4.5 below 
provides data in the form as provided by Abemethy to allow direct comparison of results.
4.5 Comparison output in the style of Abernethy et a l (2003)
Table 4.4.5: Day 4 values (end of treatment) for NRS Average breathlessness for each of 
the three interventions:
Oramorph (n=35) Oxynorm (n=35) Placebo (n=35)
Mean 3.71 3.49 3.69
Standard deviation 2.40 2.03 1.98
As can be observed in this table, day 4 scores for each of the three interventions are 
similar, with oxynorm having the lowest mean value indicating the least breathlessness 
on average breathlessness NRS scores. These means and standard deviations are similar 
to those found by Abemethy et al. (2003), which will be explored further in the 
discussion. Similar results are seen for worst breathlessness score on NRS and average 
and worst Borg scores (results not shown).
The difference between treatments for each participant was calculated for oramorph 
versus placebo and oxynorm versus placebo. The mean of these differences between 
interventions was 0.03 (95% Cl for the difference was 0.88 to 0.94) for oramorph versus 
placebo. A positive result favours placebo as it represents the oramorph average score 
minus placebo score (lower scores indicate less breathlessness). A mean of -0.20 (95% 
Cl for the difference: -0.85 to 0.45) was observed for oxynorm versus placebo. This 
result favours oxynorm as negative values here represent lower breathlessness scores for 
oxynorm and hence better breathlessness. Unlike in the Abemethy study, it is debatable 
that these distributions of differences between active and placebo interventions are 
normally distributed with Q-Q plots and histograms, however if one assumes normality, 
paired t test can be performed (although non-parametric tests would be more accurate to 
use in this study analysis).
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Paired statistical tests (for normal distributions) of the differences in the same patient 
between active and placebo interventions are shown in Table 4.4.6 below with t statistics. 
Similarly, Wilcoxon paired signed ranks test statistics are also calculated as these are 
more appropriate for our non-parametric sample (given by the Z statistic).
Table 4.4.6: Analysis of the difference of day 4 Average NRS breathlessness scores 
between active treatments and placebo using parametric and non-parametric paired tests
Treatments Test Test statistic p value
Oramorph versus placebo Paired t-test t statistic: 0.064 0.95
Oramorph versus placebo Wilcoxon Z statistic: -0.022 0.98
Oxynorm versus placebo Paired t-test t statistic: -0.626 0.54
Oxynorm versus placebo Wilcoxon Z statistic: - 0.756 0.45
It is unsurprising that both analyses are non-significant given that the 95% confidence 
intervals for the differences both cross zero. Taken together, these results indicate that for 
the primary outcome measure of breathlessness severity there are no statistically 
significant differences between active treatments and placebo whether baseline (day 1) to 
day 4 differences are used as described in the protocol, or whether other methods such as 
analysis of day 4 scores alone are utilised.
4.6 Global impression of change in breathlessness
At the end of each intervention, participants were ask to rate whether their breathlessness 
had improved, worsened or remained the same on a 15 point global impression of change 
scale. Table 4.4.7 demonstrates the mean and median result at the end of each 
intervention.
173
Table 4.4.7: Global impression of change of breathlessness over the full course of 
treatment for each intervention measured by mean change in score, standard deviations 
and median change for the three groups
Intervention Mean change Standard deviation Median change
Oramorph 1.40 2.96 2
Oxynorm 1.51 2.36 2
Placebo 1.14 2.52 0
Wilcoxon comparisons between treatments show no statistically significant differences 
(Z = -0.32; p = 0.75 and Z = -0.70; p = 0.48 for placebo versus oramorph and placebo 
versus oxynorm respectively). These results show a median difference of 2 for both 
active interventions corresponding to an improvement in global breathlessness, with no 
change for placebo. An improvement of 2 relates to a “little better” rating of 
breathlessness over that intervention period. However, mean differences do not 
demonstrate such a notable difference between interventions and non-parametric testing 
for active versus placebo interventions show no statistically significant improvement for 
either oramorph or oxynorm versus placebo. Figure 4.4.4 illustrates the range, 
interquartile range and median value for each intervention.
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Figure 4.4.4: Boxplot demonstrating global impression of change rating of breathlessness 
severity at the end of each treatment period. Higher positive scores represent a greater
improvement from baseline, negative scores indicate worsening breathlessness severity 
from treatment baseline.
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The interquartile ranges for each intervention lie at zero and above, indicating a 
perceived improvement in breathlessness for each week. The mean global change score 
for oramorph in particular is affected by a long negative whisker, suggesting a few 
participants alone rated oramorph caused a worsening of their breathlessness on global 
change measures, resulting in a lower mean value compared to the median. The placebo 
boxplot has three outliers above or below the range whiskers. The two patient samples 
that noted a large placebo response on global impression of change had the individual 
interventions investigated by Hull Pharmacy to check the sequences. The independent 
laboratory in Southport confirmed the correct randomisation sequences.
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4.7 Comparison of baseline medication characteristics with breathlessness outcomes
Given that there is no statistically significant difference overall in change of 
breathlessness severity between the three interventions, are there characteristics of 
participants that did respond to active therapy that might lead to tailored therapy to 
specific groups of individuals. Do demographic features, such as severity of disease, 
concomitant medical therapy or other factors influence response to opioids in a CHF 
population? Some of these factors are explored in the next two sections.
The change in breathlessness severity on treatment might be related to existing medical 
therapies. However, no consistent results are observed for breathlessness response to the 
three different treatment interventions for either NRS or Borg scoring systems. 
McNemars non-parametric tests for dichotomous variables were used to identify 
relationships between responders to oramorph or oxynorm (>= 1 improvement on NRS 
average breathlessness versus placebo) with beta-blocker (yes/no), ACEI or ARB 
(yes/no), Digoxin (yes/no) or Aldosterone antagonist (yes/no). Statistically significant 
results were observed for both oxynorm and oramorph responders and beta-blockers and 
ACEI treatment. Of course, these could have happened by chance alone and these 
dichotomous values are rather too simplistic. Therefore, percentages of maximum 
advised therapeutic doses were calculated in order to observe whether dose of beta 
blocker or ACEI/ARB was important, rather than just its presence or absence.
The line charts below (figures 4.4.5 and 4.4.6) show a comparison of the mean scores for 
NRS Average breathlessness for both oramorph and oxynorm in the participant sample 
dependent on beta-blocker dose. It is interesting to note an improved response to 
oramorph for patients on maximal beta-blocker therapy, whereas the opposite is true for 
oxynorm. I suspect this may have happened by chance as one would expect if opioids 
were to have a class effect on breathlessness that a consistent response would be seen for 
increasing beta-blocker dose if this was relevant for response to opioids. Similar 
calculations for ACEI or ARB doses show no such pattern with dose of ACEI/ARB and 
response to opioid (data not shown).
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F igu re 4 .4 .5 : L ine graph to sh o w  the m ean  ch an ge in N R S  A v era g e  b rea th lessn ess
sev e r ity  for oram orph (b a se lin e  to d ay  4 ) d ep en dent on  p ercen tage recom m en d ed
m a x im u m  b eta-b lock er d ose. P o sitiv e  v a lu es represent b rea th lessn ess im p rovem en t
P ercentage of recom m ended  m axim um  beta-blocker d o se
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F igure 4 .4 .6 : L ine graph to sh o w  the m ean  ch an ge in  N R S  A verage breath lessn ess
sev er ity  (b a se lin e  to d ay  4 )  for oxyn orm  d ependent on  p ercen tage recom m en d ed
m axim u m  b eta-b lock er dose. P o s itiv e  va lu es represent b rea th lessn ess im provem ent
Percentage o f m axim um  recom m ended beta-blocker dose
4.8 Comparison of demographic characteristics with breathlessness outcomes
The following boxplots (figures 4.4.7, 4.4.8 and 4.4.9) show the response of certain 
aetiological groups to change in breathlessness score with each intervention. Response by 
NYHA status, gender and aetiology are demonstrated. It can be seen that there is little 
trend for any one particular factor in most cases. However, participants with dilated 
cardiomyopathy appear to respond better to opioids than other CHF diagnostic groups.
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F igure 4 .4 .7 : B o x p lo t to sh o w  the ch an ge in  N R S  A v era g e  b rea th lessn ess scores for each
in tervention  dependent on  N Y H A  functional status (N Y H A  III n =  3 1 , N Y H A  IV n =  4 ).
P o sitiv e  v a lu es  represent an im p rovem en t in b rea th lessn ess score.
NYHA
Drug
|  Oramorph 
0  Oxynorm 
□  Placebo
Figure 4.4.8: Boxplot to show the change in NRS Average breathlessness scores for each 
intervention dependent on gender (female n = 5, male n = 30). Positive values represent 
an improvement in breathlessness score.
Gender
Drug
|  Oramorph 
H  Oxynorm 
□  Placebo
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F igure 4 .4 .9 : B o x p lo t to sh o w  the ch a n g e  in N R S  A v e ra g e  b rea th lessn ess  scores for each
intervention  dependent on a etio lo g y  o f  CF1F (D C M  n =  3 , IH D a lo n e  n =  2 5 , IHD and
h ypertension  n =  7). P o sitiv e  va lu es represent an im p rovem en t in b rea th lessn ess score.
A etio logy
Drug
|  Oramorph 
d  Oxynorm 
P  Placebo
Table 4.4.8 below details the association between change in average NRS breathlessness 
severity score for each intervention against age, renal function (GFR), ejection fraction 
and BNP. Pearson correlates were used where the data was generally normally 
distributed, spearman correlates were used for BNP and PEFR as they display non­
normal distributions. Note that negative values indicate a negative slope in the 
correlation, i.e. increasing values of one variable correlate with decreasing values of the 
other. As can be seen there are no statistically significant linear correlations between 
these factors and breathlessness outcome with opioids. Using Global impression of 
change as an outcome rather than change in NRS yields very similar results.
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Table: 4.4.8 Pearson correlation coefficients of linear association for baseline factors for 
change in Average NRS breathlessness (day 1 to day 4 change) for each intervention 
versus demographic baseline factors (spearman correlations given for BNP and PEFR as 
detailed above):
Oramorph change in 
Average NRS 
breathlessness n=35
Oxynorm change in 
Average NRS 
breathlessness n=35
Placebo change in 
Average NRS 
breathlessness n=35
Age 0.11 (p = 0.52) -0.193 (p = 0.27) 0.053 (p = 0.76)
Estimated GFR -0.048 (p = 0.79) 0.081 (p = 0.65) -0.187 (p = 0.28)
Ejection fraction -0.040 (p = 0.82) -0.172 (p = 0.32) -0.035 (p = 0.84)
BNP 0.128 (p = 0.47) -0.013 (p = 0.94) 0.293 (p = 0.09)
PEFR -0.137 (p = 0.43) -0.108 (p = 0.54) -0.159 (p = 0.36)
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Section 5) Results: Comparison of breathlessness rating scales
5.1 Comparison of worst, average and current breathlessness measures
During the progress of the trial, the impression was that current shortness of breath was 
not as discerning or not as descriptive as average or worst. How does current 
breathlessness rating compare with these other two measures? Table 4.5.1 demonstrates 
the comparison of the cumulative range of values, mode and median scores for Average, 
Worst and Current breathlessness on NRS for all 35 participants involving all three 
interventions.
Table 4.5.1: Cumulative values for range, mode and median scores for Average, Worst 
and Current NRS breathlessness rating
Average
breathlessness on NRS 
(n = 420 responses)
Worst breathlessness 
on NRS (n = 420 
responses)
Current
breathlessness on 
NRS (n = 525 
responses)
Range of 
values
0-10 0-10 0-10
Mode 5 5 0
Median 4 5 2
SD 2.15 2.55 2.26
As can be seen, the mode for current SOB was zero, with a range of values the same as 
for average and worst SOB on NRS. This is also displayed in graphical form below, with 
current SOB detailed first followed by worst SOB NRS for comparison.
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Figure 4.5.1: Bar chart demonstrating the frequency of all responses at a given score of 
Current NRS breathlessness, irrespective of intervention (n= 525 responses)
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NRS current breathlessness score
Fig
ure 4.5.2: Bar chart of the frequency of responses for a given score on the Worst NRS 
rating scale for breathlessness, irrespective of intervention (n = 420 responses)
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It can be observed therefore that current breathlessness measurement may not be as 
discerning for measurement of treatment effect as the majority of results tend towards 
zero. Note also that Q-Q plots or histograms for NRS worst (Figures 4.5.2 and 4.5.4) and 
average breathlessness (Figure 4.5.3) appear to have a near normal distribution, whereas 
those for NRS current (Figure 4.5.1) does not.
5.2 Comparison of Borg and NRS for breathlessness
Are responses on the Borg scale and NRS scales for breathlessness representative of each 
other? What does a response of moderate on the Borg score mean on an NRS of 
breathlessness for example? This sub-section details the correlation between Borg and 
NRS responses for breathlessness severity. It is divided into two parts; comparison of 
Borg and NRS for specific situations (average, worst and current) and then a cumulative 
analysis of all NRS versus all Borg results for breathlessness.
Pearson correlation coefficients were used to calculate the linear relationship between 
worse, average and current scores of Borg and NRS for breathlessness. Q-Q plots for 
normality revealed a near normal distribution for NRS for average and worst 
breathlessness, with positive skew for current breathlessness, which might make the p 
value for the current breathlessness association less reliable. Examples of these normality 
plots are shown below:
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F igure 4 .5 .3 :  N orm al Q -Q  p lo t for N R S  A v era g e  b rea th lessn ess (n =  4 2 0  resp o n ses).
D ev ia tio n  from  the lin e  b etw een  the ex p ected  norm al v a lu e  and th e actual v a lu e  at either
end represents d ev ia tion  from  the norm al d istribution .
Figure 4.5.4: Nonrial Q-Q plot for NRS Worst breathlessness (n = 420 responses). 
Deviation from the line between the expected normal value and the actual value at either 
end represents deviation from the nonnal distribution.
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Pearson correlation coefficients for NRS score against corresponding Borg for Average, 
Worst and Current responses were all significant and are described in Table 4.5.2 below. 
Not assuming normality, especially relevant for current breathlessness, Spearman 
correlation coefficients for Borg and NRS were also significant. Non parametric tests of 
association of this paired data for Average, Worst and Current breathlessness given by 
the Wilcoxon signed ranks test also noted significant results, indicating that alternative 
approaches to analysis lead to the same result.
Table 4.5.2: Comparison of NRS with Borg for Average, Worst and Current 
breathlessness scores using Pearson and Spearman tests for linear correlation and 
Wilcoxon signed ranks tests for association of paired data
NRS versus 
corresponding Borg
Pearson correlation Spearman
correlation
Wilcoxon signed 
ranks test
Average
breathlessness
0.70 p < 0.0005 0.72 p<  0.0005 Z statistic = -14.54 
p < 0.0005
Worst
breathlessness
0.79 p < 0.0005 0.83 p<  0.0005 Z statistic = -16.25 
p < 0.0005
Current
breathlessness
0.81 p<  0.0005 0.81 p <  0.0005 Z statistic = -13.66 
p < 0.0005
These tests demonstrate significant association between Borg and NRS scores for 
average, worst and current breathlessness. Error bars and boxplots for all three categories 
of breathlessness were calculated and there is a reasonable degree of separation for a 
given level of Borg score versus NRS and vice versa (data not shown here). However, 
given that Worst, Average and Current breathlessness are all determined on the same 
scale for Borg and NRS, one could cumulate all the comparative NRS results with Borg 
for Worst, Average and Current. Comparison of the cumulative NRS and Borg scores 
would increase the number of variables to directly compare in error bars, and 
subsequently reduce the size of confidence intervals around the mean values. This could 
be more informative for the analysis. Hence, when this accumulation occurs, 1365 
responses (paired for Borg and NRS breathlessness) were collated. Again, NRS 
cumulative breathlessness scores were near normally distributed (data not shown). 
However, the cumulative Borg score deviated from the normal distribution at higher
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values. Unsurprisingly, Wilcoxon signed ranks test for cumulative NRS versus 
cumulative Borg was again highly significant (Z value: -25.99; p<0.0005). Error plots 
with 95% confidence intervals around the mean were subsequently generated for NRS at 
a given level of Borg score and vice-versa (Figures 4.5.5 and 4.5.6).
Figure 4.5.5: Error plot showing the mean and 95% confidence interval for the mean 
NRS score for a given value of Borg-rated breathlessness (n=1365 paired responses). 
Circles represent mean values, with bars representing the range of the 95% confidence 
interval for the mean.
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Figure 4.5.6: Error plot showing the mean and 95% confidence interval for the mean 
Borg score for a given value of NRS breathlessness (1365 paired responses). Circles 
represent mean values, with bars representing the range of the 95% confidence interval 
for the mean.
Cumulative NRS breathlessness score
As can be seen there appears to be a straightforward near linear relationship for Borg 
versus NRS mean values of Borg for a given NRS score (Figure 4.5.6). Again there is a 
good degree of separation for NRS scores for a given Borg score (Figure 4.5.5) up until 
and including a Borg score of five, representing “severe” breathlessness. Before this 
point is reached there appears to be a near linear relationship with discrete mean values 
of NRS without overlap of the 95% confidence intervals. This is re-iterated in Tables
4.5.3 and 4.5.4.
188
Table 4.5.3: Mean value (with assessment of variability) of NRS for a given Borg score 
based on cumulative paired responses (n=1365 paired responses)
Borg Mean NRS SD 95% Cl
0 -  none 0.221 0.660 0.107-0.335
0.5 -  very very slight 1.406 1.193 1.176-1.635
1 -  very slight 2.491 1.717 2.234-2.749
2 -  slight 3.070 1.405 2.906-3.233
3 -  moderate 4.862 1.591 4.705-5.019
4 — somewhat severe 6.268 1.453 6.024-6.513
5 -  severe 7.203 1.287 6.882-7.525
6 7.210 1.228 6.619-7.803
7 -  very severe 8.767 0.817 8.462-9.072
8 8.200 1.989 6.777-9.623
Values for Borg scores of 9 and 10 (maximal) are omitted due to too few results for 
analysis. It can be observed from this table that at higher values of Borg, the c o n f i d e n c e  
intervals for the mean values become wider, thus one is less confident about the true 
mean values at these higher levels. This will be in part due to the lower number of values 
for comparison at these high levels of Borg. This can be seen graphically in the error 
plots above (Figures 4.5.6 and 4.5.7).
Table 4.5.4: Mean value (with assessment of variability) of Borg for a given NRS score 
based on cumulative paired responses (n=1365).
NRS Mean Borg SD 95% Cl
0 0.212 0.443 0.142-0.283
1 0.891 0.616 0.771-1.010
2 1.583 0.759 1.478-1.687
3 2.162 1.013 2.011-2.313
4 2.446 0.850 2.317-2.576
5 2.952 0.868 2.830-3.074
3.336 0.847 3.183-3.490
7 3.960 1.256 3.712-4.208
T 4.767 1.390 4.443-5.091
T 5.302 2.840 5.471-8.129
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Note that there is a greater degree of separation for a given Borg number than for a given 
NRS number for SOB. This is also confirmation that one cannot comment on Borg 
severity greater than 5, as the mean Borg for an NRS of 9 is only just above 5, and that 9 
is close to the very maximum of the NRS score. The comparison between NRS and Borg 
breathlessness mean scores appears to have a linear relationship. Linear regression 
analysis was therefore performed using SPSS in order to create an equation where an 
NRS can be estimated from a given Borg score and vice versa. In order for this analysis 
to be valid, the residual values (the difference between those observed and expected 
values) have to follow a normal distribution and have uniform variance and histograms 
of these unstandardised residuals demonstrate this (graphs not shown). Two sets of 
models for comparison of NRS to Borg and vice versa were produced. The first 
incorporated the comparison of the total cumulative Borg and NRS results. The second 
only included those results leading up to and including a Borg score of 5, given that the 
number of values above this point are few and may distort the model. Hence, two sets of 
equation for conversion between the two breathlessness measures are as follows:
For a given Borg score converting to NRS: NRS score = 0.945 + (1.202 x (Borg score)) 
For a given NRS score converting to Borg: Borg score = 0.336 + (0.543 x (NRS score))
For a given Borg score (up to and including 5) converting to NRS:
NRS score = 0.595 + (1.389 x (Borg score)) 
For a given NRS score converting to Borg (up to and including 5):
Borg score = 0.56 + (0.45 x (NRS score))
Significance tests and confidence intervals for the intercepts and gradients of these linear 
models are described in Table 4.5.5 below.
190
Table 4.5.5: Assessment of the linear models for Borg and NRS conversion. Significance 
levels represent the degree of confidence around the values for intercept and gradient of 
the individual model
t statistic Significance 95% Cl
Borg conversion to 
NRS (cumulative)
Intercept: 0.945 13.3 <0.0005 0.805- 1.084
Gradient: 1.202 50.6 <0.0005 1.156-1.249
NRS conversion to 
Borg (cumulative)
Intercept: 0.336 6.7 <0.0005 6.238-0.434
Gradient: 0.543 50.6 <0.0005 0.522-0.564
Borg conversion to 
NRS (Borg <6)
Intercept: 0.595 7.7 <0.0005 0.443 -  0.747
Gradient: 1.389 46.5 <0.0005 1.330-1.447
NRS conversion to 
Borg (Borg <6)
Intercept: 0.56 13.2 <0.0005 0.477 -  0.643
Gradient: 0.45 46.5 <0.0005 6.431-0.469
Which of the two sets of models are best to use? The table below allows comparison of 
these models to see the difference between the model and actual values observed in the 
participant sample.
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Table 4.5.6: Comparison of the mean Borg scores for a given NRS and vice versa from 
the actual data collected, the cumulative model and the limited linear regression model 
(for Borg scores up to 5)
NRS
Actual
Mean
Borg
Cumulative
model
Limited  
model 
(Borg <6)
Borg Actual M ean
NRS
Cumulative
M odel
Limited 
model 
(Borg <6)
0 0.21 0.34 0.56 0 -  none 0.22 0.95 0.60
1 0.89 0.88 1.01 0.5 -  very 
very slight
1.41 1.55 1.29
2 1.58 1.42 1.46 1 -  very 
slight
2 .49 2.15 1.98
3 2.16 1.97 1.91 2  -  slight 3.07 3.35 3.37
4 2.45 2.51 2.36 3 -  moderate 4.86 4.55 4.76
5 2.95 3.05 2.81 4 -
somewhat
severe
6.27 5.75 6.15
6 3.34 3.59 3.26 5 -  severe 7.20 6.96 7.54
7 3.96 4.14 3.71
8 4.77 4.68 4.16
It can be seen that for a given NRS score, the cumulative model for Borg score is closer 
to the actual mean score in the sample. Hence the formula 0.336 + (0.543 x NRS) should 
be used to calculate the corresponding Borg score. For a given Borg score, the 
cumulative and Borg <6 models are similar. For ease of use therefore, both unrestricted 
cumulative score models should be used.
5.3 Analysis of preferred week intervention with breathlessness scores
Some patients appear to have a clinical response to both active and placebo treatments. 
This is reflected both in the breathlessness scores and by studying the week of treatment 
that participants preferred the most when questioned at the end of the three-week study 
having had all three treatments. Whilst still blinded, of the 35 completed participants, 14 
preferred the week corresponding to oramorph and 9 preferred the week corresponding to 
oxynorm. However, 11 patients selected placebo as their preferred week of treatment for
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breathlessness, with one participant having no preference for any week of treatment. The 
intervention selected had no bearing on the week it was received, with 14, 9 and 11 
participants selecting their first, second and third week on treatment respectively. This 
demonstrates again that treatment sequence had no relationship on outcome, as noted 
previously in the sequence effect analysis in Section 3.2.
How did the choice of their preferred week of therapy for breathlessness compare with 
their breathlessness severity scores? The histogram below shows the comparison between 
those participants that chose each intervention compared to their scores for average 
breathlessness change on NRS. One would expect to see the greatest response in 
breathlessness improvement on NRS for the intervention that was chosen in the preferred 
week (i.e. those that chose oramorph as their preferred week should demonstrate higher 
NRS values for oramorph than for the other two interventions). One might also expect to 
see an opioid treatment effect, whereby the choice of one active intervention in the 
preferred week gave the highest mean breathlessness response, but that the other active 
treatment yielded a smaller but still greater response compared to placebo. Interestingly, 
those participants that chose oramorph at the end of therapy (n=14) had very little 
difference in NRS Average breathlessness outcomes, whereas the participants who 
selected placebo had a marked placebo response. In addition, those that preferred 
oxynorm had a notable improvement in breathlessness score, but showed no such 
improvement on the other active intervention, in fact their scores deteriorated on 
oramorph. A similar pattern is seen for all other NRS and Borg change in breathlessness 
outcomes (data not shown).
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Figure 4.5.7: Mean change in NRS Average breathlessness scores for each intervention 
for the three groups of treatment preference at the end of the trial. Positive values 
represent an improvement in breathlessness severity between day 1 and day 4 
treatment.
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Figure 4.5.8: Global impression of change scores for breathlessness severity for each of 
the three interventions for the three groups of treatment preference at the end of the trial. 
Positive scores represent an improvement in breathlessness.
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In contrast. Global impression of change scores, when compared to preferred week, do 
correspond to what one might expect (week preferred for breathlessness corresponds to 
the greatest mean improvement seen in global rating for that week compared to the other 
interventions). In addition, simply using day 4 values for NRS Average breathlessness, 
rather than change in breathlessness from baseline to day 4, also correspond to preferred 
week.
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Figure 4.5.9: Histogram to show day 4 Average NRS breathlessness values for each 
intervention for each week preferred at the end of the trial. Lower values indicate the best 
breathlessness scores in this case, in contrast to change in breathlessness scores.
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Section 6) Results: Secondary outcome measures
6.1 Comparison of additional components of shortness of breath
Additional components of shortness of breath, namely how participants coped with 
breathlessness, how much distress did breathlessness cause and their satisfaction with 
treatment were measured for each intervention. The table below (4.6.1) describes the 
difference between day 1 (baseline) and day 4 of treatment for each intervention for these 
additional components of breathlessness.
Table 4.6.1: Comparison of the change of additional components of shortness of breath 
with each intervention period
Breathlessness Oramorph change Oxynorm change Placebo change
description (n=35) (n=35) (n=35)
Distress Mean 0.57 Mean 1.40 Mean 1.77
SD 2.49 SD 2.43 SD 2.65
Median 0 Median 0 Median 1
Coping Mean 0.03 Mean -0.60 Mean -0.43
SD 1.85 SD 2.16 SD 2.17
Median 0 Median 0 Median 0
Satisfaction Mean -0.83 Mean -0.34 Mean -1.37
SD 3.14 SD 2.94 SD 2.80
Median 0 Median 0 Median -1
Comparison of day 1 and day 4 was made whereby a positive value indicates a reduction 
in value from day 1 to day 4. In this case, negative values for distress indicate a 
worsening of that factor, whereby negative values for coping or satisfaction indicates an 
improvement in those factors. As can be seen in the table, the placebo week yielded an 
improvement in patient reported distress and satisfaction, with comparable values for 
coping with breathlessness with the active treatments. Overall the changes in these 
parameters are small No significant statistical associations were noted between 
treatments using Wilcoxon signed rank tests.
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Quality of life scores were calculated for all 35 participants at baseline and at day 4 for 
each intervention. Individual scores were re-coded and divided into eight separate 
domains. These domains are then individually weighted to calculate a score out of one 
hundred for physical and mental function affecting quality of life.
Mean baseline score for physical components of quality of life was calculated as 28.15, 
whereas the mental component mean was 47.24. No significant differences were 
determined between day 4 scores for each intervention using Wilcoxon signed ranks tests 
for paired variables.
6.2 Quality of life as measured by the SF-12 survey
6.3 Adverse events: Changes in clinical observation data with each treatment
The safety of opioid treatment with reference to cardiorespiratory parameters was 
monitored at the start and end of each intervention. Table 4.6.2 illustrates the change in 
clinical cardiovascular observations from baseline (pre-intervention) to day 4 of the 
intervention for all 35 participants. Positive values represent an increase in the value of 
that observation, negative values represent an decrease in value over time.
Table 4.6.2: Changes in cardiorespiratory observations with each intervention between 
baseline and day 4 of treatment
Oramorph Oxynorm Placebo
Resting pulse difference Mean 0.03 Mean -5.83 Mean 2.34
(beats per minute) SE 1.76 SE 1.19 SE 1.14
Resting systolic BP difference Mean -5.34 Mean -1.31 Mean -0.34
(mmHg) SE 2.34 SE 2.51 SE 2.72
Resting diastolic BP Mean -5.74 Mean -2.80 Mean -1.09
difference (mmHg) SE 2.08 SE 2.69 SE 1.85
Resting respiratory rate Mean -0.46 Mean -1.60 Mean -0.86
change (breaths per minute) SE 0.46 SE 0.42 SE 0.46
Resting O2 saturations Mean -0.71 Mean -0.49 Mean -0.31
difference (%) SE 0.33 SE 0.34 SE 0.28
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Standard error of the mean is quoted as a function of how good the estimate of the mean 
is, rather than quoting the standard deviation which is more important if one was
interested in the overall distribution of the samples. Of course, standard deviation can be 
calculated from the standard error.
Treatment with either oxynorm or oramorph did not result in large reductions in either 
blood pressure, respiratory rate or oxygen saturations compared to placebo. There was a 
mean fall in systolic and diastolic blood pressure of approximately 5 mmHg for 
oramorph, with a lower corresponding fall of about 2.5 mmHg for oxynorm. A drop of 
less than 1% in oxygen saturations was observed for all three interventions. None of the
changes in these observational parameters were statistically significant using paired t- 
tests.
Similarly, clinical observations were also taken one hour after the first administration of 
each intervention in all 35 participants. Table 4.6.3 below reveals the mean changes with 
standard errors of the standard observations taken between baseline and one hour. 
Positive values represent an increase in the value of that observation, negative values 
represent an decrease in value over time.
Table 4.6.3: Change in cardiorespiratory observations following the first dose of each 
intervention at one hour post-dose compared to baseline
I Oramorph Oxynorm Placebo
Resting pulse change (beats per Mean -0.80 Mean -4.29 Mean -2.65
minute) SE 1.19 SE 1.10 SE 0.95
Resting systolic BP change Mean -0.86 Mean -1.26 Mean 0.82
(mmHg) SE 1.77 SE2.17 SE 2.78
Resting diastolic BP change Mean-1.40 Mean -0.26 Mean 0.53
(mmHg) SE 1.78 SE 1.60 SE 2.07
Resting respiratory rate change Mean -1.14 Mean -1.60 Mean-1.11
(breaths per minute) SE 0.29 SE 0.27 SE 0.33
Resting O2 saturations change Mean -0.46 Mean -0.20 Mean -0.59
(%) SE 0.29 SE 0.26 SE 0.27
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As with the follow-up data at day 4, neither active treatment causes a large drop in blood 
pressure or reduction in respiratory rate or oxygen saturations compared to placebo.
6.4 Adverse events: Physical side effect incidence
The incidence of adverse events was documented on each study day for each of the three 
interventions in all 35 participants who completed the three-week trial. The most 
common side effects with opioids were determined a priori in the protocol, with NRS 
scales developed for nausea and drowsiness and a specific question asked about 
constipation (present or absent). All other adverse events were volunteered by the 
participants themselves when adverse events in general were under enquiry. This data is 
shown in Table 4.6.4. For the NRS scales, negative values indicate a worsening of the 
symptom, positive values indicate an improvement in the severity of the adverse event.
Table 4.6.4: Adverse events documented for each intervention
Adverse event Oramorph Oxynorm Placebo
Nausea NRS (day 1 day 4 
difference)
Mean -1.57 
SD 2.90 
Median 0
Mean -0.43 
SD 1.63 
Median 0
Mean 0.20 
SD 2.18 
Median 0
Drowsiness NRS (day 1 day 4 
difference)
Mean -0.40 
SD 2.67 
Median 0
Mean 0.37 
SD 2.64 
Median 0
Mean 0.69 
SD 2.55 
Median 0
Constipation on day 4 12 10 4
Vomiting 3 2 0
Itch 3 0 0
Lightheadedness / Drunkenness 
/Dizziness
7 4 1
Headache 2 0 1
Abdominal pain 1 0 0
Sweating 1 1 0
Dry mouth 2 0 0
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For NRS rated events between day 1 and day 4, nausea and drowsiness both worsened 
slightly from baseline with oramorph. Nausea scoring with oxynorm also worsened 
slightly, but less than for oramorph. This suggests that out of the two active 
interventions, oxynorm was better tolerated. Wilcoxon signed rank test statistics showed 
a statistically significant difference between oramorph and oxynorm and oramorph and 
placebo for nausea (p = 0.04 and p = 0.01 respectively). No other statistically significant 
differences were noted between oxynorm and placebo or for any drowsiness scoring 
between groups.
Of the patient volunteered adverse events, of the two active treatments oxynorm appeared 
to be the better tolerated. The numbers represent the number of participants affected, not 
the number of episodes, but most participants only experienced a single episode of the 
adverse event. One serious adverse event (SAE) occurred during the RCT. This single 
SAE that occurred at the end of the three-week study occurred on the last day of the 
placebo therapy and was attributed to a transient ischaemic attack, of which the patient 
had suffered on numerous previous occasions.
6.5 Karnofsky performance status
Table 4.6.5 below describes the mean (with standard deviation) Kamofsky performance 
status scores for day 4 and the difference between baseline and day 4 for each treatment. 
As can be observed there are little differences in performance status over this time period 
for each intervention. Negative values for change in score represent improvement in 
performance status. The data is not normally distributed and unsurprisingly Wilcoxon 
signed ranks tests show no statistical differences between treatments (data not shown).
Table 4.6.5: Comparison of Kamofsky scores for each intervention
Kamofsky score 
on oramorph 
(n=35)
Kamofsky score 
on oxynorm 
(n=35)
Kamofsky score on 
placebo (n=35)
Mean day 4 score (SD) 70.6 (5.91) 69.7 (7.07) 69.4 (5.91)
"Mean change in score 
from day 1 to day 4 (SD)
-1.4 (4.94) -0.3 (4.13) 0 (2.43)
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6.6 Compliance
Measurement of compliance with treatment occurred in two ways. The first was 
participant reported number of missed doses of treatment. Of the total length of follow­
up for three weeks on the 35 completed patients, the number of missed doses reported 
was 47 episodes, which relates to an average per person of 0.11 missed doses per day. 
Missed doses reported on oramorph were 18, missed doses on oxynorm were 22 and 
missed doses on placebo totalled 7 episodes respectively.
Secondly, volumes of the residual medication were measured at the end of the trial to 
assess compliance by this method. One participant discarded his week one treatment 
bottle by accident, which corresponded to the oramorph week. Hence mean values were 
calculated for the other 34 completed participant datasets. Each treatment bottle 
contained 50ml of either active drug or placebo and participants were advised to take 
2'.5ml four times a day for four days, which totals 40ml. Hence, a residual of 10ml should 
be present in each bottle for each treatment if compliance with treatment was 100%. In 
fact, mean residual volumes were 16ml for oramorph, 15ml for oxynorm, and 16ml mean 
residual for placebo. In total, this relates to 0.57 missed doses per day, slightly higher 
than the participant reported level.
6.7 Breathlessness descriptors
Participants were asked to rate the quality of their breathlessness by completing an 
assessment of breathlessness descriptors (3 descriptors chosen from a list of 15) at 
baseline (day 1) and day 4 for each of the three treatments. The pie chart below (Figure 
4.6.1) reveals the proportion of descriptors chosen in total from a pooled collection of all 
baseline responses (3 responses x 3 baseline visits x 35 participants = 315 responses in 
total):
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Figure 4.6.1 : Pie chart to illustrate collective baseline responses o f the 35 completed 
participants:
Collective
baseline
responses
h  breathing 
™  more
i-i cannot get 
enough air
□  constricted 
|  effort 
n heavy 
|  hunger 
O  more work
|—| not in all 
*—1 way
I—| not out all 
L-J way
h  out of 
®  breath
O  rapid 
l~~l shallow 
|  suffocating 
□  tight
Al l l  5 potential responses are elicited in the analysis. The most common responses are: 
Feeling out o f breath
Breathing requires effort 
Breathing requires more work 
Cannot get enough air 
Breathing is shallow
Chest tightness, chest constriction and the feeling o f suffocation are the least frequently 
reported.
Do responses to breathing alter when given opioid medications? Figure 4.6.2 describes 
the change in responses from baseline to day 4 for each o f the three interventions 
Baseline descriptions are detailed in lilac, with subsequent descriptions at day 4 o f  
therapy documented in purple.
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In general, responses for all three interventions were similar. Some participants were 
unable to give a response as their perceived improvement in breathlessness rendered 
them unable to answer descriptions about how their breath felt at the time. For both 
active interventions, participants described not being able to get enough air, chest 
tightness and shallowness of breathing as becoming less prominent on opioid therapy. 
Patients also described themselves as finding that they were having to breathe more, but 
this may have been misconstrued as being able to breathe more due to success in therapy 
for breathlessness, rather than what is intended by the original description. Specifically 
for oxynorm, sensation of being out of breath seemed to be less prominent, with 
descriptions of participants breathing requiring more effort becoming more prominent. In 
addition, for oramorph, air hunger was less prominent on therapy, with breathing 
requiring more work being a more frequent response at the end of oramorph therapy.
In addition, descriptors given at the baseline of all three interventions were compared to 
breathlessness severity using NRS ratings to observe whether certain descriptors are 
associated with more severe breathlessness. The results are shown in Figure 4.6.3. A 
similar bar chart involving worst breathlessness scores on NRS has been performed but is 
not shown. The bar chart shows that average breathlessness scores for all descriptors are 
similar, but terms such as suffocating, air hunger and inability to get enough air are 
associated with more severe breathlessness.
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Section 7) Discussion: sampling, study conduct, methodological review and points to 
note in the analysis
7.1 Participant sample
The CONSORT diagram (Figure 4.3.1) illustrates some of the issues involved in trial 
recruitment using an existing database. One of the benefits of using such a utility is to 
identify potential patients that may fit the inclusion criteria prior to their clinic 
appearance, thus allowing the provision of targeted resources towards patients that may 
both fit the criteria and may be interested in participation in clinical trials. Patients who 
had expressed a preference not to be involved in clinical trials were documented on the 
database and therefore should not be approached. This approach meant that potentially 
eligible patients could be better targeted in cardiology clinics. In addition to using the 
database, clinic doctors and nurses were given the inclusion and exclusion criteria in case 
they reviewed any patients who may fulfil eligibility that did not appear to on the 
database. In this circumstance, patients were given the participant information sheet and 
were told they would be contacted by the research team within one week.
Despite these measures and persistence by both myself and the research nurse, only 39 
participants were consented for the trial over a period of just over 18 months. 
Approximately the same number of patients were eligible and approached but refused 
entry. Over two hundred patients appeared to fit the criteria from the database, but the 
majority of these did not fulfil eligibility on inspection in clinic. This highlights one of 
the major problems with the use of an existing database in the fact that it is historical. 
CHF patients describe variable symptoms and medications over time and this is 
particularly noticeable when patients are only reviewed every year as tends to be the 
policy in the Hull and East Yorkshire NHS Trust. Hence, the majority of patients who 
appeared to fit eligibility from the database who were subsequently reviewed were in fact 
ineligible at the time of review.
This highlights a number of points. Altman (1991) correctly states that there is frequently
an optimistic number of proposed recruits and this is demonstrated here as less than 5%
of breathless patients were eligible and agreed to enter the study. Future studies of a
similar nature could be multi-centred to allow greater exposure to eligible patients.
Alternatively, care of the elderly clinics or GP surgeries could be involved to approach
eligible patients, as many patients with CHF in the district may not have been referred to
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the heart failure service due to ongoing review by these other specialities. The main 
problem with this approach would be accessing echocardiography services to allow 
accurate up-to-date imaging by the cardiology service. At the start of the trial I 
considered that the inclusion criteria for the study was quite wide and had that not been 
the case, many fewer patients would have been included. This is the balance to be struck 
between making the criteria too wide, not allowing accurate review of the study 
population of interest and making the criteria too narrow and not finding sufficient 
numbers to reach preset statistical power. On reflection, I consider that this balance was 
probably correct in this study given the limits on time, resources and nature of single­
centre research, particularly as the number of participants detailed in the power 
calculation was surpassed. Future studies of a similar nature need to take this important 
point into account when protocols are being devised.
Although half of the patients approached refused entry into the trial, this figure is 
probably representative for trials of this type. I did note however that some potential 
participants declined trial entry on the basis that they were advised not to drive for the 
duration of the study. If the trial were to be repeated, I would probably rephrase that 
advice to suggest that, as with all new medications, one should not drive if they feel that 
the effects of the medication meant they felt they were unable to perform this activity 
safely.
Details of the patient sample selected are noted in Chapter 4 Section 1 of the results. 
There were no differences between the 35 participants that completed the study and the 
two that withdrew due to adverse events. Is the sample representative of advanced heart 
failure patients with NYHA class 3 or 4 symptoms? Certainly, the baseline values for 
breathlessness severity on NRS indicate that the study population has a moderate to high 
level of breathlessness. The aetiology of heart failure, taken from the database and 
therefore open to interpretation, predominantly involved patients with ischaemic heart 
disease, in keeping with available statistics of the aetiology of CHF (Davis et al., 2005). 
Hypertensive heart disease and dilated cardiomyopathy were also included, but no 
patients with documented valvular disease as the sole cause of heart failure were 
included. The sample taken was predominantly male, which is in keeping with most 
Other trials where there is a preponderance of male participants. The age of the sample is 
in keeping with other similar studies of breathlessness (Jennings et al., 2001, Johnson et 
al., 2002, Abemethy et al., 2003).
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One could argue that participants with symptomatic disease (NYHA 3 or 4) might be 
expected to have a lower mean ejection fraction, or higher mean BNP result, than that 
observed in the results. This might reflect the nature of our sample and the problems 
associated with research in advanced disease. Patients with advanced disease and the 
most troublesome symptoms may be unable to attend regular clinic follow-ups due to ill 
health and therefore may not attend for echocardiogram or blood testing. A decision may 
have been made not to subject advanced patients to unnecessary interventions. Hence, the 
sample might reflect those patients who are symptomatic with abnormal ejection fraction 
and BNP, but not those so advanced that might have a short life expectancy and worse 
heart failure parameters. The frequency of the medication for heart failure is probably 
representative for symptomatic disease, with beta-blockers, ACE inhibitors / 
adrenoreceptor blockers and aldosterone antagonists all represented in high frequencies, 
in accordance with current treatment guidelines for symptomatic CHF.
7.2 Study conduct
The process o f research recruitment and follow-up from a practical aspect can be found 
in Appendix 4. This details more of the day-to-day activities involved in non-commercial 
trials based in the NHS.
It is noticeable from the study that of the 39 patients consented, 35 participants 
completed the three-week crossover with full sets of data. This represents a very low 
drop-out rate for any clinical trial, but particularly for a trial involving symptomatic 
patients with relatively advanced disease (Dorman et a l, 2009). Withdrawals from 
crossover studies are particularly important to keep to a minimum due to the nature of the 
analysis of the subsequent data. Two patients no longer fitted eligibility between consent 
and trial commencement. This was due in part to the medication delays experienced in 
the study, which in turn was compounded by the relatively short expiry of the treatments 
(90 days). This meant that participants had to start the trial prior to three weeks before 
the medication expiry date and that medications had to be ordered with a great deal of 
advanced notice. Delays in the set-up of the trial in Huddersfield that were beyond my 
control led to the two patients consented being unable to be included as their disease 
process changed over time. This was very unfortunate and disappointing.
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A number of factors were involved in the collection of so much fully completed data. 
Firstly, the initial trial was short and hence did not involve long detailed follow-up with 
the potential for lost participant follow-up. Secondly, participants were contacted on 
every day that study data was required, which acted as a reminder for the participants to 
complete their assessments. Although this could be considered as being quite intensive 
for the participants, I believe they were quite reassured to have daily contact, it allowed a 
rapport to be established and tended to only last about 5 minutes for the telephone and 20 
minutes for the day 4 visit. Thirdly, only two researchers were involved in contact (either 
myself or the research nurse) so participants were familiar with the point of contact on 
each occasion, rather than being contacted by multiple researchers. The handling of 
missing values was documented a priori, however this did not have to be enacted due to 
the vigilance of the assessment process.
Fourthly, there was flexibility concerning the place and timings of assessments. The 
option of reviewing participants in their own homes was invaluable for both consenting 
purposes and for detailed follow-up, as symptomatic patients may not have wanted to 
attend twice a week for review. Of the 37 randomised participants, the vast majority were 
seen in their own home environment. The study did not require hospital attendance for 
monitoring so could be performed almost anywhere with portable equipment. I believe 
this was a major factor in participant recruitment and subsequent follow-up. The 
crossover nature of the design of the trial allowed participants to receive both potentially 
active and placebo medications, rather than a parallel group design that would not allow 
some to receive the active medication, which may have been important in their decision 
to continue within the study. Lastly, participants felt they had few other options for 
symptom improvement and had often had to manage their symptoms for a long period of 
time. The opportunity to try something for a short period to potentially help both 
themselves and others meant they were more likely in my opinion to continue in the trial.
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7.3 Review of methodology
Randomised controlled trials are considered the gold standard approach to quantitative 
research owing to the reduction in potential biases with the randomised double-blind 
approach (Tilling et al., 2005). A cross-over design was chosen to reduce the number of 
study participants required; it is recognised that it is difficult to recruit to palliative care 
studies (Dorman et a!., 2009). For a given level of precision in estimation fewer 
observations have to be obtained for a cross-over trial compared to a parallel-group 
design (Senn, 2002). A disadvantage of crossover studies in palliative care in particular is 
that it is necessary for the patients to be stable for the duration of the study to avoid a 
period effect and this can be a problem with malignant disease. However, the patient 
sample in this study was taken from a stable population of chronic heart failure sufferers 
and analysis for period did not reveal any such effects.
Crossover trials have the advantage of eliminating between-patient variation between 
treatments and it is very suitable for observing treatment effects in stable chronic 
diseases such as asthma that cannot be cured but involve symptom control (Senn, 2002) 
Although CHF patients may deteriorate over time, the period at which they remain stable 
can be measured in years (Lehman, 2006b) and thus could be referred to as a chronic 
disease with periods of stability. Participant withdrawals can also be difficult, 
particularly in crossovers where a participant may withdraw during the first treatment 
period. If the same occurs in a parallel trial, at least this incomplete data may be used, but 
in a crossover study use of this data is difficult as no direct information of comparison of 
treatments can be made (Senn, 2002).
Participants were allocated to their treatment sequence using a simple form of 
randomisation. If the effect of time was important (e.g. for a long period of time, rather 
than just a few weeks), in order to bring balance into the study a Latin square approach 
could be used if  there is a suspicion that trends may occur over time that might affect the 
experiment (Senn, 2002). This approach negates any effect of period. This is not the case 
for the current trial, but this method should be considered for trials of a longer duration.
Bausewein e t  a l  (2007) in their systematic review of tools used to measure
breathlessness in multiple aetiologies recommend the use of uni-dimensional scales (such
as modified Borg scale) alongside an assessment o f the impact on quality of life or
physical function and additional components such as assessment of anxiety related to
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breathlessness. The approach has been followed in this RCT, however, debate still exists 
as to the gold standard measurement tools to use for specific situations, dependent on 
setting, length of follow-up and disease aetiology. The authors recommend VAS or Borg 
as uni-dimensional measures, but actually acknowledge earlier in the article that NRS 
may be superior to VAS due to its ease of use and repeatability. The NRS and Borg 
scales for breathlessness were understandable and repeatable, could be used over the 
telephone (unlike VAS) and could be analysed using comparison of mean values (unlike 
verbal rating scales). Average, Current and Worst ratings of breathlessness are 
recommended by Wilcock et al. (1999). A recent consensus statement also recommends 
the use of NRS or modified Borg scores for measurement of breathlessness severity 
involving these timepoints for breathlessness in palliative care (Dorman et a l, 2009). It 
also recommends the assessment of mastery over breathlessness and related anxiety with 
breathlessness, both of which have been incorporated in the RCT assessment by 
additional components of breathlessness such as coping and distress rating.
The SF-12 questionnaire of quality of life was incorporated in the RCT as an easy to use 
validated measure. Its use has benefits and limitations. It is not specific to CHF, making 
the results generalisable to other studies of advanced disease causing breathlessness, but 
is not disease specific for comparison with other studies in CHF. Since there is no 
defined gold standard measure in CHF, the choice of measure is difficult. However, the 
limitations on physical function (climbing stairs, playing golf, moving a table) do not 
reflect the patient experience with CHF. Items such as inability to shower without 
symptoms, tying shoelaces or bending over would appear to better quantify the 
experience in CHF.
Immediate release preparations of the above drugs were used rather than sustained 
release preparations. This reflects current clinical practice in many centres in the UK and 
follows the recommendations in the BNF and SIGN guidelines. In addition, it was 
considered to be easier for the patients to distinguish the trial medication (in immediate 
release liquid form) from their usual multiple medication therapy in tablet form. 
Sustained release tablets may have affected compliance rates given that patients have so 
many other tablets to remember.
Oral morphine (oramorph) and oral oxycodone (oxynorm) were chosen as they do not 
have ceiling doses, unlike weaker opioids (step 2 analgesics such as codeine or tramadol)
and are used the most widely in clinical practice. The doses considered for oral morphine
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and oral oxycodone were considered to be clinically equivalent (British National 
Formulary, 2006). Oral morphine was chosen because of the previous pilot study and 
because oramorph is specified as an unlicensed indication for the management of 
breathlessness in both the British National Formulary (BNF) and Scottish NHS Clinical 
Guidelines (SIGN, 2007). Oxycodone was chosen for a number of reasons. It is used as a 
common alternative to morphine in palliative medicine. As discussed previously, it has a 
different morphine receptor profile in humans and may have less side-effects in a patient 
group who may not have consistent optimal renal function (Davis and Pasternak, 2005). 
In addition, there is some evidence to suggest that kappa agonists like oxycodone may 
promote diuresis (Leander er al., 1986, Rimoy et al., 1991) which may have an additional 
benefit in those breathless CHF patients who also have excess fluid.
The doses of oramorph and oxynorm were derived from equivalent doses used in the 
literature (Johnson et al 2002, Abemethy et al 2003 to quote 2 examples) and from 
existing clinical practice (Oxberry and Lawrie, 2009). A non-significant statistical 
difference in this RCT for the primary outcome measure (change in average 
breathlessness) was observed between active and placebo treatments. It could be argued 
that higher doses of medication might have resulted in a statistically significant result. 
Was the dosing schedule correct?
On reflection, the doses used were appropriate given the existing evidence in 
breathlessness in other aetiologies. Given the nature of the participant population and the 
design of the study it was probably the correct dose. Had the dose been too high, the 
number of withdrawals would have potentially been much greater, leading to loss of data 
and statistical problems in the analysis. Drop-outs in crossover trials present a particular 
problem and it is the case that more completed datasets are preferable to less. Future 
trials should reflect the fact that the optimum dose of opioid in CHF is as yet unknown 
and a study with a factorial design might be the best way to determine the optimum dose 
in opioid naive CHF patients. This factorial design could include a placebo arm, with 
oramoiph given at doses of 5mg QDS and 1 Omg QDS orally for example. A parallel 
group design would not have quite the same problems with loss of data from treatment 
withdrawals as would a cross-over design, although a greater participant number would 
be required. Alternatively, a sequential design could include the increase of dose of 
opioid in participants who show no or little response to the initial dose (e.g. 2.5mg QDS), 
though this may be difficult to analyse in an appropriate way. Certainly there is scope to ' 
examine this area more closely in future studies.
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The four day intervention period was chosen to allow drug to reach steady state given 
that the half life of oral morphine (oramorph) and oral oxycodone (oxynorm) is between
1.5 and 4 hours according to their summary of medicinal product characteristic literature. 
In addition, the pilot study by Johnson et al. (2002) revealed a return to baseline values 
for treatment effect over 4 days of placebo administration. A possible sequence effect 
was avoided by incorporating a three day washout period between interventions. It is 
considered that a period of five half lives is required for elimination of a drug from the 
body and therefore at least 20 hours (5x4 hours) was necessary (British National 
Formulary, 2006). This presumes a normal renal function, and given that many patients 
with heart failure also have co-existent renal impairment (Lehman, 2006b) and that these 
opioids are renally excreted (Twycross et al., 2002), a longer washout period was 
indicated. An assumption for analysis was made in that this passive washout period was 
sufficient to allow return to the patients’ natural baseline state. An alternative approach to 
this methodology was taken by the Abemethy (2003) study as discussed in Chapter 3. In 
this study, participants were switched to the alternative treatment without washout, but 
day 4 values were taken without baselines. This would allow washout to occur during the 
second treatment phase, although the criticism of this is that the treatment period needs to 
be sufficient enough to both allow treatment effect and washout from the previous 
intervention to occur. Four days in total was allowed for this process to occur, as opposed 
to a more generous seven days in this study.
Measurements for physical observations were taken using the same electronic equipment 
(blood pressure cuff, pulse oximeter) so as to reduce the bias that may have been 
introduced by using different machines with slightly different calibration. All physical 
observations were measured at rest to allow comparison at a steady state. Similarly, 
participants were reviewed by myself with or without the research nurse on every day 1 
and day 4 of therapy, with standardised telephone follow-up by myself or the research 
nurse on days 2 and 3 of treatment. Hence, data collection only occurred with two 
individuals, blind to intervention, so as not to introduce any further bias. Logistically, 
data collection by only one researcher alone would not have been possible given the 
other daily constraints on work and time.
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7.4 Points to note in the analysis
Frequently there is more than one method to analyse the data collected and I have 
attempted to describe different methods according to statistical convention, type of 
outcome most appropriate to the data described and what has been published already in 
the literature to allow direct comparison. Sometimes data has been analysed in different 
ways in order to demonstrate that the outcome is approximately the same despite the 
statistical method chosen, as long as it is appropriate according to the statistical 
requirements tests observe.
Should arithmetic means be used in the interpretation of numerical rating scales? The 
NRS could be described as a discrete quantitative measure. Altman (1991) and Campell 
& Machin (1999) state that it is reasonable to treat discrete data as continuous in 
statistical analysis. Medians and means are quoted in some parts of the analysis, as 
medians can be useful as a descriptive statistic.
Non-parametric tests were used when distributional assumptions were not met, continued 
for consistency for both oxynorm and oramorph. These tests are not as powerful as 
parametric tests (Campbell and Machin, 1999), but given the small sample size unless the 
data appeared to be clearly normally distributed using histograms or Q-Q plots it was 
probably more appropriate to use non-parametric methods. In this regard, any positive 
statistical associations that were found did not depend on a dubious assessment of data 
normality. In the data analysis though, there was little difference between the outcome of 
parametric and non-parametric tests on the sample collected, so in practice this 
distinction made little difference on study outcomes.
Paired data forms a large part of the three week analysis as a result of the cross-over 
design. Using this method one attempts to remove between subject variability to consider 
within-subject differences with intervention.
Throughout this analysis the null hypothesis is that there are no differences between 
interventions. Bland recommends in crossover trials that differences between individual 
treatment outcomes and baselines ideally should not be used, as this will increase the 
measurement error (personal communication). In this study, the three baseline 
measurements can be included in an analysis of variance equation which could improve
power and therefore the measurement of the estimate. Senn (2002) suggests that
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difference from baseline measures are frequently used in clinical trials for analysis as 
long as the variances between baseline and outcome are assumed to be the same. The use 
of the baselines has the benefit of reducing the variation in the participant sample by 
using analysis of covariance techniques. However, in practice the purpose of the 
crossover trial is to allow the reduction of variability between interventions by using the 
same subjects for each intervention, hence reducing the variability by this fact alone. 
Having the baseline data can be of benefit in complex statistical analysis and in time 
series analysis, but is not necessary for adequate comparison of interventions in a 
crossover trial (in contrast to a parallel group design).
Altman also recommends analysis of variance techniques as long as values follow a 
normal distribution. He discusses that these methods are conservative in that they err on 
the side of caution (i.e. tend not to disprove the null hypothesis) and suggests that for 
multiple comparisons modified paired t tests are recommended if the method of analysis 
is not detailed in advance. This shows that there are a number of ways to analyse the 
data, which I have attempted to demonstrate in the results and discussion. The protocol 
made reference to differences between baseline (day 1) and day 4 of therapy as the 
outcome measures used and therefore I have followed this structure in the analysis. 
However, comparison of day 4 results for each intervention would appear to be 
acceptable and if the trial were repeated less emphasis need be made with regard to 
baseline values on each intervention. From the results, using differences between time 
points appears to lead to estimates that appear to fit better to the normal distribution, 
allowing use of paired t tests, compared to using day 4 data alone. Alternatively, this day 
4 data could be transformed using log transformations for example, which could be used 
instead to allow parametric tests to be used.
Whilst there is some interest in the outcomes of the three individual treatments in the 
trial, often the outcome of most interest is not the individual outcome to intervention, but 
how the interventions compare. To that effect, as described by Senn (2002), the 
difference between treatments is the analysis of interest and response versus placebo is 
noted as the most important analysis in the results. However, some information about the 
individual intervention outcomes are recorded to allow the reader to appreciate the 
overall effect for each intervention.
The intention to treat statement is important and all participants will have had their data
analysed regardless of the latter review of their eligibility suitability. Senn (2002) would
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also not discard the data of participants that were unable to fully complete the trial as 
long as there was complete data from at least one full period of intervention. This was 
not the case in this study as both participants who withdrew did so in the first week of 
treatment. Senn (2002) describes that in practice the information derived from these 
participants can only really contribute indirect information to the overall trial process, but 
that this data should not be discarded fully if at least one period of intervention has been 
completed. Some crossover trials may have participant data that is incomplete for each 
timepoint of measurement for each intervention, but all interventions have been 
completed. There is some discussion around the best method of dealing with this 
problem. In the protocol, I had considered the use of clearly marked imputation values 
that would reflect the worst value that could be achieved. This would allow a great deal 
of confidence in any subsequent statistically significant results. However, in the event of 
large amounts of missing data, I would consider the approach by Senn (2002) who 
recommends carrying the last available measurement forward to impute, or by making an 
estimate of the missing value dependent on the other results given.' In practice, this might 
allow the continuation of any trend seen between interventions in a large patient sample 
with large amounts of missing data over time, but adequate explanation of the frequency 
of missing values and the potential effects on the statistical outcomes should be made 
clear in the discussion, as this method may lead to misleading overestimates of effect.
7.5 Sequence and period analysis
There remains much debate as to the method of analysis and importance of period and 
treatment-period interactions. For example, Senn (2002) states that he never tests for 
carry-over of treatments. He recommends that trial design should involve the use of 
adequate washout periods based on the best available estimation that drug clearance will 
have occurred and that there will always have to be the acceptance that carry-over will 
not have seriously affected the results one of many assumptions in a clinical trial (Senn 
2002).
Senn (2002) also states that if  sequences are assigned in a purely random basis, as in this
study, any period effect could be ignored in the subsequent analysis, as random
allocation is consistent with the belief that the period effect is negligible. This is converse
to the argument for block randomisation which would require the analysis of any period
effects. However, for the sake of completeness, analysis for possible period and sequence
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effects has been performed and the subsequent data analysis takes no allowance for the 
effect of period, given that no period effects have been demonstrated.
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Section 8) Discussion: Primary outcome measure: change in hra.thl>.«.M.
8.1 Baseline and end of treatment comparisons for breathlessness on NRS and Borg
scales
No statistically significant differences were shown to occur for NRS- or Borg-rated 
breathlessness severity between oramorph, oxynonn or placebo for the 3 5 completed 
patients (Table 4.4.2). Baseline (day 1) and end of treatment (day 4) differences in NRS 
and Borg scores were calculated for each intervention. In this fashion, negative results 
indicated a higher day 4 score, and hence a worsening of breathlessness. Similar results 
were observed for both worst and average scores. All calculations (except for oramorph 
treatment difference in average breathlessness on a Borg scale) resulted in positive 
values, indicating a symptom improvement between baseline and end of treatment for all 
three interventions. In particular, mean differences on NRS scoring (worst and average 
scores) were the greatest for placebo (Table 4.4.1), indicating a noticeable placebo effect. 
Smaller mean differences were observed for Borg rating compared to NRS. Non- 
parametric statistical tests for paired data were used for comparison due to the non­
normal nature of the outcome measures.
A change of 1 point on an 11 point NRS score (or 10% on a 100mm VAS) for 
breathlessness is considered as clinically important (Booth, 2006, Powers and Bennett, 
1999) and hence a mean change in score with oxynorm (1.29 for average NRS and 1.43 
for worst breathlessness NRS change) in particular might be considered, on its own, as 
being clinically important. However, given that these changes are comparable to the 
effect by placebo on breathlessness scores, this demonstrates important points. Firstly, it 
illustrates the importance of an adequate placebo comparison in clinical trials. Secondly 
it demonstrates the importance of good randomisation and double blind techniques so 
not to influence the responses to the active treatments over placebo and thus not 
potentially subvert the trial results. Thirdly, the placebo results may be affected by the 
regression to the mean phenomenon. This phenomenon can occur in all trials, but 
particularly for subjective concepts with a degree of measurement error (Morton and 
Torgerson, 2005). Measurement of extreme values at baseline are likely by chance alone 
to regress to the mean on retesting, simply because extreme values are more affected by 
error than those near the average value. Lastly, it would appear that any differences in 
breathlessness with the interventions are small on either NRS or Borg scales
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8.2 Comparison of pooled active results and placebo on breathlessness severity
Pooled responses for active treatment, incorporating results for both oxynorm and 
oramorph versus placebo were calculated. As expected from the results seen earlier, there 
does not appear to be any difference between the effect of active treatment and placebo 
on breathlessness severity at day 4.
This combination of active therapy approach to analysis is a reasonable way to assess a 
difference, but it has a number of technical issues. Firstly, it involves the combination of 
paired estimates in the same individual, rather than in a typical two to one randomisation 
versus placebo where there are twice as many participants receiving active treatment, but 
all estimates are independent and not paired. Secondly, and more importantly, if one 
treats the active interventions as having equal weighting in this pooled analysis, one 
could argue against the reasons why the analysis of two active interventions was 
performed in the first place. Taking these points into consideration, whilst this 
combination of active treatments is of interest, it should form the basis of another 
properly constructed trial of one active treatment versus placebo, or an RCT comparing 
responses in breathlessness severity between both active interventions rather than 
involving a placebo arm. Hence no further analysis has been performed involving a 
combined active intervention group.
8.3 Change in NRS and Borg scores for breathlessness over time
It is possible that results on day 4 at the end of treatment fail to capture or reflect the 
overall changes in scoring over the course of therapy (Pang et al., 2008). Line graphs 
illustrating the mean change in NRS scores (average and worst breathlessness) are shown 
in the results. Similar graphs exist for the mean change in Borg score over time (not 
shown). Collectively these graphs demonstrate an initial reduction in breathlessness 
scoring (hence symptom improvement) from day 2 of treatment which is sustained over 
subsequent days for all three interventions. Here it can be seen that responses start to 
occur by one day of treatment (four doses of intervention) and continue throughout the 
course of treatment, and that baseline placebo scores are higher than for the active 
interventions, hence the relatively large mean score differences between baseline and end
of therapy for placebo versus active interventions seen above. This difficulty in
220
extrapolation of treatment effects due to this large decrease between baseline and end of 
treatment for placebo led to the consideration of analysis in another form, to match a 
similar trial in the literature for breathlessness in mostly COPD patients. Hence a 
comparison with results with the Abemethy et al. (2003) study is made in section 8.5.
Area under the curve (AUC) methods could have been used to describe the cumulative 
response to each intervention in comparison (Pang et al., 2008). Figure 4.4.2 describes 
the response over time for the three interventions, but a formal analysis of the response 
over time could have been attempted if there was a notable difference between 
interventions. However, AUC measures are difficult to calculate and for evenly spaced 
observations over time, Altman (1991) describes that the mean of all the measurements 
could be used as an approximation. Given that Figure 4.4.2 shows no discemable 
difference over time for active treatments and placebo, this further analysis is not 
necessary to improve the understanding of the difference between interventions and has 
therefore not been performed.
8.4 Potential factors that might influence response to opioids for breathlessness in 
CHF
Non-statistically significant results were shown in the response to active treatment versus 
placebo for breathlessness rating. Could it be the case that certain individuals respond 
better to treatment and hence it might be targeted to those individuals who might derive a 
benefit? Previously, it has been considered that excessive neurohormonal activation is 
detrimental and the release of endogenous opioids may be part of a protective mechanism 
possibly similar to the release of natriuretic peptides. Endogenous opioids released at the 
time of sympathetic activation in CHF might be involved in attempting to regulate over- 
activation. Excessive sympathetic activation might also be involved in the development 
o f abnormal breathing patterns in CHF. Hence, if opioids reduce this sympathetic 
response, and this is the mechanism by which breathlessness is improved, one could 
surmise that patients with only partially controlled neurohormonal activation might show 
a greater improvement in breathlessness than those with better control. One might expect 
therefore that patients on sub-maximal beta-blocker or ACEI/ARB therapy, or those not 
receiving aldosterone antagonists, might have a better response to opioids for 
breathlessness. This theory however is not borne out by the analysis in Section 4.8.
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Beta-blockers are responsible for reducing the sympathetic overdrive in CHF. 
Sympathetic overdrive might be responsible for the altered breathing patterns in CHF. If 
opioids operate by a similar mechanism to beta-blockers, one might expect those patients 
on lower doses of beta-blockers might respond better to opioids than those on maximal 
doses, where sympathetic stimulation may be better treated. Figures 4.4.5 and 4.4.6 
correspond to the change in average NRS scores on oramorph and oxynorm respectively 
with beta-blocker dose. For oxynorm, the premise that participants receiving lower doses 
of beta-blocker have a higher mean response in breathlessness to treatment compared to 
those on higher doses appears to be true. The improvement in breathlessness severity 
with treatment is marked for those not receiving any beta-blockers. The opposite appears 
to be true for oramorph, though the values are smaller, calling this hypothesis into 
question. A longer period on treatment is probably necessary to influence sympathetic 
overdrive in CHF, as most trials with beta-blocker therapy had a much longer follow-up 
period (Whorlow and Krum, 2000). In addition, maximum treatment with ACEI or ARB 
did not alter response to opioids on breathlessness in this sample. What is apparent here 
is that any overall effect of opioids as a group is unclear, but further studies involving 
this area appear warranted.
Are there any other recognisable differences between those that have an improvement in 
breathlessness with opioids than those who do not? Given the relatively small participant 
sample, the analyses in Section 4.4 and 4.9 were calculated to act as a guide for future 
research ideas rather than definitive evidence for effect in specific groups, though it 
would be helpful if one could identify characteristics to aid physicians to target patients 
who might respond better to opioids than others. Responders to opioids involved those 
participants that had an improvement of one point or more on average NRS 
breathlessness score with either or both opioid treatments, non-responders were those 
that did not. A one point change was selected as this has been identified as the minimally 
important clinical change in breathlessness (Powers and Bennett, 1999, Booth, 2006).
Overall there is little difference between demographic groups; in particular there is not a 
consistent opioid response dependent on NYHA status (one might expect those with 
more severe symptoms should respond better to opioids for breathlessness). From a 
diagnostic perspective, those participants with dilated cardiomyopathy respond well to 
opioids, but this participant group is small (n=3) and this may just represent a statistical 
anomaly. One might expect that those more severely affected by their disease might 
respond better to opioids. As can be seen from the correlation data, there appears to be no
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association between age or severity of disease as measured by BNP and ejection fraction, 
There would appear to be no association between severity of CHF as measured by NT- 
BNP and response to opioid medications for breathlessness. In particular, those most 
severely affected on the BNP scale (ie highest BNP) did not have a consistently greater 
response to opioids. Those participants with a worse renal function also do not appear to 
have a greater response to opioids, suggesting that they are adequately cleared from the 
body in these participants with a GFR of 30ml/min or greater.
Participant data was also divided into those that did not respond to either treatment 
versus placebo, those that responded to one and those that responded to both active 
therapies against placebo. Response was again determined as a difference of NRS 
average breathlessness severity change of one or greater for active treatment versus 
placebo (those with no difference or placebo favoured were grouped as no response). 
This again is a post-hoc analysis and therefore the analysis has not been included in the 
results section. However, there were no obvious major differences between those who 
responded to treatment and those that did not in relation to ejection fraction, BNP or 
PEFR. This is also true for values just taken from day 4 rather than a change in value 
with intervention (data not shown). Overall, no consistent aetiological factors such as 
disease severity or baseline demographic factors could be identified that could help 
clinicians target individuals for therapy with opioids for breathlessness using these 
methods.
8.5 Comparison with the analysis performed by Abernethy et a l  (2003)
Analysis was performed on the data in the same fashion as set out in the Abemethy et al
(2003) study to allow direct comparison of the data and outcomes between the two
studies. As seen in Figure 4.5.7, change in breathlessness scores from baseline to day 4
for each intervention may not accurately measure the participant experience, particularly
observed in those participants that favoured oramorph treatment at the end of the three
week period, yet their change in NRS or Borg scores did not reflect this. As discussed by
Pang et al. (2008), changes in subjective assessments such as breathlessness scores have
the problem that trial participants may not accurately recollect their previous rating. This
might mean that improvement or worsening of breathlessness may not be accurately
assessed if  recollection of previous scores is not correct, though this is a potential
problem for much longer duration trials than this RCT. Hence, an alternative analysis
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was considered in the thesis write-up based on a similar study in a different patient 
group.
Average shortness of breath scores might be considered as comparable if one took the 
premise that one point on an NRS is comparable to 10mm on a VAS score (Powers and 
Bennett, 1999). Hence the quoted means for scores in the Abemethy study (40.1 for 
morphine and 47.7 for placebo) are comparable to the average NRS breathlessness scores 
in this sample (mean 3.7 for oral morphine and 3.69 for placebo). Standard deviation for 
VAS in the Abemethy study was 24 for morphine and 26 for placebo; again this is 
comparable to the variability in this study (SD 2.4 for oramorph and 1.98 for placebo). 
The main differences appear to be that the mean difference between treatments for each 
participant was very low in this study compared to the Abemethy result. In addition the 
variability around the mean for the difference between active and placebo interventions is 
lower for the Abemethy study and does not cross zero, giving rise to a statistically 
significant result between morphine and placebo. This does not occur either for oramorph 
or oxynorm versus placebo in this study and hence the results are non-significant. 
Reducing the variability by increasing the sample size may lead to a statistically 
significant difference. Hence this RCT may be experiencing a Type II error effect (i.e. 
the sample size is too low to demonstrate a difference between interventions if such a 
difference exists), although such small mean differences Eire observed that a vastly 
greater number of participants would be required, if this is a true representation of the 
population, in order to achieve a significant positive result. It is encouraging to discover 
similar mean values for breathlessness severity between intractable breathlessness of two 
different aetiologies, however the magnitude of the placebo effect in this RCT resulted in 
no statistically significant difference between active treatments and placebo, whereas a 
smaller placebo induced effect on breathlessness severity was observed by Abemethy.
Performing this type of analysis in the manner of a published article in the British 
Medical Journal was not designed to detract from the analysis method set out in this 
protocol, but to allow discussion around analysis methodology in a similar study design. 
The Abemethy study (2003) has already been discussed in Chapter 3.
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8.6 Global impression of change in breathlessness and preferred week
When participants were asked whether they considered their breathlessness had changed 
over the course of that particular treatment at the end of the treatment period (their 
“global impression” of change in breathlessness), the mean and median response to 
active interventions was greater than that for placebo. The median scores in particular 
were greater with a median change of two for oramorph and oxynorm compared to no 
median change for placebo. A difference of two points corresponds to a “little better” 
response to the change of breathlessness over the course of that intervention. This 
difference in median scores demonstrates both a skew in the data, particularly for placebo 
given the mean value of 1.14, and an appearance that the study had a number of 
individuals that rated placebo treatment as having a particularly good effect and a few 
individuals that rated active treatment as having a particularly detrimental effect on 
breathing. One can observe this in the boxplot of global change comparisons (Figure 
4.4.4). Oramorph in particular has a long whisker in negative territory for global change 
indicating that a few individuals rated the response to oramorph as being poor for their 
breathlessness, lowering the mean value.
The response to placebo on the other hand, where there are a couple of outlying points 
that show a large placebo response, causes an increase in the mean value for these 
individuals. This is an important point in the analysis of a treatment for breathlessness 
that has a small potential improvement for patients with CHF. It is clear that some 
individuals considered that their breathing either got worse on active therapy or did not 
change enough for them to notice. It would be unusual for any treatment to have a 
dramatic effect on symptoms in all individuals. Does the lack of a significant mean 
difference in rating scores between oramorph and oxynorm and placebo mean that these 
interventions have no role in the management of breathlessness in CHF? Use of the 
median values in this instance may represent the true effect for the majority of the sample 
and demonstrates the possibility of an improvement in breathlessness in opioids 
measured by the global change scale.
Comparison of global impression of breathlessness change scores with interventions and
the preferred week analysis yielded some interesting results. Figure 4.5.8 demonstrates
that global impression of change scores appear to accurately reflect the patient
experience on the preferred week analysis in that participants that chose an individual
intervention independently rated that intervention as having the greatest improvement on
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global change score. It also demonstrates that some participants favour one opioid for 
breathlessness, but the other opioid was little different to placebo. This suggests that the 
practice of switching opioids may be useful in patients who do not appear to respond to 
one opioid, but may respond to another with a slightly different receptor profile. It would 
therefore seem to be important to try another opioid if the first opioid prescribed does not 
have an effect on a patient’s breathlessness.
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Section 9) Discussion: Comparison of breathlessness rating
What is the best way to capture the patient experience in a short trial of pharmaceutical 
intervention for breathlessness? During the study it became apparent that the rating of 
current breathlessness was not as discerning as either worst or average breathlessness 
ratings. This is demonstrated in the results, where the mode or most frequent response in 
participants for the current rating of breathlessness was zero and median value was only 
two (contrast average and worst ratings). The variability around the results as indicated 
by the standard deviation was similar for current as the other two parameters. The bar 
charts (Figures 4.5.1 and 4.5.2) further emphasise the point that current breathlessness 
does not follow the same distribution as average or worst breathlessness. This problem is 
particularly true for ambulant patients, who consider that they only feel breathlessness 
during or directly after movement and do not describe breathlessness at rest. The ratings 
were taken when participants were sitting at rest, hence this cohort of participants who do 
not consider themselves breathlessness at rest would score zero on current rating. This 
therefore would not change if their breathing improved on treatment and hence current 
rating would not be a useful measure in this circumstance. It would appear that current 
measures should be considered for movement-related trials of breathlessness (such as use 
of treadmills or exercise bicycles) and not interventional trials at rest in my experience.
Average and worst ratings of breathlessness did appear to be measuring different 
qualities of breathlessness and although some participants would occasionally score 
average breathlessness higher than worst (which is counter-intuitive), most understood 
that different modalities were under enquiry. Virtually all participants considered their 
worst breathlessness was during or after movement with showering, climbing stairs and, 
for the more severely affected, tying shoelaces and bending down being the most 
frequently reported activities to induce breathlessness. Future studies could make a more 
detailed enquiry, using patient narrative, as to the induction of breathlessness on 
movement and consideration sought to improving the patient experience at home by 
adaptations or aids appropriate to CHF patients with breathlessness. Consideration could 
be made for occupational therapist interventions such as hand-held “pick-me-ups”, 
Velcro shoes or stairlifts as examples.
Which of the two rating scales, numerical (NRS) or Borg scale for breathlessness should 
be considered for use in clinical trials of breathlessness in CHF? There appears to be
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little consensus in the existing literature as to which is the best scale to use in what 
situation and whether both are measuring the same quality of the breathless experience. 
The most commonly used scales for breathlessness in advanced disease are NRS, VAS 
and modified Borg (Bausewein et al., 2007). NRS scores have been shown to correlate 
highly with VAS scores (Gift and Narsavage, 1998, Powers and Bennett, 1999), but both 
NRS and Borg are considered to be as repeatable and as reproducible measures as VAS 
(Wilson and Jones, 1989, Wilcock et al., 1999, Grant et al., 1999). There is a gap in the 
knowledge here. Firstly, NRS and Borg scales have not been compared in breathlessness 
outcomes thus far. Secondly, comparison of breathlessness scales has not occurred in 
CHF, as the above examples have concerned cancer-related breathlessness or 
breathlessness in normal individuals. It is considered that NRS scales are easier to use 
than VAS and are preferred by patients (Powers and Bennett, 1999), so comparison of 
NRS and Borg scores in CHF is important if these are the easiest scales to use and have 
the ability to be used over the telephone (unlike the VAS score).
The NRS scale is designed as an eleven point discrete quantitative scale of gradually 
ascending severity. The Borg scale has been designed as a similar discrete scale with a 
verbal description of the severity of breathlessness next to the numerical rating and has a 
graduated incremental quality whereby a rating of 4 is twice as severe as a rating of 2, or 
a rating of 2 is twice as severe as a rating of 1 (Bausewein et al., 2007). This is not the 
case for the numerical scale. This allows a comparison of scales. For example if a study 
quoted breathlessness severity on a Borg scale, what would that severity be on an NRS 
scale and vice-versa? It would be useful if one was familiar with one scale and not the 
other to be able to have a calculation of comparison of scales to allow one to understand 
the potential impact of the findings and whether those findings were representative of 
previous trials that have reported an outcome using the other rating strategy. To the best 
of my knowledge, no study has been published in CHF that addresses this important 
quality.
Correlations for Borg and NRS for each parameter of breathlessness rating (Average, 
Worst and Current) showed a high degree of statistical significance between scores. 
Cumulating the scores from these three parameters allows a greater sample number to be 
compared between Borg and NRS, which similarly shows a very high degree of 
statistical significance between Borg and NRS rating for this cumulative scoring. A 
linear relationship between NRS and Borg is observed up to and including a Borg score
of 5 (severe) with a reasonable degree of separation between mean values. For a given
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Borg score up to 5 (severe), none of the 95% confidence intervals for mean values of 
NRS overlap, indicating statistically significant associations. Hence one can observe that 
a Borg score of 2 (slight) for breathlessness approximately equates to a score of 3 on 
NRS, a score of 3 on Borg (moderate breathlessness) translates to 5 on NRS and a score 
of 5 on Borg (severe) equates to a score of 7 on NRS for breathlessness. As higher values 
are reached of Borg, the decreasing number of samples result in higher variability and 
less confidence of the true mean value.
Similarly, for a given value of NRS, mean Borg scores follow a similar near linear 
distribution with very little overlap of 95% confidence intervals for the mean values of 
Borg for a given NRS score. Hence, a score of 3 on NRS can be translated as a score of 2 
(slight breathlessness) on Borg, 5 on NRS equates to 3 (moderate) on Borg and 7 on NRS 
translates to a score of 4 (somewhat severe) on Borg. What is interesting here is that a 
high score on NRS (9 out of a maximum of 10) only translates to a score of 5 on Borg 
(severe). The NRS scale is at its maximum at 10 and therefore cannot exceed this level. 
This suggests that NRS scoring should be used for studies with a lower expectation for 
the severity of breathlessness and that Borg scores should be used for studies with a 
higher degree of symptom severity. Conversely, NRS may be better for lower scores for 
breathlessness, as it can determine more subtle changes at lower levels than for Borg.
The high degree of separation of points on both scales allows a reasonable comparison 
between rating scales, so that studies that involve one scoring system could be interpreted 
and compared with studies that involve the other method of scoring.
Linear model equations were generated for a given Borg or given NRS for 
breathlessness. These models are shown below and appear to produce a close 
approximation to the actual mean values described in the sample.
For a given Borg score converting to NRS: NRS score = 0.945 + (1.202 x (Borg score)) 
For a given NRS score converting to Borg: Borg score = 0.336 + (0.543 x (NRS score))
O f course, i f  there w ere a greater amount o f  data, the variability w ould  be reduced around
the true mean values and a better set of linear regression equations could be calculated
(though calculations incorporate 1365 responses in total). Rather than producing an exact
value for Borg or NRS therefore, they should be used to determine approximate values
on each scale when compared to each other. This then allows comparison between
quoted NRS or Borg results in the literature, not so exact to the mean values described
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and although modelling equations are useful, tables of the mean values seen may be more 
accurate.
Do average NRS or Borg breathlessness scores measure change in breathlessness 
accurately? This is impossible to tell, but comparison of scores compared to the 
participant-rated preferred week gives one an interesting insight. Participants were asked 
to rate which week they preferred the most for their breathlessness at the end of the study 
and were invited to continue on open label therapy on that basis. Participants who stated 
they preferred the week corresponding to oramorph did not rate that week very highly 
over and above the other two interventions, unlike those that preferred the oxynorm or 
placebo week for their breathlessness. Although this outcome may have occurred simply 
by chance, it shows that the differences in outcome between the three interventions are 
small even in those who stated a preference for a particular intervention.
It also demonstrates two other points. Firstly, those participants who favoured oramorph 
for breathlessness did not rate oxynorm highly and vice versa, particularly on global 
impression of change (Figure 4.5.8). In clinical terms, this might allow the opioid 
switching of therapy as occurs in pain management. For some individuals, oramorph 
might be poorly effective for their pain, or cause side effects at specific doses. Switching 
to an alternative opioid such as oxynorm may allow better symptom control (Quigley, 
2004). This is also true in reverse for oxynorm to oramorph and may be due to individual 
variation to opioid medications. What is clear from Figure 4.5.8 is that participants might 
not respond to one type of opioid, but may to another. Hence any trial of therapy in 
clinical practice may benefit from consideration of an opioid switch should initial 
treatment prove ineffective for that individual for breathlessness.
Secondly, global impression of change more accurately predicts a participants’ preferred 
week of treatment than change in NRS average breathlessness scores (Figures 4.5.7 and 
4.5.8). This might support the theory that NRS average breathlessness measures are not 
correctly recording the actual change in breathlessness process on treatment. In addition 
to the large placebo response in a few individuals and negative response in a few 
individuals to active treatment, this may have a role in the neutral outcome in 
breathlessness severity in the trial. If participants knew their previous NRS or Borg 
scores, would this outcome change? One might expect that knowledge of previous scores 
might result in a better association between preferred week for breathlessness and NRS
or Borg rating. Certainly, the change in NRS scores contrasts to those seen with global
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impression of change scores, which do associate with the patient rated preferred week. 
Using day 4 values only rather than change in NRS scores should perhaps be used to 
provide a more accurate representation of response, as these values in breathlessness do 
correspond to the week preferred for breathlessness by participants at the end of the study 
in a similar fashion to global impression of change in breathlessness. As Bland & Altman 
(2007) correctly describe, measurement errors involved in calculating differences from 
baseline have the potential to influence outcome. This may be the factor behind the 
anomaly of the oramorph change in breathlessness score with preferred week using this 
method compared to global change or day 4 NRS values alone (Figures 4.5.7 to 4.5.9)..
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Section 10) Discussion: Secondary outcome measures
10.1 Secondary outcome measures: Additional components of shortness of breath
Additional components of shortness of breath, namely satisfaction with treatment, coping 
with breathlessness and distress caused by breathlessness were analysed as surrogates for 
breathlessness improvement in addition to direct questioning about breathlessness 
change. No significant differences were noted with change in these parameters between 
the three interventions. Improvements in distress rating and coping with breathlessness 
were most notable for oxynorm and placebo, whereas satisfaction with treatment was 
best for oramorph and placebo.
Participants found responses to these parameters with varying degrees of certainty. 
Frequently, participants would state that they were not “distressed” by their breathing, 
but nonetheless did find the condition problematic. Most participants stated that they 
coped “pretty well” with their breathlessness at baseline and therefore any change in this 
parameter was not particularly discriminatory. The satisfaction scoring question had 
interference from how the participant felt with the conduct of the trial, rather than 
satisfaction with the intervention. Participants also found satisfaction with existing 
therapy at the start of each intervention difficult to quantify, as many did not consider 
that they were on existing therapy to manage breathlessness. One could infer that their 
existing treatment for CHF managed breathlessness by preventing a worsening of the 
disease process, but participants did not make this inference themselves and did not find 
this question easy to answer at baseline. Hence the value of these questions in their 
current form, in language or statements that CHF patients may find difficult to 
comprehend in the manner intended, should be put under scrutiny as useful adjuncts to 
breathlessness scoring.
10.2 Secondary outcome measures: Quality of Life (QOL) change
The SF-12 measure (acute version) was utilised to assess quality of life in this sample of 
CHF patients. The individual scores given are recalculated into separate domains and this 
was performed using the SF-12 Users manual (Ware et al., 2002). Further calculation 
allows the determination of physical and mental components of quality of life. The
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authors of the SF-12 have based their calculations on the general US population and a 
mean value of 50 out of 100 represents the mean value for the average population.
Hence, lower values than 50 are lower than the average for this US population sample, 
higher values representing a better than average score.
The mean values for this sample of 35 patients with CHF were 28.15 for the physical 
components and 47.34 for the mental components of quality of life. Both mean values are 
given out of a maximum score of 100. According to Ware et al (2002), the physical 
component value is lower than two standard deviations away from the standard 
population mean (50/100). This suggests that CHF patients in our sample are 
compromised in their quality of life predominantly due to physical restrictions, rather 
than adverse psychological effects of disease. The mental or psychological component 
mean scores are little different to the typical average for the US population upon which 
the scoring system is based.
The SF-12 manual also quotes mean physical and mental component quality of life 
scores for heart disease in general based on 678 patients. Physical mean component 
scores for heart disease are quoted as 39.16 out of 100, whereas mental component scores 
are quoted as 47.00 (Ware et al., 2002). This suggests that our sample of CHF patients 
specifically rate their overall quality of life lower than the standard for heart disease, 
predominantly through physical rather than psychological limitations.
None of the three interventions caused a significant change in any of the domains of 
participant reported quality of life. However, this is unsurprising for the three week 
component of the study and change over time with treatment will be more revealing 
rather than very short term changes.
10.3 Secondary outcome measures: Observation data
It could be argued that part of the reluctance to use opioids in CHF patients derives from 
historical evidence of either adverse cardiovascular changes or respiratory depression. 
Both of these properties would be considered as potentially detrimental in this patient 
group. It was therefore important to note changes with treatment at doses considered 
clinically relevant for breathlessness management. Historically, data on the effects of
opioids on a population have involved the use of large doses of drug administered
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intravenously in normal participants free from disease. This data is then extrapolated to 
different patient groups as a justification for use of the drug or to prevent its use (see 
Chapter 2). The data presented here provides evidence that suggests that there is little 
effect of oral opioids in the short term on pulse, blood pressure, respiratory rate or 
oxygen saturations at these doses in CHF patients. The analysis incorporates both 
immediate effects within one hour and over the four day treatment period. Results for the 
three month follow-up on opioids are detailed in Chapter 5.
Treatment with oramorph derived the largest mean fall in blood pressure (5mmHg) at the 
end of the intervention period compared with oxynorm and placebo. This effect appears 
to manifest itself over time as one hour follow-up data does not support the magnitude of 
this fall as an initial response. Is a fall of this magnitude clinically significant? As 
detailed in the side effect profile, oramorph did have more episodes of associated 
dizziness on treatment and this may be manifested by a fall in blood pressure. One could 
argue therefore from this sample that oxynorm may be the better opioid to use in patients 
with low blood pressures as the fall in blood pressure is smaller than that for oramorph in 
this patient sample, even though the differences are small. Changes in all respiratory 
parameters (respiratory rate and oxygen saturations on air) are minimal for both opioids 
versus placebo and do not support the notion that opioids are detrimental on respiratory 
function in these oral doses.
These findings are supported by the study by Allen et al. (2005) in 11 patients with 
pulmonary fibrosis. A clinically equivalent dose of 2.5mg diamorphine given 
intravenously to elderly opioid naive patients did not cause significant reductions in heart 
rate, respiratory rate, systolic blood pressure or oxygen saturations at 30 minutes post 
dose compared to baseline, although the magnitude of the reductions seen in blood 
pressure and heart rate surpass those seen in this RCT. Similarly, Mazzocato et al. (1999) 
revealed no significant differences in cardiorespiratory observations with a higher dose of 
subcutaneous morphine (5mg) in seven opioid naive patients with cancer. From the data 
in the present study, opioids are safe to use clinically in CHF and do not appear to 
interact with concurrent anti-CHF medications at the doses described.
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Table 4.6.4 displays the adverse effect profile for each intervention. The differences in 
NRS between baseline (day 1) and day 4 for both nausea and drowsiness demonstrate a 
worsening of those symptoms for oramorph. This effect is not seen for either oxynorm or 
placebo. The differences are not statistically significant between treatments except for 
nausea, but if  oxynorm and oramorph had similar effects on breathlessness, one might 
choose oxynorm as the drug of first choice if  it produced less in the way of adverse 
events. Similarly the number of other patient volunteered adverse events possibly, 
probably or definitely associated with treatment were higher for oramorph than for 
oxynorm or placebo. Typically these involved the kinds of adverse events normally 
associated with opioid therapy, such as itch, vomiting, sweating, dry mouth and 
lightheadedness. It has been noted that oxynorm has a different side effect profile to 
oramorph, particularly for the incidence of opioid-induced itch (Kalso, 2005). Given that 
the frequency of these adverse events was notably higher for oramorph than oxynorm, for 
similar levels of breathlessness improvement a clinician may choose to prescribe 
oxynorm first line if  for no other reason than toleration of therapy at these doses.
Constipation was difficult to measure in the study and day 4 comparisons have been 
given between treatments, rather than a change in bowel habit between days 1 and 4 of 
treatment. This approach has been taken in part to simplify the overall outcome to allow 
easy comparison between interventions. In addition, constipation is a symptom that may 
not be fully resolved as part of a short washout period between interventions. Although 
the active drugs themselves will have been cleared from the body, their effects on a 
symptom like constipation in a population whose bowel habits may be sluggish in the 
first place may carry-over into the next week of treatment and may therefore affect the 
overall results if  days 1 and 4 of the next therapy are compared. The three month follow­
up data may reveal a trend to constipation on those continuing active treatment and may 
be a better indicator as to whether constipation becomes a problematic symptom on 
active therapy (Chapter 5). The only serious adverse event documented in the study 
occurred during placebo and was not considered to be related to the trial interventions.
10.4 Secondary outcome measures: Side effect profile
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10.5 Secondary outcome measures: Physical function
The Kamosfky tool was utilised to assess change in performance status in the trial 
participants. As the results show in Section 6.5, there are little differences over the short 
course of intervention using this method of assessment. As with change in QOL, the 
main outcome measure envisaged for this assessment was change over 3 months of 
intervention to allow change to occur over time. So, as expected, little immediate change 
is observed on intervention. A slight trend towards benefit is seen with oramorph in 
particular compared to placebo, but this improvement is very small and not likely to be 
clinically significant. The assessment is also physician rated, and although blinded, 
remains a proxy assessment of physical function based on what the physician is told by 
the participant.
10.6 Compliance
Compliance, or concordance with medications, is difficult to measure. Two attempts 
were made to estimate the degree of non-compliance in the trial. Firstly, participants 
were asked daily whether they had missed any doses of trial medication. Reasons for any 
missed doses were not sought. Similar numbers of missed doses were noted for both 
active treatments with less for placebo. Some participants may have simply forgotten to 
take their medicine which allows for a certain degree of non-compliance, but the greater 
number of episodes on active treatment suggests that side effects were also partly 
responsible. Overall, compliance with intervention as measured by this method was high.
Participants may be unwilling or unable to volunteer whether they had missed doses of 
medication, which suggest that simply enquiring whether they had missed doses may 
lead to an exaggerated assessment of overall compliance. The residual volumes from 
each week were also measured when the trial bottles were collected. Accurate monitoring 
of residual volumes relies on factors such as collection of the residual amounts without 
tampering to the contents (such as washing the bottle out by accident) or by accidental 
spillage. Using the measurement of residual volumes did not show any differences 
between the active interventions or the placebo. One might expect that non-toleration of 
active therapy may lead to reduced compliance. However, this might be counterbalanced 
by the possible effectiveness of active treatment, whereby participants may be tempted to
take more of a medication they find helpful for breathlessness during the washout phase.
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In any case, compliance overall was high and the study results were not influenced by 
non-compliance by a few individuals.
10.7 Secondary outcome measures: Breathlessness descriptors
Breathlessness descriptors provide useful additional information regarding the language 
of dyspnoea, which is a complex symptom to quantify and describe. Most trials, 
including this one, have a primary focus on breathless severity, but there is growing 
recognition that the patient experience also involves the quality of the sensation and that 
common physiological mechanisms may operate in generating the patient experience of 
breathlessness in respiratory disease (Smith et al., 2009). Descriptors can be grouped into 
clusters, which have been modified by different authors since their inception. The 15 
item descriptions most commonly used in CHF by Mahler et al. (1996) and Simon et al. 
(1990) are the same, but their entry into different clusters áre different (Garrard and 
Williams, 2008). Given this discrepancy, I have not used clustering in the primary 
analysis but simply quoted the individual descriptions expressed. Comparison of the data 
with some of these clusters will be performed later.
A total of four previous studies have detailed the nature of breathlessness descriptors in 
CHF, involving a total of 82 patients. Hence, this current RCT represents the largest 
study of breathlessness descriptions in stable CHF thus far (n=35). The most common 
descriptions from these trials are described in the Table 4.10.1 below. An X has to be 
provided in the columns for Simon et al. (1990) as no numerical detail is available from 
their paper.
237
Table 4.10.1: Frequency of breathlessness descriptor responses or the four trials that 
involve CHF patients
Descriptor Simon 1990 
(n=5)
Mahler 1996 
(n=17)
Wilcock 
2002 (n=30)
Caroci 2004 
(n=30)
Most
common
described
Rapid X 3
Not out all 
way
5 4
More work 10
Constricted 3
Shallow 9
Effort X 8 16 X
Hunger X 10
Smothered X 11
Heavy X 7
Out of breath X 6 17 17 X
Not in all 
way
5 7
Tight 5 10 9 X
Unable to get 
enough air
X 10 19 X
Breathing
more
6
Suffocating X 11
Simon and colleagues (1990) describe five patients with CHF in their study, though at 
the time of data collection two of those had acute symptoms and probably do not have 
the same experience as those with stable CHF. Their paper does not define actual values 
for the descriptors proposed by the patients and a list of 19 was originally used, revised 
down to 15 in the final outcome. However, the “best three” responses were selected out 
by the study authors. Eight descriptors were selected out by the study authors and it is 
difficult to draw conclusions from this, as only 15 responses in total would be expected 
from 5 participants.
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Mahler et at. (1996) move forward from this initial study and involve a total of 17 
participants with CHF asked to rate their best 3 of 15 descriptors. Most frequent 
responses involve the work and effort of breathing, corresponding well to the data in 
Section 6.7. They attempt to devise clusters of descriptions, whereby responses that are 
commonly volunteered together, or that appear to reflect a similar participant experience 
are grouped into defined clusters. This appears to work well for smothering and 
suffocating (the “suffocating” cluster), breathing requiring effort, more work, inability to 
get enough air and feeling out of breath (the “work/effort” cluster) and my chest is tight 
or constricted (the “tight” cluster). The “work/effort” cluster contains four of the top six 
responses in Section 6.7, hence it would appear that this cluster represents a good fit to 
the patient experience in CHF. Clustering becomes less significant for other responses in 
the analysis by Mahler, which makes their overall use difficult as it appears that some 
responses have a better association in a cluster than others. Hence certain clusters can be 
open to some debate as to which descriptors are incorporated and this occurs with all four 
o f the studies quoted here.
The study by Wilcock et al. (2002) was designed to compare descriptors between 
different patient groups. Participants with CHF (n=30) described feeling out of breath 
(57% of respondents), chest tightness (33%) and inability to get enough air (33%) as 
being the three most frequently selected responses. Unfortunately, there is no other data 
quoted as to the frequencies of the other descriptors for CHF. Again, participants 
described all descriptors that applied to them, but these responses were reduced to a “best 
three” per participant for the purpose of analysis. The descriptor “I cannot get enough 
air” was common to patient groups of all aetiologies in their study. Similarly, inability to 
get enough air was prominent in this RCT, but “feeling out of breath” was the most 
prominent descriptor for our CHF patients. This concurs with Wilcock, whose most 
prominent descriptor in CHF was also feeling “out of breath”.
The article by Caroci & Lareau (2004), designed as a comparison between patients with
COPD and CHF, does not appear to have used descriptions in the same way as this
current RCT or the other trials quoted, as the total number of descriptions should total 90
(3 given by each of the 30 CHF patients) instead of the total number described in their
table (142 responses). I suspect that patients were asked to volunteer which of the 15
descriptors applied to them, without a necessity to select three descriptors only. Hence
this study can be used as a reference point, but cannot be directly compared to studies
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that have kept to the total of three rule as a greater number of references have been 
selected by a number of different individuals. Of course, we do not know whether some 
individuals selected fewer than 3 descriptions and whether some selected almost all of 
the descriptions. This approach may give a sense of the patient experience, but having 
three descriptors for each patient allows equal weighting of responses for each patient, 
rather than in their analysis whereby one patient who only scores one descriptor has a 
tenth of the weighting in the results to one that describes 10 descriptors. Inability to get 
enough air, feeling out of breath and breathing requiring effort are the most frequent 
responses, which concurs with the most popular choices in the RCT.
Although it is difficult to draw accurate conclusions from the four studies above the most 
frequently volunteered descriptions in CHF are; my breathing requires effort, my chest 
feels tight, inability to get enough air and feeling out of breath. This compares to the four 
most common descriptions in the RCT, all greater than 10% of all responses, and two of 
which that correspond to the literature overall, namely; effort, more work, out of breath 
and breathing is shallow. Inability to get enough air is relatively common in our sample 
(7.5% of responses), chest tightness is lower than 5% but the more commonly associated 
descriptions in the early literature with breathlessness in CHF, smothering and 
suffocating, only represented a total of less than 2% in our sample. Clustering responses 
appears to make a prominence of the breathing work and effort cluster in our sample of 
CHF patients.
Requesting breathless descriptors had a number of practical problems in the trial. One 
potential problem would be that of using exactly the same list in the same order of 
response, whereby participants may always choose descriptors at the top of the list as 
they read through if they feel they apply. This is not the same as which descriptors best 
reflect the participant experience. By ensuring that the sequence is delivered in a purely 
random order (using randomisation.com for the random sequences) this ensures that the 
order of descriptors has no bearing on the overall selection of descriptors.
If participants considered their breathing had improved markedly, they were unable or 
unwilling to give descriptions, and it is unclear as to how this should be managed in the 
analysis. Also, as described previously, participants at rest might not consider themselves 
breathless, so descriptions of current breathlessness caused some consternation with 
some participants. One way round this to provide greater clarity may be to ask for their
three descriptions as they are today, rather than the prompt “right now”. The analysis of
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descriptions have involved all baseline descriptions or all changes in descriptors with 
treatment. It should be considered that in this analysis the same 35 participants have 
responded and given the apparent consistency of response care must be taken in the 
interpretation of the results, since the same patient may have responded in the same way 
on multiple occasions, leading potentially to a source of bias. However, allowing all 
responses to be analysed allows a greater number of responses to be compared, allowing 
the potential for greater clarity and inclusion of greater amounts of useful data.
What is interesting in this RCT is that there is a consistency in response to breathlessness 
descriptors over time and with different interventions, as evidenced by the bar charts for 
each intervention. Some descriptions changed with active therapy, notably inability to get 
enough air, chest tightness and shallowness of breathing for both active interventions and 
being out of breath and air hunger becoming less prominent for oxynorm and oramorph 
respectively. This is an interesting outcome as chest tightness, inability to get enough air 
and feeling out of breath are prominent descriptions for CHF in the literature and in 
addition shallowness of breathing is also prominent in our sample. This might suggest 
that, from use of descriptors alone, opioids may be influencing the underlying 
mechanisms behind shortness of breath in CHF.
Breathing requiring more work or effort however appeared not to be changed by opioid 
therapy at day 4. Lansing et al. (2009) suggest than descriptions of work and effort of 
breathing are more associated with peripheral respiratory factors such as muscle fatigue 
and respiratory nerve afferents rather than increased chemoreceptor drive, which, it is 
suggested, is more compatible with the sensation of air hunger. Although these 
descriptions are prominent in our sample, they are little changed by opioid therapy, 
which might suggest that opioids have the potential to alter perception of breathlessness 
at the peripheral respiratory level given their receptor locations as described in Chapter 2, 
but in practice do not affect this area of the cardiorespiratory pathway.
The differences here are small and overall one can see that there is a good degree of 
consistency of response for each of the interventions (Figure 4.6.2). Hence the impact of 
opioids at these doses on the sensation of breathlessness as measured by breathlessness 
descriptors would appear to be small. One has to be careful in interpreting in change of 
breathless descriptions as their presence or absence does not indicate improvement or 
worsening, simply that the participant related emphasis is different, rather than the
complete absence of the previous description. Also, three descriptors are volunteered at
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each assessment, but there is no emphasis on the rating of those descriptions. It would be 
interesting to ask participants to grade the importance of each description in order to 
observe whether the relative emphasis changes with intervention in future studies.
For the first time, baseline values of NRS average breathlessness scores were compared 
to the descriptors given at baseline in CHF patients. In general, mean breathlessness 
severity was the same for all descriptors, however the description of suffocating in 
particular was associated with more severe breathlessness. This description was not 
frequently reported in this sample, so the score may be a chance finding. Descriptions 
such as breathing more, chest tightness and chest constriction were associated with less 
severe mean average breathlessness. Sadly, these are not amongst the most frequent 
responses in CHF in this sample. It would have been interesting to monitor response with 
treatment had the most common descriptions of breathlessness in this CHF sample 
(namely breathing requiring more work and effort, feeling out of breath and my breathing 
is shallow) had also been associated with more severe breathlessness scores. However, 
analysis of breathlessness severity and descriptors of breathlessness nevertheless gives an 
interesting insight into the potential relationship of breathing severity with patient 
experience and further studies should seek to address this in other populations.
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Section 11) Conclusion
This study is the largest RCT of opioid therapy for breathlessness in CHF, reaching the 
required number for statistical power, involving thirty five completed participants. 
Opioids appear to be safe to use in the doses quoted in CHF and are generally well 
tolerated as only two participants withdrew due to adverse effects from the thirty seven 
randomised. Breathlessness remains a problematic symptom in CHF, with respondents 
quoting a mean average breathlessness severity score of over five on an eleven point 
NRS in this representative sample.
No statistically significant differences were apparent for either opioid treatment versus 
placebo on NRS or modified Borg breathlessness severity scores. A large placebo effect 
was observed which may represent temporal changes or regression to the mean effects. A 
small improvement in breathlessness severity is apparent on global impression of change 
scores for opioid therapy over placebo, but again this improvement is not statistically 
significant. This indicates that there is little short-term benefit for opioid therapy for 
breathlessness over placebo. No specific characteristics of those participants who did 
respond to opioid therapy have been identified from assessment of disease severity, 
aetiological or demographic factors. However, responders to one opioid frequently did 
not respond to the other and vice versa. Hence, opioid switching may be useful in CHF 
patients who initially do not respond to one particular opioid. Oxycodone in particular 
was better tolerated than oramorph, with a lower incidence of reported adverse events 
and might be considered as the first line opioid to use.
For the first time, modified Borg scores and NRS scores have been compared for 
breathlessness severity in CHF. The modified Borg appears to be more useful to assess 
extreme values of breathlessness severity in very symptomatic disease, whereas NRS is 
more sensitive for smaller changes at lower values of breathlessness severity. Similarly, 
measurement of current breathlessness is less descriptive than average or worst 
breathlessness ratings due to its skewed distribution towards zero, which coincides with 
its modal value. Assessment of breathlessness descriptions were in keeping with other 
studies in CHF, with work and effort of breathing being prominent in responses in this 
sample. These descriptions did not dramatically change with opioid therapy.
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Although not formally assessed, it became clear during the trial that many participants 
had to adapt their lifestyle in accordance with their limiting symptoms. This adaptation to 
circumstance had a number of effects on activity, role, mood and self esteem. Some of 
these concepts were taken forward into the qualitative trial, involving different patients 
with CHF, as will be discussed in Chapter 6. All participants who completed the RCT 
were asked their preferred week of treatment for breathlessness. If this corresponded to 
an opioid medication, and the participant wanted to continue therapy, they were invited 
for further review at three months on treatment. Those that did not want opioid treatment 
or did not select their best week for breathlessness as an opioid week were invited back at 
three months as a control group. This open label treatment period forms the basis of the 
analysis in Chapter 5.
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Chapter 5:
Randomised controlled trial: Three month open label follow-up
250
Section 1) Introduction
Initial changes in breathlessness and related quality of life are important to measure with 
the introduction of a new therapy. The three-week RCT, involving a crossover of three 
interventions for four days each, monitored the initial changes in these parameters and 
proved the initial safety of opioids at small doses in CHF. However, in a clinical 
situation, it is likely that a patient may be exposed to a longer treatment course, 
especially when provided on an outpatient basis. Away from the research environment, 
patients may receive therapy on a trial period for a number of days or weeks to ascertain 
the efficacy of the treatment. This allows the patient to have a greater perception of 
symptom changes and whether continuation of therapy would be of benefit in their 
individual circumstance.
Continuation of open-label therapy in this way following a research trial bears a more 
similar relationship to the clinical environment. Clinically, patients are given a treatment, 
then assessed whether they perceive that treatment has been effective for them. 
Therapeutic efficacy may occur even if  the patient is experiencing a kind of placebo 
effect. Does this mean that treatments that have not been proved to be fully effective 
using RCTs be withdrawn from individuals even though they perceive a symptom or 
quality of life benefit? From the myriad of medications used in clinical practice, very few 
have been proven in their efficacy in well constructed RCTs, yet use of these medications 
persists on an individual basis for all manner of conditions.
This three month open label extension to the RCT allows a greater comparison with the 
potential use for opioids in the clinical environment. The aims were to assess the longer- 
term effects o f opioids on breathlessness, quality of life, physical function and safety in 
CHF. In addition, a longer follow-up period allows any changes to occur with therapy 
that might not be observed over a four day treatment period, such as neurohormonal 
changes. The open label follow-up may provide preliminary data that could be used to 
inform clinical trials in the future. No such trial has yet been performed over this time 
period for opioids for breathlessness in CHF. No requirement was made of participants to 
continue treatment in the active group. This was to allow greater comparison with the 
clinical situation observed in the case of a therapy not having a perceived beneficial 
effect when used on a trial basis in the management of symptoms.
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Section 2) Three month follow-up trial methods
Participants who completed the RCT were invited to proceed with therapy based on the 
description of their preferred week of treatment for breathlessness. This did not involve a 
review of the breathlessness scores made for each week or comparison of the global 
impression of change values. It simply relied on the participants’ recollection of their 
best week of breathlessness control. Participants could continue on the therapy selected if 
they wished to do so as long as it coincided with an active treatment. Those not wishing 
to continue or those that selected placebo on the de-blinding of their preferred week did 
not receive active treatment but were placed into a control group. Un-blinding needed to 
occur to allow the administration of a hospital prescription for opioid treatment 
(subjected to the scrutiny of any prescription for controlled drugs). Hence participants 
were not randomised into active and control groups but instead were self-selected.
After three months all participants were invited to attend for one final assessment of 
breathlessness scores, quality of life scores, physical observation assessment, impression 
of therapy and overall change in breathlessness. A BNP blood sample was also requested 
to compare with baseline values. Those participants who were initially in receipt of open 
label therapy, but then either declined to take it, or did not take it regularly, were still 
classed as being in the treatment group. This allowed the principle of intention to treat to 
be observed. Those that did not receive open label treatment remained in the control 
group. The active and control group assessments were compared using t-tests for 
independent samples (compare the RCT analysis) where the data was normally 
distributed, or Mann-Whitney U tests for non-normal continuous data.
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Section 3) Three month follow-up results: Descriptive data of those that continued 
therapy and those that did not
Thirty-three participants allowed one further assessment to occur at 3 months as shown 
in Figure 5.3.1. Of which, 13 participants had continued to take the trial medication on an 
open label basis. Eight of these participants still took regular treatment for breathlessness 
either TDS or QDS; five participants took open label treatment on an as required basis at 
the time of assessment. Of these five, two did not continue with treatment due to 
potential adverse events (abdominal cramps, diarrhoea). Twenty participants did not 
continue with open label therapy at the time of assessment. Two participants were lost to 
follow-up, one had moved abroad and the other declined further assessment. One of these 
had continued on therapy, one had not.
Of those continuing therapy, seven were prescribed oxynorm and six were prescribed 
oramorph. Due to the small numbers involved, the data for those continuing therapy was 
analysed mostly as a single group with a few exceptions. No significant differences were 
noted for the response to oramorph or oxynorm as individual medications, probably due 
in part to the small sample sizes involved.
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F igure 5 .3 .1 : Participants in the three m onth  fo llo w -u p  op en  label trial
The demographic properties of participants that continued with opioid therapy and those 
that did not are shown in Table 5.3.1. In particular, there was no difference with age or 
gender, but participants with a higher ejection fraction, higher BNP concentration and 
those with poorer renal function were more likely to continue. Mann Whitney U tests 
revealed a statistically significant difference with estimated renal function (eGFR) for 
continuers and non-continuers (Z = -2.08, p = 0.04), though a non-significant result was 
observed for ejection fraction and baseline BNP concentrations between these two 
participant groups (Z = -1.68, p = 0.09 for ejection fraction and Z = -1.00, p = 0.32 for 
BNP). Non-parametric tests did not reveal any difference between beta-blocker dose or
2 5 4
ACEI/ARB dose and whether participants continued or not (Mann-Whitney U test: Z = -
0.55, p = 0.59 for beta blockers; Z = -0.39, p = 0.73 for ACEI/ARB).
Table 5.3.1: Demographic properties of participants that continued with opioid therapy at 
the end of the original RCT (n=13) and those that did not (n=20)
Demographic property Continuers Non-continuers
Mean Age (years) 71.8 71.9
Gender M = 10, F = 3 M = 18, F = 2
Aetiology IHD = 7; DCM = 1; IHD / 
hypertension = 5
IHD =17; DCM = ; IHD/ 
hypertension = 2
Mean EF (%) 34.7 (SD 7.0) 31.5 (SD 5.6)
Mean eGFR (ml/min) 47.3 (SD 17.6) 59.1 (SD 19.5)
NYHA Grade III = 10, IV = 3 III = 19, IV = 1
Baseline BNP (pmol/1) Mean 243.3 (SD 281.6) Mean 208.5 (SD 273.7)
BNP concentrations were taken at the three month assessment and compared to baseline 
levels for those 33 participants who completed the three month visit to assess the effect 
o f opioids on BNP. Figure 5.3.2 shows the BNP difference between these two points for 
those that continued opioid therapy (n=13) and those that did not (n=20). Positive values 
represent a worsening of BNP concentration. Mean values were 60.6 pmol/1 (SD 242.0 
pmol/1) and 36.2 pmol/1 (SD 86.7pmol/l) for opioid continuers and non-continuers 
respectively. However, given the extreme outlier in the active treatment group, median 
values may be more representative. The median change for the opioid continuers was -
2.2 pmol/1, whereas non-continuers had a median change in BNP of 4 pmol/1.
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Figure 5.3.2: Boxplot to illustrate the change in BNP concentrations (pmol/1) between 
baseline and three month follow-up for those that continued opioid therapy (n=13) and 
those that did not (n=20)
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Section 4) Three month results: Primary outcome measure: change of 
breathlessness severity
4.1 Change in NRS and Borg breathlessness measures
Comparisons were made for worst and average ratings of breathlessness between the first 
participant baseline visit and those taken at the end of the three month follow-up period. 
Mean values for change in breathlessness measures over this period are shown in Table
5.4.1 for those continuing on treatment and those not. Negative values indicate a 
worsening of the symptom over time. In addition independent samples t test results and 
Mann-Whitney U test results are also shown for comparison of continuers with non­
continuers. Normality is not assumed and although NRS and Borg measures for average 
and worst tend to show a near-normal distribution, this might not be assumed given the 
small sample size and hence the less powerful non-parametric measures have also been 
given for completeness.
Table 5.4.1 : Change in mean breathlessness severity scores from day 1 baseline of the 
RCT to the end of the three month open label extension for those that continued opioid 
treatment and those that did not
Change in score (day 1 baseline to 3 
month follow-up)
Continuers (n=13) Non-continuers (n=20)
NRS Average breathlessness: Mean 
difference (SD)
2.00 (3.37) 0.00 (2.13)
NRS Worst breathlessness: Mean 
difference (SD)
2.54 (3.04) 0.15(2.54)
Borg Worst breathlessness: Mean 
difference (SD)
1.81 (3.26) 0.50(1.81)
"Borg Average breathlessness: Mean 
difference (SD)
1.31 (2.18) -0.08(1.31)
Greater variance as detailed by the standard deviation is noted for the group continuing 
treatment due in part to the smaller sample size in that group. Mean differences for Borg 
are lower than for NRS, which can be explained with the comparative work involving 
NRS and Borg shown earlier in Chapter 4 Section 5. Although there is a trend to
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improvement in these breathlessness measures, for all continuers the outcomes are not 
statistically significant except for worst NRS breathlessness, shown in Table 5.4.2. This 
may be due to the comparatively small sample size. Non-parametric tests to assess 
difference between treatment outcomes at three months did not show any statistically 
significant differences between oramorph and oxynorm for NRS and Borg outcomes, 
though it should be noted that the numbers involved are small.
Table 5.4.2: Statistical tests for the comparison of the change in breathlessness severity 
scores from baseline to the end of three month follow-up for those that continued opioid 
therapy (n=13) and those that did not (n=20)
t statistic p value Mann Whitney U p 
value
NRS Average 
breathlessness’
-1.91 0.07 Z = -1.72 (p = 0.09)
NRS Worst breathlessness -2.51 0.02 Z= -2.42 (p = 0.02)
Borg Worst breathlessness -1.33 0.20 Z =-1.07 (p = 0.29)
Borg Average 
breathlessness
-1.84 0.08 Z =-1.30 (p = 0.19)
4.2 Change in breathlessness scores on active therapy
Does the effect on breathlessness severity become greater or does it reduce over time on 
active treatment? In order to investigate this, comparison has been made with day 4 
scores and three month scores on those continuing active treatments. Seven participants 
continued with oxynorm and six with oramorph therapy.
Table 5.4.3 below describes the change in breathlessness over time for those continuing 
on treatment between the day 4 values for that particular drug at the end of the RCT 
phase and the three month follow-up results (n=13). Negative values represent a 
deterioration in breathlessness score over this period. Greater differences are observed 
with the NRS scores compared to Borg, in keeping with the previous comments.
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Table 5.4.3: Comparison of breathlessness severity scores from the end of the treatment 
phase in the RCT for that drug (day 4) and the end of the three month open label follow­
up phase for those receiving active treatment (n=13)
NRS average NRS worst Borg worst Borg average
breathlessness breathlessness breathlessness breathlessness
change change change change
Mean -1.15 -1.08 -0.42 0.00
Median -1.0 -1.0 0 0
SD 1.28 1.55 1.00 1.19
There are no differences between treatments (oramorph and oxynorm) over this period. 
The data is not shown as the numbers are small (n=7 for oxynorm and n=6 or oramorph) 
but there would appear to be little difference between the treatments in terms of 
breathlessness measure improvements between day 4 and three months of treatment.
Though there is a reduction in the effect of treatment over the three month treatment 
period, if one compares the non-continuers scores at three months with their placebo day 
4 scores, the worsening of breathlessness scores over time is more marked with the non­
continuers compared with those that continued with active treatment. This point is 
illustrated in Table 5.4.4. In particular, scores for worst breathlessness for non-continuers 
are much worse over the three month time period.
Table 5.4.4: Comparison of breathlessness severity scores from the end of the treatment 
phase in the RCT for placebo (day 4) and the end of the three month open label follow­
up phase for those not continuing with active treatment (n=20)
NRS average NRS worst Borg worst Borg average
breathlessness breathlessness breathlessness breathlessness
change change change change
Mean -1.60 -2.70 -1.33 -0.80
"Median -1.0 -2.0 -1 -0.5
"SD 2.23 2.81 2.61 1.87
259
4.3 Global impression of change
Comparison for the global impression of change rating was made at three months from 
baseline for those continuing of treatment and those not, shown in Table 5.4.5.
Table 5.4.5: Mean and median global impression of change in breathing scores over 3 
months for those continuing opioid therapy and those not continuing treatment
Continuers (n=13) Non-continuers (n=20)
Mean (SD) 2.62 (3.36) -0.65(1.76)
Median 3 0
Continuers rated an improvement in overall breathlessness equating to a “moderate” 
improvement in global rating, whereas those not continuing noted a slight worsening of 
mean rating. Global impression of change is near normally distributed using a Q-Q 
normality plot (data not shown), and independent samples two tailed t-test between those 
continuing and those not reveals a statistically significant association (t -3.2, p = 0.005). 
Similarly, non-parametric Mann Whitney U tests show a p value of 0.005 if normality is 
not assumed. Hence the null hypothesis that there is no difference between continuers 
and non-continuers is rejected for global impression of change measures and it appears 
that those continuing have a statistically significant improvement in breathlessness at 
three months.
A comparison for those that continued with oramorph and those that continued with 
oxynorm was analysed for global change in breathlessness to assess the relative effects of 
both drugs on the improvement observed versus non-continuers. The mean score for 
oramorph (n=6) was higher than the mean score for oxynorm (n=7): 3.67 compared to 
1.71, but due to the sample size involved this difference was not statistically significant 
using non-parametric tests (Mann Whitney U: Z statistic: -1.16 p = 0.25).
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Section 5) Three month follow-up results: Secondary outcome measures
5.1 Change in additional components of breathlessness
Distress, coping with breathlessness and satisfaction with treatment were compared 
between baseline (day 1 treatment 1) and three-month follow-up for both continuing and 
non-continuing groups. Negative values indicate a worsening of distress at three months 
and an improvement in coping and satisfaction scores at three months. Mann Whitney U 
tests were used as the data were not normally distributed.
Table 5.5.1 Mean change in additional components of breathlessness scores from 
baseline to the end of the three month follow-up for those on opioid treatment and those 
not continuing with treatment. Mann Whitney U test results are given to show the 
comparison between these two groups.
Non-continuers 
(n=20) mean 
score (SD)
Continuers 
(n=13) mean 
score (SD)
Mann Whitney 
U Z statistic
Statistical
significance
Distress 0.80 (3.75) 1.31 (3.07) -0.30 0.77
Coping 0.30 (2.00) -Ö.85 (3.18) -0.82 0.41
Satisfaction -0.45 (3.46) -2.85 (3.63) -2.06 0.04
It can be seen in the above table that there is a statistically significant improvement in 
satisfaction with treatment in continuers compared to non-continuers and that distress 
and coping scores also improved with treatment but not by enough to reach statistical 
significance.
5.2 Change in quality of life parameters at three months
The physical and mental component scores for quality of life were calculated at three 
months for all 33 participants. The mean physical component score for all participants 
was 31.41 with the mean mental component score o f49.49 (both scores calculated out of 
100). Scores were also compared for those that continued with opioid therapy (n=13) and 
those that did not (n=20). Treatment with opioids resulted in an improvement in both
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mean physical and mental component quality oflife scores. For physical components of 
QOL, opioid continuers scored a mean value of 34.13 for physical components of QOL, 
compared to a mean of 29.65 for non-continuers. Similarly, mental component scores for 
opioid continuers were also higher with a mean of 53.18 for continuers and 47.10 for 
non-continuers. However, no statistically significant differences were noted between 
those that continued with opioids and those that did not (p = 0.097 and p = 0.105 for 
physical and mental component scores respectively).
Figure 5.5.1: Comparison of physical and mental component scores for those that 
continued opioid therapy and those that did not continue.
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To assess whether an improvement with physical components of QOL correlated with an 
improvement in worst breathlessness scores (often associated with movement), QOL 
scores were compared with NRS and Borg worst breathlessness severity. Spearmans 
correlation coefficients revealed no significant correlation between three month worst
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breathlessness scores on either scale with QOL physical function (data not shown; p=
0.11 for physical components and p=0.15 for mental components).
5.3 Change in observation data from baseline to three months
Results were compared for the three month continuers and non-continuers with therapy 
with the initial baseline (day 1 week 1 treatment) scores. The change in score was 
calculated for each participant (n=33) with means and standard deviations for each 
clinical observation under study documented in Table 5.5.2 below. Negative values 
represent an decrease in value over time. The standard errors and standard deviations for 
pulse and blood pressure in particular are large, indicating the variability of this small 
sample. These changes in observations are near-normally distributed (data not shown), so 
independent t test results were calculated between those that continued on treatment and 
those that did not. There is little difference in observation data between those on 
treatment and those not on treatment at three months and any small differences are not 
statistically significant at the 5% level.
Table 5.5.2: Change in clinical observations from initial baseline to the end of the three 
month follow-up period for those continuing with opioid therapy and those not 
continuing. T test statistics for independent samples are given for comparison of these 
two groups for each cardio-respiratory parameter
Non-continuers 
(n=20) mean 
change (SE
Continuers 
(n=13) mean 
change (SE)
t statistic Statistical
significance
"pulse -0.30(1.12) -0.31 (1.49) -0.004 0.97
Systolic BP 
(mmHg)
3.55 (3.29) -2.46 (5.53) -0.93 Ö.36
Diastolic BP 
(mmHg)
4.40 (3.08) -4.23 (6.57) -1.19 Ö.25
Respiratory
Rate
-1.40(0.73) -0.62(1.23) 0.55 Ö.59
~02 saturations 
(%)
0.80 (0.36) -0.46 (0.56) -1.89 0.07
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Although the numbers involved are small, the data was analysed to compare baseline and 
three month values for those participants who continued on oxynorm with those on 
oramorph. The table below displays this change in observation data and again negative 
values represent an decrease in the value of that observation over time.
Table 5.5.3: Change in clinical observations from initial baseline to the end of the three 
month follow-up period for those continuing with opioid therapy with oramorph and 
oxynorm. T test statistics for independent samples are given for comparison of these two 
groups for each cardio-respiratory parameter where appropriate. Standard errors of the 
mean are given in brackets
Oramorph 
(n=6) mean 
change
Oxynorm (n=7) 
mean change
t statistic Statistical
significance
Pulse (beats per 
minute)
0.83 (1.45) -1.29(2.52) -0.73 0.48
Systolic BP 
(mmHg)
-0.83 (7.42) -3.86 (8.57) -0.27 0.80
Diastolic BP 
(mmHg)
2.83 (7.25) -10.29 (10.27) -1.03 0.33*
Respiratory 
Rate (breaths 
per minute)
-2.00 (2.48) 0.57 (0.84) 0.98 0.36
02 saturations 
(%)
-0.33 (0.78) -0.57 (0.88) -0.20 0.84
*Mann Whitney-1LJ test more relevant to use, please see prose for explanation
Independent t tests were used for those values that were near normally distributed. For 
diastolic BP, the data was markedly positively skewed and therefore the non-parametric 
Mann Whitney U test should be used instead of t tests. From this analysis, the Z statistic 
is -7.14 with a significance value of p=0.48. On first appearance it would appear that the 
change for diastolic BP is markedly different for oxynorm than oramorph, with an 
apparent reduction of blood pressure of 12mmHg on oxynorm compared to oramorph. 
However, closer inspection of the data shows the skewness in the data, as evidenced by 
the boxplot below (Figure 5.5.2). This shows that the median difference is similar
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between the two treatments and that the mean for oxynorm is distorted by lower outlying 
points, and the oramorph mean is higher due to a single high outlier.
Figure 5.5.2: Boxplot to show the medians and interquartile ranges for change in 
diastolic blood pressure at three months compared to baseline values for participants who 
did not continue on active therapy (n=20) and those that continued oramorph (n=6) or 
oxynorm (n=7).
oramorph oxynorm non-continued
Drug
5.4 Change in Karnofsky performance status at three months
Does a continuation of opioid therapy result in an improvement in perfonnance status? 
Comparison was made between day 1 baseline and three month follow-up for continuers 
and non-continuers. Non continuers had a mean fall in Kamofsky status of 1.00 (SD 
4.47) whereas continuers had a mean improvement of 2.31 (SD 5 59) over the tl 
month follow-up period. The data was not normally distributed and non-parametric
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testing revealed a trend towards improvement with active therapy but ultimately no
statistically significant difference at the 5% level between continuers and non-continuers
(Mann Whitney U test; Z= 1.77: p = 0.07)
5.5 Breathlessness descriptors at three months
Comparison was made between continuers and non-continuers with regards to their 
descriptions of breathlessness at three months. The results are displayed in Figure 5.5.5, 
in keeping with the figures in the RCT analysis (Chapter 4 Section 6). However, a bar 
chart may not be representative here as there are unequal numbers in each group, 
distorting the frequencies. Hence pie charts have been produced to show the relative 
differences between descriptions for continuers and non-continuers (Figures 5.5.3 and 
5.5.4):
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Figure 5.5.3: Breathlessness descriptions from participants who continued on opioid 
therapy at three months
Descriptors
n  breathing 
“  more
□  constricted
□  effort
I  enough air 
I I heavy 
■  hunger
□  not in all way
r - 1  not out all 
1—1 way
l~~l out of breath 
|  shallow
□  tight
i—| unable to 
1—1 comment
Figure 5.5.4: Breathlessness descriptions from non-continuers of opioid therapy at three 
months
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As can be seen from both of these methods, there are minor differences between the 
types of descriptions noted by continuers and non-continuers. Some of those continuing 
felt unable to complete all descriptions given that their breathing had markedly 
improved, but taking this difference into account there is little difference in the 
percentages of the responses between the two groups. The only two responses that are 
not noted by continuers are “my breathing is rapid” and “my breathing requires more 
work” compared to non-continuers.
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Section 6) Discussion: Demographic data and analytical points
The majority of randomised participants allowed open label follow-up assessment at 
three months. Two participants, one continuing treatment and one not continuing did not 
complete this three month assessment and therefore analysis proceeded with 33 
participants only. Whilst this is not ideal, this represents a comparatively small level of 
withdrawal.
Not all participants continued therapy despite initially wanting to continue and not all of 
the remainder took the medication regularly. If one simply analysed the sample of those 
who continued on full treatment, not only would this potentially represent a biased 
sample but it would also reduce the number analysed. Although participants were not 
randomly assigned to intervention in this three month follow-up phase and were not blind 
to treatment (two of the major methodological drawbacks of the methodology of this 
three month extension), one can still analyse the results with other best practice 
principles in mind. By including all those who opted for continuation of treatment in one 
group, involving those that did not continue on regular medication, we are incorporating 
the principles of intention to treat analysis. Similarly, those not taking opioid medication4 
as part of the trial may still be prescribed opioids by another health professional for 
another indication, yet they remain in the non-continuers group for intention to treat 
purposes.
It should be noted that self-selection of treatment continuation by participants, rather than 
randomisation to treatment as would occur in a properly constructed parallel group RCT, 
dilutes the relative importance of the three month results compared to the gold standard 
RCT methodology. In particular, the possibility of selection bias cannot be avoided. The 
three month follow-up results are nonetheless of interest, given that this has not been 
performed for opioids in CHF before, but a properly constructed parallel group RCT with 
a long follow-up period would be the preferential method of assessment of reaction to 
opioids on breathlessness over time.
Given the small numbers involved it was difficult to analyse the two opioids separately 
and compare their outcomes with each other given that there were only six and seven sets 
of results to compare for oramorph and oxynorm respectively. Where there was a 
statistically significant change with therapy compared to non-continuers, assessment of
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the relative contributions of the two drugs towards that improvement were made. 
Otherwise, the two opioids were treated as one treatment entity. Independent t tests were 
used for analysis as unlike the RCT there was no paired data. Small numbers also 
prevented reasonable analysis of the participant characteristics of responders to treatment 
in those that continued active treatment over and above what had been documented 
earlier in the responders section of the RCT.
Table 5.3.1 reveals the demographic properties in those that continued treatment and 
those that did not. In the majority o f factors, there were no differences between the two 
groups of participants (with respect to age, gender and aetiology for example). However, 
there was a significant difference in renal function as estimated by the GFR between 
those that continued opioid therapy and those that did not. Those continuing treatment 
had a lower mean GFR which suggests that their opioid treatment may have been cleared 
from the body less efficiently than those with higher GFRs. Opioids are removed by the 
renal system, which might indicate that some of those in the non-continuing group may 
have cleared their opioid treatment more readily than those that continued active 
treatment. This suggests that some of these participants might have received a 
comparative under-dosing o f opioid treatment during the initial RCT, and they might 
have benefitted from a higher dose of opioid for breathlessness. Severity of CHF as 
measured by ejection fraction and BNP concentration was also different between groups, 
with participants with more severe CHF being more likely to respond and continue with 
opioid treatment, although this was a non-statistically significant finding.
In this three month open label extension, there appeared to be little difference in the 
median change in BNP between opioid continuers and non-continuers. Whilst there was 
a mean worsening of BNP concentrations for both groups, it can be seen in Figure 5.3.2 
that the extreme negative outliers in both groups skew this data. Median values show 
very little difference, suggesting that BNP concentrations have been stable over this time 
period in this patient cohort. It is reassuring that opioid therapy has not caused a marked 
escalation in BNP values in the active therapy group on follow-up. However, a recent 
systematic review of the literature by Balion et al. (2008) indicated that NT-proBNP 
levels reduce in line with improving clinical outcomes in CHF, although they suggest 
that changing therapy simply by analysing the BNP results and adjusting treatment 
accordingly has not yet been shown to be beneficial. In an ideal situation BNP levels 
should improve with clinical outcomes on opioid therapy, whilst those not on active
therapy at three months should demonstrate worsening BNP concentrations with disease
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progression. Whilst this is the case with the median values, the values are so small that it 
is very unlikely that this is clinically significant.
The results demonstrate that assessment over three months noted an improvement in 
breathlessness with continuation of active therapy. Improvement with active therapy was 
not observed during the crossover RCT. This suggests that the initial period of treatment 
may not have been long enough to fully assess response to treatment. It also indicates 
that opioid therapy at the low doses involved in the study can be beneficial for some. In 
the crossover RCT, one of the potential reasons for no differences in breathlessness 
severity between active treatment and placebo was that the active treatment dose may 
have been too low. However, given the adverse effect profile and the improvement in 
breathlessness severity rating at three months, it is clear that the doses used could be 
adequate for some patients. Future studies in this area may wish to note these facts and 
have both a longer initial period of assessment in the RCT phase for perhaps 10 to 14 
days rather than a maximum of 4 days and an escalation in dose in the absence of 
treatment or adverse effects for some of the participants. Withdrawals were low during 
this period and the doses well tolerated overall so a longer period in the RCT would be 
warranted.
Whilst participants were generally good at notifying any changes during the initial RCT, 
during the three month extension those on active treatment did not consistently discuss 
any changes in their medication. For example, some participants stopped the opioid 
medication and some reduced the dosage used without discussion. Although this was 
discussed a priori with the participant as acceptable, I considered that a three month 
follow-up was too long to maintain an awareness of the medication compliance in this 
period. Perhaps the addition of an initial one month telephone follow-up would be useful 
both for the participant to discuss any potential problems on treatment, compliance issues 
and for further assessment of change in breathlessness.
Three month comparison was made for those on treatment and those not on treatment on 
an open label unblinded basis. Participants could have selected their preferred week and 
remain blinded for the follow-up as they could have received placebo if this was selected. 
This kind of follow-up could have enhanced the robustness of the results from the three 
month follow-up period. However, some participants did not want to continue on 
treatment and might not have entered with the prospect of being in a three month study, 
rather than their perception of a three week study with extended optional follow-up. This
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would also not be randomised as participants would choose their own treatment to 
continue. A properly constructed parallel group trial would probably be of more benefit 
to assess long term follow-up outcomes.
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Section 7) Discussion: Primary outcome measure: Change in breathlessness severity
at three months
7.1 Comparison with baseline NRS and Borg scores
Assessment was made for average and worst breathlessness scores for continuers and 
non-continuers between their day 1 treatment 1 baseline values and their three month 
follow-up scores to assess whether continued treatment with opioids resulted in an 
improvement in breathlessness compared to baseline. Participants could not make 
reference to their original baseline scores.
As expected from the previous comparisons of Borg and NRS scores, a greater 
magnitude of difference between continuers and non-continuers occurs for NRS 
compared to Borg scores. However, it can be seen, for both NRS and Borg assessment of 
breathlessness for average and worst breathlessness that compared to the original 
baseline, those that continued therapy had an improvement in breathlessness rating at 
three months compared to those that did not continue. Non-continuers had little 
difference in Borg or NRS scores from baseline, whereas those that continued treatment 
had an improvement in all breathlessness parameters. A change in score of one on the 
NRS would be clinically significant (Booth et al 2006) and this change is observed for 
both average and worst scores. Scores for worst breathlessness in particular improved 
and this may relate to scores in those participants that continued active treatment on an as 
required basis only, as one might expect that opioid use only occurs in those participants 
at stages when their breathlessness is particularly troublesome. Change in NRS scores 
tended to show a near-normal distribution and tests of significance using parametric 
means reveal a statistically significant difference between active therapy and non­
continuers for worst score at the 5% level and average score at the 10% level. Greater 
numbers for comparison might allow a greater confidence in these differences, but it is 
clear that there has been some response to opioids on breathlessness severity at three 
months.
7.2 Comparison with end of treatment scores
NRS and Borg scores for breathlessness severity have been shown above to improve 
from baseline for those continuing on active treatment. In the crossover RCT, all three 
interventions (oramorph, oxynorm and placebo) resulted in an improvement in 
breathlessness severity at day 4 (see Figures 4.4.2 and 4.4.3). Is this improvement in 
scores maintained for those that continued treatment? Comparison was made for the day 
4 end of treatment scores and the subsequent three month NRS and Borg scores. 
Reference was made to oramorph and oxynorm continuers’ day 4 scores on that therapy, 
whereas non continuers scores were compared with the day 4 placebo score. Although 
this comparison is not ideal, it was used to demonstrate whether there was a change in 
breathlessness over time on therapy.
Breathlessness severity measured on NRS and Borg ratings for active therapy showed a 
slight worsening over the three month period compared to the end of treatment score. 
The difference is small and lower than the comparative difference seen between day 4 on 
placebo and those not on opioid therapy at three months. This demonstrates that 
breathlessness has deteriorated over time for both groups, as one might expect with this 
patient cohort, but this deterioration on therapy is lower and some therapeutic effect 
appears to be maintained. This maintenance of effect is most marked for worst 
breathlessness scoring, perhaps again relating to those participants who took their opioid 
on an as required basis when moving. No differences were noted between individual 
opioid treatments and maintenance of effect, implying that oramorph is similar to 
oxynorm for relief of breathlessness.
7.3 Global impression of change at three months
Participants were asked to rate whether their breathlessness had changed at the three 
month assessment from their normal level prior to the start of the trial. Those that 
continued therapy noted a statistically significant improvement in breathlessness using 
this global impression of change measure for breathlessness. As one might expect, those 
not continuing on treatment noted a slight worsening of breathlessness over this period, 
with a mean difference of over three points between continuers and non-continuers using 
this 15 point scale. This outcome is encouraging for the use of opioids to manage
breathlessness, however a degree of caution must be exhibited. Those in receipt of
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therapy may note an improvement just because of the action of taking something 
additional for breathlessness, rather than actual clinical effects. This warrants further 
research but suggests that at three months participants consider that their breathing had 
improved from baseline with opioid therapy.
There was a trend towards a greater improvement in score for those that continued 
oramorph compared to those that continued oxynorm at three months. Although one 
could argue that the improvement with oramorph was twice as much as for that with 
oxynorm on the global change rating scale, the numbers of participants are small and 
definitive conclusions concerning this matter cannot be made. However, this possible 
difference may be explored further in future studies.
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Section 8) Discussion: Secondary outcome measures at three months
8.1 Additional components of shortness of breath at three months
Not too surprisingly, participants who continued with active therapy had a greater 
improvement from initial baseline in satisfaction with their overall treatment for 
breathlessness at three months compared to those that did not. This was statistically 
significant at the 5% level, but one might expect this outcome as these participants were 
in receipt of what they considered was active therapy for breathlessness. De-blinding 
participants to allow open label therapy was necessary with the logistics of the trial at the 
time, but if active and control groups remained blinded one may have witnessed a 
different outcome. Change in coping with breathlessness and distress due to 
breathlessness over time were also better on therapy than in those not receiving opioids. 
This was not statistically significant, but demonstrated a trend for improvement in the 
active treatment group.
8.2 QOL change at three months
What would be the correct measure to use to assess quality of life in CHF? The SF-12 
generic validated measure was compared to two of the more widely disease specific 
validated measures in CHF by Bennett et a l (2002) in 211 CHF patients. The Chronic 
Heart Failure Questionnaire (CHQ) was devised by Guyatt and colleagues (1989) 
following assessment of 88 patients with CHF who were asked what factors were most 
important to their quality of life. The most common responses were encompassed in the 
CHQ, allowing assessment of three domains: dyspnoea during daily activities, fatigue 
and emotional function. The (Minnesota) Living with Heart Failure Questionnaire 
(LHFQ) is a similar validated measure specifically for CHF. Comparisons between 
components of all three scores demonstrated a high degree of correlation between all 
three scales. Both disease specific scales, but not the SF-12 revealed either floor or 
ceiling effects of the scores provided. This can be problematic in analysing changes in 
health related quality oflife. However, the SF-12 was not as useful as the disease specific 
questionnaires in determining NYHA class. This is not too surprising as NYHA class is 
derived from abilities that the patient is unable to achieve due to breathlessness, fatigue 
or other CHF symptoms, which arc not directly enquired about by the SF-12 unlike the
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two disease specific questionnaires. The SF-12 does not have categories for disease 
specific qualities of CHF, namely dyspnoea and fatigue, but this was not problematic for 
the RCT and three month follow-up as dyspnoea in particular was adequately covered by 
other measures (NRS, Borg and additional components of breathlessness). In addition, 
the SF-12 can be used to compare other aetiologies other than CHF, important for the 
small but expanding area of breathlessness research.
In this current study, the SF-12 was easy to use, with only a couple of questions posing 
problems with participant responses. In particular, participants were unlikely to be 
completing activities such as playing golf. Analysis of the SF-12 at first glance was 
complicated, with the need to reverse some responses, divide into eight different groups, 
convert to compare to a standardised normal population and finally calculate physical 
and mental component scores from all eight different groups given different weightings 
to divide into the two component groups. However, this process does allow direct 
comparison between different aetiologies.
Comparison of quality of life scores at three months showed a non-statistically 
significant improvement in both physical and mental components of QOL for those still 
receiving opioid therapy compared to those that did not. For those not continuing, mean 
scores were almost identical to baseline scores (28.15 and 47.24 at baseline to 29.65 and 
47.1 at three months for physical and mental components). Whilst one might expect a 
slight reduction in mean QOL scores over time with disease, it is reassuring that these 
scores are consistent between these two time points. For those continuing opioid 
treatment there was a particular improvement in the physical rating components of QOL, 
which although non-significant warrants further investigation as to the improvement of 
QOL with opioid therapy. This improvement demonstrates that opioid treatment may be 
having more than just a psychological or emotional effect.
8.3 Observation data at three months
Opioids appear to be safe over the three month period in respect to cardio-respiratory 
parameters. Although there is a small reduction in blood pressure in continuers compared 
to those not continuing in relation to their original baseline values, these are unlikely to 
be clinically significant and are not statistically significant (due in part to the wide 
variability in the sample as evidenced by the large standard errors). In particular,
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respiratory rate and oxygen saturations are not reduced significantly over time on opioids 
in CHF patients at these doses (less than half a percent reduction in oxygen saturation 
and less than one breath per minute in respiratory rate compared with baseline on 
treatment at three months). This demonstrates that at this level of opioid (equivalent to 
5mg oramorph QDS) there are no adverse effects on respiratory function in particular 
with short to medium-term opioid treatment in CHF,
No statistically significant differences are seen between opioid treatments and overall 
mean values on treatment are comparable. This is slightly different to the initial day 4 
values for all patients in the RCT, where oramorph appeared to cause a greater reduction 
in blood pressure than oxynorm. Simple comparison of the three month follow-up results 
for those continuing on therapy would suggest the converse effect. However, Figure 5.6.1 
illustrating the change in diastolic blood pressure over time demonstrates the problems of 
using means for small skewed samples, in the fact that the oramorph mean value is 
affected by the single low outlier and the oxynorm mean value is affected by the 
(positive) skewness of the sample. Hence caution must be exhibited throughout the 
analysis of very small samples. As can be seen in the graph, both median values for 
active treatment, less influenced by outlying points, are similar, which would suggest 
little difference between opioid treatments on cardiorespiratory parameters at three
months.
8.4 Change in physical function at three months
Change in Kamofsky status from initial baseline at three months was little different 
between opioid continuers and non-continuers. The three point difference between the 
two groups described is unlikely to be clinically significant and it should be remembered 
that Kamofsky status was determined by the observer, which may introduce bias as the 
observer at the time was unblinded. This measure of physical function is unlikely to 
detect the small physical changes that may occur with opioid therapy in CHF patients
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8.5 Breathlessness descriptors at three months
Descriptors of breathlessness were compared between groups at three months. Overall, 
the only main differences were that some participants who continued on treatment felt 
unable to complete the descriptions as they felt their breathing had improved too much to 
be able to describe problems with breathing. Descriptors such as breath not going in all 
the way, shallow breathing and the sensation of breathing more were comparatively less 
frequent in the group receiving opioid treatment and breathing being rapid and requiring 
more work were completely absent in this treatment group. Although one might not be 
able to predict from descriptors alone which participants may respond to treatment from 
these results it is interesting to note the relative changes in breathlessness.
However, only breathing requiring more work is part of the most common descriptions 
detailed in the CHF literature (see Chapter 5 Section 6 for the previous analysis of 
breathlessness descriptors in RCT). Other descriptors in the “work/effort” cluster (effort, 
feeling out of breath and inability to get enough air) are comparable at three months of 
treatment compared to baseline values for those continuing opioid therapy. Those 
descriptions that appeared to change with opioid therapy in the RCT, namely inability to 
get enough air and chest tightness, are comparable with baseline values at the three 
month follow-up. A slight improvement in opioid continuers of shallowness of breath at 
three months was observed, in keeping with the day 4 improvement with therapy.
Whether breathing changes with opioid therapy, enough to influence the patient 
experience and description of breathing, is impossible to tell from this small sample. An 
improvement in one of the key descriptors of breathlessness in CHF, namely breathing 
requiring more work, is encouraging. Unfortunately, other common descriptions in CHF 
are relatively unchanged with opioid therapy. However, descriptions of breathing that 
one might expect to observe with opioid therapy, namely reduction in frequency of 
breathlessness and taking deeper breaths with opioid therapy (Keats, 1985), do appear to 
be prominent in the treatment sample (such as absence of rapid breathing and reduction 
in frequency of shallow breathing and breath not going in all the way). This suggests that 
descriptions of breathlessness may be a useful tool in the response to therapy and perhaps 
in the understanding of how breathing modifications occur with opioids.
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Section 9) Three month follow-up trial conclusion
This three month open label extension is the first reported study of opioids for 
breathlessness in CHF lasting greater than four days of opioid therapy. It also follows a 
pattern of treatment that is more aligned with that observed in clinical practice, whereby 
patients know they are receiving a drug that might have a symptom benefit, as opposed to 
the placebo controlled trial methodology. However, the trial extension potentially suffers 
from selection bias, meaning that results should be interpreted with some caution. The 
stability of the research population has been demonstrated with little change in 
performance status, BNP concentrations and QOL measures particularly in the 
participants not-continuing active therapy.
In contrast to the crossover RCT described in Chapter 4, the open label extension 
revealed a significant improvement in the rating of worst breathlessness on NRS between 
opioid treatment and no treatment. A mean change of two points from baseline for 
average breathlessness and over two for worst breathlessness was observed for 
continuers of opioid therapy compared to those that did not continue. Whilst 
breathlessness severity appeared to increase slightly from the equivalent treatment values 
at day 4 of the RCT for those that continued opioids, for those that did not continue there 
was a notable increase in breathlessness severity at three months compared to their day 4 
placebo values. This suggests that any early improvement in breathlessness severity on 
treatment is maintained at the same dose over time, given that some treatment continuers 
did not take the frill QDS therapy as they did in the trial.
Similarly, global impression of change scores were much improved for those continuing 
opioid therapy than those that did not. A change equating to a “moderate” improvement 
occurred on opioids, whereas non-continuers revealed a slight worsening in global 
change score. This difference between these two groups was statistically significant, 
rejecting the null hypothesis that there is no difference between opioid continuers and 
non-continuers on global impression of breathlessness change at three months. 
Unfortunately the sample of those that continued with opioid therapy was small and 
therefore differences between the opioids themselves with these outcomes was difficult 
to elucidate with any degree of reliability.
There was a slight improvement in performance status in those that continued opioid 
treatment compared to those that did not, however this difference was very small and
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unlikely to be clinically significant. Quality of life scores at three months were also 
greater in the opioid continuing group, particularly in respect of physical components of 
QOL. In addition, although breathlessness descriptors were not found to predict the 
response to opioid treatment, as described in the RCT, those on opioid therapy over three 
months did note an absence in “rapid” breathing and “breathing requiring more work” 
descriptions compared to their baseline responses. The latter descriptor is one of the key 
descriptions noted in other studies of breathlessness in CHF and suggests a change in the 
participants’ experience of breathlessness. It also may indicate that the mechanisms that 
are involved in the formation of breathlessness in CHF may be being subtly altered by 
opioid therapy over time.
In conjunction with the results on cardio-respiratory parameters in the RCT, opioids do 
not appear to cause significant respiratory depression or cardiovascular problems over a 
longer treatment course at these doses in CHF. BNP values taken to ensure that there was 
not a significant deterioration in cardiovascular function, revealed no differences between 
the opioid continuers and non-continuers. It would appear therefore that opioids are safe 
to use on an individual patient basis for the attempted relief of breathlessness in CHF.
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Chapter 6:
Qualitative Study;
Opiophobia: Attitudes to morphine in CHF patients
284
Qualitative research seeks to find the meaning behind beliefs and attitudes seen in day- 
to-day life. It does not try to determine absolute values but to find meaning and 
application (Rogers et al., 2002). This chapter will detail the qualitative study that was 
performed as part of this thesis. Firstly, the background of opioids in healthcare will be 
discussed alongside the expanding role of palliative and supportive care in Chronic Heart 
Failure (CHF) and the reasons why CHF patients may have greater exposure to these 
medications in the future. The aims of the research will be followed by the application of 
and reasons for the methodology employed in the research study prior to the 
interpretation and the implications of the data analysis. Considerations for future work in 
this area and key points from this study will form the conclusion to the piece. As 
documented previously in the thesis, the terms opioid, morphine and morphine-like 
medicines will be used interchangeably. Different terminologies will be used dependent 
on the situation, typically with “morphine” used when relating to patient experience and 
“morphine-like” medicines when patient-centred descriptions are being used.
Section 1) Background: The importance of heart failure patient attitudes to opioids
1.1 Opioids in healthcare
Opioids or “morphine-like” medicines, traditionally considered as analgesics, conjure a 
variety of different thoughts in the minds of both medical and lay people. Many articles 
in the medical press and lay media suggest both positive and more frequently negative 
connotations regarding the use of opioids both in healthcare and recreationally. Historical 
medical associations of morphine with relaxation, sedation, respiratory depression and 
use at the end of life has left a legacy of consideration that opioids are harmful or even 
dangerous, particularly in a healthcare setting. Of course, a history of illicit use of 
morphine-like medicines may also form part of the consciousness of the populous. These 
associations may lead to patients eligible to receive opioid medications, and healthcare 
professionals, reluctant to consider opioids for medical conditions, where they may prove 
to be helpful. In particular, an association of morphine exists with the end of life, 
especially in patients with cancer (Blake et al., 2007).
The Barriers Questionnaire (Ward et al., 1993) was devised to demonstrate the reasons 
why patients were reluctant to report pain or use medicines such as opioids that are
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utilised in more severe pain states. Themes that emerged from this and other studies in 
cancer patients included: addiction and tolerance to analgesics; saving a drug until the 
pain becomes much worse; medication side effects; fatalism (pain is to be expected); 
“good” patients don’t complain; increased pain may indicate disease progression; 
discussing pain may detract from trying to cure the disease; strong painkillers require 
injections. Addiction and fear that opioids may mask important changes in a disease were 
the most common anxieties expressed in a 20 patient sample of palliative care patients 
with cancer (Lambert et al., 2007). This questionnaire based study also highlighted that 
knowledge of opioids is generally quite poor and that most patients derive their 
knowledge about these medicines from their own experience rather than from patient 
information leaflets (Lambert et a l, 2007). Many articles have described why some 
healthcare professionals have a reluctance specifically for opioid prescribing (Elliott and 
Elliott, 1992, Zenz and Willweber, 1993, Zenz et al, 1995, Wells et a l, 2001, Bennett 
and Carr, 2002) despite evidence that controlled use of these medicines is safe and 
effective (Hanks et a l, 2004).
Evidence exists to suggest that opioids are useful in the management of breathlessness 
and cough (Jennings et a l, 2001, Morice et a l, 2007). This expands the use of opioids in 
palliative medicine from the treatment of pain, typically in cancer patients, to the 
management of breathlessness and cough in both cancer and non-cancer patients, such as 
those with cardiac and respiratory disease. Currently there is no evidence as to the 
acceptability of “morphine” therapy to patients with CHF.
1.2 Palliative care and symptom control in heart failure
Palliative care should not be restricted to just oncology patients, but that a number of 
different life threatening chronic conditions (such as heart failure, chronic obstructive 
airways disease etc.) can be managed using palliative care principles as the condition 
advances. However, the patient experience for different diseases is not universally the 
same between different conditions.
CHF is a syndrome that impacts on many different systems in the body and requires a 
pharmaceutical approach to management to attempt primarily to modify further disease 
progression. This results in patients receiving multiple medicines as part of their standard 
therapy. In addition, these patients are often elderly and frequently have multiple other
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co-morbidities, often resulting in further polypharmacy. It has been highlighted that 
knowledge about these medications is generally poor (Boyd et a l, 2004). To improve the 
approach to management of these patients, Heart Failure Nurse Specialist (HFNS) 
services have been devised to help co-ordinate services.
The presence of heart failure leads to a clinical spectrum of symptoms with progressive 
severity. In fact, this disease course has likened advanced heart failure to the malignant 
cancer disease process (Stewart et al., 2001). Indeed, there has been growing recognition 
that the symptoms experienced in advancing disease should be better palliated 
(Department of Health, 2000, Hauptman and Havranek, 2005, Lewis and Stephens, 
2005). A study of carers of CHF patients indicate that pain, dyspnoea and low mood 
impact on the quality of life of over half of patients with end stage disease (McCarthy et 
a l, 1996). In addition, quality of life is adversely affected by loss of activity and function 
due to CHF (Thornhill et a l, 2008, Europe and Tyni-Lenne, 2004, Martensson et al, 
1997). These factors have resulted in greater collaboration between cardiology, primary 
care and palliative medicine in some areas of the UK (Davidson et a l, 2004, Johnson and 
Houghton, 2006). However, symptom based research or assessment of quality of life and 
patient experience in CHF through qualitative methods has been lacking in the literature
thus far.
1.3 Qualitative research in heart failure
Quantitative research involving multi-centre RCTs of drug therapy are prevalent in the 
CHF literature. Conversely, articles exploring meaning and the patient experience of 
heart failure are much less prevalent. Studies either involve small numbers of heart 
failure patients alone, or perform a comparison of the patient experience of different 
disease states involving common symptoms. For example, Murray et a l (2002) 
compared the experiences of 20 advanced lung cancer and 20 advanced heart failure 
patients through qualitative interviews. They demonstrated that heart failure patients 
tended to focus on the stresses of balancing and monitoring a complex drug regimen; had 
poor knowledge of diagnosis and prognosis; and experienced frustration, progressive 
losses and social isolation. This was in contrast to the lung cancer patients who were 
more pre-occupied with facing death and had greater access to social and financial 
resources. Rogers et al (2002) confirm some of these themes using qualitative interviews
in heart failure patients. They also found that patients generally had little knowledge
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about the medications they were taking, and how use of the medications related to the 
symptoms they described. Willems et al. (2004) expanded on this work using semi- 
structured interviews in 31 advanced heart failure patients. They demonstrated that 
patients with advanced heart failure tended only to consider the prospect of dying during 
episodes of acute decompensation. It would therefore appear that heart failure patients 
may experience a loss of function due to health and might struggle more with coping 
with multiple medicines and acute changes in their condition than patients with other 
diseases. One might consider that other patient groups are more prepared for these 
changes due to the nature of their disease possibly due to an effort for greater 
communication from healthcare professionals. It has been noted that prognostication in 
heart failure is difficult (Lehman, 2006) and the disease trajectory for a condition such as 
cancer may be easier to communicate or understand. Indeed, Rogers et al. (2000) noted 
that there were barriers to effective communication between clinicians and heart failure 
patients. This finding is particularly important in the context of discussion of a medicine 
such as morphine between clinician and patient, particularly if that medicine is believed 
to have negative connotations attached to it. What has not been discussed in the literature 
is what preconceived ideas about morphine exist in heart failure and whether its use 
would be prevented by these connotations or through avoidance of a discussion by a 
clinician who might perceive it to be a difficult area to approach.
1.4 The importance for research regarding opioids in heart failure
It is likely in the next few years that opioids will be used more widely to manage pain, 
breathlessness and cough in advanced heart failure populations with increasing exposure 
to palliative care methods. As detailed previously, in the Department of Health guidelines 
for the management of heart failure, low dose opioids are suggested for the management 
of intractable breathlessness (Department of Health, 2000). To date, there is no evidence 
to describe how acceptable this will be to this patient population and what beliefs, 
attitudes and existing knowledge these patients have. Would heart failure patients find 
the use of opioid medication acceptable? What do patients already understand about their 
use? What fears or anxieties do CHF patients already have and how would information 
regarding opioid use be best targeted? The existing literature has not addressed these 
issues in CHF. The aims of the qualitative research performed are to explore the beliefs 
about and acceptability of opioid medication held by patients with heart failure. In 
particular:
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• How acceptable is the use of opioids in the management of symptoms (especially 
breathlessness) to heart failure patients already in receipt of complex 
polypharmacy?
• What are the specific anxieties regarding potential opioid use in this patient 
group?
• What beliefs concerning the use of opioids already exist in heart failure patients? 
Does past experience of morphine alter attitudes?
• What hopes would heart failure patients have for opioid therapy?
• How has information about medicines (including opioids) been obtained by this 
patient group? Who would be best placed to provide information about opioids to 
patients?
• How are the daily lives of heart failure patients affected by their disease and can 
symptoms related to this be identified as having the potential for palliation with 
opioids?
1.5 Key points
• Attitudes to opioids in both medical and lay circles centre around a number of 
pre-conceived ideas, based on patient experiences that are often unfounded given 
the current clinical use of opioid medicines -  leading to “opiophobia”.
• Some physicians have a reluctance in the prescription of opioids despite evidence 
to suggest appropriate use for symptom control can be beneficial.
• Overall, knowledge about opioids in cancer patients currently or previously using 
these medicines is generally quite poor.
• When compared to cancer patients, heart failure patients have a poorer knowledge 
of their diagnosis and prognosis and their focus is directed towards monitoring a 
complex drug regimen.
• CHF patients may have a greater exposure to opioids for symptom control in 
future years.
• No studies have yet highlighted the acceptability of opioids in CHF or identified 
reasons that may preclude their use.
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Section 2) Methodology for the qualitative study
2.1 Patient sample
A theoretical purposive sample of symptomatic chronic heart failure patients was used 
for this qualitative study. All potential participants were known to the Academic 
Department of Cardiology and classified in New York Heart Association (NYHA)
Grades II, III or IV. This sample of symptomatic patients was chosen as they represent 
the most likely group to have prescription of opioids in the future and may have 
considered the potential use of medicines for symptoms. A theoretical sample allows the 
identification of a selection of cases that is able to produce as many categories as 
possible for that topic (Hammersley and Atkinson, 1995). This is performed by both 
reducing the differences between cases so that common basic properties of a category can 
be identified, and by subsequently increasing the differences between cases so that the 
properties of that category can be further developed (Hammersley and Atkinson, 1995).
In this study, identification of symptomatic heart failure patients allows categories to be 
generated from the specific population of interest (purposive sampling).
Participants involved in the ongoing randomised controlled clinical trial involving 
opioids for breathlessness (Chapter 4) were not approached. These patients will have 
read the participant information sheet for this trial and may therefore have a different 
experience to those patients who have not be approached or enrolled into the RCT.
Heart failure patients were approached by invitation letter following identification and 
screening by use of the Academic Department of Cardiology computer database of heart 
failure patients. It may have been that these patients were also known through the Heart 
Failure Nurse Specialist (HFNS) Service and eligible patients could be approached with 
an invitation letter via these nurse specialists. Included in this correspondence was a copy 
of the participant information sheet and consent form for the patient to review.
The timing, people and context of the data collection is important in qualitative research 
(Hammersley and Atkinson, 1995). In this study, the timing of the interview coincided 
with the daytime attendance of the heart failure patient to the clinic, not performed out- 
of-hours or in the acute situation, where responses may be different. In addition, this 
would allow the minimum inconvenience to the participant. As an alternative, the 
interviews could occur on hospital wards or in the participants’ home, whichever was
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most convenient to the participant as long as a quiet area was found free from 
interruption. The setting of the interview was important, as changes in setting could 
affect the responses given. The context in which the data is collected is therefore 
important (Charmaz, 2004), for example the presence of a carer at the interview may 
affect what the interviewee thinks or feels within that social context. In addition, the 
physical location should be reported as data collected may be influenced by changes in 
the “ethnoarchitecture” (Atkinson and Delamont, 2004). The sample of patients studied 
involved people of different backgrounds and different severity of symptoms in order to 
maximise the data for each category formulated.
The logistics of contacting the potential participant, inviting them to discuss the study 
further and taking informed consent, then allowing the participant to return to complete 
the interview at least 24 hours after giving consent may have resulted in more 
inconvenience than was necessary for the participant given that this was a single 
interview study. At the ethics committee meeting I argued that to prevent this occurring, 
if  the participants so wished they could give consent at the same time as performing the 
semi-structured interview. In this way, inconvenience to the participants was minimised 
if this suited them and the ethics committee agreed with this policy. It is recognised that 
this is a potentially frail population who may experience undue burden if repeated visits 
are necessary. However, in general, written informed consent was taken at least 24 hours 
after participant invitation.
No formal sample size was calculated for this qualitative study, in keeping with the 
qualitative methodological approach. Data collection was continued until theoretical 
saturation of both the coding and collection of data was achieved. It was originally 
considered that twenty participants involved in single semi-structured interviews was an 
adequate number considering the nature and scope of the of the topic, experience of the 
interviewers and quality of the data obtained (Morse, 2000). The topic guide for the 
interview had been reviewed by volunteers from the Scarborough-Whitby-Ryedale Heart 
Failure Patient Support Group. Review of the content is important to achieve by a peer 
group of the patient sample of interest. If the wording is too complicated, the participant 
may not understand what is being asked, or it may prevent a full answer being given if 
the participant feels pressure to answer in a manner they perceive as being appropriate. 
Topic questions that this patient group might feel uncomfortable in answering (such as a 
very personal question) should also be highlighted prior to the interview stage. This
might allow the interviewer may ask this in a more sensitive fashion, or may structure the
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question asked differently, or alternatively review whether this type of question is 
required at all to meet the objectives of the study.
2.2 Inclusion, exclusion and withdrawal criteria
Inclusion criteria 
Patients who:
1) Were known to the Hull and East Yorkshire Academic Cardiology Heart Failure 
Service.
2) Had a diagnosis of NYHA grade II, III or IV heart failure of any aetiology.
3) Were aged 18 years and over.
4) Were able to complete written informed consent and semi-structured interview.
Exclusion criteria 
Patients who:
1) Were unable to complete informed consent or semi-structured interview without 
assistance. Some patients may have found a long and intensive interview too 
demanding if they were acutely unwell or if they were particularly frail.
2) Had known true allergies to opioids (morphine-like medicines). It would not be 
correct to involve patients who were unable to take opioid medications due to 
known allergies and their experience of opioid medicine use is likely to be 
different due to their experience of adverse events not encountered by those not 
allergic.
3) Had been approached or are participating in the concurrent randomised controlled 
trial (RCT) involving opioids in heart failure. This would be selecting a different 
sample of patients that have read the patient information sheet about opioids 
which may influence their understanding of morphine use.
4) Had previously stated not be approached for consideration for research trials.
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Withdrawal criteria
Participants were withdrawn from the study on either withdrawal of participant consent 
or withdrawal o f the participant by the treating physician or medical researcher due to the 
patient no longer meeting the eligibility criteria. This was unlikely to happen if consent 
and interview occurred at the same visit.
2.3 Sources of data and interview process
Once the participant had enrolled into the study, background data was collected. This 
included age, gender, NYHA status and date of diagnosis, taken from the Academic 
Cardiology Heart Failure database. The hospital notes for each participant were also 
obtained. Participants were each assigned a unique identification number for the trial, so 
that confidentiality could be maintained.
A topic guide was employed as a framework for the semi-structured interview to 
investigate themes that may be important to heart failure patients. Table 5.2.1 
summarises the key points from the topic guide, which can also be found in Appendix 6. 
The interview itself was conducted in a quiet area and involved the participant and 
interviewer only, however a friend or family member was allowed to observe the 
interview if  the participant so wished. It was made clear that the views of the participant 
alone are of interest to this current study. Provision was made after the interview to 
discuss any issues raised and at this point carers, friends or family could become 
involved in any subsequent discussions.
Interviews were tape-recorded and professionally transcribed verbatim. The transcriber 
did not have access to participant details except for the unique identification number 
assigned to that participant. Contemporaneous notes of any particular items of 
importance, conduct of the interview and physical characteristics not likely to be 
identified by voice alone were made immediately following the interview process by the 
interviewer. Both the taped interview transcript and notes taken regarding the conduct of 
the interview were drawn together to identify and gain consensus regarding the key 
themes that emerge. All interviewee responses and notes were anonymised and 
confidential. A summary of the study outline for the participant is detailed in Figure 
6.3.1.
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Figure 6.2.1 : Study outline summary for the qualitative study
Those patients who meet eligibility criteria on the Academic Cardiology Heart Failure
database approached by invitation letter
Researcher contacts patient after one week to confirm interest
Meeting with researcher set up at patient’s convenience to answer questions
i
Written informed consent taken
±
Semi-structured single interview taking no longer than 30 minutes using tape recorder 
with opportunity to discuss or ask further questions about points raised thereafter
1
Participant data anonymised and collated
!
Study conclusions disseminated to participants via letter and written up in peer reviewed
journal and for conferences
2.4 Data management plan
Data obtained from the interview process was analysed according to the principles of 
modified Grounded theory. One definition of Grounded theory is “theory that was 
derived from data, systematically gathered and analysed through the research process. In 
this method, data collection, analysis and eventual theory stand in close relationship to 
one another” (Strauss and Corbin, 1998). It is an inductive process, whereby categories 
are gradually obtained from the emerging data (Pope et al., 2000). These methods allow 
the simultaneous collection and analysis of data, so that subsequent data collection is 
informed by the previous analysis (Charmaz, 2004). This is turn allows a dynamic 
ongoing refinement of the analysis, and so on. In this process, each item of data is 
identified and compared with other components of the data as a whole, allowing the 
emergence of analytical categories. This process is also known as a constant comparison 
approach (Pope et al., 2000). It allows the researcher to take an interactive stance in the 
research process, allowing the researcher to remain close to the studied world (Charmaz,
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2004). This is one approach that allows a systematic disciplined approach to data 
handling and management.
The data collected was broken down into component parts and given identifiable names 
(coding). Open coding of data was utilised to yield concepts and categories.
Coding allows a close study of the data and gives a framework on which to derive 
concepts and categories for the data (Charmaz, 2004). Coding occurred alongside data 
collection in a dynamic manner to allow changes in emphasis in the topic guide as 
necessary. Data collected previously could then be re-analysed with knowledge of the 
codes to see if it allows further interpretation of previous data (Charmaz, 2004). Formal 
theory was generated from exploration of these concepts and categories which allowed 
the formation of subsequent hypotheses.
It is important that the data collection was thorough to provide accuracy to properly 
inform the subsequent analysis. In accordance with the process of modified Grounded 
theory, themes that emerge from the interview data were sought and subsequent 
participant interviews were refined to take any new concepts or themes into account. This 
“triangulation” of the data allows the review of inferences drawn from one interview 
alongside data from other interviews in different patients (Hammersley and Atkinson, 
1995). Conclusions drawn from multiple sources of data leads to a greater confidence in 
the strength of that conclusion in the population under study (Hammersley and Atkinson, 
1995). In addition to this, triangulation between researchers allows both a consensus to 
be made concerning the conclusions themselves through analysis of the codes and 
subsequent concepts and also confidence in the main outcomes of the study. This does 
not mean that the inferences made are correct, only that confidence in the conclusions is 
greater than analysis by a single researcher alone (Hammersley and Atkinson, 1995). It 
can also allow greater understanding of the data which can be categorised from different 
viewpoints dependent on the emphasis or previous experience of the reviewer. 
Triangulation between researchers did not happen as a part of this thesis to allow easier 
separation of the work done by student and supervisors. This will occur however for 
subsequent research publications in peer-reviewed journals as allowing this to happen in 
general is good practice.
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Table 6.2.1: Key points from the topic guide (please see Appendix 6 for full topic guide)
Area of interest Example interview questions / probes
Medicine use Can you tell me about the medicines you take for 
your heart? Where do you go to get information 
about your medicines? How could your knowledge 
be improved?
General condition How much does your heart failure trouble you? 
What do your symptoms prevent you from doing? 
If morphine could make you less breathless, would 
this benefit you?
Anxieties concerning opioids What does the word “morphine” make you think of? 
Would you have any concerns about taking 
morphine? Would you worry about side effects?
Beliefs about opioids What is your previous experience of morphine-like 
medicines? What was the setting as was it a good or 
bad experience? In what situations should morphine­
like medicines be used for patients?
Hopes concerning opioids Do you think morphine-like medicines have any 
helpful effects? Would this help you?
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Section 31 Data Analysis
3.1 Participant characteristics
Of the seventeen patients were invited for interview, seven refused. Reasons given for 
refusal included the overall state of the patients’ health and a consideration that the 
subject under review was not of relevance to their specific health. Ten male participants 
were interviewed in total. The mean age was 71.7 years (range 53 to 86 years). The mean 
number of types of medication each patient was receiving was nine (range 6 to 14 types). 
Three patients were in receipt of morphine-like medicines at the time of interview 
although one participant didn’t realise that his solpadol was opioid based. None were 
taking strong opioids.
The interviews lasted between. 17 and 43 minutes. Three patients were seen at their own 
homes; seven were interviewed in a hospital clinic room (not always post heart failure 
clinic). Three participants had their spouse present during the interview. Six patients 
were described as NYHAII, three were NYHA III and one NYHA IV. The participant 
characteristics are described in the table below.
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Table 6.3.1: Study participant characteristics
Pt
ID
NYHA Age Wife
present
Location Current
opioids
No. of tvnes 
of meds
1 2 75 N Clinic N 10
2 2 83 Y Home N 6
3 4 86 Y Home N 13
4 2 82 N Clinic N 7
5 2 53 N Clinic Y 9
6 3 65 Y Clinic Y 14
7 3 66 N Clinic N 6
8 2 70 N Clinic N 6
9 3 67 N Clinic N* 10
10 2 70 N Home N 12
Total 6x11 Mean age 3x 7xClinic Mean no. 9.3
3xIII 71.7 years Wife 3xHome types per
1x1V Range 53- present patient
86 years Range 6-14
* Participant receiving solpadol on repeat prescription. Two others on codeine, none 
receiving “strong” opioids
Four key areas emerged from the analysis. These are also shown displayed in Figure
6.3.1 below:
• Medication use in CHF
• Symptomatic CHF
• Prior morphine experience
• Morphine attitudes, concerns and anxieties
These four areas are important in the context of starting morphine therapy in this patient 
group. Firstly, what is the impact of the existing medications? Do patients feel they are in 
receipt of too many medicines, which may prevent them from wanting to take any other 
ones? Morphine therapy may also involve the use of concomitant medicines such as 
antiemetics or laxatives, which may further add to the polypharmacy. What is their 
existing knowledge of their medications and who are they most likely to consult
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regarding starting a medicine like morphine? Would they trust the prescriber that 
recommended the use of additional medications?
Secondly, what is the impact of CHF and other factors on patients’ daily lives and how 
may they be best served by using a drug like morphine? Which symptoms might it 
improve which would benefit them?
Thirdly, what has been their previous experience of morphine use and would this 
influence their use of it for symptomatic reasons? For many, morphine has connotations 
with addiction, death and cancer. Would explanation of its use in long-term illness allow 
CHF patients be more open to receive morphine; that it was not associated with 
impending death in their cases and that addiction was unlikely? Has their previous 
experience given them a positive or negative outlook on the use of opioids? Do they 
exhibit signs of opiophobia?
Lastly, what would be their attitude to take opioids if they were offered to them? Do 
patients have concerns or anxieties around the use of opioids in CHF? Is this shaped by 
the other areas mentioned already and how might be the best way of introducing the 
concept of morphine use in this patient group? These four areas will be described in 
detail below.
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Figure 6.3.1 Key areas that emerged from the data analysis divided into themes and 
subthemes (boxed)
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3.2 Medication use in CHF
3.2.1 Polypharmacy
All patients were taking some form of medication for their CHF, but most were also 
taking medications for other co-morbidities. Frequently, interviewed patients were 
receiving an average of nine different types of medication per day. Given this high 
number of tablets (four patients recognised the high level of tablets they were receiving), 
it was not surprising that some found this perceived polypharmacy was burdensome:
“You wouldn ’t believe it, five/six years I  used to take nothing, the odd Paracetamol for a 
headache or anything, and now it’s, i t ’s like a pick and mix " Patient 5
The majority of the sample commented on the number of tablets they were taking. Of 
course, being in receipt of large amounts of medication made it more difficult to 
remember all the types of tablets taken, let alone what they’re for and frequently patients 
found it difficult to remember all these tablets without writing a list.
3.2.2 Knowledge
Knowledge about the use and reason for their medications was variable; about half of the 
patients had a relatively clear understanding of what the medications were for; but 
similarly about half of the sample were happy to take the medications without having to 
understand why they were important:
“They ’re for me tick-tock but I  don’t know what they do. ” Patient 6
And in a similar response:
“/  don V know a lot about my medicine at all and, quite frankly, i f  I  did, 1 don V know how 
much i t ’s going to help me. ..1 ’m happy as I  am ” Patient 3
3.2.3 Faith in the medical community
Similarly, some participants referred this lack of apparent knowledge about their 
medication to their faith of the greater knowledge of the medical profession:
“i f  there’s anything wrong with my car I ’ll take it to a garage, and the mechanic who
knows a lot more about the car will give me the right things to get it working right, and I
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have the same trust in ... the clinicians here, that they know what they’re doing. ” Patient 
9
In this regard, most patients were deferential to the knowledge of the prescriber (typically 
a doctor). They felt assured that the medication would be helpful to them and would not 
interact with their other medications. They understood that the clinician had an initial 
reason why it had been administered, but could not necessarily remember the indication 
themselves.
All patients in the sample described their respect, trust or faith in the medical community 
which served them:
“You people (doctors) years ago when I  was a hoy used to be God, no-one dare speak to 
you or look up, you know, you was like the Dalai Lama at one time ” Patient 1
Thankfully things have changed! This respect and faith in the doctors’ knowledge was 
also expressed by another respondent in a referential but less spiritual tone:
“I  believe when you say, trust me I ’m a doctor, I ’m a big believer in that and i f  you told, 
me to take this and take this it would be better for me 1 will do that simply because as a 
layman I ’m subject to your abilities. ” Patient 1
Faith in the doctors’ ability and their use of medication was referred to by another:
“the specialists or the doctors must know they (the medications) work or else they 
wouldn ’t prescribe 'em ” Patient 5
3.2.4 Finding further information
Information finding for the medications, their effects and adverse effects took a number 
of different routes. Some patients made enquiries directly to the prescriber, often the 
HFNS was involved in re-iterating the reasons for the medications and most found this 
helpful. Indeed, the HFNS was mentioned specifically in helping improve a patient’s 
knowledge by five patients. Use of patient information sheets included with the 
medication was also discussed. Most patients said they had read these leaflets at some 
point, but that their usefulness was questionable. Some patients found the leaflets 
counterproductive, unhelpful or not relevant:
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"sometimes when you read the notes to the, the medical notes, the., bits o f paper they
put inside, this shouldn’t be taken ifyou’ve got a heart problem. I  thought hang on a 
minute, I ’ve got a heart problem. ” Patient 5
Another respondent mentioned the potential conflict that the leaflets may create:
"I mean things start going through your mind and by the time you’ve finished reading 
that in your leaflet, you think I  don’t wanna take these, you know what I  mean, what are 
the mind that plays tricks? You think oh why do they, why have they prescribed these for 
me, because according to them they don’t work i f  I  m taking Aspirin or they don't work i f  
I  m taking Paracetamol. But.. the specialists or the doctors must know they work or else 
they wouldn’tprescribe ‘em, and then you sit there and think.. oh you’ve frightened 
yourself to death over this lot but you didn ’t need to because the doctor was right"
Patient 5
One interviewee could also see the contradictions provided by the information sheets:
“Q: Yes, yeah. The information sheets, are they...
A: Yes.
Q: ...helpful do you think?
A: They are providing you don’t read the side effects...
Q: Yeah, right, (laughs)
A: ...or you ’d never wish to take any o f them. ” Patient 7
Conversely, two patients found the information sheets a useful prompt to discuss further 
with the prescriber:
"I was given Ramipril a few years ago and.. I  was breathless after taking it, and I  
thought well may be this is a, an initial thing and I  did read through the.. the list and it 
did say that could be one o f the side effects. But after four days o f taking it the 
breathlessness had got to a stage where 1 had to, well 1 had to ring up the.. Academic 
Cardiology and ask them i f  they could., change it. ” Patient 7
And:
“when I  got the leaflet out I  saw some o f the possible side effects and I  thought no I ’m 
not taking it, until I  go and see him and then I ’ll ask him (the doctor). " Patient 8
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Only one patient in the sample used the internet to obtain further information. He 
discovered that the same problems that beset the patient information sheets were also 
prevalent in cyberspace. The language was often too technical and conflicting 
information was portrayed. Most participants realised that their current medications were 
balanced and alterations in this regime could cause an upset to their control of disease. 
Other sources of knowledge therefore from information sheets or the internet tended to 
cause a tendency to worry or produced consternation that ultimately lead back to 
reassurance from the clinician.
3.2.5 Responsibility for medication
Many patients had lists of their medications which they kept on their person or developed 
routines to remember what to take and when. Those that had a partner or spouse found 
that they were useful in helping them to remember to take their medications. There was a 
strong belief in good compliance being related to having a routine to take their 
medications.
Responsibility for medication was not explored with all patients, but responses varied 
between full responsibility for medications lying with the individual and full 
responsibility being with the prescriber:
“All I  go to is my doctor’s and he says .. “I ’m going to put you on so and so” so I  say 
“All right”. ” Patient 4
Again, it was clear that faith in the clinician’s skills allowed this participant to relinquish 
responsibility to the prescriber as described by the following quote:
“I f  they ve (the doctors) got patients that have done well with these, they must think well 
it could work for him. ” Patient 5
3.2.6 Perceived effectiveness of existing medication
When it came to the perceived effectiveness of the medications which the patients were 
taking, some referred back to their faith in the medical staff who prescribed the therapy. 
Their perceptions of efficacy varied however with one patient described the fact that he
had no discemable adverse events or side effects as an indication that the medication was
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effective and one patient could not discern either any positive or negative effects, making 
it difficult to determine their effectiveness.
“1 can’t say anything about the tablets what I ’m taking because nothing has happened. 
So, to me, they ’re doing me some good. ’’ Patient 4
3.3 Role of symptoms in CHF
3.3.1 Volunteered symptoms of CHF
The patients were asked what their main troublesome symptom was, in order to discuss 
whether an additional drug in the form of morphine would be useful. Specifically pain, 
cough and breathlessness were identified as symptoms that could be potentially improved 
by morphine therapy. Breathlessness was identified as the most troublesome symptom by 
five respondents, with three patients considering that the alleviation of pain would be 
most beneficial for their quality of life. One patient (patient 1) denied any symptoms 
attributable to heart failure during the interview, despite telling the doctor during his 
prior heart failure appointment that he was very symptomatic. Another patient (patient 2) 
described his main symptom was that of a cough, but that this was “natural” inferring 
that it wasn’t related in any sense to his overall health or CHF.
3.3.2 Role of age with symptoms
A number of patients in the sample noted the effect of age on their own overall wellbeing 
and some even equated the majority of their symptoms on the fact that they were old 
rather than their CHF or co-morbidities:
“My only problem is, is that as I ’ve got older the old Ano Domini has got hold o f me ” 
Patient 1
“Well I, I  should imagine at my age.. I ’m eighty-four this year, and .. anything could 
happen now, cos at present moment all our friends are all in that bracket o f eighty, 
eighty-four, eighty-six including this year we’ve lost two o f 'em already, but that’s life, 
that’s the way things are. ” Patient 2
“I ’m eighty-six, you can’t be, you can ’t be brilliant all your life, but.. you know, you try 
to do as best you can. ” Patient 3
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One patient was also stoical when it came to the matter of what might happen in the 
future and had a sense of what little influence he might have over that:
“ Well I, Ishould imagine at my age . . I ’m eighty-four this year, and.. anything could 
happen now, cos at present moment all our friends are all in that bracket o f eighty, 
eighty-four, eighty-six including this year we ve lost two o f 'em already, but that’s life, 
that’s the way things are. ” Patient 2
In response to the question “how much does your heart failure bother you”, one patient 
said:
“I f  I ’m gonna go I ’m gonna go and there’s nobody on this earth ’ll stop me, will they? I  
mean even Kings die, oh they ’re millionaires, multi-millionaires, they all die. ” Patient 4 
The implications of this will be discussed later.
3.3.3 Attitude to CHF
The patients’ attitudes to their disease created a number of different responses in this 
male sample. Some patients denied the severity of their illness, or would attribute their 
symptoms to other co-morbidities or their age as described above. Two patients exhibited 
a type of “optimistic fatalism”, cheerful at the fact that either things have been worse for 
them in the past, or that others are worse off than them:
“but you always turn to yourself and say there’s always somebody worse o ff than you, 
you don’t realise how.. lucky some things are. ’’ Patient 5
The other expressed it as:
“we 're only on this place for once, aren’t we, so make it a good one (laughs). ” Patient 5
In addition, the variable nature of their symptoms meant that an “every day at a time” 
attitude was employed:
“I t ’s a strange thing, you go to bed and feel reasonably comfortable and all the rest o f it, 
go to sleep, and maybe about two o ’clock you wake up feeling breathless ” Patient 3
Another respondent noted the daily variability of symptoms, implying that it was difficult 
to plan ahead:
"when I  get up in a morning I ’m thinking mm, feel OK, and sometimes i f  you’ve had a 
bad night, you can 7 sleep and you ’re breathless and everything and you think mm, and 
some days you just can 7 be bothered to do anything. ” Patient 5
Similarly, this participant also discussed the inability to plan to do routine jobs due to 
daily variations:
'‘It, it very much varies, sometimes even, you know, but the whole, my whole condition 
seems to vary a lot. Sometimes I  can be fin e .. doing reasonably, you know, well.. oh 
cleaning and one thing and another, another day after I ’ve bent down with the dustpan 
and brush to sweep up a few bits I  can feel breathless. ” Patient 7
1.3.4 Loss of role and function
A sense of loss was displayed by virtually all respondents, both a loss of role and loss of 
function. Most patients revealed a functional loss, such as an inability to go dancing, do 
the gardening or other activities that they may have enjoyed in the past and might have 
looked forward to in retirement:
“Ifound that with the heart failure, you get to a point where it says stop and it means 
stop ” Patient 6
In addition to the physical limitations of heart failure, others described a general lack of 
mobility due to their condition:
“because I ’m aware that.. I ’m limited now to what I  can do, I  mean I  used to love doing 
gardening, but I  can 7 do it now, I  don 7 do it now, whether I  could do it or I  can 7 do it 
because I  can 7 get about, but... ” Patient 3
“Now, for instance, when we go dancing, we go, used to go dancing on a Tuesday 
afternoon, on a Friday night at the club, and.. when the dance band is playing the 
dances, they always play two records you see, but at the present moment I  dance one, 
then I  walk back o ff the floor, or come on to the second one you see, so as I  don 7.. get 
out o f breath... ’’ Patient 2
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Inability to go dancing or complete other hobbies due to health was a common theme:
“le a n ’t do no gardening, which I ’m glad (laughs). I  mean .. dancing, which ..1,1 did 
like to dance and I  can't. But, as I  say.. I  don't, I  don’t sit down and moan about it, you 
know what I  mean ? ” Patient 4
“I t ’s restricting. I t .. I  mean I  have always been, up till my heart problems, a do-it- 
yourselffiend.. well no longer can I  do the do-it-yourself work that I  used to do. The 
frustrating thing, a lot o f people will not understand it unless they ’re in the same 
position, ” Patient 9
Other than hobbies, other aspects of normal daily life can be disrupted:
“So I  can't drive, that's taken one part o f me life away ” Patient 5
Secondary to this physical functional loss, was the impact on the inability to enjoy family 
events (e.g. playing with the grandchildren), or a sense of guilt with the loss of role that 
could be perceived as being a “male” role:
“last year me son took me to .. Hornsea and he said “Come on, I ’ll take you in the car” 
cos I  was a bit, bit low on breathing, he said “Come on ” he said “and I ’ll take you on a 
car and get some ’’just for the half day, well when I got to Hornsea I  walked maybe say 
two or three hundred yards and then I  had to sit down. They carried on walking and then 
they come back and said “Here we are ” and picked me up again and that’s how it was. 
But now I  can go say from .. my house here to about, say, three minutes ’ walk across the 
road there, through the passageway, then out to the shop, we have a shopping centre, I  
can walk that and walk back again, and then o f course I  sit down. ” Patient 2
Actions that this patient performed to help in the household became difficult due to 
symptomatic disease:
“I  used to take my wife shopping, you know, for the local grocers, well I  can’t now,” 
Patient 3
Similarly, jobs or chores that are normally shared are difficult to perform:
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“w e’ve chucked papering and painting, you know, which we chucked it about.. about 
three month ago, and I said to our lass, I  said “That’s it, no more'’. But knowing our lass 
like, she ’ll say “Well I  could do with that front bedroom doing ”, ” Patient 4.
He goes on to say:
“We ’ll get, get the family to do it (...). We.. normally we’ve done ourselves, but with .. i f  
you ’re climbing the steps and that like, you’ve got to be careful, at my age anyway, this is 
what they always keep telling me like, at, you know, at your age. ”
Another man gave a clear account of lifestyle restriction with associated sense of loss of 
role and feeling of inadequacy:
“Q: OK. So did you find, by the sound o f things, that you had to modify your lifestyle 
around how you were feeling with your heart failure?
A: Oh yeah, yeah, yeah, very much so, yeah.
Q: What sorts o f  things did you feel that you miss, miss out on, or missed out on?
A: Well I  miss, 1 miss on, on general.. messing about with grandkids, any .. like
normal......normal exercise, like doing a bit o f gardening, or doing, mending stuff. Ijust
.. i t ’s an effort to put a screw into, even, even with electric screwdriver, which I ’m not
supposed to use and i t’s frustrating watching your wife doing what you know that you
ought to be doing. I  mean you know why you ’re not doing it, but it does stop you feeling 
you ’re inadequate. ” Patient 6
One man in particular discussed his sense of loss in activities, his loss of role and how he 
perceived he was viewed by his wife:
“But I ’ve always been used to doing the manly things, like carrying out the rubbish, the 
big black.. bin that’s in, in the rubbish, now I  have to watch her take that out. I  have to 
watch her cut the grass, I  have to watch her doing the heavy lifting and, you know, that, 
that drives me potty.. and every now and again, i f  she’s not around, I  lift something a bit 
too heavy that I  know I  shouldn ’t lift. I  suffer for it, you know, virtually straight away I  
have to go and have a sit down, and she comes in and, she’s like a bloody hawk “Who 
moved that for you? ’’you know, I, I ’m caught, you know. ” Patient 9
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And he goes on to describe:
“The, the manly bit, it, it makes you feel less o f a man. It does for me .. I  don’t know how 
a woman would fee l... B ut.. you try and make up for that by doing the jobs that you can 
do. Like I ’ll do the cooking, you know, which ¡never used to do. I  mean .. I ’d need a map 
to find the bloody kitchen (laughter). Now 1 know where everything is more than J  
{name} does, I  know where, how much gear we’ve got, how much .. various things we’ve 
got, how many red kidney beans we’ve got, how many, you know, all that sort o f stuff, 
because your responsibility.. circle has changed, you know. Where, where at one time 
I ’d be able to tell you how many nails I ’ve got, how many wood screws and what have 
you. I  still do the odd bit o f  do-it-yourself, and I  get a lot o f enjoyment and satisfaction 
out o f that, but doing some o f the heavy stuff, like I  built wardrobes and put in a new 
bathroom suite when we moved.. when we were in the south, I  couldn’t undertake that 
now, i t’s too heavy. And that annoys me as well, where I  have to employ a bloody builder 
to come in and do things that I  used to do, and then pass money over to him, and I  know 
it only takes a couple o f minutes, you know, i t’s just frustrating. ” Patient 9
And later:
“So I'm in a vicious circle at the moment. I  can’t exercise, I ’ve cut down on me food .. 
because I  know what ’ll happen i f  I  don’t exercise .. you know, I ’ll become pregnant 
again, so .. but I  can’t do anything about it at the moment.. and i t ’s not an excuse.. 
although J  {name} thinks it is an excuse. But i t ’s just that I  can’t do it. ” Patient 9
3.3.5 Adaptation to CHF
Lifestyle adaptations were commonplace in this patient cohort, with a stoical attitude 
relating to the loss or inability to be able to perform what the patients perceive they 
should be able to do resulting in changing the day-to-day activity of the patients 
themselves:
“I had a big Rover, a lovely car, and.. well i f  we ’re gonna get me wife driving again it 
has to be smaller so it was swapped, swapped it for a little one. ” Patient 3
This sense of loss of ability due to health was remarked upon by another man:
“there’s silly little things you miss, you know, you can’t do, le a n ’t bend down and tie my 
shoelaces, I  can’t, i f  I  drop something on the floor 1 can’t pick it up, I ’ve got to have one
o f them handy Andy things to pick it up ” Patient 5
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And in another example of loss of ability and lifestyle adaptation:
" Well i t ’s strange, I  used to be .. I  was off like the clapper, you know, walking, now i f  I  
go out anywhere, like me sisters, they ’re off, and I ’m saying “Hang on it's, I  can’t keep 
up with you, I ’m gonna stop ” and they know he ’ll catch us up when, i f  they go shopping 
or anything, or i f I  go into places. 1 always have to make sure, i f  we ’re going anywhere, 
there’s a lift.. ” Patient 5
Even relatively simple everyday activities need to regulated according to health:
“At the, at the top o f the stairs.. I  have to stop normally.. and get a bit o f breath. I  have 
to be careful when I ’m getting up off the settee that I  don’t automatically rush and go 
and do the job that I  was gonna do. I  have to sort o f get up and familiarise myself with 
where I ’m standing. Just a couple o f minutes and it, then I  don’t get the out o f breath... I f  
I  pick anything heavy up that’s me knackered for about an hour, you know, I  am really 
breathless. ” Patient 9
One respondent commented on the need to have planned non-spontaneous activities with 
the option of having a strategy for getting home if his health deteriorates whilst going 
outside:
“A: I ’m not too bad, cos I ’m not going out just much now. B ut.. yesterday, for first time,
I  walked into, here into Brid to do a bit o f  shopping, just steady away. But I  know all 
places where to stop where i t ’s warm in shops, you know, Trading Post, i t ’s warm in 
there...
Q: You’ve got like a route planned out?
A: Oh yeah, and then I  know where seats are to sit down. But one or, once or twice I ’ve 
been in town and i t ’s been cold and I ’ve flagged a taxi down and got home with a taxi, 
yeah. ” Patient 10
3-3.6 Perception of others
Frightening experiences lead one respondent to consider the impact o f their health on the 
thoughts of others around them:
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“The one thing that does frighten us, I ’m walking on a steep hill, I  know what’s gonna 
happen. It, it, it just doesn ’t like, I  I ’ve tried hills and I ’ve tried steps, in fact other week I  
were shopping so I  popped into Boyes in .. Bridlington, they have an upstairs. Well the 
queue for the lift was absolutely packed out so I  thought I ’d try and walk up the stairs. I  
didn ’t get very far, I  had staff running out all over place and.. they wanted to send for an 
ambulance, I  said “No just leave me alone, I ’ll take me spray’’ and I  won’t do that again, 
will I, when I ’m by mesen, I ’ll make sure somebody’s with me. It happened at me son’s 
house, you see, when we go visiting him at Bradford, he lives in a big house and the 
bathroom and toilet’s upstairs, so you have to go upstairs, and it’s .. effort and it’s a .. a 
worry, but what’s more worrying is the look on people’s face when you come back in 
room, cos they are absolutely taken aback aren’t they? ’Tatient 9
Similarly, there may be a perception of what CHF patients think they are viewed as:
"to look at me, you know, and all, you’d think oh there’s nowt wrong with him, ” Patient 
10
3.4 Prior morphine experience
Patients reveal a wide range of experience and for the purpose of the results I have 
divided prior encounters with morphine-like medicines into those that directly been 
administered to the patients themselves and those effects that they have observed in 
others (friends, family and in the media). I have termed these observations as a direct 
(involving self), a direct (involving others like family or friends) and an indirect (media / 
television) patient experience. These terms are not designed to attach a greater 
importance or emphasis to one type of experience over another and frequently patients 
described both the effects of morphine-like medicines on themselves, on others and in the 
media. All of these types of prior experience are important in forming the views and 
ideas that patients may have about opioid therapy.
3.4.1 Direct experience involving self
The direct patient experience of morphine involving the patients themselves was at times 
difficult to elucidate from the patient sample. Four patients admitted that they had been 
administered opioid medications before and all of these were in injectable form. All four 
had received opioids during acute events such as myocardial infarctions or during
surgery. In addition, three had received oral opioids for other conditions such as for
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arthritic pain or angina pain. In general, use of opioids resulted in a positive experience 
in those interviewees, particularly when used to treat the pain of a myocardial infarction. 
What was interesting was their recall of what medical professionals had told them about 
taking these medications: this is detailed in the section of attitudes below, but some 
surprise was expressed as to the nature of the conversations lead by medical 
professionals as to the selective highly cautious approach taken for the use of opioid 
medications.
This leads on into those patients who denied having been given opioids in the past. These 
patients often had a similar history of myocardial infarcts and operations and it is likely 
that they have been in receipt of opioid medications at these times. Indeed case note 
review revealed three of these patients had received opioids at these times. The 
remaining patients notes did not include the events described and so use of morphine 
could not be corroborated in those patients.
3.4.2 Experience from observation of use in others
Interviewees had a wide range of experience of opioid use in other individuals. These 
included use for pain management in the majority of these cases in friends or family. The 
overall consensus of this use of opioids was, again, positive. Typically the underlying 
diagnosis in these examples was cancer and opioids were administered to relieve cancer 
pain. In addition, one patient had a son taking morphine for pain management following 
an accident -  he “wouldn’t have the quality o f life he has now without morphine” and 
“h e ’s got life again, you know, so, which is great” (Patient 9).
The only non-pain example volunteered was the use of opioids for breathlessness in a 
relative with COPD. This description was useful as the patient also had knowledge of the 
use of opioids for cancer pain in another relative. His insight on the situation was of 
interest as he didn’t believe that the medication used for breathlessness was the 
“powerful s tu ff  used to treat cancer pain (Patient 5).
3 4.3 Indirect experience
Participants volunteered less information about what they had observed about morphine 
use in the media, such as on television programmes or in the press. One patient had 
knowledge of the use of morphine through being an avid reader of Charles Dickens:
“it is an opiate., used for virtually any medical ailment & taken recreationally" Patient 7
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Another commented on the way that morphine was portrayed in the media:
"We don 7 see the medical side o fit.. used properly. You see that illegal side o f it ” (on 
television) Patient 8
3.5 Morphine attitudes, concerns and anxieties
3.5.1 Associated adverse effects with opioids
Addiction, tolerance and side effects that interviewees were aware of were discussed. 
Surprisingly few responders discussed addiction and tolerance issues.
Catch 22, i f  I  take it and it does me any good, good i f I  take it but it don’t do me any 
good, but I  get addicted, is that good or bad? ” Patient 5
"when people talk about morphine... you think o f addicts ” Patient 5 again
Side effects were also difficult to elucidate with many of the patients not sure of any side 
effects that they could think of to do with morphine use. One patient expected that 
morphine would give him side effects, even though he couldn’t name any. Sleep and loss 
of concentration were the most commonly mentioned, with one respondent saying it had 
made someone that he had seen in hospital made “unrational” by therapy. Nausea, 
constipation and lightheadedness were the other adverse effects that were associated with 
morphine use.
3.5.2 Consideration for the use of opioid medicines in healthcare
The interviewees were asked, given their previous experience, in what sort of situations 
opioids should be used and in whom. Nearly all patients identified the use of morphine as 
a painkiller particularly in accidents, on the battlefield, in cancer or other painful 
conditions including, somewhat surprisingly, arthritis. Use for severe pain was expressed, 
often described as used to “kill” the pain interestingly. Three patients also noted that it 
could be used as a sedative. No patients had heard of its use in heart failure. Did 
morphine always have a negative connotation? Only two patients discussed its illicit use, 
and one of those had worked with heroin addicts in the past. Only one of the ten patients 
considered that the illness had to be sufficiently serious before morphine was considered 
for symptom control and that it should never be used prior to this point. Two respondents 
noted that morphine, when used properly and appropriately, could be a very useful
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intervention. When discussing the subject of pain, one interviewee noted that his friends’ 
quality of life had improved on therapy and another respondent had a novel way of 
thinking about pain management with morphine in his experience:
“I  think i t’s just something like you put a plaster over your bleeding to stop it bleeding, 
and so i t ’s, and that’s how I  look at Morphine, ” Patient 6
Connotations with illicit use still seem unavoidable for some. This patient discussed 
morphine’s use as an illegal substance, without any prior prompting:
“I  don’t connect it at all with modern day people abusing acids and things that they Ve 
put into their bodies that are unnecessary. I  purely mean it as a, it is a medicine, it ’s a 
medicinal factor and I  treat it as, when you say Morphine to me, purely from a medicine 
point o f  view. ” Patient 1
Two other thoughts emerged from the discussions related to attitudes towards morphine. 
First, Patient 6 was concerned that morphine could potentially mask ongoing or 
worsening pathological or disease processes:
“The, the trouble with Morphine, it works very well at reducing pain, but I  think it can 
also hide the pain that they ought, ought to be knowing about. ” And:
“you say how you feel, and 1 feel fine, well actually you ’re not cos i t ’s something going 
on that you ’re .. you, you can’t see and i t’s just not showing itself. ”
Another consideration expressed by some was the perception of the use of opioids at the 
end of life. Six patients in total noted the association, but not exclusivity, of morphine 
with the end of life. One patient noted how morphine was seen on television programmes 
when in the context of end of life care:
“helps them (patients) on i f  they give them a big dose... ” Patient 10
The avid reader of Dickens volunteered the fact that he had never heard morphine used to
hasten death, although this issue had not been prompted or had not been mentioned
previously in our discussions, further illustrating the link of morphine with death. One
respondent noted that morphine was associated with advancing illness if not death and
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that their situation was “not so serious yet” for morphine (Patient 3). In converse, only 
one patient commented that one didn’t have to be seriously ill to try morphine (Patient 6) 
and two others that suggested that morphine could be used to prolong or preserve life.
3.5.3 Attitudes to the terminology of morphine
Did the CHF patients find that the terminology of “morphine” was a problem and that 
calling it by another name might help it to become more accepted? Most responders 
found that the term “morphine” was acceptable to them, but realised that it may not be 
acceptable in a wider context or in the general population given its illicit connotations. 
One patient associated the word morphine with “relief’.
Some patients also commented on the fact that use of morphine may be more or less 
acceptable to those treating the patients as well as themselves:
"funnily enough the doctors have various ideas about these things ” Patient 3
One patient was given an oral form of morphine to help combat his angina pain, but was 
discouraged by his GP the prescriber when he was told not to take them “unless you 
could avoid it” and that if he did have to take if his chest pain was “really bad” he should 
“just take one”. No repeat prescription was issued, although the morphine tablets were 
effective in symptom control when the patient had severe angina (Patient 10).
3.5.4 Attitudes to opioid prescription in CHF
The final question to be put to the patients was would they be prepared to try morphine if 
it was offered to them as a therapeutic intervention? Nearly all the respondents would be 
in favour, with certain caveats. Two patients considered that their situation was not so 
advanced or so serious to consider using morphine yet. It would have to be recommended 
by a doctor, with the benefits outweighing any potential side effects, in small doses 
initially for pain or breathlessness. Two would continue to take it if it help them feel 
more active or if it extended their lives. Overall, the general consensus is summed up by 
the following:
“/  would not hesitate i f  it was Morphine, because I ’ve seen the good that it does, and i f  
somebody recommended it who I  trusted, yeah, I ’d take it. No problem ’’
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Section 4) Discussion
4.1 General points
The 10 male interview participants collectively brought a wide range of experience to 
this qualitative research. This type of research attempts to provide accounts that give 
insights to the patients’ experiences and are not necessarily representative of a wider 
population of patients. This single centre study reflects the local experience of CHF 
patients and experiences in other parts of the world may differ dependent on different 
treatment regimens. Limiting the sample by gender of course limits the findings to male 
patients, but given the time constraints placed on the study it would appear to be logical 
to follow this course to allow comparison with other gender-specific findings. Ideally, the 
sample size would have been large enough to allow comparison of male and female 
respondents, but this was not feasible given the time available.
Constant comparison of the data collected by myself allowed consideration to the point 
o f saturation of the data collected. It is important ethically not to subject participants to 
procedures that are not necessary, however it is important to collect enough data to 
ensure that the findings in the other participants are meaningful. Ideally, coding of the 
data should occur with greater than one person. In addition, the role of the researcher 
should be considered in the analysis of the data and subsequent write-up. Having other 
people to review the research who may approach it from a different standpoint would be 
a useful process. Ideally this would have occurred and will be employed during the 
publication of the research away from the PhD process. I was aware throughout the 
interview process that participants may be responding to my role as a doctor. Of course, 
all researchers have different standpoints and previous experiences, but it is important 
that the role of my previous experiences and views as a researcher are considered in the 
research process as a whole. It was important to try to remain as objective as possible. I 
did not attempt to consciously pre-empt how a patient CHF would respond to the 
questions about morphine, but I suppose I did have some preconceived ideas, some of 
which have been confirmed and some of which have been disproved. The important point 
is to allow the participant to express their own thoughts and for the interpretation of those 
ideas to be performed as objectively as possible. Naturally, my past experience and ideas 
will influence what data is selected and what is reported as being of interest, and what is 
not. A lay person conducting the interviews may collect different data, or have a different 
emphasis on the data collected. Participants did not know my role as a previous palliative
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care physician, as I did not want that to exaggerate any thoughts that opioids may be 
associated with death and dying. This makes the volunteering of information about this 
fact by the participants more interesting as it was not perceived by the interviewees as the 
focus of the interview, which it might have been given my background.
Patients known to have symptomatic CHF were approached to participate, with over half 
of those approached agreeing to take part. Of course, those patients not wishing to take 
part may have a different experience of morphine-like medications to those that do. In 
particular, these patients may have negative experiences, or associations with previous 
use that they do not wish to recant in an interview situation. Hence it must be appreciated 
that those taking part may either have a narrative to tell about morphine or might have 
had a positive experience that they wished to elaborate upon. After discussion with the 
participants, most involved wished to be interviewed if it helped to expand the research 
process in CHF rather than having such a vivid experience of morphine that they had to 
become involved in an interview based around opioid use.
Use of a topic guide was invaluable in the research process. It allowed discussions 
around subject areas of interest, but was flexible enough to allow respondents to express 
their own experiences. I would certainly be happy to use this method again. A purely 
open-ended question would allow complete flexibility in questioning, but may yield a 
great amount of data outside of the researchers’ area of interest. Questionnaire based 
interviews would be specific for data collected to be within the area of interest, but may 
not allow the expression of ideas or concepts that are important to the participant and 
may be very relevant to the research in question, but are not volunteered by participants 
if they feel they are not relevant to the specific question asked. For example, direct 
questioning concerning the use of morphine in death and dying may have yielded a 
greater number of factual responses on that subject, but it may not be as interesting as the 
responses in those participants who volunteer the link without being prompted. Given 
that the interview process was designed to determine experience and feelings about 
morphine the use of a semi-structured interview would appear more appropriate than a 
questionnaire based approach, which is more suitable for determining factual 
information. Constant reflection of the previously collected data allowed refinement in 
questioning in areas of interest that were emerging which was useful to help streamline a 
large initial topic.
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Attempts have been made to address issues of methodological quality in qualitative 
research and there have been many attempts to standardise criteria for quality. Mays & 
Pope (2000) have published guidelines for assessing the quality of qualitative studies and 
I have attempted to adhere to these suggestions in this study.
Respondent validation (also known as member checking) is a technique whereby the 
investigator’s interpretation of the participant interviews are subsequently discussed with 
the participants themselves, allowing the participant to react to the analyses and add 
further comment which can then be incorporated into the analysis. This method can add 
further credibility to the study outcomes. Mays and Pope (2000) suggest that this method 
is useful, though they note it is a process to be used primarily to reduce the frequency of 
errors, rather than acting purely as an all encompassing credibility check. In future 
studies though I would consider it to be interesting to show the analysis in general to the 
contributors and incorporate any comments in the subsequent write-up.
Four distinct but interrelated areas emerged from the analysis and components of these 
will be discussed in detail:
• Medication use in CHF
• Symptomatic CHF
• P rio r m orphine experience
• M orphine attitudes, concerns and anxieties
4.2 Medication use in CHF
Prior to the consideration of any additional medication, including opioids, in CHF it is 
advisable to understand the perception of the medication currently taken and whether 
additional medication would be acceptable. An average of nine different types of 
medication were taken by these participants, which often equated to double the number 
of actual pills taken as many were on these medicines twice or three times a day. Initially 
I considered that this polypharmacy would be burdensome on patients. Often it occurred 
following an acute event, whereby patients were admitted with myocardial infarction or 
acute heart failure having been relatively fit and well and not having to take much in the 
way of regular medication.
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Following such events, patients are frequently discharged on at least five different 
regular medications (aspirin, statin, beta-blocker, diuretic and ACE inhibitor in the case 
of myocardial infarction). Some patients joked about how many medications they were 
taking and although some realised that they were receiving a lot of medication, they felt 
that their medications were in a state of balance and were probably required. Participants 
remembered to take the medications by relying on a list, routine or by their spouse. The 
formation of a routine for taking medications is discussed by Reid et al. (2006) in their 
study of 50 CHF patients. They detail the formation of set routines, devised by the 
patients themselves out of necessity due to the high tablet burden which typically 
involves input from the spouse or main carer to maintain concordance with medications. 
Indeed, single CHF patients are more likely to be re-admitted or die after initial diagnosis 
necessitating hospital admission than non-single participants (Chin and Goldman, 1997), 
which in turn might be related to issues of medication compliance.
It has been noted that many CHF patients have coexisting cognitive impairment (Sloan 
and Pressler, 2009, Woo et al., 2009, Sauve et al., 2009). Indeed, one would imagine 
keeping track of all the medications, particularly when they were altered by their 
prescribes, would be difficult in any case. Knowledge about the medications and what 
they were for was variable, some good and some poor. This was interesting as those who 
had good knowledge tended to accept greater responsibility over their medications and 
overall health. Other studies detail a general lack of understanding as to the purpose of 
heart failure medications in CHF patients (Rogers et al., 2002, Boyd et al., 2004). 
However, I would consider that this is only part of the problem for the participants in our 
sample. Those with less apparent knowledge were more likely to suggest that they were 
only following what the prescriber had provided for them. This question of responsibility 
interlinks with polypharmacy, knowledge and cognitive impairment; those patients were 
less likely to question the approach by prescribers and were happy to be entirely guided 
by the medical profession.
It surprised me a little that the concept of “doctor knows best” still held true for a 
generation of CHF patients. I suspect that factors such as increasing complexity of the 
advancing disease process, increasing cognitive impairment and co-morbidities and 
increasing types of medication leads to a dependence on professionals who are 
considered to appreciate the nuances of the human condition. It also probably reflects the 
patient demographic in a relatively deprived area of the UK. Understandably trust in 
healthcare is already prominent given that the majority of patients had been in hospital
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with acute events (MI or AHF) where they were acutely unwell, treated with appropriate 
therapy and discharged on a variety of medications that seek to prevent the re-emergence 
of these acute symptoms. Hence the patient experience is one of acute potentially life 
threatening illness followed by physician guided treatment preventing further episodes 
and hence the overall perception of the medical intervention is both positive and 
necessary for health.
Participants volunteered information about where they derived knowledge about their 
medications, with the heart failure specialist nurse service (HFNS) mentioned most 
frequently as a useful conduit for information. Frequently participants had their existing 
medications altered during admissions to hospital with the HFNS often involved with 
subsequent explanation of why this had occurred. It was unclear whether the changes had 
been fully discussed in hospital and this may be an interesting point to explore further 
comparing the experiences of hospital inpatients and outpatients as to their satisfaction of 
the way information has been translated to them about their condition.
The use of patient information sheets was discussed, with many patients feeling them 
unhelpful or counterproductive. They did not appear to be specific enough for patients 
with CHF and patients were discouraged from reading further when they realised either 
the nature of the side effects or the potential interactions there may be on other drugs that 
they were taking for CHF. This no doubt further emphasises or reinforces deference to 
the medical profession and responsibility for medication use shifts further away from the 
patients themselves to the prescriber. Rogers et al. (2002) documented that some CHF 
patients in their study were actually alarmed by the patient information sheets, 
particularly the list of contraindications or the magnitude of the doses prescribed. The 
authors highlight the potential for confusion with such patient information leaflets and 
that in general, information given to patients can be of poor quality. Undoubtedly, the 
information sheets can only provide a general approach whereas a medical professional 
can provide an individualised or tailored service. However, information sheets tailored to 
individual patient groups such as CHF or hypertension, in language that can be 
understood may be an appropriate compromise to allow patients to have greater 
involvement in their medication decisions.
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4.3 Symptomatic CIIF
Many patients limited their acknowledgement of the severity of their symptoms related to 
heart failure. Some considered that their increasing age was as much of a problem as the 
disease process and that some symptomatic changes were to be expected with advancing 
age. Was this just a case of male bravado? Their responses may have been different to a 
female interviewer; they may not have wanted to show health vulnerability to another 
male and it might be considered that reduction in role is more acceptable to link with age 
than health in male patients. Rogers et al. (2000) also comment that symptoms in CHF 
patients are attributed to the ageing process in a 27 patient sample of predominantly male 
participants with CHF.
Some patients noted the points noted in the section above, notably that they had 
previously been very unwell with an acute event and that now even though they were 
describing limitations in life and’health that they were better off than lying in a hospital 
bed. These patients realised the life-threatening nature of their condition and displayed 
stoicism relating to their condition. Comments such as “always someone worse off than 
you” and “everyones gotta go sometime” were a demonstration of a stoical attitude to 
health and disease. Again, this response may have been different in female patients. A 
qualitative study of predominantly male patients with advanced heart failure (Willems et 
al., 2004) determined the perception of CHF patients about death and dying. Most of the 
18 participant sample who wanted to discuss end of life issues did not consider their 
heart condition would result in a premature death, but considered if their overall 
condition was poor they would not want life prolonging treatment at all costs.
This attitude of stoicism was a developed response to the symptoms currently or 
previously experienced. Participants volunteered few symptoms related to CHF, but 
breathlessness, cough and chest pain were prominent among them. These were in 
keeping with those symptoms described in other studies of CHF (Rogers et al., 2002, 
Seongkum et al., 2006) although I had expected participants to volunteer many more 
symptoms. An open question was asked about symptoms in general, rather than specific 
questions concerning specific symptoms, which probably would have yielded more 
symptom descriptions. Two patients in particular denied any symptoms attributable to 
heart failure, even though they were selected for the interview because they were 
symptomatic as described by both themselves and their treating physicians. One patient 
denied symptoms when questioned, even though his prior clinic appointment that day
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detailed him as being very symptomatic requiring medication changes. Another patient’s 
cough was described as “natural”, again playing down both the symptom itself and the 
impact it might have on daily life.
Do these patients not want to engage in discussion about symptom severity on tape or do 
they simply not want to appreciate the impact of these symptoms? Does a stoical attitude 
protect them from considering advancing disease and having to come to terms with 
morbidity and mortality? A positive outlook was considered important for maintaining a 
good quality of life in a predominantly male sample of 20 American CHF patients (Heo 
et a l, 2009). However, this view in male CHF patients is not supported by other studies 
of gender differences in living with CHF (Martensson et a l, 1997, Evangelista et al, 
2001) who might attach more negative meanings to their illness, though in the case of the 
Evangelista study (2001) this difference between gender is modest at best. Perhaps 
having a perceived experience of individuals with a worse condition to their own allows 
patients to maintain positivity. Why CHF patients need to maintain this positivity or why 
they think it is so important is not clearly understood and could form the basis for future 
research. Certainly the attitude of stoicism that is displayed in our sample links into this 
notion of positivity. Perhaps this attitude is a form of disavowal, described by Buetow et 
al. (2001) as a “selective perceptual blindness to unpleasant facts” considered by Yu et 
al. (2008) as another form of denial in coping with CHF, which is considered a negative 
trait. However, the Buetow article considers disavowal as a useful coping strategy 
between avoidance and acceptance in CHF. They consider some patients to acknowledge 
the reality of their situation, but to palliate that emotional burden they try to dissociate 
that awareness from its personal impact. Male patients in our sample may be describing 
this phenomenon as part of their stoical outlook on their condition. However, such 
stoicism may hide a degree of acceptance of their condition and realisation that they 
alone are unable to dramatically alter its course or outcome; the “one day at a time” 
strategy of coping with chronic illness, which is considered as a positive response to 
allow psychological adjustment to the effects of CHF.
Symptom variability was a key feature in the daily lives of some CHF patients. This did 
not allow the patient to plan the day ahead in some circumstances and left them having 
an approach of taking one day at a time (the old sporting cliché). This had two 
consequences; to perpetuate the stoical attitude about their disease, having the feeling 
that they have no choice but to carry on with what is expected of them despite their
symptoms; and variability also leads eventually to reduction in activity as planned
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activities may have to be cancelled on days where symptoms are at their worst. This 
withdrawal from activity might lead to a sense of loss as described below.
A sense of loss was noted in almost all participants, whether it was a sense of loss of 
functional capabilities, or as a result of this a sense of loss of role. Lack of independence 
and the need to reduce activity levels with symptomatic CHF has previously been 
described, again in a predominantly male sample of CHF patients (Thornhill et al., 2008, 
Europe and Tyni-Lenne, 2004). The feeling of limitation due to disease both as a social 
and a physical restriction has been noted elsewhere in male CHF patients (Martensson et 
al., 1997). A common group of activities that could no longer be achieved in our study 
was observed in less restricted participants such as dancing, gardening, DIY and driving. 
Similar reductions in the ability to perform hobbies has been noted elsewhere in the CHF 
literature (Edmonds et al 2005). Very restricted participants sometimes found it difficult 
to complete normal activities of daily living without help or observance by the family. 
This reliance on others may lead to a loss of personal identity as to the role played as part 
of the family unit and the wider community.
Days out away from the house were restricted, associated with a sense of loss of role 
either as a man (for example doing chores) or as a father or grandparent. The Hornsea 
day trip described by Patient 2 is a good example of a number of related concepts: a 
sense of guilt by slowing the family down; being left behind by the family whilst they did 
activities that the patient felt he could not; a stoical attitude to his health and the impact 
of it on both his physical and emotional behaviours; modifying his behaviour and activity 
in the confines of his disease; and being aware of his own limitations. How a patient with 
chronic disease might be viewed by others was touched on here and is continued by the 
remarks of patient 9. He describes how his family perceives him being unwell, elderly 
and possibly unable to cope and how this creates worry and apprehension in both the 
patient and family. In addition, there was guilt from his part on his spouse having to 
undertake jobs that he perceived as being traditionally male orientated. He was 
representative of other respondents. He had his spouse present in the interview, 
illustrating that he felt able to discuss these matters in front of his spouse. His wife’s 
opinions on this would be interesting to gauge and it would be interesting in general to 
explore the impact of chronic disease on men and their families further in future studies.
Other respondents found the loss of function made them both guilty that someone else 
had to perform the task and frustrated that they were no longer able to accomplish it
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themselves. This guilt concerning reliance on other family members has been 
documented in a focus group study in CHF (Fitzsimons et al., 2007). No doubt this 
impacts on a patients’ quality of life as both having the ability to perform tasks and 
having fulfilling relationships with family and others have been identified as important 
for a good quality of life from the patient perspective (Heo et al., 2009). One can infer 
from our sample that quality of life will be adversely affected if patients perceive that 
they may be a burden on others given that they are more reliant on their family or carers, 
but future studies may address this point in more detail.
Lifestyle adaptations are a natural consequence of functional loss and interviewees 
described a number of changes. Allowing others, such as spouses or carers, to complete 
tasks was one feature that was common in the interviews. Men who lived on their own 
felt they had to carry out certain tasks themselves, leading to prior planning of events 
such as shopping to allow for concurrent health issues. Adaptations may be limitations in 
time out, shops visited, catching lifts or even ensuring enough money for a taxi home. 
This adaptation of course is not helped by the apparent variability of CHF symptoms. 
Adaptation to disease is also prominent in another study of 12 male CHF patients 
(Martensson eta/., 1997), though they purport that a strategy of avoidance is employed 
in their population, limiting the amount of physical and social activity through reduction 
of tasks and subsequent resignation to their plight. In our sample, adaptation appears to 
occur through necessity of functional impairment but the attitude is different for some 
participants where there is a realisation that a task must be done and adaptation occurs 
accordingly, rather than complete avoidance of the task.
4.4 Prior Morphine experience
Respondents described a number of experiences involving morphine administered to 
themselves (described as direct -  self), friends and family (direct -  others) and in the 
media. Surprisingly, few participants noted the perception of morphine use in the media. 
Most had direct experience of morphine use. Descriptions of this experience was difficult 
as some were unsure whether they had received morphine, even though I discovered 
written information in the notes on medication charts of its use, typically during acute 
events such as myocardial infarction or surgical procedures. Why could some 
participants not recall its use? Possibly, the acute nature of the event precluded
discussion or recall of a discussion about therapeutic options. It is possible however, that
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discussion of the use of morphine is avoided or deferred by some medical professionals. 
What is unclear is whether these clinicians believe it is not relevant to discuss with 
patients, or that patients might refuse to take it if discussion takes place. Some might see 
it as a therapeutic intervention, beneficial to the patients which therefore needs not to be 
covered in detail as part as an overall holistic approach to healthcare. As has been 
determined earlier, some patients are deferential to the skills of the clinician and are not 
particularly bothered about how improvements are going to be made, simply that an 
attempt to alleviate symptoms will be made. However, the research literature suggests 
that some professionals may avoid either use or discussion of the use of morphine due to 
perceived “opiophobia”. This area is discussed further in the attitudes to morphine 
section.
In general, the direct experience of morphine use on themselves or on their friends and 
family was positive. Most experience involved morphine use for pain, particularly cancer 
pain, which is to be expected. Interestingly, the same patient who had seen beneficial 
effects of morphine in both a relative with end-stage COPD (for which morphine was 
used for breathlessness) and in a relative with pain related to cancer, considered that the 
cancer pain morphine was significantly stronger than that used for breathlessness. 
Unfortunately the types and doses of morphine are not known in these two clinical 
situations, but his insight appears to be that cancer pain necessitates strong analgesics as 
it is likely to be severe, whereas troublesome breathlessness does not necessarily require 
such radical intervention. Clinically patients with cancer pain are more likely to be 
prescribed higher doses of opioid than those with breathlessness, but frequently the same 
forms of opioid are used in both scenarios. Expansion of this concept would be 
interesting to analyse in future studies. Is there more acceptance of the use of morphine 
for cancer pain due to better education and dialogue? Is it because opioids are more 
commonly used for cancer pain, that the patient experience is greater and therefore there 
is greater acceptance of its use in therapeutic doses in such patients? Anxiety regarding 
the potential use of opioids is likely to be reduced with greater exposure to them in 
clinical situations with symptom improvement.
Less information came from the indirect experience of patients through media, television 
or further reading. This is partly due to the open-ended nature of the question about their 
experience and I attached greater priority to discovering their direct experiences. A future 
study could determine the possible juxtaposition of a positive direct experience with an 
often negatively portrayed experience of morphine in the media or on television; would
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patients be reluctant to take morphine if the media frequently portrayed an unbalanced 
negative view of it, and how would their position change if a subsequent direct 
experience was positive?
4.5 Morphine attitudes, concerns and anxieties
Despite many participants having taken morphine in the past, few adverse events related 
to morphine were volunteered. Addiction and tolerance were infrequently mentioned in 
open questioning about side effects. These questions were discussed typically towards 
the end of the interviews, which may have had a bearing on the lower level of response 
given that most participants were elderly with a number of symptomatic chronic diseases. 
Fear of experiencing side effects was low, with one patient expecting to get side effects 
even though he could not detail what they might be.
Morphine use was associated typically with the control of pain during acute events or for 
the management of severe pain in cancer. Fewer patients than I expected discussed its use 
in an illicit sense. The majority noted its use at the end of life, whilst realising that 
morphine could be employed prior to the phase of imminent death. Only one deviant case 
from this analysis commented that morphine use should be restricted to very serious 
situations. Perhaps this was reflected in the patient sample; participants may have been 
more likely to enter an interview trial about morphine if they were more open to it 
potential uses. Use of an open question about the respondent’s associations of morphine 
again may not have yielded specific information about illicit use, although having an 
open question allowed those that wished to discuss illicit connotations of morphine the 
opportunity to do so. However, even considering this, the potential use of morphine in 
these patients does not seem to be guided solely by advanced disease or end of life 
situations alone or by illicit non-prescriptive use.
This is not in keeping with the experience of morphine use in cancer patients for pain 
management. Reid et al. (2008) found that cancer patients who were to be commenced 
on morphine-like medicines for pain were frightened that it was being used as a last 
resort. This study is limited though by the nature of the study sample as participants were 
entered into a concurrent clinical trial of opioid analgesics and therefore may not 
constitute a representative sample. I had sought to avoid patients who had already
considered entry into a clinical study of opioids as this may result in a biased sampling
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strategy. That patient cohort was one of advanced cancer where thoughts of impending 
death may be interspersed with uncontrolled pain, linking morphine use with end-stage 
disease. The CHF cohort was symptomatic, but not necessarily reaching the point where 
end of life considerations are at an acute stage. It would therefore appear that early 
consideration of morphine in the trajectory of an illness, once patients are maintained on 
maximal standard conventional therapy, may increase its acceptability rather than leaving 
it to a very advanced stage with the inference that it can be only used at the end of life.
Prior to the study I anticipated that CHF patients might associate morphine with death 
and dying as evidenced in the literature (Blake et al., 2007) and that this might preclude 
its use in these patients. It is true that the majority of the sample noted a link between use 
of morphine in the terminal phase, either through their own experience of family and 
friends or in the media as a cultural perception. This link however, did not appear to 
prevent many of these patients from considering the use of morphine in their own clinical 
situation. One person volunteered a link to death without any prompting, which shows 
that this association is held firmly by some individuals. It would seem that this link is not 
absolute for all forms of morphine and that lower doses or non-injectable forms may be 
acceptable away from the imminent death scenario. Only one patient volunteered that 
their situation did not warrant use of morphine for their symptoms as their disease was 
not so advanced yet. I had expected this level of response to be higher. The patients’ 
perception of disease severity may differ from that of the treating clinician and it is only 
correct that it is the individual’s right to choose or refuse therapy. Interestingly though 
this patient was the most severely affected by his CHF, so potentially might have the 
most to gain from additional symptom control based intervention. Perhaps the perception 
that morphine is only used in severe illness allows that patient to deny his own advanced 
disease, which is another feature of the stoical attitude seen in this cohort of CHF 
patients.
Attitudes towards the use of morphine are guided by past exposure to the drug, societal 
attitudes perpetuated by the media and perceived adverse events, all of which have been 
discussed in earlier sections. Other opinions included the fact that morphine use may 
mask a change in symptoms related to the disease process. This potential to mask 
pathologies is a feature in another study of cancer patients in a palliative care setting 
(Lambert et al, 2007) and of papers involving the Barriers questionnaire, particularly 
noted by Gunnarsdottir et al. (2002). This questionnaire detailed reasons why there was a 
reluctance to report pain in cancer patients. Specific concerns included the fear of
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addiction, tolerance or side effects with strong painkillers amongst others and the authors 
noted that large numbers of patients appeared to have misconceptions and concerns about 
using strong analgesics with may delay their presentation (Ward et a!., 1993). A further 
smaller study involving the questionnaire suggested that non-cancer patients may hold 
similar beliefs (Ward and Gatwood, 1994). Attitudes may have changed over the past 15 
years since these studies with improving use of and education about morphine-like 
medicines. The term “morphine” itself was universally accepted, although respondents 
did realise that this terminology may preclude others from trying it due to its association 
with illegal or illicit use.
Patients attitudes may also be influenced by how they have seen morphine prescribed. 
The opiophobia of some medical professionals, not forgetting that they are held in such 
esteem and deference at times by these men, will certainly influence its use. Despite 
patients finding morphine use acceptable, particularly in acute or cancer pain states, it is 
notable that some prescribes find its use so daunting, at least in the eyes of their patients. 
Even when morphine has been successfully employed in severe symptomatic angina as in 
the case of patient 10, he was left with the impression that the drug should only be used 
very much as a last resort. This would seem unfortunate given that the patient would 
likely be on maximal tolerated therapy at that time, with morphine added in as a method 
of additional symptom control. Whilst no evidence is available specifically for 
cardiologists, which provides an avenue for future research, much qualitative research 
has been performed in oncologists and other healthcare professionals who can hold 
negative misconceptions of the use of morphine-like medications (Zenz and Willweber 
1993, Larue et al., 1995, Pargeon and Hailey, 1999).
Finally and perhaps most importantly, would patients with CHF be prepared to take 
morphine? This concept had to take into account the noted polypharmacy that some 
participants had expressed, the negative connotations and positive experiences that some 
had witnessed and how it would be of potential benefit to them given symptoms of pain, 
breathlessness and cough. The general consensus was that morphine would be acceptable 
if  it was prescribed by a trusted healthcare professional on a trial basis in a low dose 
initially to see if it would benefit them. In a way, this could be extrapolated for all drugs; 
prescribed correctly with benefits outweighing detrimental effects. Morphine prescription 
should be seen as being no different to this general model in CHF.
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4.6 Implications for morphine use in CHF
Would CHF patients be amenable to accepting a prescription for morphine-like 
medicines if there was a potential symptom benefit? Despite considerable polypharmacy 
for some CHF patients, it would appear that the addition of a medication directed 
towards symptom improvement may be acceptable in the context of the disease 
modifying agents that patients are already accepting. Hence discussion of medications for 
symptom benefit is appropriate despite the co-prescription of multiple medications in this 
group. This discussion may also involve the patients’ spouse or carer as from our sample 
it would seem that they are important in medication compliance issues.
The importance of symptoms attributable by the patients to age and other co-morbidities 
was of interest to myself as a palliative care physician, given that the importance of 
patient-centred symptom management is one of the key factors to good palliative and 
supportive care. It could be argued that the attachment of perception of the patient to 
specific disease aetiologies is less important than the acceptance of intervention for a 
given symptom as often symptoms such as pain or breathlessness can have multiple 
aetiologies in the same patient. The acceptance of palliative intervention for symptoms 
could therefore be argued as one of the more important factors in a symptomatic CHF 
patient. It would certainly appear that CHF patients in this sample would be agreeable to 
morphine-like medications for symptom control.
The knowledge of disease or the medications taken for CHF is variable in this and other 
samples of CHF patients. One can see from the participant testimonies in this sample that 
this knowledge is hampered by changing diagnoses, recurrent hospitalisations, changing 
treatments and different approaches by healthcare individuals. Unless the individual 
enquires about the details every drug change, the reasons for it and potential implications 
in relation to their other medications it is extremely difficult to understand what 
medications are for and why they are used. Frequently, acute events leading to 
hospitalisation results in a raft of changes in medications, some through necessity and 
some through the different approaches of the treating physician. If one combines these 
facts with the profound faith in healthcare professionals expressed in this sample and the 
lack of targeted sources of information, understandably CHF patients lose the ability to 
determine what their medications were for and why they were administered. In turn, 
these factors undermine a patients’ understanding about their health and will reduce their 
ability to take more responsibility for their condition. In an age where patients are
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generally encouraged to take more direct input into their health (Steinbrook, 2006), not 
only are CHF patients faced with having to be very perceptive and make detailed 
enquiries at every medication change, they also demonstrate significant symptom 
variability often necessitating short term treatment changes, such as transient increases in 
diuretic therapy for fluid retention for example. Ideally, patients with CHF should be 
able to monitor these changes themselves, through noticing weight gain and shortness of 
breath in the example of the transient increase in diuretic therapy. Early intervention in 
these matters may prevent further selaeque such as hospital admissions. This approach 
though would seem very difficult to institute in this patient sample who at times seem 
bamboozled by multiple medications and changing therapies. It is notable that the 
patients’ appreciate the role of the heart failure specialist nurse, who has the time and 
ability to discuss the disease and current treatments on an individualised basis. These 
professionals may be the best to target with information about symptom relief with 
morphine-like medicines as they often describe the impact and implications of both 
changes in disease and changes in therapy. From this sample however, it would seem that 
doctors, in which these patients hold in such regard, would still need to prescribe 
morphine-like medicines as part of the overall therapeutic regimen. Given the patients’ 
perception of physician opiophobia and from the literature in general (Zenz and 
Willweber, 1993, Larue et al, 1995, Pargeon and Hailey, 1999), it would appear that a 
greater understanding of the use of morphine-like medicines for symptom benefit in CHF 
patients may be required in physicians to allow greater consideration of this type of 
therapy. One could hardly expect an open conversation about morphine-like medications 
with the patient if the treating physician was highly selective with the type of information 
given about morphine-like medications due to their own pre-conceived ideas or attitudes 
about this form of therapy. This potential physician reluctance in CHF could be explored 
with future studies.
It is currently unclear as to the nature of any potential benefit that morphine-like 
medications may provide for breathlessness in CHF. It is clear though that in this small 
patient sample a stoical attitude to health and physical limitations is demonstrated and 
there remains a distinct sense of loss of both activity and role. Patients adapt to their 
changing physical state by avoidance or reduction in physical activity. Interventions for 
breathlessness may not make a dramatic prolonged improvement in activities of daily 
living but CHF patients may appreciate the possibility of symptom intervention to allow 
them to try to participate in activities that they no longer appear to be able to perform.
Pharmaceutically induced symptom improvement may provide an initial platform to
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allow the cycle of inactivity and further physical deconditioning to be broken, thus 
empowering the patient to improve both activity and physical conditioning, leading to 
greater levels of activity and so on. This patient sample in general would appear to be 
receptive to a trial of symptom control therapy.
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Section 5) Conclusion
The prevalence of CHF will increase in coming years, resulting in more patients with 
symptoms potentially amenable to opioid therapy. Such symptoms can markedly reduce 
physical function and adversely affect quality of life. Historical associations of morphine 
has allowed it to be viewed with suspicion by some lay and medical populations alike, 
leading to a reluctance in use of this potentially useful medicine. As demonstrated in this 
sample, male CHF patients are stoical in their outlook to CHF but are willing to accept 
symptom control measures if it has the potential to alter their loss of function or role. 
Hobbies restricted by breathlessness are prominent in the interviews of those that still 
enjoy a reasonable level of physical function. This would suggest that symptoms have an 
impact on the quality of life in earlier stages of CHF than simply end stage disease. The 
participants current pharmacotherapy is mostly directed to disease modification, with 
symptom control measures relatively neglected. Clearly, this needs some attention.
Are CHF patients opiophobic? This small sample of symptomatic male patients would 
suggest not. Morphine for symptom relief would be generally acceptable in this sample 
despite their concurrent polypharmacy. Many have already had direct experience of 
morphine use, which has generally not been a negative experience. End of life use of 
morphine or its use in cancer was not a barrier to accepting morphine as it was perceived 
that high doses were used in those situations. It would seem to have to be prescribed by a 
trusted physician following a dialogue about how their symptoms of pain or 
breathlessness might warrant to trial of therapy.
Patients would expect a discussion about risks, benefits and whether morphine therapy 
would affect their other medications that are seen to be in balance. Given the descriptions 
made by the participants in the study, maybe it is the physicians or medical professionals 
that are more at risk from opiophobia than CHF patients. Descriptions such as “strong”, 
“use sparingly” and “severe” are reportedly attached to morphine by healthcare 
professionals in this sample. It cannot therefore be surprising that patients may be left 
with a biased view of morphine use; that it should be feared as a drug of abuse that might 
hasten death. Of course, morphine prescription should only be made on an individual 
basis for a specific identified reason in patients whose symptoms may not be palliated by 
other means, such as curative interventions or other medical therapies with lesser side 
effects or proven disease modifying benefit. However, this taboo of morphine use will
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only be dispelled with greater and better dialogue of the risks and benefits of morphine 
use on an individual basis. Physicians may be apprehensive to approach such issues, but 
exposure to morphine is noted by many patients with chronic disease such as CHF and 
although there is some realisation that it is used at the end of life, that is not the sum total 
of its use in the experiences of CHF patients. It is clear that symptom control measures' 
are required in CHF to address the loss of function experienced, and morphine is one 
such measure that deserves consideration.
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Chapter 7:
Onioids for breathlessness in heart failure; Past, present and future
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Opium-based compounds have been used for centuries to treat a variety of different 
ailments. We now understand that the administration of these exogenous compounds 
manipulates receptors that are involved in a naturally occurring “endogenous” opioid 
system within the body. In recent years, their use has been concentrated in pain 
management, typically in cancer patients. This has enabled a greater understanding of the 
opioid system, yielding the isolation of the three main opioid receptors, the endogenous 
opioid families and an appreciation of proposed methods of action and activation.
However, the opioid system is complex and may be involved in a whole range of body 
processes. In addition, endogenous opioid-like compounds have been identified that do 
not activate the main opioid receptors, opioid receptors that do not bind typical opioid 
compounds and there would appear to be a wide species variation regarding the site of 
specific opioid compounds or receptors. Even in humans there is a individual variation in 
response to the administration of exogenous opioids. Although there is a substantial body 
of work investigating the sites of endogenous opioids and their receptors relating to their 
proposed analgesic properties, relatively little research has involved sites of interest for 
the cardiorespiratory system and these studies have incorporated a number of different 
animal models rather than human subjects. Because little is understood regarding opioids 
in normal cardiorespiratory function, even less is known in diseased states, including 
CHF.
One of the historical associations of pharmaceutical opioids is the development of 
respiratory depression with increasing doses. This has allowed two bodies of opinion to 
develop. Firstly, opioid administration may be useful in smaller doses for regulating 
breathlessness in certain disease states. There has been some evidence to support this 
notion, mostly in non-CHF patients. Secondly, this detrimental effect of opioids indicates 
that these medicines are dangerous and should only be used with caution. This second 
point has led to the development of physician “opiophobia”, where opioid use is viewed 
with suspicion, and secondly to an initial lack of opioid trials in CHF, in favour of the 
use of opioid antagonists that ultimately appeared to have little influence on 
cardiorespiratory function.
Section 1) Opioids in heart failure: What has gone before
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This thesis has investigated the potential role for opioids in the cardiorespiratory system 
and specifically in CHF. Endogenous opioids and opioid receptors have been isolated at 
sites involved in both cardiovascular and respiratory control in different animal species. 
Basic science and animal studies have identified the antagonism of opioid peptides to one 
of the key neurohormones involved in the development and propagation of CHF, namely 
norepinephrine. Endogenous opioids are raised in human CHF, however it is unclear 
whether this is a cause or effect of this disease. Far from being detrimental, potentiation 
o f opioids may be beneficial, especially as another group of beneficial neurohormones, 
namely the natriuretic peptides, are degraded by one of the same enzymes as endogenous 
opioids (NEP). NEP inhibitors have been shown to have a beneficial effect in human
CHF.
A variety of mechanisms for the formation of generalised breathlessness have been 
proposed. Trials in intractable breathlessness as a whole suggest that opioids are 
beneficial, though trials are small and tend to involve cancer or COPD patients.
Typically, exogenous opioids that predominantly activate mu receptors have been 
utilised in these studies. Antagonism of the sympathetic nervous system by opioids 
suggests that opioids may have an additional effect on breathlessness in CHF as 
sympathetic activation is implicated in some of the mechanisms of dyspnoea in CHF.
The small trials of the assessment of opioids for breathlessness in CHF have been 
discussed, showing a small positive benefit for opioid use. Participant numbers in these 
studies are small and there is only one documenting repeat doses of opioid, as would 
occur in normal clinical practice. Additionally, opioid compounds that activate kappa 
receptors as well as mu receptors may have an additional effect on breathlessness in CHF 
as kappa receptors may be involved in inhibiting fluid retention. Oxycodone is such an 
opioid, with mu and kappa activating properties. Therefore, there was a need to 
investigate whether repeat dosing of opioids for breathlessness in CHF was actually 
beneficial; to corroborate the safety of opioids in CHF; to identify patient factors such as 
aetiology, stage of disease or level of sympathetic blockade that might influence response 
to opioids; and to assess whether CHF patients would be accepting of such an 
intervention.
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Section 2) Opioids in heart failure: Present study findings
This thesis involves a double blind crossover randomised controlled trial (RCT), a three 
month open label study and a qualitative study of CHF patient attitudes to opioids. This 
is only the second multiple dose study in CHF of opioids for breathlessness following the 
first involving ten participants. It is the first to compare two opioids with placebo and the 
first to include oxycodone as an opioid. It adds to the evidence base that low-dose 
opioids are safe in CHF. No detrimental impact was observed on cardiovascular or 
respiratory parameters and overall opioids were well tolerated.
The RCT did not reveal any statistically significant improvement with either opioid for 
breathlessness severity versus placebo, but did show that at baseline breathlessness 
appeared to be a significant problem in this patient sample. This may have been in part 
related to the large placebo, response seen in some participants, indicating possible 
regression to the mean, or the short treatment period. Overall oxycodone was better 
tolerated than oramorph at equivalent doses. A variety of breathlessness measures were 
used, some of which appeared to reflect the participant experience better than others. For 
the first time, Borg and NRS measures of breathlessness were compared to each other in 
CHF with the development of formulas for conversion between rating scales. Types of 
descriptions of breathlessness concurred with the other small trials in CHF, adding to the 
evidence base. This study is the first to document the effect of opioids on breathless 
descriptors and the first to investigate breathlessness severity with individual descriptors.
This work incorporates the first published open-label treatment follow-up of opioids for 
breathlessness in CHF. In contrast to the RCT, a statistically significant improvement 
was seen on breathlessness severity with opioids on the NRS worst breathlessness scale. 
This difference approximated to a moderate improvement in breathlessness severity on 
global impression of change scores compared to those not continuing with opioid 
therapy. The open-label design approximates more closely to the actual clinical situation 
of opioid prescription, so this finding is important. It also demonstrates that opioids at 
these low doses were effective for breathlessness, rather than consideration of higher 
doses given the neutral RCT results.
Overall, no difference between opioid treatments on breathlessness severity was 
observed. However, those that responded to one opioid may not respond to the other,
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suggesting that opioid switching might be appropriate if initial success in breathlessness 
management was not forthcoming. No association was observed with dose of beta- 
blocker for opioids in general, hence no link with sympathetic inactivation due to opioids 
could be made. Markers of disease severity, such as BNP or ejection fraction, also did 
not correlate to response with opioids. In general, the effect on breathlessness severity 
was maintained from the initial improvement observed after four days of treatment in 
those that continued opioid therapy, with a marked deterioration in breathlessness 
severity from end of placebo treatment in those that did not continue. This suggests that 
the effects of opioids are maintained over time, whereas breathlessness markedly 
worsens with time if no opioid treatment is taken. Continuation of opioid therapy also 
resulted in an improvement in quality of life scores in both physical and mental 
(psychological) domains compared to those not continuing treatment, suggesting that 
therapy does not just improve symptoms through a psychological response alone.
A separate group of symptomatic CHF patients were interviewed regarding their attitudes 
to CHF and the possibility of morphine treatment for breathlessness. This study was the 
first to assess the attitudes o f CHF patients to the potential for morphine use. Perhaps 
surprisingly, most participants thought that morphine would be acceptable, as 
breathlessness was a troublesome symptom and they had some experience of morphine 
use before. This work also corroborates other studies in CHF regarding the importance of 
functional loss due to physical restriction and subsequent adaptation. It is the first work 
to concentrate on factors affecting male patients with CHF as a separate group. Despite 
acceptability in patients often with complex pharmacotherapy, attention needs to be 
focussed on prescribers that may restrict use due to opiophobic tendencies. In addition, 
the use of mixed methodological techniques has a synergistic approach in understanding
in this area.
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Section 3) Opioids in heart failure: Future directions
This thesis illustrates the potential role of opioids in the management of breathlessness in 
CHF. Future studies should expand upon this work. Firstly, a definitive multi-centre RCT 
is warranted. A greater number of centres are required to increase the number of potential 
participants. The inclusion and exclusion criteria should be relatively broad, as in the 
current RCT, as it is clear that many patients will not fit stricter eligibility criteria. A 
longer treatment phase should be employed, perhaps up to fourteen days as an example, 
to allow more standardisation of clinical variation. As documented in this thesis, NRS 
scores appear to be more flexible at lower levels of breathlessness and change in NRS 
should be documented as the primary outcome measure. Borg scores can always be used 
as a comparative measure. NRS rating scores could be taken simply at the end of each 
treatment period in conjunction with global impression of change rating of breathlessness 
as these measures may reflect the patient experience better than change in scores from 
baseline. It is also clear that current rating scores may not be as descriptive as average or 
worst ratings for these patients. Following the crossover part of the RCT, and extended 
follow-up period could be initiated. This could follow similar lines to the three month 
follow-up in this thesis, but additional assessments, for example at one, two, three and six 
months could derive more useful information. In addition, if this follow-up period was 
blinded to intervention, this would improve the robustness of the study. Participants 
could select the treatment they felt most benefitted them (first, second or third), then 
continue on this open label, even if it was the placebo. This would eliminate some of the 
potential criticisms of the follow-up period, as all participants would be receiving a 
treatment.
Opioid doses should be based on the equivalent doses utilised in the RCT, however in the 
absence of side effects the dose could be increased incrementally in those whose 
breathlessness does not respond. This would allow a dose range for breathlessness to be 
investigated, as some participants may only respond at higher doses than the ones 
previously quoted. As demonstrated in the results in Chapter 5, some of those 
participants that did not respond to opioid therapy in the initial RCT may have tolerated 
much higher doses as their renal function was good and the trial drugs may have been 
cleared more rapidly than in those that responded to opioid treatment. Increasing the dose 
in these participants may allow more to respond to treatment. Oxycodone should be the 
choice of opioid if only one were to be investigated in this fashion, as adverse effects
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were lower compared to oramorph. Drug delays and placebo manufacture caused 
difficulty in the RCT, so sourcing commercial manufacturers of investigational medicinal 
products should be a priority prior to trial commencement.
From the existing literature it is still unclear as to the relationship of sympathetic 
activation, endogenous opioids and level of breathlessness. Using beta-blocker 
prescription as a proxy measure for sympathetic activation is not ideal. Measurement of 
serum concentrations of norephinephrine as an approximation for sympathetic activity 
may be more accurate. Serum norepinephrine and circulating endogenous opioid 
concentrations could then be measured against breathlessness rating to elucidate whether 
high norephinephrine concentrations and low endogenous opioid levels correlate with 
high levels of breathlessness. In addition, given that sympathetic overdrive is associated 
with breathing disorders in CHF such as periodic breathing, cheyne-stokes respiration 
and sleep-disordered breathing, measurement of these breathing patterns in a sub-section 
o f enrolled participants would be of interest. The effect of opioids over time on these 
abnormal breathing patterns can then be assessed. One quality of symptomatic CHF that 
should also be measured in conjunction with this would be an assessment of sleep and 
whether this is improved with opioids both through improvement in breathing patterns 
and from the drug’s adverse effect profile.
Opioid therapy would appear to be acceptable in advanced heart failure and discussion 
about the potential role of this therapy should be encouraged. Whilst patients may not 
exhibit opiophobic tendencies, what is unknown is whether their treating cardiologists 
may have preconceived ideas about opioid use. The possibility of CHF physician 
opiophobia should be explored in future studies in order to allow appropriate prescription 
o f opioids for symptoms. There is a sense that cancer patients are more willing to 
consider morphine and this point should be explored further; does greater information 
about morphine improve the willingness of patients to consider its symptomatic use?
The stoical outlook of patients and their possible sense of disavowal should also be 
further explored, with comparison between groups of patients with different aetiologies. 
Further comparison of the attitudes to disease between genders should also be 
encouraged, with a similar study involving the attitudes of women to CHF. The sense of 
how CHF patients feel they are perceived by carers and the wider community was only 
partially explored in the thesis, but this again would provide an interesting avenue for 
future qualitative research.
345
The use of mixed methodological techniques involving both quantitative and qualitative 
design in this thesis has allowed a synergistic improvement in the understanding of 
opioids in CHF. An adequate understanding of the previous work undertaken, an 
assessment of treatment efficacy and an appreciation of the potential role for therapy 
from a patient’s perspective has provided a more complete picture than the use of these 
techniques in isolation. Future studies should have an appreciation of all these separate 
areas of research importance with a view to providing more studies of good quality 
mixed methodology.
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Appendix 1) Glossary of terms
Acute Heart Failure
The sudden onset of a physiological state in which cardiac output is insufficient to meet 
the body’s needs, typically caused by sudden events such as myocardial infarction or 
cardiac rhythm disturbances. Pulmonary oedema is a key feature and is treated acutely 
with diuretic therapy
Afferent neurons
Carry nerve impulses from sensory receptors or organs towards the central nervous 
system
Afterload
The systolic load on the left ventricle after it has started to contract. If this occurs 
chronically and increased afterload is sustained the left ventricle must hypertrophy to 
compensate for the increased pressure
Agonist
A compound or drug that binds to a receptor of a cell and triggers a response by that cell
Antagonist
A drug that blocks the action of an agonist on a cell 
Atria
Chambers o f  the heart that receive blood from the venous systemic circulation (right 
atrium) or pulmonary circulation (left atrium) to pump into the cardiac ventricles
Autonomic
Pertaining to the autonomic nervous system, part o f  the peripheral nervous system and 
comprising o f sympathetic and opposing parasympathetic components. It has sensory and
motor properties.
Baroreceptors
Sensory receptors that monitor the pressure o f  blood flowing through blood vessels and 
feed this information back to the central nervous system
i
Bruce protocol
A standardised method of exercise testing in cardiac patients to monitor cardiac function 
with exercise using a treadmill
Cardiomyopathy
A general term indicating disease of cardiac muscle, causing dilatation of heart muscle, 
hypertrophy of heart muscle or restriction in heart muscle function dependent on 
aetiology
Central Nervous System 
Neurons of the brain and spinal cord
Chemoreceptors
Sensory receptors that detect chemical stimuli in the circulation and relate the 
information to the central nervous system. Peripheral chemoreceptors exist in the aortic 
and carotid bodies, whereas central chemoreceptors occur near the medulla oblongata in 
the brain. Collectively they can detect changes in carbon dioxide, oxygen concentrations 
and pH.
Cheyne-Stokes
An abnormal breathing pattern involving periods of alternating hyperventilation and 
apnoea
Chronic Heart Failure
The gradual onset of a physiological state in which cardiac output is insufficient to meet 
the body’s demands. Can occur after periods of acute heart failure or due to ongoing 
myocardial damage. Chronic heart failure is seen as a stable condition, with periods of 
decompensation where acute signs and symptoms can occur (acute decompensated heart 
failure).
Efferent neurons
Also known as motor neurons, carry nerve impulses from the central nervous system to 
effector organs (e.g. muscles)
n
Ejection fraction
The fraction of blood pumped out of the left ventricle with each heart beat 
End-diastolic volume
The volume of blood in a ventricle at the end of diastole (filling). Increases in this 
volume increases the pre-load on the heart and subsequently the volume of blood ejected 
from the ventricle during systole.
Haemodynamic
Relating to the circulation of the blood 
Hypercapnea
An excess of circulating carbon dioxide in the blood 
Hypoxia
Deprivation of adequate oxygen supply (hypoxaemia -  abnormally low oxygen 
concentration in the arterial blood is one such cause)
Ischaemia
Insufficient blood supply to a tissue or organ 
Ischaemic Heart Disease
A condition characterised by reduced blood supply to heart muscle, usually due to 
coronary artery disease
Inotropic
Drugs or factors that increases the strength of contraction of heart muscle (positively 
inotropic). Negative inotropes reduce cardiac contractility
Ligand
Molecule that binds to a receptor forming a complex 
Mechanoreceptors
Sensory receptors that respond to mechanical stimuli and relate information to the central 
nervous system
iii
Myocardium
Striated muscle of the heart (individual muscle cells known as myocytes)
Naloxone
An opioid receptor antagonist, inhibiting opioid transmission at relatively low doses 
across all receptor subtypes
Neurohormonal
Pertaining to neurohormones, any hormone-like protein produced and released by 
neurons (including but not exclusively into the circulation)
Noradrenaline 
See norephinephrine
Norepinephrine (noradrenaline)
A hormone released by the adrenal glands and neurotransmitter in the central nervous 
system and sympathetic nervous system where it acts as an agonist for sympathetic 
activity
Oedema
The abnormal accumulation of fluid in skin, soft tissues or body cavities 
Oramorph
A short acting oral liquid form of morphine, predominantly a mu opioid receptor agonist 
Oxynorm
A short acting oral liquid form of oxycodone, a mu and kappa opioid receptor agonist 
Parasympathetic nervous system
Modulates vital functions with the sympathetic nervous system, for which it is 
continually in a state of balance. Parasympathetic activity tends to oppose the actions of 
the sympathetic system by returning body functions to their resting state.
Parenchyma
IV
Typically used to describe lung components, including alveoli and bronchioles
Parenteral
Route o f administration through the skin or mucous membranes (examples include 
intravenous and subcutaneous)
Periodic Breathing
An abnormal breathing pattern characterised by intervals of apnoea within periods of 
normal breathing
Peripheral Nervous System
The neuronal connection between the central nervous system and the organs. It is divided 
into somatic and autonomic types.
Post synaptic
Occurring in neurons after a nerve junction (synapse) with another neuron 
Pre synaptic
Occurring in neurons prior to a nerve junction (synapse) with another neuron 
Step 2 analgesics
“Weak” opioid medicines (codeine, tramadol as examples) used for moderate pain as the 
step 2 of the traditional World Health Organistion analgesic ladder. Their use is limited 
by ceiling dose effects
Step 3 analgesics
“Strong” opioid medicines (morphine, oxycodone, fentanyl as examples) used for severe 
pain as the step 3 of the traditional World Health Organisation analgesic ladder
Stroke volume
The volume of blood pumped from one ventricle with each heart beat (calculated from 
subtracting the end-systolic volume from the end-diastolic volume)
v
Sympathetic nervous system
Modulates vital functions with the parasympathetic nervous system, tending to promote a 
“fight or flight” response, increasing heart rate, heart muscle contractility, blood flow to 
skeletal muscles, dilates lung alveoli and coronary blood vessels. One of its principle 
neurotransmitters is norepinephrine.
Vasoconstriction
Narrowing of blood vessels through muscular vessel wall contraction, resulting in 
reduced blood flow due to an increase in vascular resistance. It is part of the mechanism 
that regulates arterial pressure
Ventricles
Chambers of the heart that receives blood from the atria to pump around the pulmonary 
circulation (right ventricle) or systemic circulation (left ventricle)
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Appendix 2) List of abbreviations
ACEI Angiotensin Converting Enzyme Inhibitor
ADH Anti-Diuretic Hormone
ANP Atrial Natriuretic Peptide
ARB Adrenoreceptor blocker
ATI I Angiotensin II
BP Blood pressure
BNP B type Natriuretic Peptide
CHD Coronary Heart Disease
CHF Chronic Heart Failure
Cl Confidence Interval
CNS Central Nervous System
COPD Chronic Obstructive Pulmonary Disease
DCM Dilated Cardiomyopathy
ECG Electrocardiogram
EF Ejection Fraction
FEVi Forced Expiratory Volume in one second
GFR Glomerular Filtration Rate
IIFNS Heart Failure Nurse Specialist
ICD Implantable Cardioverter Defibrillator
IHD Ischaemic Heart Disease
LVEF Left Ventricular Ejection Fraction
LVSD Left Ventricular Systolic Dysfunction
NT-ProBNP N-terminal Pro-B type Natriuretic Peptide
NYHA New York Heart Association (functional classification)
ON Once nightly (omni nocte)
PCR Polymerase Chain Reaction
PEFR Peak Expiratory Flow Rate
QDS Medicine taken four times a day (quater die sumendus)
QOL Quality of Life
RAAS Renin Angiotensin Aldosterone System
RCT Randomised Controlled Trial
SD Standard Deviation
SE Standard Error
TDS Medicine taken three times a day (ter die sumendus)
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Appendix 3) RCT study protocol
OPIOIDS IN THE MANAGEMENT OF BREATHLESSNESS IN ADVANCED 
HEART FAILURE PATIENTS
S Oxberry 25/09/07
M Johnson, D Torgerson, J Cleland, A Clark
This proposal has been developed by Dr Stephen Oxberry and Dr Miriam Johnson in 
collaboration with the York University Trials Unit (Professor David Torgerson) and the 
Hull Academic Unit of Cardiology (Professor John Cleland and Dr Andrew Clark).
1.0 Introduction
1.1 Background
Breathlessness is a defining symptom of heart failure and forms the basis of the New 
York Heart Association (NYHA) grading. In addition to the physical burden, it is a cause 
of patient distress and has a significant impact on quality of life, which is thought to be 
poorer than some patients with incurable cancer (l). Heart failure has become a common 
chronic disease in the developed world and thus this represents a large symptom burden 
that impacts greatly on health resources. The prevalence of heart failure is increasing 
with the increasing age of the population (2). Patients with advanced heart failure can 
still be limited by breathlessness, despite the development of therapies currently used in 
standard clinical practice.
The precise mechanism of breathlessness in various disease states remains unclear 
though there are a number of different hypotheses (3). In addition to general mechanisms 
of breathlessness, it has been shown that some chronic heart failure patients also 
demonstrate abnormal breathing patterns (such as Cheyne-Stokes breathing or Periodic 
breathing) {4}. In heart failure, there is also a chronic activation of the sympathetic 
nervous system which is considered to be detrimental to the failing heart (5).
It has been noted that opioid receptors are located within the sympathetic nervous 
system, heart, lungs and brainstem (6) that may influence the sensation of breathlessness
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in heart failure. Endogenous opioids are released in acute and chronic heart failure but 
their role is somewhat unclear. In general, opioids have an inhibitory role and it has been 
suggested that they may balance the sympathetic overactivity seen in heart failure (7).
Opioids or “morphine-like medicines” have been used for years in the management of 
pain and have a good safety profile when administered appropriately by trained 
healthcare professionals (8). The side effect profile is well described and can include 
nausea, vomiting, drowsiness, impaired concentration, constipation and itch (9). 
Respiratory depression, tolerance and addiction are considered to be rare particularly at 
low doses when prescribed appropriately (8). Parenteral administration of naloxone is 
considered as the treatment of overdose due to opioids if respiratory depression is 
sufficient to compromise respiratory function.
Opioids like morphine and oxycodone are metabolised by the liver and excreted via the 
kidneys. They bind to the 3 types of opioid receptor that are distributed in the body, but it 
is considered that morphine preferentially binds to mu-opioid receptors, whereas 
oxycodone has a greater affinity for kappa as well as mu receptors (10). Both the oral 
morphine and oxycodone preparations proposed in the study are termed immediate 
release, but sustained release preparations of opioids are available.
Opioids have also been used clinically in the management of breathlessness in advanced 
disease. A Cochrane review of 18 small placebo controlled double blind randomised 
trials in advanced disease populations (116 participants in total) revealed improvement in 
the severity of breathlessness when opioids were given by oral or parenteral 
administration (11). Only one of the included trials involved heart failure patients 
specifically (the majority of patients had cancer or chronic obstructive pulmonary 
disease).
Unlike breathlessness in cancer where there have been a number of studies evaluating the 
effects of opioids, there has only been one small pilot study of repeat dosing in heart 
failure patients by Johnson et al. (12). The safety of diamorphine in heart failure patients 
during exercise has also been demonstrated in a small study (13). Weak opioids have 
been shown to improve the abnormal breathing patterns seen in some heart failure 
patients in a pilot study (14). The paucity of research into opioids and heart failure has
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been noted (15,16). Current clinical practice either involves the prescription of morphine 
for breathlessness or a reluctance to use morphine without efficacy studies.
We aim to conduct a double blinded cross-over study to compare the effects of two 
opioids against placebo for the relief of breathlessness in advanced heart failure. Oral 
morphine (Oramorph) and oral oxycodone (Oxynorm) have been chosen as they do not 
have ceiling doses like weaker opioids (such as codeine or tramadol) and are used the 
most widely in clinical practice. The doses considered for oral morphine and oral 
oxycodone are considered to be clinically equivalent (9). Oral morphine has been chosen 
because of the previous pilot study and because Oramorph is specified as an unlicenced 
indication for the management of breathlessness in the British National Formulary (9). 
Oxycodone has been chosen as a common alternative to morphine in palliative medicine 
that has a different morphine receptor profile in humans and may have less side-effects in 
a patient group who may not have consistent optimal renal function (10).
Key points:
•  Breathlessness is a common problem in heart failure patients which affects their 
quality o f  life.
• Opioids are already used, albeit inconsistently, in the management of 
breathlessness for cancer patients and COPD.
• A pilot study indicates that morphine relieves breathlessness in heart failure 
patients.
1.2 Primary research question:
Do morphine and oxycodone relieve breathlessness in patients with NYIIA grade III/IV 
heart failure receiving optimal medical therapy?
2.0 Study objectives
Primary objective:
• To assess the relative benefits of oral morphine and oral oxycodone in the 
management of breathlessness in advanced heart failure.
Secondary objectives:
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• To monitor any subsequent changes in distress caused by breathlessness, physical 
function, coping with breathlessness and satisfaction with treatment.
• To assess the impact of morphine or oxycodone on quality of life in heart failure.
• To confirm tolerability of therapy in this patient population and to assess relative 
merits of morphine versus oxycodone.
• To explore the characteristics of breathlessness in heart failure patients.
3.0 Overview of design
3.1 Design and summary treatment plan
This study is a 3-arm prospective, double-blind, randomised, placebo controlled, cross­
over study involving patients with NYHA Grade III/IV heart failure receiving optimal 
medical therapy. The two intervention arms consist of oral morphine sulphate (5mg) and 
oral oxycodone (2.5mg) administered four times a day for a total of four days. At the end 
of the study, patients will be asked their preference, and if this is an opioid rather than 
placebo, they will be able to continue taking this medication after the study.
The four day intervention period is chosen to allow drug to reach steady state given that 
the half life of oral morphine (oramorph) and oral oxycodone (oxynorm) is between 1.5 
and 4 hours. It will also allow the placebo benefit and adverse effect of sedation to return 
to baseline as indicated by the pilot study (12). Thereafter a three day washout period 
will occur before the next intervention / control to avoid a sequence effect. A generous 
wash out period is planned as both opioids are renally excreted.
Participants will be randomly allocated using a Latin-square pattern to receive oral 
morphine, oral oxycodone or placebo. All of the study drugs will be dispensed in liquid 
form. A schematic representation is detailed in section 3.2. A cross-over design has been 
chosen to reduce the number of study participants required; it is recognised that it is 
difficult to recruit to palliative care studies. The disadvantage of crossover studies in 
palliative care is that it is necessary for the patients to be stable for the duration of the 
study to avoid a period effect and this can be a problem with malignant disease. 
However, is thought that heart failure patients are more likely to be stable over the study 
time period.
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3.2 Schedule summary
Key: A = morphine, B = oxycodone, C = placebo, W = washout period
Patient identification by treating physician or from database
4
Eligibility criteria fulfilled
i
Informed consent
4
Baseline data collection
I
Simple randomisation to 1 of the 6 following groups
I
Days 1-4 A A B B c c
(Daily assessment*) 4 4 4 4 4 4
Days 5-7 W w W W w W
1 4 4 4 4 4
Days 8-11 B c A c A B
(Daily assessment*) 4 4 4 4 4 4
Days 12-14 W w w w w w
1 4 4 4 4 4
Days 15-18 c B c A B A
(Daily assessment*) 1 4 4 4 4 4
Days 19-21 w w w w w w
4
Day 28 Follow-up /  open label therapy
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*Daily assessment of the patient will occur during this period with the first and last days 
requiring completion of face-to-face assessments with the remaining two days as 
telephone assessments. Please refer to section 5.5 for further details of the schedule of 
assessments.
3.3 Endpoints
Primary: Change in severity of breathlessness as measured by the validated Borg
score and Numerical Rating Scale (NRS) for breathlessness (average and 
worse over past 24 hours and current level).
Secondary: 1) Distress from breathlessness as measured by the NRS score for distress.
2) Satisfaction with treatment of breathlessness and coping with 
breathlessness as measured by the NRS scores for satisfaction and coping 
with breathlessness.
3) Assessment of the overall change in breathlessness severity as 
measured by the Global rating of change score.
4) Assessment of the characteristics of breathlessness in heart failure 
patients by using the descriptors for breathlessness.
5) Adverse effects as measured by NRS scores for nausea and drowsiness, 
constipation assessment, use of concomitant medications and 
identification through self report of other events that may or may not be 
attributable to study drug.
6) Quality o f life scores as measured by the validated SF-12 Quality of 
Life Questionnaire.
7) Change in validated Kamofsky performance scale of physical activity.
At the end of the study, the participants will be asked which of the three arms they prefer 
most and will be given the opportunity to continue that treatment in consultation with the 
physician on an open-label basis if an active drug is identified. Participants will be 
invited to return three months after cessation of the study for a repeat BNP blood sample 
and repeated assessment measures but this will not be compulsory. Overall, the study 
itself will be deemed to have finished following the final visit of the last participant.
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4.0 Study population
The Academic Department of Cardiology in the Hull and East Yorkshire NHS Trust 
maintain a database of heart failure patients to facilitate patient screening. Patients 
attending heart failure out-patient clinics and in-patients will also be screened. Patients 
with NYHA grade III/IV heart failure on optimal medical therapy will form the study 
population. This group has been selected where the impact of breathlessness is high and 
therefore may have the most to gain from improved breathlessness management. The 
Academic Department is run by Professor John Cleland.
4.1 Inclusion criteria 
Patients with:
•  Heart failure grade NYHA III/IV with Left Ventricular (LV) dysfunction 
confirmed by echocardiography.
• Heart failure from any aetiology with stable NYHA status for at least one month.
• Optimal (and unchanged over previous one month) medical management of their 
heart failure (diuretic and ACE inhibitor/AII antagonist).
• Adequate renal clearance (using Cockroft and Gault: GFR>30ml/min)
• Aged 18 years or over.
• Provided written informed consent and able to complete patient assessments.
•  An estimated prognosis of more than eight weeks.
4.2  Exclusion criteria 
Patients who:
• Are unable to complete patient related information on entry.
• Have significant co-existing lung disease (e.g. COPD, Asthma, Lung fibrosis) 
contributing significantly to the patients’ breathlessness i.e. PFR <150.
• Have co-existing malignant disease if this would affect the study in the 
investigators’ opinion.
• Have significant renal impairment (Using Cockcroft and Gault GFR<= 
30ml/min).
• Are unable to provide informed consent.
Version 1.1:25/09/07; R&D R0452
Eudract: 2006-006718-13 xiv
• Are involved in other medicinal trials currently.
• Have used morphine-based medications within the last month.
• Have known true morphine allergies.
• Have conditions contraindicated in the Summary of Product Characteristics 
(SmPCs) for Oramorph and Oxynorm, namely:
Respiratory depression, obstructive airways disease, acute and chronic bronchial 
asthma, cor pulmonale, hypercarbia, acute hepatic disease, moderate to severe 
hepatic impairment, acute alcoholism, acute abdomen, delayed gastric emptying, 
chronic constipation, head injury, coma, convulsive disorders, raised intracranial 
pressure, paralytic ileus, severe renal impairment, known hypersensitivity to 
product constituents and those receiving Mono-amine Oxidase inhibitors 
(MAOIs) or within 2 weeks of cessation of these drugs.
• Are planning to undergo a surgical or interventional procedure, those taking a 
medicinal product with a known interaction with opioid based compounds, and 
women who are pregnant or lactating will also be excluded.
4.3 Withdrawal criteria
Patients will be withdrawn from the study on:
• Withdrawal of patient consent.
• Withdrawal of the patient by the treating physician or medical researcher due to 
the patient no longer meeting the eligibility criteria.
5.0 Method and procedures
5.1 Recruitment
Eligible patients will be approached following identification from the Academic Unit of
Cardiology Heart Failure database. Only patients who have expressed a wish to
participate in clinical trials previously or have expressed an interest when seen in clinic
will be approached. An invitation letter will be sent out with details of the trial and
contact details of the researcher included in the patient information sheet in the first
instance. Eligible patients may also be assessed by the researcher if the treating physician
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has approached the patient for possible entry into the study during routine heart failure 
clinic visits or on hospital wards. At a time and place that is convenient to the patient, the 
researcher or research nurse will be available to discuss the study further and to answer 
any questions that may arise from the patient information sheet. Each subject will be 
adequately informed of the aims, methods, anticipated benefits, potential hazards and 
discomforts the study may entail. The subjects’ right not to participate and the right to 
withdraw at any time, without the need to give an explanation and without detriment to 
their overall treatment will be clearly stated.
Once a patient has accepted the invitation to take part, written consent will be obtained 
by the researcher. At least 24 hours should elapse between receipt of the patient 
information sheet and giving informed consent. It will be made clear that the participant 
will be able to withdraw consent at any time should they wish. All consent forms will be 
documented and stored in accordance with local Hull and East Yorkshire NIIS 
requirements. A copy of the consent form will be given to the participant, one copy will 
be entered into the patients hospital notes and the original will be kept in the study file in 
the Academic Unit of Cardiology. The consent form for participants must be completed 
prior to study entry and this form contains a section requiring consent to inform the 
patients GP regarding entry into the study. A GP letter regarding the study and copy of 
the Participant Information Sheet will be sent to the GP following the consent procedure.
5.2 Randomisation
Simple randomisation of the six possible combinations of receiving treatment will occur 
in the Calderdale and Huddersfield NHS Trust hospital pharmacy. This is following 
statistical advice from Professor Martin Bland. Randomisation will usually take place at 
the same visit as completion of the consent form.
5-4 Blinding
This crossover study involves two active medications (oral morphine and oral 
oxycodone) and placebo. It is important that the participant is unaware of the order that 
these medications are taken in as this knowledge may bias the subsequent results. It is 
also important the assessor of the participant outcomes is also blinded to the order so that 
potential bias in recording the results can be prevented. Therefore neither the researcher,
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participant or research nurse will be aware of the order of treatments. Calderdale and 
Huddersfield NHS Trust hospital pharmacy will be aware of the order of treatments but 
will label the medications so that the order cannot be deduced by the research team or 
participant. A copy of the randomisation codes will be kept locally in Hull and East 
Yorkshire NHS pharmacy so that local access to the randomisation sequence for each 
participant can be obtained for the purposes of de-blinding should the need arise due to 
adverse events. Both pharmacies will be independent to the study process.
5.4 Intervention
In this crossover trial all participants will receive oral morphine (5mg), oral oxycodone 
(2.5mg) and oral placebo. All of these compounds will be administered in liquid form. 
Given the difference in the concentrations of the interventions used each patient will take 
2.5ml of liquid four times a day (morphine, oxycodone or placebo). The oral liquid 
placebo will be manufactured in accordance with MHRA guidelines by Calderdale and 
Huddersfield NHS Trust pharmacy manufacturing unit (MHRA site number: 11706). The 
placebo will have very similar characteristics to the active medications (a clear, 
colourless liquid with the same viscosity and similar taste). The formula of the placebo 
mixture is as follows:
Syrup BP 15%v/v
Methyl Hydroxybenzoate 0.1% w/v 
Propyl Hydroxybenzoate 0.01% w/v 
Citric Acid 5% soln q.s 
Distilled water to 100%v/v
The liquid placebo will be manufactured in the Calderdale and Huddersfield NHS Trust 
Pharmacy Manufacturing Unit (Non-sterile product) at Huddersfield Royal Infirmary.
The method of production is detailed as follows:
1. Make up the citric acid 5% solution
2. Dissolve the Methyl and Propyl hydroxybenzoate in 200ml of boiling distilled 
water
3. When dissolved add to the syrup in a 1 litre measure
4. Make up to volume with distilled water. Mix well. Check the pH (needs to be
between 4-5). Reduce the pH using the Citric Acid solution above.
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5. Pack, cap and label in a 500ml amber glass bottle with Clic Loc tamper evident 
cap.
For a more detailed process of manufacture and monitoring please refer to the Pharmacy 
Manufacturing Sheet produced by Calderdale and Huddersfield NI IS Trust Pharmacy, 
Huddersfield Royal Infirmary, Acre Street, Lindley, Huddersfield I ID3 3EA.
Placebo and active medications will be labelled by Calderdale and Huddersfield NHS 
Trust hospital pharmacy and transported as packs of 50ml bottles of oral oxycodone, oral 
morphine and placebo. Each pack will contain one bottle of each of the three medications 
to be taken in a randomised sequence and one pack will be given to each participant. The 
bottles will be placed in a plastic minigrip bag and labelled according to the guidance in 
Annex 13 for the Manufacture of Investigational Medicinal Products (IMP). Both the 
immediate containers and the outer packaging will be labelled.
Click-locked bottle adapters and tamper evident seals will be employed. These 
medication packs will be dispensed by Hull and East Yorkshire NHS hospital pharmacy 
from the controlled drug register. An expiry time of 90 days will apply to each 
medication pack (in accordance with the manufacturers guidelines). Opened bottles will 
be collected every week following use and residual medication will be measured to 
assess compliance.
In addition, Domperidone lOmg pm (an antiemetic) and Senna 7.5mg pm (a laxative) 
will be co-prescribed at the start of the trial to ensure that participants have appropriate 
medications in case of side effects to take as required. Eleanor Dakkak (Chief Clinical 
Pharmacist) and Vicki Lowthorpe (Senior Pharmacy Technician, Hull Royal Infirmary) 
will help us in this regard.
5.5  Measurements
Baseline assessments will be carried out by the researcher or research nurse. Some of 
these variables can be derived from information on the Academic Unit of Cardiology 
heart failure database at the discretion of the researcher. These assessments will include:
•  A ge and gender
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• Aetiology of heart failure
• NYHA Grade
• Current medication
• Left Ventricular dysfunction on echocardiography
•  Peak Flow  Rate
• Serum Urea and Creatinine
• BNP (B-type Natriuretic Peptide) measurement
A blood sample will be required at baseline to assess the participants’ BNP level (BNP is 
released by the cardiac ventricles and is raised in proportion to heart failure severity) and 
renal function if not done within the last month. Blood samples for BNP will be stored at 
-80°C in the freezer in the Academic Unit of Cardiology, Castle Hill Hospital, Hull. 
Samples will be identified by unique trial number and participant initials. Once the study 
is complete, these will be transferred to Anne Anderson in the Immunoassay section of 
the Pathology department in Hull Royal Infirmary, Hull. The blood sample for renal 
function assessment will be analysed directly by the pathology laboratories in Hull Royal 
Infirmary. The results of these tests will be inputted onto the Academic Cardiology 
computer database.
Participants will be directly observed by the investigator (Dr Stephen Ox berry) for one 
hour after the first administration of each compound (oramorph, oxynorm and placebo). 
Measurements will be taken at baseline (pre-administration) and at one hour on Day 1 to 
assess effect and side effect profile as detailed below. The one hour observed period for 
each compound is to ensure that participant safety is maintained after the first dose. With 
this in mind, participants will be telephoned for assessments on the following two days 
on treatment, with a further face to face assessment on Day 4. When the researcher is not 
present the participant will be given a number to contact in case of any questions, queries 
or problems.
Palliative care patients are frequently commenced on opioid based medication on an 
outpatient basis without a period of observation by the clinician. This is part of routine 
clinical practice. The previous pilot study involving oramorph by Johnson et al (12) 
allowed for a similar period of one hour of observation of the trial participant. The time 
to clinical effect for oral oxynorm and oramorph will be observed within the first hour
following administration.
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As part of the study, participants will be assisted in completion of a diary card at baseline 
(pre-treatment), 1 hour, day 2, day 3 and day 4 for each of the three study medication 
periods (morphine, oxycodone and placebo). Daily assessments will occur whilst on 
treatment (Days 1 to 4 in each treatment period). These daily assessments include:
• Borg score for breathlessness (worst, average and current)
• 11 point Numerical rating scale of breathlessness severity (worst, average 
and current) and distress caused by breathlessness
• 11 point Numerical rating scale for side effects (drowsiness, nausea)
• Assessment of constipation (Do you feel constipated?: Yes/No)
• Enquiry into any further side effects
•  Change in medication or use of concomitant medication
The SF-12 Quality of life score, Kamofsky performance score and physical 
measurements (pulse, blood pressure, respiratory rate and oxygen saturation) will be 
taken on days 1 and 4 of each treatment period. The requirement of additional 
medications (such as anti-emetics or laxatives) will be monitored and supplies of these 
concomitant medications will be prescribed by the medical researcher to be used as 
necessary. Global impression of change in breathlessness due to the study medication 
will be assessed on day 4 of each treatment period. A summary table of the schedule of 
assessments is outlined below.
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Schedule of assessments
Day 1 
Baseline
Day 1 
1 hour
Day 2 Day 3 Day 4
Data collection Visit Visit Phone Phone Visit
Pulse
Blood pressure 
Respiratory rate 
Oxygen saturation
X X X
NRS*
breathlessness, 
distress, satisfaction, 
drowsiness, nausea
X X X X X
Constipation X X X X
Borg score** X X X X X
SF-12*** X X
Breathlessness
descriptors****
X X
Karnofsky 
performance statusf
X X
Global rating of 
change in 
breathlessnessff
X
Concomitant
medication
X X X X
Adverse events X X X X X
Key:
* 11-point Numerical rating scale (NRS) of average breathlessness over the past 24 hours 
(anchored with “not breathless” and “worst breathlessness imaginable”):
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Not breathless Worst
Breathlessness
Imaginable
11-point NRS of distress caused by breathlessness (17), satisfaction, drowsiness and 
nausea will also be completed by the participant. In addition, daily assessments of bowel 
function will be made.
** The Borg score, a self-assessment instrument validated for use in breathlessness (18) 
will be completed.
*** The SF-12 validated Quality of Life (QoL) score version 2 (19) will be assessed at 
baseline (pre-treatment) and day 4 for each of the three study arms.
♦ ♦»♦Breathlessness descriptors (20) used to describe the quality of a participants’ 
breathlessness from a fifteen item questionnaire. These 15 items will be presented in a 
random order.
f  The validated Karnofsky performance status scale (21). This scale incorporates the 
components of physical activity, work and self care of patients.
f f  The Global rating o f  change score is a measurement o f  response to treatment (22). 
Participants are asked i f  their breathlessness has changed and i f  so by how  much on a 
verbal rating scale.
Given the nature of the patient population, we have tried to incorporate the minimum 
number of assessments and measurements necessary so not to inconvenience the 
participant unduly but to monitor the effects of treatment closely. The length of the trial 
overall (three weeks), the nature of assessments (face to face on days 1 and 4 and via 
telephone on days 2 and 3) and the flexibility of the researcher in the place of assessment 
(clinic, hospital ward or home) reflects the consideration for participants that we have 
tried to incorporate into the study. We will ensure that we adhere to the Good Clinical 
Practice guidelines for the reporting of adverse events as set out by the Mull and East
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Yorkshire NHS Trust R&D department standard operating procedures. In particular, all 
serious and unexpected adverse reactions (SUSARs) will be reported to the sponsor (Hull 
and East Yorkshire NHS Trust) who will subsequently inform co-investigators, local 
ethics committee and the MHRA as per guidelines. According to local policy guidelines 
from the sponsor (Hull and East Yorkshire {HEY} NHS Trust), a serious adverse event 
becomes a SUSAR (suspected unexpected serious adverse reaction) if the event is 
suspected (possibly, probably or definitely) to be related to the IMP and unexpected i.e. 
not previously documented in any of the product information (e.g. SmPC) or protocol. 
Within 24hrs of knowledge of event, an initial SUSAR reporting form is to be completed 
by the investigator, faxed to HEY Trust R & D  department (01482 622368) keeping the 
original form in the Trial Master File. An additional SAE/SUSAR follow-up form is then 
to be completed by the investigator within 5 days of knowledge of event. It is the 
sponsors responsibility to record these details and report them as soon as possible to the 
licensing authority and ethics committee (not later than seven days after the sponsor was 
first made aware of the adverse reaction if it is lifethreatening). As sponsor, the HEY 
R&D department has responsibility for informing the relevant regulatory authorities.
An optional invitation to have a repeat blood test for BNP and repeat assessments (Borg 
score, NRS for breathlessness and side effects, breathlessness descriptors, SF-12 quality 
of life questionnaire and assessment of additional medications) will be made for all 
participants approximately three months after cessation of the initial study whether they 
have or have not continued to take active medication on an open label basis. Participants 
will be able to attend this follow-up without having to complete any participant 
information and the follow-up is on a purely voluntary basis.
6.0 Data management plan
A formal monthly assessment of recruitment into the study and six-weekly meetings with 
the research nurse to check study documentation will occur between the researcher (Dr 
Stephen Oxberry) and the Academic Supervisors (Dr Miriam Johnson and Professor 
David Torgerson). This will allow issues concerning the study to be addressed at the 
earliest opportunity. Reasons will be sought for missing data and recurring problems will 
be solved where feasible. Professor Torgerson will also arrange a Research Advisory 
Group at York University which will convene every six months.
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6.1 Analysis plan
Primary outcome measures;
.  Change in worst and average NRS- and Borg-rated breathlessness severity over 
the previous 24 hours and current breathlessness at time of assessment.
.  Change in global rating of breathlessness at the end of each inetervention
Secondary outcome measures:
• Distress and Quality of Life.
• Change in physical function.
• Between drug comparison of effect on breathlessness.
• Between drug comparison of adverse effects.
For a description please refer to assessment schedule in section 5.5 above. The Medical 
Research Council (MRC) Clinical Trials Unit and the Cicely Saunders Foundation have 
recently recommended a one point change in Borg score or 10% improvement in Visual 
Analogue Score (VAS) as significant (23). In pain measurement it has been shown that a 
Numerical Rating Score (NRS) is easier for patients to understand and complete than a 
VAS (24). In breathlessness it has been shown to be highly correlated with VAS scores 
and more repeatable (17,25).
6.2 Sample size
Initial assessment by a statistician of sample size using modelling techniques from the 
morphine pilot study suggested that a sample size of 33 evaluable patients would be 
required to determine a one point change in breathlessness score (a = 0.05; p = 0 8) 
Further discussions with Professor Martin Bland, Professor of Statistics in Healthcare at 
York University led to a feasible aim for recruitment of 48 participants in order to 
achieve enough data for analysis allowing for a generous withdrawal rate of over 30%.
This is important to allow for in studies with patients with advanced disease where 
withdrawal rates may be quite significant.
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6.3 Statistical considerations
The clinical trial will be reported according to the CONSORT guidelines for clinical 
trials. Baseline data (gender, age, diagnosis distributions etc.) will be presented in tabular 
form. Data will be analysed according to intention to treat criteria. Statistical 
comparisons will compare the measurements of primary and secondary outcomes 
between individuals for each treatment. As the results from a crossover trial are not 
independent, this is likely to involve the use of non-parametric methods of comparison of 
outcomes between treatments, for example the Wilcoxon Signed Rank test for continuous 
data. Paired t-tests will be used if the data is normally distributed. McNemars test will be 
used for any paired dichotomous data. All of these statistical tests do not allow for period 
effects, as we suspect that participants will remain relatively stable over a 3 week period 
and the sequence of medications to be taken has been randomised. Statistical help with 
this crossover trial will be accessed through Professor Bland.
Missing data is a well recognised problem in longitudinal studies, particularly with 
patients with advanced disease. We aim to handle missing data by using extreme values. 
By making the assumption that the missing value is the worst it could be for the 
intervention and the best it could be for the placebo, if there remains a statistically 
significant difference between active treatment and placebo then one can be sure that the 
results are robust. Other techniques that we have considered involve building a 
regression equation to predict the value of the missing data from the baseline 
characteristics from patients with no missing values or the use of other imputation 
techniques. We will take expert statistical advice from Professor Martin Bland.
7.0 Ethical considerations
The patient population under study is a potentially vulnerable group and care should be 
taken not to introduce further physical, psychological or financial burden with entry into 
studies. However, this must be balanced with the need for good research to identify 
practices that are potentially beneficial or prevent practices that are unhelpful or unduly 
burdensome. In order to try to address some of these concerns, this study:
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• Will follow Good Clinical Practice consenting and follow-up procedures
• Is being performed by a Palliative Care registrar (Dr Stephen Oxberry) as the 
principle researcher, with supervision by Dr Miriam Johnson (Consultant in 
Palliative Medicine). These physicians have considerable experience of opioid 
management in frail patients
• Incorporates flexibility to review participants in the setting of their choice and 
incorporates the use of telephone follow-up
• Re-imburses reasonable travel costs
• Is comparatively short in length (three weeks on treatment in total with optional 
three month follow-up) for a Cardiology study
• Will withdraw patients from the study if they become too unwell due to 
progression of disease or intercurrent illness
• Allows for any additional medical treatment as necessary
• Allows continuation of the treatment of most perceived benefit to that patient on 
an open label basis once follow-up has been completed
• Will obtain Ethics committee and Research and Development approval prior to 
commencement
8.0 Dissemination of findings
It is intended that the results will be disseminated in peer reviewed journals, through the 
local cardiology network and at national and international meetings in both palliative 
care and cardiology. Participants will also have the opportunity to ask for the treatment 
that they found most beneficial and will continue this on an open label basis.
9.0 Anticipated costs
Projected costs are as follow s:
•  Research nurse (F grade 3 sessions per w eek for 18 m onths) salary 
/superannuation /em ployer’s NI contribution = £13,033
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• Travel (patients’ taxi fares, and research nurse / researcher mileage) = £4000 (this 
assumes 48 x 6 for taxi fares at £15 each and assumes that some assessments will 
be at the participant’s home and mileage for the researcher / research nurse may 
be cheaper)
• Paper and telephone costs = £800
• MHRA application fee = £2607
• Annual MHRA service fee = £234
• Calderdale & Huddersfield Pharmacy trial set-up charge = £1400
• Pharmacy Archiving = £25
• Randomisation / medication labelling = £150
• Batch release of medication packs (based on 9 packs per batch every 3 months) = 
£600 = £600x5 batches = £3000
• Delivery = £30 per batch = £30x5 = £150
• Medication costs = £9.43 for oral oxycodone (oxynorm) liquid plus £1.87 for oral 
morphine (oramorph) liquid = 48 x 11.3 = £542
• Laxative and anti-emetic costs = to be confirmed
•  Hull pharmacy storage and release fee = to be confirmed
• Cost of placebo ingredients = to be confirmed
• B-type natriuretic peptide (BNP) test and analysis = 48 x £15 = £720
• SF-12 registration and authorisation = $90US = £50
Total estimated cost = £ 26711. This will be funded through the Clinical Research 
Fellowship study budget.
10.0 Revised project milestones
Finalise protocol: May 2007
Finalise study documentation: May 2007
Confirm placebo preparation details: May 2007
Apply to Eudract / MHRA: July 2007
Submission to ethics and R&D committees: July 2007
Recruit research nurse: July 2007
Complete updated literature review: July 2007
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Research nurse commence and training given: 
Commence patient screening and entry: 
Patient recruitment at 1-2 per week:
Data entered and cleaned:
Data analysed and written:
Dissemination of data:
September 2007 
September 2007 
by Sept 2008 
September 2008 
November 2008 
December 2008
11.0 Study reference and contact numbers
Hull And East Yorkshire Hospitals NHS Trust R&D 
Eudract number:
Funding reference number (HYMS):
ISRCTN:
trial number: R0452
2006-06718-13
ZNA-502
ISRCTN85268059
Calderdale and Huddersfield NHS Trust Pharmacy reference 
numbers for placebo manufacture: MIA (IMP) 19055 
MHRA site 11706
Contact details for the study are as follows:
Dr Stephen Oxberry (Principle Investigator):
Carolyn Medlam (Clinical Trials Secretary) 01482 675102
Dr Miriam Johnson (Academic Supervisor): 01723 351421 
Hull NHS Pharmacy 01482 675939 
Hull Royal Infirmary (HRI) 01482 328541 
HEY R&D department 01482 622681
Emergency Contact Number: Dr Stephen Oxberry 07949 109726
Ward 8, HRI 01482 674347
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Appendix 4) RCT sequence of events for each participant
Generate list of patients coming to NHS outpatients and screen them for eligibility
4
Approach those patients who appear to Fit the criteria on this list and assess
I
If patient displays interest given patient information sheet
I
Patient contacted by telephone >1 day after
4
If agreeable, consent date arranged with opportunity to ask questions
4
Consent date: written informed consent taken, eligibility check and BNP blood test
1
GP letter sent, patient number assigned and prescriptions sent to pharmacy
I
Patient notes obtained and trial documentation added to them
I
Trial patient registered on NHS heart failure database and in Trial Master File
1
Prescriptions collected and signed for on Week 1 Day 1 of trial & given to patient
4
3 week trial commences -  2 days of patient visits and 2 days of telephone follow-up each 
week (see Appendix 5 for example of a day 1 assessment) followed by 3 day washout for
each intervention
4
Patient written folders completed alongside entries into patients hospital notes with 
attention to adverse events (specific procedures to follow for serious adverse events and
serious unexpected adverse reactions
xxxi
Trial Access database completed with patient entries
1
Progress documented on NHS heart failure database
i
Medication bottles collected in and signed for
I
Open label therapy to start if patient agreeable -  arrange prescriptions and inform GP
i
3 month optional follow-up for all patients (letter, visit, BNP test)
i
Ensure all documentation (patient folders, Access database, NHS database, TMF)
completed
i
Repeat process for all patients
i
Ensure all documentation up to date for regulatory authority inspections and complete 
annual assessment reports and end of trial documentation
i
xxxii
Thesis Appendix 5) Example of day 1 assessment booklet 
Case Report Form (CRF): Front page 
Participant ID:
Inclusion criteria check: (tick boxes to confirm)
Heart failure grade NYHA III/IV with LV dysfunction confirmed by echo □
Heart failure from any aetiology with stable NYHA status for at least one month □
Optimal (and unchanged over previous one month) medical management of their 
heart failure (diuretic and ACE inhibitor/AII antagonist) □
Adequate renal clearance (using Cockroft and Gault: GFR>30ml/min) □
Aged 18 years or over ^
Provide written informed consent and able to complete patient assessments □
An estimated prognosis of more than eight weeks n
Study number: Date:
Trial week / Visit number:
Exclusion criteria check: (tick boxes to confirm none apply)
Are involved in other medicinal trials currently
Have used morphine-based medications within the last month
Have known true morphine allergies
Have significant co-existing lung disease (e.g. COPD, Asthma, Lung fibrosis) 
contributing significantly to the patients’ breathlessness i.e. PFR <150 
Have co-existing malignant disease if this would affect the study in the 
investigators’ opinion
Have conditions contraindicated in the Summary of Product Characteristics 
(SmPCs) for Oramorph and Oxynorm, namely:
Respiratory depression, obstructive airways disease, acute and chronic 
bronchial asthma, cor pulmonale, hypercarbia, acute hepatic disease, 
moderate to severe hepatic impairment, acute alcoholism, acute abdomen, 
delayed gastric emptying, chronic constipation, head injury, coma,
xxxiii
Study number: Date:
Trial week /  Visit number:
convulsive disorders, raised intracranial pressure, paralytic ileus, severe 
renal impairment, known hypersensitivity to product constituents and those 
receiving Mono-amine Oxidase inhibitors (MAOIs) or within 2 weeks
of cessation of these drugs 0
Are planning to undergo a surgical or interventional procedure □
Taking a medicinal product with a known interaction with opioids □
Pregnant or lactating women □
Study inclusion? Included / Excluded
If excluded, why? (sign & date)
Blood samples taken and dates:
Renal function: Date taken:
Sodium (mmol/1) =
Potassium (mmol/1) =
Urea (mmol/1) =
Creatinine (micromol/1) =
eGFR (if available) =
Cockcroft and Gault calculation of GFR:
Men:
Creatinine clearance (ml/min) = (140 - ace) x weight (kg) x 1.23
Plasma Creatinine
Women:
Creatinine clearance (ml/min) = (140 - aae) x weicht (kg) x 1.04
Plasma Creatinine
Calculated GFR in subject =
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Study number: Date:
Trial week / Visit number:
BNP: Date taken:
Visit dates:
Date Purpose (initial / follow-up 
/ open label visit / 3/12 
follow-up)
Study Status 
(completed / ongoing / 
withdrawn)
Assessor
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Study number: Date:
Trial week / Visit number:
Eligibility assessment booklet
Study Number:
Date:
OPIOIDS IN TIIE MANAGEMENT OF BREATHLESSNESS IN HEART FAILURE
PATIENTS
XXXVI
Study number: Date:
Trial week / Visit number:
For researcher use:
Age _____
Sex ____ _
Heart failure aetiology
NYHA grade
Echocardiogram Date:
Ejection fraction: 
Reported severity:
Peak flow rate |______
Serum urea and creatinine 
Calculated GFR (ml/min)
BNP measurement |
Date:
Date:
Date:
Medication
Medication Dose Indication Date started if < 7 days ago
Other relevant treatment
XXXV11
Study number: Date:
Trial week / Visit number:
Baseline (day 1) assessment booklet: Study Number:
Trial week: (1 st/2nd/3rd)
Date:
OPIOIDS IN THE MANAGEMENT OF BREATHLESSNESS IN HEART FAILURE
PATIENTS
XXXVlll
Study number: Date:
Trial week / Visit number:
Section 1 : For researcher use:
Resting Pulse 
Blood pressure 
Respiratory rate 
Oxygen saturation
Medication
Medication Dose Indication Date started if < 7 days ago
XXXIX
Study number: Date:
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Section 2: To be completed by participant with assistance from researcher
Please could you give the following a score from 0 -10 by circling the number that 
best describes how you feel.
1. How bad has your breathlessness felt on average over the past 24 
hours?
Not breathless at all 0 1 2 3 4 5 6 7 8 9 10
The worst imaginable 
breathlessness
2. What is the worst that your breathlessness has been over the past 24 
hours?
Not breathless at all 0 1 2 3 4 5 6 7 8 9 10 The worst imaginable 
breathlessness
3. How bad is your breathlessness right now?
Not breathless at all 0 1 2 3 4 5 6 7 8 9 10
The worst imaginable 
breathlessness
4. How much distress has your breathlessness caused you on average 
over the past 24 hours?
No distress at all 0 1 2 3 4 5 6 7 8 9 10
The worst imaginable 
distress
5. How well have you coped with your breathlessness on average over the 
past 24 hours?
I have not coped at all 0 1 2 3 4 5 6 7 8 9 10 I have coped very well
6. How satisfied have you felt with the treatment you have received for your 
breathlessness?
Not satisfied at all 0 1 2 3 4 5 6 7 8 9 10 Completely satisfied
Study number: Date:
Trial week / Visit number:
7. How bad has any nausea been on average over the past 24 hours?
No nausea at all 0 1 2 3 4 5 6 7 8 9 10
8. How bad has any drowsiness/sleepiness been on avei
24 hours?
No drowsiness at all 0 1 2 3 4 5 6 7 8 9 10
The worst imaginable 
nausea
The worst imaginable 
drowsiness
9. Do you feel constipated?
Yes / No
10.1s there anything else you would like to mention that has not been 
covered already?
Borg scale (1)
Please circle the number that best describes your shortness of breath at its 
worst over the past 24 hours
0 Nothing at all
0.5 Very, very slight (just noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very, very severe (almost maximal)
10 Maximal
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Trial week / Visit number:
Borg scale (2)
Please circle the number that best describes your shortness of breath, on 
average, over the last 24 hours.
0 Nothing at all
0.5 Very, very slight (just noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very, very severe (almost maximal)
10 Maximal
Borg scale (3)
Please circle the number that best describes your shortness of breath at this 
moment
0 Nothing at all
0.5 Very, very slight (just noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very, very severe (almost maximal)
10 Maximal
xlii
Study number: Date:
Trial week / Visit number:
Your Health and Well-Being
This survey asks for your views about your health. This information will 
help keep track of how you feel and how well you are able to do your 
usual activities. T hank y o u  f o r  com pletin g  th is su rvey!
For each of the following questions, please tick the one box that best 
describes your answer.
1. In general, would you say your health is:
Excellent Very good Good Fair Poor
▼ ▼
□  . □  3
2. The following questions are about activities you might do during a typical day. 
Does vour health now limit you in these activities? If so, how much?
Yes, Yes, No, not
limited limited limited
a lot a little at all
Y y y
Moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf □  l □  2 □  3
Climbing several flights of stairs □  l □  2 □  3
xliii
Study number: Date:
Trial week / Visit number:
3. During the past week, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result ofvour 
physical health?
V V V ▼
All of Most of Some of A little of None of
the time the time the time the time the time
Accomplished less than von 
would like.............................. .... ...... □ * ..... ..... ......□ * ..... .....□ .
Were limited in the kind of 
work or other activities................ ...... □  »..... .....□  >.... ......□  «..... .....□ .
4. During the past week, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)?
All of 
the time
. Accomplished less than you
would like................................... [311
b Did work or other activities
less carefully than usual....  ..........□ .
Most of Some of A little of None of
the time the time the time the time
▼ V V
. . . .□ a - . ......□ » ... . ...... ...Os
......□ » ... . ...... ...Os
5. During the past week, how much did pain interfere with your normal work 
(including both work outside the home and housework)?
Not at all A little bit Moderately Quite a bit Extremelyy V V V V
□  . □  .
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Trial week / Visit number:
6. These questions are about how you feel and how things have been with you 
during the past week. For each question, please give the one answer that comes 
closest to the way you have been feeling. How much of the time during the past 
week...
All of Most of Some of A little of None of
the time the time the time the time the time
^pr ▼ y p ▼
Have you felt calm and 
peaceful?.............................. .....□ . ..... ......□ » ...... ...... .......□ ....... ..... □ .
Did you have a lot of energy? .....□ . ..... ......□ . ...... ...... ....... ..... □ .
Have you felt downhearted 
and low?............................... ......□ . ..... ......□ . ..... ...... ....... ..... □ .
7. During the past week, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)?
therune
Mo&Lofwv
the Mme
Soujj^of
thewme
A li^ â o f 
themne
N^jj^of
therime
□  « □  3 □  « □  3
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Breathlessness descriptors
Please tick THREE of the following statements that BEST reflect how your 
breathing feels right now. Carefully consider the three statements that apply 
most. Please do not choose more than three.
1. My breathing is shallow
2. My chest is constricted
3. I feel out of breath
4. My breathing requires effort
5. My chest feels tight
6. My breath does not go in all the way
7. My breath does not go out all the way
8. I feel hunger for more air
9. I feel that I am suffocating
10. My breathing requires more work
11.1 cannot get enough air
12.1 feel that my breathing is rapid
13.1 feel that I am being smothered
14.1 feel that I am breathing more 
15. My breathing is heavy
Study number: Date:
Trial week / Visit number:
xlvi
Karnofsky Performance Scale:
100 Normal; no complaints; no evidence o f  disease
90 Able to carry on normal activity; minor signs or symptoms
80 Normal activity with effort; some signs or symptoms o f  disease
70 Cares for self; unable to carry on normal activity or to do active work
60 Requires occasional assistance but is able to care for most o f  their needs
50 Requires considerable assistance and frequent medical care
4 0  Disabled; requires special care and assistance
30 Severely disabled; hospitalisation necessary; active supportive treatment is
necessary
20 Very sick; hospitalisation necessary; active supportive treatment is necessary
1 o Moribund; fatal processes developing rapidly
0 Dead
Study number: Date:
Trial week / Visit number:
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Study number: Date:
Trial week / Visit number:
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OPIOPHOBIA -  ATTITUDES TO MORPHINE IN HEART FAILURE 
PATIENTS
15th January 2008
1. Overview:
This protocol proposal has been produced by Dr Stephen Oxberry with assistance from 
Drs Miriam Johnson and Lesley Jones at Hull York Medical School and Professor David 
Torgerson at the University of York. It will form part of a PhD project funded by a 
Clinical Research Fellowship by Hull York Medical School awarded to Dr Oxberry. 
Opioid (“morphine-like”) medications are increasingly being used for symptom 
management in non-malignant conditions. We intend to discover whether heart failure 
patients would find the use of opioid medication acceptable, what patients already 
understand about their use and what fears or anxieties they may have, and how 
information regarding their use can be best targeted.
2. Background:
Opioids in healthcare
Opioids or “morphine-like” medicines conjure a variety of different thoughts in the 
minds of both medical and lay people. Opioid use can be associated with addiction, 
dependence, side effects and thoughts of the consequences of non-prescription opioid 
drugs such as heroin. These ideas can often prevent the clinical use of opioids by medical 
professionals (Bennett and Carr 2002) despite increasing evidence that controlled 
informed use of these medicines is both justified and has a good safety profile.
Opioids are most commonly employed in the sphere of pain management, particularly 
with advancing disease. The Barriers Questionnaire (Ward et al. 1993) was devised to 
demonstrate the reasons why patients were reluctant to report pain or use medicines such 
as opioids that are utilised in more severe pain states. Themes that emerged from this and 
other works in cancer patients included: addiction and tolerance to analgesics; saving a 
drug until the pain becomes much worse; medication side effects; fatalism (pain is to be
xlix
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expected); “good” patients don’t complain; increased pain may indicate disease 
progression; discussing pain may detract from trying to cure the disease; strong 
painkillers require injections. From our own work in palliative medicine patients with 
cancer, we noted that addiction and fear that opioids may mask important changes in a 
disease were the most common anxieties expressed. This small pilot questionnaire based 
study also highlighted that knowledge of opioids is generally quite poor and that most 
patients derive their knowledge about these medicines from their own experience rather 
than from patient information leaflets (Lambert et al. 2007). Many other articles have 
described why some healthcare professionals have a reluctance specifically for opioid 
prescribing ((Elliott and Elliott 1992; Zenz and Willweber 1993; Zenz et al. 1995; Wells 
et al. 2001).
However, the role of opioids in symptom management is changing. There is increasing 
evidence to suggest that opioids are useful in the management of breathlessness and 
cough (Jennings et al. 2001; Morice et al. 2007). This expands the use of opioids in 
palliative medicine from the treatment of pain typically in cancer patients, to the 
management of breathlessness and cough in both cancer and non-cancer patients, such as 
those with cardiac and respiratory disease.
Palliative care and heartfailure
It has been recognised that palliative care should not be restricted to just oncology 
patients, but that a number of different life threatening chronic conditions (such as heart 
failure, chrome obstructive airways disease etc.) can be managed using palliative care 
principles as the condition advances. The prevalence of heart failure is increasing 
(Thomas and Rich 2007) and the prognosis of heart failure patients is likened to that of 
many advanced cancers (Stewart et al. 2001). Heart failure patients with chronic 
advancing disease often experience a multitude of physical symptoms, including 
breathlessness, pain and fatigue, in addition to non-physical symptoms including loss of 
role/independence, reduced quality of life and mood disturbances (Barnes et al. 2006). 
The disease trajectory is often difficult to predict with acute exacerbations of symptoms 
punctuating a variable chronic disease course. The impact of heart failure on daily 
physical function is assessed by the New York Heart Association (NYHA) grading of
1
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heart failure severity. It assesses the restriction of patient activity by breathlessness and 
fatigue (Grade 1 indicating no limitation on activity, Grade 4 indicating symptoms at 
rest).
Murray et al (2002) compared the experiences of 20 advanced lung cancer and 20 
advanced heart failure patients through qualitative interviews. They demonstrated that 
heart failure patients tended to focus on the stresses of balancing and monitoring a 
complex drug regimen; had poor knowledge of diagnosis and prognosis; and experienced 
frustration, progressive losses and social isolation. This was in contrast to the lung cancer 
patients who were more pre-occupied with facing death and had greater access to social 
and financial resources. Rogers et al (2002) confirm some of these themes using 
qualitative interviews in heart failure patients. They also found that patients generally 
had little knowledge about the medications they were taking, and how use of the 
medications related to the symptoms they described. Willems et al (2004) expand on this 
work using semi-structured interviews in 31 advanced heart failure patients. They 
demonstrated that patients with advanced heart failure tended only to consider the 
prospect of dying during episodes of acute decompensation. Rogers et al (2000) noted 
that there were barriers to effective communication between clinicians and heart failure 
patients.
It is likely in the next few years that opioids will be used more widely to manage pain, 
breathlessness and cough in advanced heart failure populations. To date, there is little 
evidence to describe how acceptable this will be to this patient population and what 
beliefs, attitudes and existing knowledge these patients have.
Key points:
• Attitudes to opioids in both medical and lay circles centre around a number of 
pre-conceived ideas, based on patient experiences that are often unfounded given 
the current clinical use of opioid medicines -  leading to “opiophobia”.
• Overall, knowledge about opioids in cancer patients currently or previously using 
these medicines is generally quite poor.
• When compared to cancer patients, heart failure patients have a poorer knowledge 
of their diagnosis and prognosis and their focus is directed towards monitoring a 
complex drug regimen.
li
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3. Research Aims:
To explore the beliefs about and acceptability of opioid medication use held by patients 
with heart failure. In particular:
• How acceptable is the use of opioids in the management of symptoms (especially 
breathlessness) to heart failure patients already in receipt of complex 
polypharmacy?
• What are the specific anxieties regarding potential opioid use in this patient 
group?
• What beliefs concerning the use of opioids already exist in heart failure patients?
• What hopes do heart failure patients have for opioid therapy?
• How has information about medicines (including opioids) been obtained by this 
patient group?
4. Design:
Qualitative data will be derived from the use of semi-structured interviews in twenty 
heart failure patients. A topic guide of key themes will be used to guide the researcher 
during the interview. This is outlined in the Appendix.
4.1 Sample:
A theoretical sample of symptomatic chronic heart failure patients will be used for this 
qualitative trial. AH potential participants will be known to the Academic Department of 
Cardiology and classified NYHA Grades II, III or IV. This sample of patients has been 
chosen as they are the most likely group to have prescription of opioids in the future and 
may have considered the potential use of medicines for symptoms. Participants involved 
in the ongoing randomised controlled clinical trial involving opioids for breathlessness 
will not be approached. These patients will have read the participant information sheet 
for this trial and may therefore have a different experience to those patients who have not 
be approached or enrolled into the RCT.
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Heart failure patients will be approached by invitation letter following identification and 
screening by use of the Academic Department of Cardiology computer database of heart 
failure patients. It may be that these patients are also known through the Heart Failure 
Nurse Specialist Service and eligible patients can be approached with an invitation letter 
via these nurse specialists. Included in this correspondence will be a copy of the 
participant information sheet and consent form for the patient to review. Potential 
participants will have the opportunity to contact the research team or Academic 
Department of Cardiology trials secretary directly if they express an interest or if they 
wish to decline the invitation. If this has not occurred within one week, the researcher 
will contact the potential participant by telephone to find out if the patient requires any 
additional information or if they wish to discuss the study in more depth. At all times 
during this process the researcher will be available to answer questions either via 
telephone or face to face.
It is anticipated that participants will be asked to perform the semi-structured interview 
during their next heart failure clinic attendance. This will allow the minimum 
inconvenience to the participant. Alternatively, the interviews can occur on hospital 
wards or in the participants’ home, whichever is most convenient to the participant as 
long as a quiet area is found free from interruption.
Informed consent may be taken on the day of the interview to minimise inconvenience to 
the participant if it is deemed appropriate by the researcher. It is recognised that this is a 
potentially frail population who may experience undue burden if repeated visits are 
necessary. However, in general, written informed consent will be taken at least 24 hours 
after participant invitation. The original consent form will be kept in the trial site study 
file, with copies of the signed consent form given to the participant and entered into the 
participants’ hospital notes. It will be made clear to the participant they will be free to 
withdraw consent at any time.
No formal sample size has been calculated for this qualitative study, but we suspect that 
theoretical saturation of both the coding and collection of data will be achieved with 
twenty participants. It is considered that twenty participants involved in single semi- 
structured interviews is an adequate number considering the nature of the topic,
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experience of the interviewers and quality of the data obtained (Morse 2000). The topic 
guide for the interview has been reviewed by volunteers from the Scarborough-Whitby- 
Ryedale Heart Failure Patient Support Group.
4.2 Inclusion, exclusion and withdrawal criteria:
Inclusion criteria:
Patients who:
Are known to the Hull and East Yorkshire Academic Cardiology Heart Failure 
Service.
Have a diagnosis of NYHA grade II, III or IV heart failure of any aetiology. 
Are aged 18 years and over.
Are able to complete written informed consent and semi-structured interview.
Exclusion criteria:
Patients who:
Are unable to complete informed consent or semi-structured interview without 
assistance.
Have known true allergies to opioids (morphine-like medicines).
Have been approached or are participating in the concurrent randomised 
controlled trial (RCT) involving opioids in heart failure.
Have previously stated not be approached for consideration for research trials.
Withdrawal criteria:
Participants w ill be withdrawn from the study on:
Withdrawal of participant consent.
Withdrawal of the participant by the treating physician or medical researcher due 
to the patient no longer meeting the eligibility criteria.
4.3 Sources of data:
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Once the participant has been enrolled into the study background data will be collected. 
This will include age, gender, NYHA status and date of diagnosis. This demographic 
data will be obtained from Academic Cardiology Heart Failure database. Participants will 
each be assigned a unique identification number for the trial. Dr Stephen Oxberry will 
hold the list of numbers matched to each participant and this information will remain 
confidential.
A topic guide will be used by the researcher as a framework for the semi-structured 
interview. The interview itself will be conducted in a quiet area and will involve the 
participant and interviewer only. If the participant wishes, a friend or family member will 
be allowed to observe the interview, however it will be made clear that the views of the 
participant alone are of interest to this current study. Provision will be made after the 
interview to discuss any issues raised and at this point carers, friends or family can 
become involved in any subsequent discussions should the participant wish. Interviews 
will be tape-recorded and professionally transcribed verbatim. The transcriber will not 
have access to participant details except for the unique identification number assigned to 
that participant. Contemporaneous notes of any particular items of importance, conduct 
of the interview and physical characteristics not likely to be identified by voice alone will 
be made immediately following the interview process by the interviewer. Both the taped 
interview transcript and notes taken regarding the conduct of the interview will be drawn 
together by the research team to identify and gain consensus regarding the key themes 
that emerge. All interviewee responses and notes will be anonymised and confidential. 
The audio tape interviews will be retained in a locked storage unit in the Department of 
Academic Cardiology, Hull and East Yorkshire NHS Trust once transcription of the 
interview has occurred. These audio tapes will be kept for the duration of the study and 
then deleted. Transcripts of the interviews will not be sent to the participant, but an 
executive summary of the key points raised by the study will be sent out by post to the 
participant. A summary of the study outline for the participant is detailed below:
Those patients who meet eligibility criteria on the Academic Cardiology Heart Failure
database approached by invitation letter
i
Researcher contacts patient after one week to confirm interest
l
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Meeting with researcher set up at patient’s convenience to answer questions
i
Written informed consent taken
I
Semi-structured single interview taking no longer than 30 minutes using tape recorder 
with opportunity to discuss or ask further questions about points raised thereafter
i
Participant data anonymised and collated
i
Study conclusions disseminated to participants via letter and written up in peer reviewed
journal and for conferences
5. Data management plan:
A formal monthly assessment of recruitment into the study and six-weekly meetings to 
check study documentation will occur between the researcher (Dr Stephen Oxberry) and 
the Academic Supervisors (Dr Miriam Johnson, Dr Lesley Jones and Professor David 
Torgerson). This will allow issues concerning the study to be addressed at the earliest 
opportunity. Professor Torgerson has also arranged a Research Advisory Group at York 
University which meets every six months as part of the overall PhD project incorporating 
the RCT, Qualitative work and Thesis production.
Data obtained from the interview process will be analysed according to the principles of 
modified Grounded theory. One definition of Grounded theory is “theory that was 
derived from data, systematically gathered and analysed through the research process. In 
this method, data collection, analysis and eventual theory stand in close relationship to 
one another” (Strauss and Corbin 1998). The topic guide has been produced to 
investigate themes that we consider may be important to heart failure patients. However, 
in accordance with the process of Grounded theory, themes that emerge from the 
interview data will be sought and subsequent participant interviews may be refined to 
take any new concepts or themes into account.
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The data collected will be broken down into component parts and given identifiable 
names (coding). Open coding of data will be utilised to yield concepts and categories. 
Coding will occur alongside data collection to allow changes in emphasis in the topic 
guide to be made where necessary. Formal theory will be generated from exploration of 
these concepts and categories allowing the formation of subsequent hypotheses by the 
researcher and Academic supervisors.
6. Dissemination:
Results from the study will be disseminated locally in the Academic Cardiology 
Department in Hull, in peer reviewed Cardiology or Palliative Medicine literature and at 
national and international conferences. Participants will have the opportunity to ask 
questions of any topics that emerge at the time directly after the interview. In addition, a 
short summary sheet of the findings of the research will be posted out to the participants 
to their home address at the completion of the study.
7. Ethical issues:
The patient population under study is a potentially vulnerable group and care should be 
taken not to introduce further physical, psychological or financial burden with entry into 
studies. However, this must be balanced with the need for good research to identify 
issues that may enhance or inhibit good patient care. In order to try to address some of 
these concerns, this study:
• Will follow Good Clinical Practice consenting procedures
• Is being performed by a Senior Palliative Care registrar (Dr Stephen Oxberry) as 
the principle researcher, with supervision by Dr Miriam Johnson (Consultant in 
Palliative Medicine). These physicians have considerable experience of both 
opioid management and sensitive discussions with frail patients
• Incorporates flexibility to review participants in the setting of their choice as long 
as confidentiality can be maintained and the setting is as free from potential 
interruption as possible
lvii
R&D study number: R0613
Protocol version 1.0 dated 15/01/08
• Re-imburses reasonable travel costs
• Is a single 30 minute interview rather than a series of lengthy interviews or 
questionnaires
• Will withdraw patients from the study i f  they request
• Will obtain Ethics committee and Research and Development approval prior to 
commencement
8. Project milestones:
Finalise protocol
Complete updated literature review 
Ethics submission 
Commence patient recruitment 
Complete patient recruitment 
Complete write-up 
Dissemination of results
9. Project team:
Dr Stephen Oxberry: Cardiology Clinical Research Fellow / Specialist Registrar in 
Palliative Care / PhD student at Hull York Medical School.
Email oxbs@vahoo.co.uk: Mobile 07949 109726.
Dr Miriam Johnson: Senior Lecturer in Palliative Medicine, Hull York Medical School, 
Hull University.
P r o f David Torgerson: Director York Clinical Trials Unit, York University.
Dr Lesley Jones: Senior Lecturer in Social Sciences, Hull York Medical School, York 
University.
October 2007 
September 2007 
January 2008 
March 2008 
March 2009 
May 2009 
June 2009
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10. Anticipated costs:
Written transcription costs of each interview:
Travel costs (patient taxi fares / researcher mileage): 
- assumes taxi fares at £15 return 
Paper & telephone costs
20 x £15 = £300 
20 x £15 = £300
£200
These costs will be funded through the Clinical Fellowship research budget.
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Appendix:
Topic guide:
Medicine use
Probes: Tell me about the medicines you’re taking for your heart / heart failure
Where do you go to get information about your medicines? (Doctor, 
nurse, media, friends, family, internet?)
How could your knowledge about medicines be improved (and would this 
be of benefit to you)?
Would you regard yourself as being good at taking medicines everyday? 
Why?
What would prevent you from taking a medicine every day?
General Condition
Probes: How much does your heart failure trouble you?
Is breathlessness / pain / cough a particular problem? What do they 
prevent you from doing if anything?
If morphine could help people feel less breathless, would this be useful for 
you? Why, what difference would it make to you?
Anxieties concerning opioids
Probes: What does the word “morphine” make you think of?
Does the term or word “morphine” put you off?
Would you have any concerns about taking morphine if it was offered? 
Would you worry about side effects? What sort of side effects have you 
heard of?
Would you be concerned to receive morphine-like medicines on a long 
term basis if you found them helpful?
Is there anything that might stop you from taking morphine even if you 
thought it might help you?
Beliefs regarding opioids
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Probes: What is your previous experience of morphine-like medicines? (Own,
Family & Friends). Have you come across morphine medicines before, 
either yourself or someone you know?
What was the setting and was it a good or bad experience?
Do you think morphine medicines should be used for patients... if so -  in 
what situations?
Have you ever thought that morphine-like medicines could be helpful in 
heart failure?
Hopes concerning opioids
Probes: From what you know about morphine-like medicines, do you think they
would have any helpful effects? Would this help you?
Close
Any questions or comments 
Thanks
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Appendix 7) Financial costs of the trials: Estimated and Actual
Expediture Predicted cost (£) Actual cost (£)
Research nurse salary through Academic Cardiology 13033 5097
"Travel: taxi’s
researcher mileage
3500
500
290
2457
"Paper / Telephone / Postage / Laptop / Documents 1000 873
Study equipment (Pulse oximeter, SF-12 purchase) 215 219
MHRA application & ISRCTN registration 2996 2810
Huddersfield Pharmacy manufacture (set-up fee, 
archiving, randomisation, batch release, delivery, 
drug constituents)
4875 2835
■Hull pharmacy costs (dispensing fee, set-up fee, 
temperature recording, concomitant medications)
830 830
-
"BNP laboratory analysis 720 1020
"Transcription costs for qualitative trial 300 489
"Archiving 0 150
"Total 27969 17070
Ixiii
Please see the protocols for a more complete analysis of expected costs prior to study 
commencement. The researcher’s salary was not included in the study budget and is therefore 
excluded. The study budget was generously donated as part of the clinical trial fellowship 
through Hull York Medical School. Trial costs were less than predicted, mostly due to the 
savings in nurse salary and Huddersfield manufacturing costs. Research nurse time was 
invaluable for maintenance of study procedures, but more assessments than originally 
predicted were performed by the researcher. In addition, medication delivery delays meant 
that a significant saving was made in these costs, as a reduction in these prices was 
negotiated.
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